{"question": "When comparing regulatory approaches to unauthorized activities involving controlled substances, which statement best describes a key difference between Chinese and US frameworks?", "choices": ["A. Chinese regulations focus primarily on financial penalties for unauthorized production, while US regulations emphasize procedural safeguards during transportation.", "B. Both systems impose identical penalties for smuggling violations, including mandatory license revocation.", "C. US regulations require dual-employee oversight during destruction processes, whereas Chinese regulations lack specific personnel requirements for such operations.", "D. Chinese regulations automatically suspend future license applications for violators, while US regulations do not address application suspension in their penalty provisions."], "answer": "D", "type": "Parallel", "explanation": "Chinese regulations explicitly authorize authorities to suspend acceptance of new license applications from violators for up to three years following a penalty decision. The provided US text focuses on destruction and transportation procedures without mentioning license application suspension as a penalty. Option A incorrectly characterizes Chinese penalties as solely financial (they include confiscation and license revocation). Option B is false as penalty details for smuggling differ between the systems. Option C is misleading as the Chinese text doesn't discuss destruction procedures, making a comparison on that specific point invalid based solely on the provided excerpts.", "category": "Controlled_Substances", "related_concept": "penalties for violations, suspension of license applications", "id": "PA_P_00703_004", "match_type": "weak", "match_score": 0.7306150187631569, "lang": "EN", "source_cn": "易制毒化学品管理条例.txt", "source_us": "PART_1317DISPOSAL.txt", "old_id": "comp_0013_0007_1"}
{"question": "在何种情况下，监管机构可能命令停止信息传播？请结合中美法规差异进行选择。", "choices": ["A. ①根据中国法规，任何组织或个人对中医药作虚假、夸大宣传时，可能被要求停止相关宣传。②根据美国法规，当FDA终止一项关于药品新用途信息传播的豁免批准，并认定该信息可能对公众健康构成显著风险时，可能命令制造商停止传播。", "B. ①根据中国法规，只要传播中医药知识，就必须事先获得FDA的批准。②根据美国法规，任何关于药品的学术讨论都需要事先向FDA备案，否则可能被命令停止。", "C. ①根据中国法规，只有省级政府有权命令停止任何健康信息的传播。②根据美国法规，FDA可以随时命令停止任何它认为不准确的医学信息传播，无需特定程序。", "D. 两国法规均规定，停止信息传播的命令只能由法院发出，监管机构没有此项权力。"], "answer": "A", "type": "Parallel", "explanation": "选项A的①和②均正确描述了中美法规下的相关情形。\n① 中国《中医药法》第四十六条规定：“任何组织或者个人不得对中医药作虚假、夸大宣传……”违反此规定，监管机构当然有权并要求其停止违法行为，包括停止虚假宣传。\n② 美国FDA法规（21 CFR 99.403(a)(3), (b)(1)-(2)）明确，当FDA终止一项“被视为批准”的豁免，并且确定所传播信息中描述的新用途会对公众健康构成显著风险时，可以命令制造商停止传播并采取纠正措施。\n其他选项的描述存在事实性错误或过度简化，不符合两国法规的具体规定。", "category": "Drugs", "related_concept": "cease dissemination order", "id": "PA_P_00010_006", "match_type": "weak", "match_score": 0.7169394057387558, "lang": "CN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0010_0008_4"}
{"question": "关于防晒产品的监管分类，请判断以下陈述：\n陈述1：根据美国法规，任何在标签中使用“防晒”术语的产品，无论其声称的具体功能如何，通常都会被归类为药品进行监管。\n陈述2：中国法规对多色号系列防晒化妆品的定义要求除着色剂外，基础配方成分必须完全相同，且系列名称一致。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：美国FDA明确规定，在产品标签中使用“防晒”或类似防晒保护术语，通常会导致该产品被作为药品监管，因为防晒活性成分会影响身体结构或功能。\n陈述2正确：中国法规明确定义多色号系列防晒化妆品是指除着色剂种类或含量不同外，基础配方成分含量和种类相同，且系列名称相同的产品。", "category": "Cosmetics", "related_concept": "sunscreen as drug definition, multi-color series sunscreen cosmetics definition", "id": "PA_P_00641_002", "match_type": "weak", "match_score": 0.747778714054564, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0011_0008_2"}
{"question": "When comparing regulatory modifications in the US and China, which statement best describes a key difference in how modified requirements or exemptions become effective?", "choices": ["A. In the US, modifications become effective upon Federal Register publication unless otherwise specified, while Chinese amendments typically specify effective dates within the legislative text.", "B. In China, all regulatory modifications require a public comment period before taking effect, similar to US procedures.", "C. Both systems require identical waiting periods (typically 1 year) after publication before modifications become effective.", "D. Chinese modifications always take effect immediately upon announcement, while US modifications require judicial review first."], "answer": "A", "type": "Parallel", "explanation": "US regulations specify that modified requirements or exemptions become effective upon Federal Register publication unless otherwise stated. Chinese regulatory amendments, as seen in the context, typically specify changes to existing articles without detailing effective date procedures in the amendment text itself, implying effectiveness follows legislative promulgation timelines.", "category": "General_FDA", "related_concept": "modified requirements adoption, Federal Register notice publication", "id": "PA_P_00753_001", "match_type": "weak", "match_score": 0.7345896164938663, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第666号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0004_0115_1"}
{"question": "在支持性信息提交方面，中美法规对国际销售经验的要求体现了不同的监管逻辑。请判断以下两个陈述：\n陈述1：美国FDA允许药品基于在多个国家的OTC销售历史来支持其安全性有效性认定，特别关注销售持续时间、市场规模和文化多样性。\n陈述2：中国法规明确要求，所有中药产品必须提供在五个以上国家的连续销售记录才能获得上市批准。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：美国法规（330.14）确实允许基于在五个或更多国家的OTC销售经验（包括至少一国连续5年销售）来支持药品专论认定，并考虑销售规模和文化多样性。陈述2错误：中国《中医药法》主要关注国内中医药事业发展、服务体系建设和政府规划管理，并未对外国销售经验设定此类强制性要求。中国对中药的批准主要基于传统使用、临床经验和国内研究。", "category": "Drugs", "related_concept": "supporting information submission, foreign marketing experience", "id": "PA_P_00006_002", "match_type": "weak", "match_score": 0.7114403728051812, "lang": "CN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_330OVER-THE-COUNTER_OTC_HUMAN_DRUGS_WHICH_ARE.txt", "old_id": "comp_0001_0002_2"}
{"question": "In comparing national approaches to cosmetic adverse reaction monitoring systems, which statement best describes a key difference between typical US and Chinese regulatory frameworks?", "choices": ["A. The US system relies primarily on post-market surveillance by manufacturers, while China establishes a centralized government-led monitoring network with designated national bases.", "B. China delegates all monitoring responsibilities to provincial authorities, while the US maintains exclusive federal control over all adverse reaction investigations.", "C. Both systems require identical reporting timelines and use the same standardized forms for all adverse events.", "D. The US system focuses only on carcinogenic ingredients, while China monitors all types of adverse reactions equally."], "answer": "A", "type": "Parallel", "explanation": "This question tests understanding of structural differences in monitoring systems. The US FDA operates a post-market surveillance system where manufacturers have primary reporting responsibilities, while China's NMPA (as implied by the context) establishes a more centralized, government-managed national monitoring system with designated bases, reflecting different regulatory philosophies and administrative structures.", "category": "Cosmetics", "related_concept": "national adverse reaction monitoring system", "id": "PA_P_00598_001", "match_type": "weak", "match_score": 0.6923319212599675, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0002_0003_1"}
{"question": "When a cosmetic ingredient's manufacturer changes its name or address, which regulatory system requires the submission of official documentation from the government or relevant authorities of the country of origin to prove the entity's continuity?", "choices": ["A. The US FDA system requires this for color additive certification updates.", "B. The Chinese NMPA system requires this for updating the registrant/filer information of a new cosmetic ingredient.", "C. Both the US FDA and Chinese NMPA systems require this type of documentation for any manufacturer change.", "D. Neither system requires official government documentation for such updates; a simple notification suffices."], "answer": "B", "type": "Parallel", "explanation": "The Chinese NMPA regulation explicitly requires that when the name or address of a new cosmetic ingredient registrant/filer changes, proof from the government or relevant agencies of the country/region must be provided to demonstrate the entity has not fundamentally changed. The provided US FDA text on color additives does not mention such a requirement for manufacturer information updates; it focuses on batch certification, identity, uses, and labeling.", "category": "Cosmetics", "related_concept": "information update requirements", "id": "PA_P_00617_006", "match_type": "weak", "match_score": 0.7333939492570869, "lang": "EN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0009_0020_1"}
{"question": "关于化妆品动物试验标准，中美法规在数据记录要求上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求记录每日每只动物的积分均值并保留两位小数，而美国法规对此无具体规定", "B. 美国法规要求对动物试验数据进行批次认证，而中国法规仅要求记录试验结论", "C. 中国法规要求试验动物必须来自特定许可证机构，而美国法规无此要求", "D. 美国法规要求皮肤刺激试验必须使用家兔，而中国法规允许使用其他动物"], "answer": "A", "type": "Parallel", "explanation": "中国法规在动物试验（如皮肤刺激试验）中通常对数据记录有具体规定，例如要求计算每日每只动物的积分均值并保留两位小数，体现了对试验过程数据记录的细致要求。美国法规（如FDA对化妆品颜色添加剂的规定）更侧重于产品的安全使用、标签和批次认证，对动物试验的具体数据记录格式通常不作统一规定，而是遵循良好实验室规范（GLP）等原则性要求。", "category": "Cosmetics", "related_concept": "animal test standards", "id": "PA_P_00637_019", "match_type": "weak", "match_score": 0.7298684217497523, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0034_0019_1"}
{"question": "关于强制隔离戒毒场所对戒毒人员的管理方式，中美法规在核心理念上存在差异。以下哪项最能体现中国法规中分级管理的核心原则？", "choices": ["A. 根据戒毒人员的性别、年龄、患病情况实行分别管理", "B. 根据戒毒治疗的不同阶段和人员表现实行逐步适应社会的分级管理", "C. 对吸食不同种类毒品者采取有针对性的治疗措施", "D. 允许严重疾病患者经批准后所外就医"], "answer": "B", "type": "Parallel", "explanation": "中国法规中的分级管理（graded management）核心在于根据戒毒治疗的不同阶段和强制隔离戒毒人员的表现，实行逐步适应社会的管理方式，这体现了动态调整和康复导向的理念。选项A是分别管理，C是针对性治疗，D是医疗处置，均不直接体现分级管理的核心原则。", "category": "Drug_Rehabilitation_Management", "related_concept": "graded management", "id": "PA_P_00696_010", "match_type": "weak", "match_score": 0.729339662800933, "lang": "CN", "source_cn": "戒毒条例.txt", "source_us": "PART_1300DEFINITIONS.txt", "old_id": "comp_0007_0002_1"}
{"question": "关于医疗器械质量管理体系，中美法规的主要差异体现在：", "choices": ["A. 中国法规侧重于运输贮存环节的具体操作要求，美国法规则基于ISO 13485标准构建体系框架", "B. 中国法规要求企业必须建立自动化仓库，美国法规对此没有强制规定", "C. 美国法规仅适用于三类医疗器械，中国法规适用于所有医疗器械", "D. 中国法规要求质量管理体系必须获得第三方认证，美国法规则不需要"], "answer": "A", "type": "Parallel", "explanation": "中国法规对医疗器械运输、贮存服务企业的质量管理提出了具体操作要求，如视频监控、温湿度监控、计算机信息系统等。美国法规则以ISO 13485质量管理体系标准为基础，要求制造商建立符合该标准的体系，并补充特定监管要求。选项B错误，中国法规鼓励但不强制自动化仓库；选项C错误，美国法规适用范围不限于三类器械；选项D错误，两国法规都未强制要求第三方认证。", "category": "Medical_Devices", "related_concept": "quality management system", "id": "PA_P_00514_007", "match_type": "weak", "match_score": 0.7355000577900845, "lang": "CN", "source_cn": "医疗器械经营质量管理规范附录：.txt", "source_us": "PART_820QUALITY_MANAGEMENT_SYSTEM_REGULATION_EFF_2.txt", "old_id": "comp_0011_0002_1"}
{"question": "Statement 1: Under Chinese regulations, if a non-standard test method is used for efficacy evaluation, the full text of that method must be archived with the test report. Statement 2: US regulations, as referenced, primarily specify that color additives like D&C Red No. 6 can be used in cosmetics generally, subject to good manufacturing practice and batch certification.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly reflects the Chinese requirement to archive the complete text of any non-standard test method used. Statement 2 accurately summarizes the core 'uses and restrictions' principle from the provided US text for color additives, which permits general use consistent with good manufacturing practice and requires certification. The statements correctly highlight a difference in focus: China's detailed rules on efficacy test documentation versus the US's principle-based approach for color additive use.", "category": "Cosmetics", "related_concept": "test methods and results, uses and restrictions", "id": "PA_P_00602_005", "match_type": "weak", "match_score": 0.7189163507259795, "lang": "EN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0002_0020_2"}
{"question": "关于化妆品中辅料（稀释剂）的法规管理，以下哪项描述最准确地反映了中美法规的常见差异？", "choices": ["A. 中国法规通常对辅料建立正面清单制度，美国法规则可能允许使用符合安全性要求的适宜辅料", "B. 美国法规禁止在化妆品中使用任何辅料，中国法规则允许自由添加", "C. 两国法规均要求所有辅料必须经过单独认证才能使用", "D. 中国法规对辅料的使用量没有限制，美国法规则有严格限量要求"], "answer": "A", "type": "Parallel", "explanation": "在美国FDA法规中（如对D&C Red No. 36和39的规定），对于色素添加剂混合物中使用的稀释剂，要求是“合适的（suitable）”且列在相应章节（如part 73）中“安全用于药物着色”的稀释剂，这体现了基于安全性评估的正面清单或认可列表的管理思路。中国化妆品法规对于原料（包括辅料）的管理，也日益趋向于建立和完善原料目录（正面清单）制度。但典型差异在于，美国此类规定常与具体产品类型（如药物用色素）绑定，并强调“适宜性”和“安全性”；中国法规则更倾向于在通用性原料安全技术规范或标准中规定。题目中A选项概括了这种基于安全性清单管理的常见模式差异。", "category": "Cosmetics", "related_concept": "diluent specifications", "id": "PA_P_00590_004", "match_type": "weak", "match_score": 0.7384851112445922, "lang": "CN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0002_0014_2"}
{"question": "关于健康养生/保健服务的规范制定，中美法规的主要区别是什么？", "choices": ["A. 中国法规明确由国务院中医药主管部门制定中医养生保健服务的规范和标准；而美国法规中，此类非治疗性的健康服务规范通常不由FDA以药品监管法规的形式统一制定。", "B. 中国法规由省级政府各自制定养生保健标准；美国法规则由FDA统一制定全国性的保健品服务标准。", "C. 中国法规不涉及养生保健服务规范；美国法规则由FDA详细规定各类健康促进服务的操作标准。", "D. 两国法规均明确规定，由中央/联邦药品监管机构负责制定所有健康养生服务的强制性国家标准。"], "answer": "A", "type": "Parallel", "explanation": "中国《中医药法》第四十四条明确规定：“中医养生保健服务规范、标准由国务院中医药主管部门制定。”这赋予了国家中医药管理局在中医养生保健领域制定行业规范和标准的法定职责。在美国，FDA的监管核心是药品、医疗器械、食品（包括膳食补充剂）等产品。对于非产品性质的“健康养生服务”（如按摩、健身指导等），其规范通常由州级政府、专业协会或通过其他法律（如消费者保护法）来管理，而非由FDA依据药品法规进行统一规制。选项A准确捕捉了这一监管权限和范围的根本差异。", "category": "Drugs", "related_concept": "health preservation service standards", "id": "PA_P_00010_005", "match_type": "weak", "match_score": 0.7169394057387558, "lang": "CN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0010_0008_3"}
{"question": "关于化妆品标签上生产商主要营业场所的标注，请判断以下陈述：\n陈述1：根据中国法规，化妆品标签必须标注产品的实际生产地址。\n陈述2：根据美国法规，在某些条件下，化妆品标签可以标注主要营业场所而非实际生产地址。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误。提供的中国法规文本主要关注功效宣称评价摘要，未直接规定标签上的地址标注要求。中国《化妆品监督管理条例》及标签管理规定通常要求标注生产企业的名称和地址。陈述2正确。美国法规明确允许，如果化妆品在主要营业场所以外的地方生产、包装或分销，只要不会产生误导，标签上可以声明主要营业场所来代替实际地点。", "category": "Cosmetics", "related_concept": "principal place of business labeling", "id": "PA_P_00604_004", "match_type": "weak", "match_score": 0.7212471404943008, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0012_0007_2"}
{"question": "In regulatory frameworks for cosmetics, which approach to platform management obligations is more likely to involve direct administrative penalties for failure to perform duties such as inspection and reporting?", "choices": ["A. The approach that treats platform operators as intermediaries with limited liability", "B. The approach that imposes specific fines and operational restrictions on platform operators", "C. The approach that relies primarily on post-market surveillance and voluntary compliance", "D. The approach that delegates all enforcement to industry self-regulatory bodies"], "answer": "B", "type": "Parallel", "explanation": "The Chinese regulatory approach typically imposes direct administrative penalties, including fines and operational restrictions, on platform operators (like market organizers and e-commerce platforms) for failing to fulfill specific management obligations such as inspection, reporting, and stopping violations. This contrasts with approaches that might rely more on intermediary liability models, voluntary compliance, or industry self-regulation without direct administrative fines.", "category": "Cosmetics", "related_concept": "platform management obligations", "id": "PA_P_00679_001", "match_type": "weak", "match_score": 0.6870844683549887, "lang": "EN", "source_cn": "化妆品监督管理条例 (1).txt", "source_us": "PART_81GENERAL_SPECIFICATIONS_AND_GENERAL_RESTRICT.txt", "old_id": "comp_0022_0003_1"}
{"question": "A medical device manufacturer is developing a new product for both the US and Chinese markets. Regarding the composition of the device's official name, which regulatory approach is correct?", "choices": ["A. The US requires a core word with up to three feature words, while China requires English-only names with symbols.", "B. China requires a core word with up to three feature words, while the US has no specific structural requirements for device names.", "C. Both regulations require identical naming structures with core and feature words.", "D. The US mandates Chinese language names, while China allows symbols without explanatory text."], "answer": "B", "type": "Parallel", "explanation": "Chinese regulations specifically require medical device general names to be composed of one core word and generally no more than three feature words that describe characteristics like use location, structural features, technical characteristics, or material composition. US regulations do not specify such structural requirements for device names, focusing instead on labeling language requirements and symbol usage specifications.", "category": "Medical_Devices", "related_concept": "naming composition, core and feature words", "id": "PA_P_00541_001", "match_type": "weak", "match_score": 0.7325607601175604, "lang": "EN", "source_cn": "医疗器械通用名称命名规则（2015年第19号令）.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0001_0005_1"}
{"question": "In regulatory frameworks for cosmetics, which approach to human trial duration and adverse reaction monitoring is typically mandated for safety assessment?", "choices": ["A. Minimum trial duration with periodic observation of skin reactions", "B. No specific duration requirement with continuous monitoring", "C. Trial duration based on product type with daily observation", "D. Optional trial duration with endpoint-only assessment"], "answer": "A", "type": "Parallel", "explanation": "Regulatory frameworks often specify minimum trial durations (e.g., at least 4 weeks) with periodic observation (e.g., weekly) to systematically monitor adverse reactions like skin responses, ensuring comprehensive safety data collection over a defined period.", "category": "Cosmetics", "related_concept": "human trial duration, skin reaction observation", "id": "PA_P_00641_013", "match_type": "weak", "match_score": 0.7046794552564835, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0054_0003_1"}
{"question": "关于化妆品用着色剂的认证要求，以下哪项描述最准确地反映了中美法规的异同？", "choices": ["A. 中国要求所有着色剂每批均需经指定机构检验并出具报告，美国则无此类强制性批次认证", "B. 美国FDA要求某些着色剂（如D&C、Ext. D&C系列）每批必须经FDA认证，中国对着色剂的监管主要通过原料清单和规格标准进行", "C. 两国均要求所有化妆品着色剂在进口时每批提交样品进行官方测试认证", "D. 中国对着色剂实行备案管理，美国对着色剂实行自由销售，均无需批次认证"], "answer": "B", "type": "Parallel", "explanation": "美国FDA对用于食品、药品和化妆品的着色剂（特别是煤焦油类着色剂，如D&C Violet No. 2）有严格的批次认证（certification）要求，每批产品必须由FDA检测并认证符合规格后方可使用。中国对化妆品着色剂的监管主要依据《化妆品安全技术规范》中的《化妆品禁用原料目录》《化妆品限用原料目录》和《化妆品准用着色剂目录》等，要求着色剂符合规定的质量规格，但并未像美国那样对特定着色剂设立强制性的、每批由监管机构进行的认证程序。中国的符合性通常通过生产商质量控制、原料供应商报告或必要的注册备案检验来体现。", "category": "Cosmetics", "related_concept": "certification requirement", "id": "PA_P_00637_023", "match_type": "weak", "match_score": 0.7081736505764256, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0032_0023_3"}
{"question": "关于环境病原体的定义，中美药监法规的侧重点有何不同？", "choices": ["A. 中国法规强调病原体在食品加工环境中的存活能力，美国法规则关注其是否会导致食源性疾病", "B. 美国法规明确列举了具体病原体（如李斯特菌），中国法规则未提供具体示例", "C. 中国法规要求对所有环境病原体进行强制性检测，美国法规则允许基于风险评估", "D. 美国法规将环境病原体定义为所有可能污染食品的微生物，中国法规则仅限于细菌"], "answer": "B", "type": "Parallel", "explanation": "美国FDA法规（如21 CFR Part 1）在定义环境病原体时，通常会明确列举示例（如李斯特菌、沙门氏菌），以提供具体指导。而中国NMPA相关法规（如《食品安全国家标准》）在定义类似概念时，通常采用更原则性的描述，较少直接列举具体病原体种类，更侧重于通用要求和风险控制原则。", "category": "General_FDA", "related_concept": "environmental pathogen definition", "id": "PA_P_00770_004", "match_type": "weak", "match_score": 0.6765810234667524, "lang": "CN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0002_0043_1"}
{"question": "In regulatory frameworks governing administrative procedures, which approach best describes the principle of non-discrimination?", "choices": ["A. All applicants meeting legal standards must have equal opportunity to obtain approvals, with no discrimination permitted", "B. Agencies may prioritize applications based on public interest considerations while maintaining basic fairness", "C. Discrimination is prohibited only when explicitly stated in procedural regulations", "D. Equal treatment applies only to procedural aspects, not substantive approval decisions"], "answer": "A", "type": "Parallel", "explanation": "The non-discrimination principle in administrative law requires that all qualified applicants have equal rights to obtain approvals without discrimination. This ensures fairness in regulatory processes and prevents arbitrary decision-making by authorities.", "category": "General_FDA", "related_concept": "non-discrimination principle", "id": "PA_P_00797_001", "match_type": "weak", "match_score": 0.7473150765483156, "lang": "EN", "source_cn": "中华人民共和国行政许可法.txt", "source_us": "PART_10ADMINISTRATIVE_PRACTICES_AND_PROCEDURES.txt", "old_id": "comp_0001_0018_1"}
{"question": "关于防晒产品SPF值计算中算术均数的应用，中美法规在最终结果呈现上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求计算全部受试者SPF值的算术均数后取整数部分作为最终值，而美国法规无此特定要求。", "B. 美国法规要求SPF值必须精确到小数点后一位，而中国法规允许取整数。", "C. 两国法规都要求计算算术均数，但中国法规额外要求计算95%可信区间以评估数据可靠性。", "D. 美国法规要求SPF值必须基于至少25名受试者的算术均数，而中国法规无最低人数限制。"], "answer": "C", "type": "Parallel", "explanation": "中国法规明确要求计算被测物防护全部受试者SPF值的算术均数，并取整数部分作为最终SPF值，同时要求计算均数的95%可信区间（95%CI）以评估抽样误差，确保不超过均数的17%。美国法规文本主要关注色素添加剂的安全性评估原则（如安全系数应用、安全性测试要求等），并未针对防晒产品SPF值的具体计算方法和最终呈现格式（如是否取整、是否计算可信区间）做出与中国法规相对应的详细规定。因此，两国法规在SPF值计算的具体数据处理和可靠性验证环节存在差异。", "category": "Cosmetics", "related_concept": "SPF calculation, arithmetic mean", "id": "PA_P_00642_044", "match_type": "weak", "match_score": 0.668742140787648, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0073_0004_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中国药品监督管理法规，GLP机构在证书有效期内发生质量管理体系相关重大变更时，需在规定时限内向省级药监部门报告，主管部门经审查可能要求限期改正。\n陈述2：根据美国FDA法规，当ANDA申请人提交特定专利无效声明且符合通知要求时，申请可立即获批，无需等待固定的30个月诉讼期。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规（对应文本CN第二十七条）要求GLP机构在发生相关变更后20日内报告，省级药监部门审查后必要时可要求限期改正。这体现了动态监管原则。\n陈述2正确：美国法规（对应文本US第(2)段）明确规定，当申请人提交Paragraph IV专利认证（声明专利无效、不可执行或不侵权）并履行了通知义务后，ANDA或505(b)(2)申请可立即批准，此时不适用45天诉讼提起期或30个月等待期。这体现了其专利链接制度下的例外情形。", "category": "Drugs", "related_concept": "change processing within 30 days, patent certification, patent litigation disposition", "id": "PA_P_00336_002", "match_type": "weak", "match_score": 0.7012685219609188, "lang": "CN", "source_cn": "药物非临床研究质量管理规范认证.txt", "source_us": "PART_314APPLICATIONS_FOR_FDA_APPROVAL_TO_MARKET_A_.txt", "old_id": "comp_0006_0059_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在美国FDA的法规框架下，如果专员审查后认为提交的批次认证请求不符合要求，他必须拒绝认证并说明理由，同时申请人有权要求举行监管听证会。\n陈述2：在中国NMPA的法规框架下，化妆品人体试验的结果报告必须由具有相应资质的注册和备案检验检测机构出具并盖章。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。根据美国法规文本，若专员认定请求或批次不符合要求，应拒绝认证并通知申请人说明理由，且申请人有权依据相关章节要求举行监管听证会（Regulatory Hearing）。这体现了程序正当性和申诉机制。陈述2正确。根据中国法规文本中“注册和备案检验检测机构全称”及“检验报告”的上下文，可以推断此类正式的人体皮肤试验报告需由官方认可或指定的检验机构出具，这是中国化妆品注册备案体系的典型要求。因此，两个陈述都正确。", "category": "Cosmetics", "related_concept": "certificate issuance, regulatory hearing, registration and filing inspection agency", "id": "PA_P_00639_010", "match_type": "weak", "match_score": 0.7206579547762448, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0051_0001_2"}
{"question": "Statement 1: In the US, a color additive can be listed for general use in cosmetics only if the Commissioner finds it suitable and safe for that broad application based on all scientific data presented.\nStatement 2: In China, a safety assessment report for a cosmetic ingredient must be issued by a registered or filing inspection and testing institution, and include specific in vitro mammalian cell tests as part of the standard data requirements.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly reflects the US 'safe-for-use' principle from §70.42(a), where listing for general use requires a finding of suitability and safety. Statement 2 correctly describes the Chinese regulatory expectation: the need for a formal inspection report (检验报告) from an authorized institution (注册和备案检验检测机构) and the reference to specific tests like the '体外哺乳动物细胞基因突变试验' (in vitro mammalian cell gene mutation test) indicates standard genotoxicity data requirements.", "category": "Cosmetics", "related_concept": "color additive listing conditions, 检验报告, 注册和备案检验检测机构", "id": "PA_P_00642_024", "match_type": "weak", "match_score": 0.612465759624019, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0044_0004_2"}
{"question": "关于化妆品生产中的杂质限量管理，中美法规在合规逻辑上存在显著差异。以下哪项最能体现这种差异？", "choices": ["A. 中国法规强调对主观过错的认定，而美国法规直接设定具体化学物质的数值上限", "B. 中国法规要求所有杂质必须完全消除，而美国法规允许一定比例的杂质存在", "C. 美国法规仅关注重金属限量，中国法规则涵盖所有类型的杂质", "D. 中国法规的杂质标准比美国法规更为宽松和模糊"], "answer": "A", "type": "Parallel", "explanation": "中国化妆品监督管理条例第六十二条规定，当事人有证据足以证明没有主观过错的，不予行政处罚，体现了过错责任原则。而美国FDA对D&C Red No. 22等色素添加剂的规定，直接列出了20多种具体化学成分的百分比或ppm限量值（如铅≤20ppm、砷≤3ppm），属于典型的客观标准管理。两者分别代表了“主观过错认定”和“客观数值合规”两种不同的监管逻辑。", "category": "Cosmetics", "related_concept": "impurity limits, no penalty without subjective fault", "id": "PA_P_00661_021", "match_type": "weak", "match_score": 0.7275532982770672, "lang": "CN", "source_cn": "化妆品生产经营监督管理办法（2021年第46号）.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0018_0012_1"}
{"question": "关于医疗器械临床试验基本文件的保存责任，以下哪项描述最准确地体现了中美法规的差异？", "choices": ["A. 中国法规明确规定了研究者、临床试验机构和伦理委员会的具体保存责任与期限，而美国法规主要关注在特定监管指令（如扣留令）下的记录保存要求。", "B. 两国法规均要求申办者永久保存临床试验基本文件，直至产品停止使用。", "C. 美国法规要求研究者个人承担主要文件保存责任至试验结束后10年，而中国法规则未对此做出规定。", "D. 中国和美国法规都规定，所有临床试验记录的保存期限统一为试验完成后2年。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（NMPA）对医疗器械临床试验基本文件的保存责任主体（研究者、机构、伦理委员会、申办者）和具体期限（如机构保存10年，申办者保存至无该器械使用）有明确分层规定。美国法规（FDA）提供的文本片段主要涉及在特定监管行动（如扣留令）下相关记录的保存要求（通常最多2年），这属于合规性记录范畴，与全面的临床试验基本文件管理体系侧重点不同。选项B错误，因为美国文本未提及申办者永久保存；选项C错误，因为美国文本未指定研究者个人责任及10年期限；选项D错误，因为两国法规的保存期限规定不同且取决于具体情境。", "category": "Medical_Devices", "related_concept": "investigator responsibility, file preservation period", "id": "PA_P_00403_001", "match_type": "weak", "match_score": 0.7423128375385728, "lang": "CN", "source_cn": "医疗器械临床试验质量管理规范.txt", "source_us": "PART_800GENERAL.txt", "old_id": "comp_0019_0007_1"}
{"question": "Statement 1: Both US and Chinese regulations prohibit misleading statements about medical devices in labeling. Statement 2: Both regulations allow symbols without adjacent explanatory text under all circumstances.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct as both US regulations (specifically §801.6) and Chinese regulations (which require names to be scientific, clear, and consistent with product attributes) prohibit misleading statements about medical devices. Statement 2 is incorrect because while US regulations allow symbols without adjacent explanatory text under specific conditions (such as when included in recognized standards with proper glossary references), Chinese regulations require medical device general names to use Chinese language that complies with national language norms, with no provisions for symbol-only labeling.", "category": "Medical_Devices", "related_concept": "misleading statements prohibition, symbol usage specifications, general name requirement", "id": "PA_P_00541_002", "match_type": "weak", "match_score": 0.7325607601175604, "lang": "EN", "source_cn": "医疗器械通用名称命名规则（2015年第19号令）.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0001_0005_2"}
{"question": "在化妆品监管中，关于商业秘密保护的责任主体，以下哪项描述最准确地反映了中美法规的异同？\n陈述1：中国法规明确禁止药品监督管理部门及专业技术机构工作人员擅自披露商业秘密。\n陈述2：美国法规在色素添加剂审批中，未对受理申请的FDA官员设定类似的商业秘密保密义务。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：中国《化妆品监督管理条例》第五十六条明确规定，负责药品监督管理的部门、专业技术机构及其工作人员，未经同意不得披露在监督检查中知悉的商业秘密。陈述2错误：美国法规（如《联邦食品、药品和化妆品法案》及实施条例）普遍包含对政府机构及其工作人员保护商业机密信息的法定要求，这在FDA的色素添加剂等审批程序中同样适用，并非没有设定保密义务。", "category": "Cosmetics", "related_concept": "trade secret confidentiality", "id": "PA_P_00666_005", "match_type": "weak", "match_score": 0.7262080695421185, "lang": "CN", "source_cn": "化妆品生产经营监督管理办法（2021年第46号）.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0016_0004_2"}
{"question": "关于物料记录的保存与管理，请判断以下陈述：\n陈述1：中国法规要求，物料名称若使用代码标示，必须制定代码对照表以确保可追溯性。\n陈述2：美国法规要求，色料添加剂的处置记录必须与其他所有记录分开保存。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。中国法规（第三十一条）明确规定：“物料名称用代码标示的，应当制定代码对照表，原料代码应当明确对应的原料标准中文名称。”这是确保物料标识清晰、可追溯的重要措施。\n陈述2正确。美国法规（§ 80.39(c)）明确规定：“The records required to be kept by paragraph (a) of this section shall be kept separately from all other records.” 即要求色料添加剂的处置记录必须与其他所有记录分开保存。这体现了对关键物料记录的隔离管理要求。因此，两个陈述都正确。", "category": "Cosmetics", "related_concept": "record segregation", "id": "PA_P_00668_004", "match_type": "weak", "match_score": 0.743629626545878, "lang": "CN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0010_0004_2"}
{"question": "关于研究时限的延长，中美法规程序的主要区别体现在？", "choices": ["A. 美国法规规定了在FDA同意延长研究时限后，制造商需重新提交包含新时限的证明的具体程序；中国提供的法规文本未涉及研究时限延长的具体监管程序。", "B. 中国法规规定所有研究项目均可自动无限期延长；美国法规则禁止任何形式的研究时限延长。", "C. 中国法规要求研究时限延长必须由全国人大批准；美国法规则由制药公司内部决定即可。", "D. 两国法规对于研究时限延长的要求和程序完全相同，都需要监管机构的事先书面批准。"], "answer": "A", "type": "Parallel", "explanation": "美国FDA法规（21 CFR 99.403引用的章节）明确规定了时限延长的程序：当FDA延长了完成研究和提交补充申请的时间后，制造商必须根据§99.201(a)(4)(ii)(B)提交一份新的证明，其中列明完成临床研究和提交申请的新时间框架。这是一个清晰、步骤化的监管要求。而所提供的中国《中医药法》章节主要聚焦于中医药的传承、文化传播和保障措施，并未涉及具体科研项目（如药物临床试验）的研究时限及其延长在监管层面的程序性规定。两者在文本内容和监管细节的呈现上存在明显差异。", "category": "Drugs", "related_concept": "extension of study timeframe", "id": "PA_P_00010_007", "match_type": "weak", "match_score": 0.7169394057387558, "lang": "CN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0010_0008_5"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据相关法规原则，如果一种已获批准用于化妆品的颜色添加剂因其安全性问题被撤销许可，那么所有含有该添加剂的已上市化妆品会立即被自动视为掺假产品。\n陈述2：在监管行动中，如果企业认为FDA暂停其颜色添加剂认证服务的决定不当，该企业有权要求举行监管听证会进行申辩。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "D", "type": "Parallel", "explanation": "陈述1错误。美国法规（US）文本明确指出，当颜色添加剂的许可状态发生变化（如被撤销）时，使用该添加剂的食品、药品或化妆品并不会仅仅因此自动被视为掺假。法规设定了例外情况，即只有当健康危害大到现有库存无法安全使用时，监管机构才会做出相应认定并发布专门规定。这体现了法规的合理性和过渡期管理原则。\n陈述2正确。美国法规（US）文本在§ 80.34(b)中明确规定，任何对暂停认证服务有异议的人，都有机会依据相关章节要求，在FDA举行监管听证会。这保障了行政相对人的程序性权利。", "category": "Cosmetics", "related_concept": "adulterated status change, regulatory hearing opportunity", "id": "PA_P_00620_002", "match_type": "weak", "match_score": 0.7282082959026532, "lang": "CN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0007_0003_2"}
{"question": "Which regulatory approach to postmarket surveillance emphasizes proactive risk identification through designated data collection points, while the other focuses on verifying compliance through facility and record inspections?", "choices": ["A. The US FDA approach emphasizes proactive risk identification through sentinel points, while the Chinese NMPA focuses on compliance verification through inspections.", "B. The Chinese NMPA approach emphasizes proactive risk identification through sentinel points, while the US FDA focuses on compliance verification through inspections.", "C. Both regulatory systems prioritize proactive risk identification through sentinel points over compliance inspections.", "D. Neither system uses sentinel points; both rely exclusively on manufacturer-submitted reports and random inspections."], "answer": "B", "type": "Parallel", "explanation": "The Chinese NMPA system explicitly establishes 'monitoring sentinel points' (监测哨点) to actively collect data for risk evaluation, representing a proactive surveillance model. The US FDA regulations focus on the agency's authority to inspect manufacturing sites and copy records to verify compliance with postmarket surveillance plans, representing a compliance verification model.", "category": "Medical_Devices", "related_concept": "monitoring sentinel points, manufacturing site inspection", "id": "PA_P_00391_001", "match_type": "weak", "match_score": 0.7491517747275017, "lang": "EN", "source_cn": "医疗器械不良事件监测和再评价管理办法（2018年第1号令）.txt", "source_us": "PART_822POSTMARKET_SURVEILLANCE.txt", "old_id": "comp_0014_0006_1"}
{"question": "关于化妆品原料安全资料的真实性与合规性要求，中美两国法规在责任主体和证明方式上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求原料生产商通过提交《企业信息表》和承诺书，对资料真实性承担法律责任；美国法规要求提交支持性数据时，必须声明非临床研究是否符合GLP规范。", "B. 中国法规要求注册人/备案人对原料资料真实性负责；美国法规要求原料生产商对临床研究合规性负责。", "C. 中国法规要求所有原料资料必须经过第三方认证；美国法规仅要求对变更资料进行合规声明。", "D. 中国法规要求原料安全信息必须公开；美国法规要求所有研究数据必须提交给FDA备案。"], "answer": "A", "type": "Parallel", "explanation": "中国法规通过《原料安全相关信息备案企业信息表》及附带的承诺书，明确要求原料生产商（或被授权企业）对提交资料的真实合法性承担法律责任，这是一种事前承诺备案机制。美国法规（21 CFR 10.30(b)）则规定，在提交支持性数据（如非临床实验室研究）时，必须声明该研究是否符合GLP（良好实验室规范，part 58）的要求，这是一种针对研究过程合规性的声明要求。两者在责任主体（生产商 vs. 数据提交方）和证明焦点（整体资料真实性承诺 vs. 特定研究合规性声明）上体现了不同的监管逻辑。", "category": "Cosmetics", "related_concept": "安全资料真实合法, nonclinical laboratory study compliance", "id": "PA_P_00659_006", "match_type": "weak", "match_score": 0.6373926376727486, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0047_0001_1"}
{"question": "Consider the following statements about contact information maintenance in cosmetic product establishment registration:\n\nStatement 1: In China's regulatory system, registrants must maintain and update contact information through a self-maintenance process, with separate requirements for mobile phone, landline, email, and fax numbers.\n\nStatement 2: In the US regulatory system, any change to establishment information, including contact details, requires submission of an amended registration form within 30 days of the change.\n\nWhich option correctly evaluates these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: China NMPA requires registrants to maintain contact information through a self-maintenance process with specific fields for different contact methods. Statement 2 is correct: US FDA requires submission of an amended Form FD-2511 within 30 days after any change to the information contained in the original registration, which would include contact information changes.", "category": "Cosmetics", "related_concept": "Contact information maintenance", "id": "PA_P_00652_007", "match_type": "weak", "match_score": 0.678616435033923, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0029_0001_2"}
{"question": "Statement 1: The US FDA requires clinical validation results to demonstrate both clinical sensitivity and specificity for test values based on disease presence/absence. Statement 2: The Chinese NMPA evaluates trial results based on comprehensive verification of implementation processes and data integrity against trial protocols and regulatory requirements.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes FDA requirements for clinical performance validation including sensitivity/specificity demonstration. Statement 2 accurately characterizes NMPA's approach focusing on verifying trial implementation processes, data integrity, and compliance with protocols and regulations.", "category": "Medical_Devices", "related_concept": "result determination principles", "id": "PA_P_00404_002", "match_type": "weak", "match_score": 0.7477805874060952, "lang": "EN", "source_cn": "医疗器械临床试验项目检查要点.txt", "source_us": "PART_866IMMUNOLOGY_AND_MICROBIOLOGY_DEVICES.txt", "old_id": "comp_0001_0025_2"}
{"question": "Statement 1: Under Chinese regulations, when an applicant disputes a comprehensive assessment result, the authority must organize an expert consultation committee within 50 days of receiving the request. Statement 2: Under US regulations, applicants may incorporate by reference previously submitted raw data when requesting a hearing, provided the data was part of a prior application or report.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 accurately reflects the Chinese requirement that the authority must organize an expert consultation committee within 50 days of receiving the applicant's request following a dispute. Statement 2 correctly describes the US provision allowing incorporation by reference of previously submitted raw data when requesting a hearing.", "category": "Drugs", "related_concept": "expert consultation committee organization within 50 days, incorporation by reference of data", "id": "PA_P_00208_002", "match_type": "weak", "match_score": 0.7151453350767615, "lang": "EN", "source_cn": "药品注册审评结论异议解决程序（试行）.txt", "source_us": "PART_314APPLICATIONS_FOR_FDA_APPROVAL_TO_MARKET_A_.txt", "old_id": "comp_0002_0072_2"}
{"question": "In comparing US and Chinese regulations for controlled substances, which statement best describes the approach to experimental research management?", "choices": ["A. Both systems require pre-approval for all experimental research on controlled substances, but China specifically defines experimental research as preclinical studies for drug registration purposes.", "B. The US system focuses on quota hearings for manufacturing and procurement, while China requires explicit approval for experimental research on listed substances and those with dependency potential.", "C. China's regulations emphasize applicant responsibility after approval, whereas the US system places the burden of proof on the Administration during quota hearings.", "D. Both systems allow for regulatory flexibility through waiver provisions, but only the US system includes specific hearing procedures for quota adjustments."], "answer": "B", "type": "Parallel", "explanation": "The Chinese regulation explicitly requires approval for experimental research on listed controlled substances and those with dependency potential, defining experimental research as preclinical studies for drug registration. The US regulation focuses on hearings related to manufacturing, procurement, and import quotas rather than experimental research approval. Option A is incorrect because the US text doesn't mention experimental research approval requirements. Option C describes true elements but doesn't capture the fundamental difference in regulatory focus. Option D incorrectly suggests both systems have waiver provisions for experimental research management.", "category": "Controlled_Substances", "related_concept": "experimental research management", "id": "PA_P_00721_001", "match_type": "weak", "match_score": 0.7273108254843883, "lang": "EN", "source_cn": "麻醉药品和精神药品实验研究管理规定.txt", "source_us": "PART_1315IMPORTATION_AND_PRODUCTION_QUOTAS_FOR_EPH.txt", "old_id": "comp_0001_0010_1"}
{"question": "关于兽用麻黄素类原料药及制剂的生产经营监管，以下两个陈述是否正确？\n陈述1：根据中国法规，兽药生产企业购用盐酸麻黄素原料药需同时遵守农业部和国家药监局的联合规定。\n陈述2：美国法规对兽用麻醉药品的监管完全由食品药品监督管理局统一负责，不涉及农业部。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：中国法规明确规定对兽药生产企业购用盐酸麻黄素原料药以及兽用盐酸麻黄素注射液生产、经营等的监督管理，按照农业部和国家食品药品监督管理局的规定执行，体现了部门协同监管。\n陈述2错误：美国对兽用药品的监管同样涉及多部门，兽用麻醉药品的监管并非完全由FDA统一负责。例如，美国农业部（USDA）在动物健康、兽药残留等方面有监管职责，与FDA存在协作关系。陈述2的“完全由FDA统一负责”表述不准确。", "category": "Veterinary_Drugs", "related_concept": "supervision of veterinary drug production", "id": "PA_P_00717_002", "match_type": "weak", "match_score": 0.7243081525191875, "lang": "CN", "source_cn": "药品类易制毒化学品管理办法（卫生部令第72号_2010年）.txt", "source_us": "PART_1311REQUIREMENTS_FOR_ELECTRONIC_ORDERS_AND_PR.txt", "old_id": "comp_0016_0011_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在药品质量控制中，系统适用性测试（如HPLC系统适用性）的主要目的是确保分析仪器和方法在分析前处于受控状态，以获得可靠数据。\n陈述2：根据风险管理原则，识别出的风险控制措施应体现在试验方案设计、监查计划以及标准操作规程的依从性等多个方面。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。系统适用性测试是分析化学中的通用要求，旨在验证色谱系统（如分辨率、精密度）是否适合进行样品分析，这是确保数据可靠性的关键步骤，与美国法规中描述的HPLC系统适用性测试（如计算分辨率、检查相对标准偏差）的逻辑一致。\n陈述2正确。这是基于风险的质量管理（QRM）的通用原则。中国法规明确指出，减少风险的控制措施应当体现在试验方案的设计和实施、监查计划、标准操作规程的依从性等多个层面。这体现了风险控制措施的综合性。两个陈述分别对应了“系统适用性测试”和“风险控制措施”的核心原则，且均正确。", "category": "Drugs", "related_concept": "system suitability testing, risk control measures", "id": "PA_P_00315_002", "match_type": "weak", "match_score": 0.7219982427811855, "lang": "CN", "source_cn": "药物临床试验质量管理规范.txt", "source_us": "PART_201LABELING.txt", "old_id": "comp_0017_0079_2"}
{"question": "针对医疗器械可能危害人体健康的风险，中美监管机构均可采取紧急控制措施。请判断以下陈述：\n陈述1：中国法规允许药品监督管理部门在发现可能危害人体健康的证据时，采取暂停生产、进口、经营、使用的措施。\n陈述2：美国法规规定，如果监督计划被拒绝或未按批准计划执行，FDA可启动针对掺假或冒牌设备的行动，包括扣押设备。", "choices": ["A. 两个陈述都正确", "B. 只有陈述1正确", "C. 只有陈述2正确", "D. 两个陈述都不正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规（NMPA）明确授权药品监督管理部门在有证据证明可能危害人体健康时，采取暂停生产、进口、经营、使用的紧急控制措施。陈述2正确：美国法规（FDA）规定，如果企业未能提交或执行批准的监督计划，可能导致设备被视为掺假或冒牌，FDA有权启动执法行动，包括扣押设备。这体现了双方在应对安全风险时都具备采取紧急控制措施的权力。", "category": "Medical_Devices", "related_concept": "emergency control measures for safety risks", "id": "PA_P_00475_016", "match_type": "weak", "match_score": 0.7471626347595011, "lang": "CN", "source_cn": "医疗器械生产监督管理办法（2022年第53号令）.txt", "source_us": "PART_822POSTMARKET_SURVEILLANCE.txt", "old_id": "comp_0019_0003_2"}
{"question": "关于化妆品企业关键岗位的职责分离原则，以下哪项描述最准确地反映了中美法规的共同要求？", "choices": ["A. 质量管理部门负责人可以兼任生产部门负责人，但需确保职责不冲突", "B. 质量安全负责人可以将其法律责任完全转移给被指定人员", "C. 质量管理部门负责人与生产部门负责人应由不同人员担任，以确保独立监督", "D. 生产部门负责人需对产品质量文件的最终审核负责"], "answer": "C", "type": "Parallel", "explanation": "中美化妆品法规均强调质量与生产职能的分离原则。中国法规明确规定质量安全负责人、质量管理部门负责人不得兼任生产部门负责人，以确保质量监督的独立性。美国CGMP（现行药品生产质量管理规范）虽未在本题文本中直接体现，但其核心原则同样要求质量部门独立于生产部门，这是全球药品和化妆品质量管理的基本要求。选项A违反职责分离原则；选项B错误，因为质量安全负责人的法律责任不转移；选项D属于质量部门职责，不应由生产部门负责。", "category": "Cosmetics", "related_concept": "non-concurrent roles", "id": "PA_P_00667_004", "match_type": "weak", "match_score": 0.7454394300032434, "lang": "CN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0003_0005_1"}
{"question": "关于检查任务的指派，中美药监法规在程序上存在差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规要求检查机构在接到任务时，必须获得被检查对象的全部信息；美国法规则无此要求。", "B. 中国法规明确规定了上级部门向检查机构交办任务时需提供信息和明确要求；美国法规则未详细规定此类行政指派程序。", "C. 美国法规要求检查任务必须由专员个人决定启动；中国法规则要求必须由检查机构集体决定。", "D. 两国法规在检查任务指派程序上完全一致，均要求书面授权和明确范围。"], "answer": "B", "type": "Parallel", "explanation": "解析：中国法规（如NMPA相关规章）通常对药品监督管理部门向检查机构交办检查任务的程序有明确规定，包括提供被检查对象信息和明确检查要求，这体现了行政层级和任务下发的规范性。而美国FDA的相关法规（如21 CFR部分）在描述检查或认证活动时，通常更侧重于专员（Commissioner）的职权和决定过程，对于“任务指派”这一内部行政程序的细节规定相对较少，更多体现在对检查员资质和检查行为本身的要求上。选项A过于绝对（“必须获得全部信息”不准确），选项C（“必须由专员个人决定”）是对美国法规中专员职权的片面理解，选项D与事实不符。", "category": "General Pharmaceutical/Color Additive Regulation", "related_concept": "inspection task assignment", "id": "PA_P_00632_001", "match_type": "weak", "match_score": 0.7356040608795475, "lang": "CN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0003_0001_1"}
{"question": "关于药品信号检测的触发与频率，中美法规在监管逻辑上存在显著差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规强调基于产品生命周期和风险特征的主动、周期性检测，而美国法规更侧重于临床试验期间基于研究方案的被动监测。", "B. 中国法规要求对所有上市药品进行统一的年度信号检测，而美国法规仅要求对高风险药品进行不定期检测。", "C. 中国法规的信号检测完全依赖人工审阅报告，而美国法规强制要求使用计算机数据挖掘技术。", "D. 美国法规要求信号检测必须由独立的第三方机构执行，而中国法规允许持有人自行开展。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如NMPA相关指南）明确要求持有人主动、定期开展信号检测，其频率需根据药品上市时间、特点（如创新药）、风险特征及监管要求等因素动态调整，体现了基于风险管理的主动监测逻辑。美国法规（如FDA对IND的要求）在题干相关文本中，其核心语境是临床试验申请（IND），对上市后安全监测（如信号检测）的详细规定通常在其他章节（如Postmarketing Safety Reporting）。在IND框架下，对安全性的观察更侧重于按既定研究方案在试验期间收集数据，是一种与研究进程绑定的、相对被动的监测模式。两者反映了对上市后阶段与临床研究阶段不同的安全监管思路。", "category": "Drugs", "related_concept": "signal detection", "id": "PA_P_00324_009", "match_type": "weak", "match_score": 0.7423792316511116, "lang": "CN", "source_cn": "药物警戒质量管理规范.txt", "source_us": "PART_312INVESTIGATIONAL_NEW_DRUG_APPLICATION.txt", "old_id": "comp_0011_0004_1"}
{"question": "请判断以下关于中美化妆品监管中调查与程序时限的陈述：\n陈述1：中国法规为特定化妆品安全风险调查设定了明确的完成时限，并可因特殊原因申请延长。\n陈述2：美国法规中，若对已提交的申请进行实质性修订，将导致审查时钟重新开始计算。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规明确规定，针对风险监测发现问题的调查处理工作应当在90日内完成，并规定了因特殊原因需要延长时的报告程序。\n陈述2正确：美国法规规定，如果申请者提交的补充信息或数据被认定为实质性修订，则该修订后的申请将被赋予新的提交日期，相应的审评时限限制将重新开始计算。这体现了程序性时限管理的灵活性。", "category": "Cosmetics", "related_concept": "investigation completion period, substantive amendment", "id": "PA_P_00607_006", "match_type": "weak", "match_score": 0.7469456086646495, "lang": "CN", "source_cn": "化妆品安全风险监测与评价管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0005_0001_2"}
{"question": "A cosmetics manufacturer is developing a sunscreen product for both the US and Chinese markets. Regarding the verification of Sun Protection Factor (SPF) values, which regulatory approach is most accurate?", "choices": ["A. The US FDA requires SPF testing under simulated sunlight using specific light source standards, while China NMPA mandates human testing with defined subject criteria and light source specifications.", "B. Both US FDA and China NMPA rely solely on in-vitro laboratory testing without human subjects for SPF determination.", "C. China NMPA does not regulate SPF testing methods, while the US FDA has detailed protocols for human clinical trials under controlled lighting.", "D. The US FDA specifies exact SPF values for all sunscreen products, whereas China NMPA allows manufacturers to self-declare SPF without verification."], "answer": "A", "type": "Parallel", "explanation": "This question tests the understanding of regulatory approaches to SPF verification. Option A correctly identifies that China NMPA requires human testing with specific criteria (subject demographics, light source specifications like xenon arc lamps) as part of compliance, while the US FDA also mandates testing under simulated sunlight with performance standards. The other options present incorrect or incomplete regulatory requirements.", "category": "Cosmetics", "related_concept": "SPF value, light source specifications", "id": "PA_P_00637_036", "match_type": "weak", "match_score": 0.712230169705373, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0069_0004_1"}
{"question": "关于中医药知识宣传与医疗保险纳入，以下哪项陈述正确反映了中美监管逻辑的差异？\n陈述1：中国法规要求媒体宣传中医药知识时必须聘请专业技术人员，以确保信息准确性。\n陈述2：美国法规在评估药品新用途时，会考虑该用途是否已成为广泛接受的标准医疗治疗。", "choices": ["A. 两个陈述都正确", "B. 只有陈述1正确", "C. 只有陈述2正确", "D. 两个陈述都不正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规（文本中）明确规定广播、电视等媒体开展中医药知识宣传应聘请中医药专业技术人员，这体现了对专业性的要求。陈述2正确：美国法规（文本中）提到，在评估新用途研究时，制造商可提供证据表明该新用途已被广泛接受为当前标准医疗治疗，这反映了其对临床实践现状的考量。两者分别体现了在信息传播专业性（中国）和临床证据与标准治疗关联性（美国）方面的监管逻辑。", "category": "Drugs", "related_concept": "media promotion by professionals, standard medical treatment, medical insurance inclusion", "id": "PA_P_00010_002", "match_type": "weak", "match_score": 0.7394700213790468, "lang": "CN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0011_0006_2"}
{"question": "关于药品包装材料和药用辅料的年度报告制度，中美药监法规的主要差异体现在哪个方面？", "choices": ["A. 美国法规要求所有药包材和辅料必须提交年度报告，而中国法规仅对特定高风险产品有此要求。", "B. 中国法规对药包材和药用辅料均建立了年度报告基本要求，而美国法规中未明确提及此类针对药包材和辅料的统一年度报告制度。", "C. 两国法规均要求药包材和辅料生产商每年向监管机构提交详细的变更报告，但报告格式和内容要求完全相同。", "D. 美国法规要求年度报告需包含所有产品的稳定性数据，而中国法规则无此要求。"], "answer": "B", "type": "Parallel", "explanation": "中国国家药监局发布的公告附件中明确包含了“药用原辅料、药包材年度报告基本要求”，这表明中国已为这两类物料建立了制度化的年度报告监管框架。而提供的美国法规文本主要涉及血液制品的储存、效期和通知要求，并未提及针对药包材或药用辅料的统一年度报告制度。美国对这类物料的监管可能分散在其他具体法规或指南中，但在此处未体现。选项A、C、D的描述均与两国法规的典型特点或提供的信息不符。", "category": "Drugs", "related_concept": "药包材年度报告基本要求", "id": "PA_P_00136_001", "match_type": "weak", "match_score": 0.6530452776460516, "lang": "CN", "source_cn": "国家药监局关于进一步完善药品关联审评审批和监管工作有关事宜的公告（2019年 第56号）.txt", "source_us": "PART_610GENERAL_BIOLOGICAL_PRODUCTS_STANDARDS.txt", "old_id": "comp_0006_0009_1"}
{"question": "A cosmetics company is preparing documentation for a new moisturizer with a 'hydrating' claim in both the US and Chinese markets. Which statement accurately compares the regulatory requirements for summarizing efficacy evidence?", "choices": ["A. The US requires a detailed summary linking methods to conclusions, while China mandates batch certification for color additives.", "B. China requires a concise summary including product info, methods, results, and conclusion linkage, while the US focuses on color additive certification for such claims.", "C. Both jurisdictions require identical, highly detailed technical reports to be submitted with the initial product registration.", "D. The US mandates that all efficacy summaries be translated into Chinese if originally in English, while China has no translation requirements."], "answer": "B", "type": "Parallel", "explanation": "The Chinese regulation explicitly requires a concise 'efficacy summary' containing product information, evaluation items/institutions, a brief on methods/results, and a conclusion linking the claim to the results. The provided US text focuses on color additive certification and does not specify efficacy summary requirements for general claims like 'hydrating', indicating a different regulatory emphasis. Option A incorrectly assigns the summary requirement to the US. Option C is false as requirements differ. Option D reverses the translation requirement, which is specified for foreign documents in China.", "category": "Cosmetics", "related_concept": "efficacy summary content", "id": "PA_P_00602_004", "match_type": "weak", "match_score": 0.7189163507259795, "lang": "EN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0002_0020_1"}
{"question": "When comparing US FDA and Chinese NMPA regulatory approaches to medical device clinical trials, which statement best describes their respective focuses on device stability requirements?", "choices": ["A. The FDA emphasizes real-time stability under various storage conditions, while the NMPA focuses on stability as part of comprehensive trial implementation verification.", "B. Both agencies require identical stability testing protocols for all device categories.", "C. The NMPA mandates more extensive stability testing than the FDA for all medical devices.", "D. Only the FDA requires device stability data; the NMPA does not address this requirement."], "answer": "A", "type": "Parallel", "explanation": "The FDA specifically requires device stability data including real-time stability under various storage times and temperatures as part of performance characteristics. The NMPA approach incorporates device management (including stability considerations) within broader trial implementation verification focused on process standardization and data integrity.", "category": "Medical_Devices", "related_concept": "device stability", "id": "PA_P_00404_001", "match_type": "weak", "match_score": 0.7477805874060952, "lang": "EN", "source_cn": "医疗器械临床试验项目检查要点.txt", "source_us": "PART_866IMMUNOLOGY_AND_MICROBIOLOGY_DEVICES.txt", "old_id": "comp_0001_0025_1"}
{"question": "When a company submits a petition for exemption from color additive certification in the US, what must be included regarding clinical investigations?", "choices": ["A. A statement that the investigation was conducted in compliance with institutional review and informed consent requirements", "B. A detailed description of the clinical trial protocol and patient demographics", "C. A certification from the principal investigator about the study's validity", "D. A comparison of the investigation methods to international standards"], "answer": "A", "type": "Parallel", "explanation": "US regulations require that when clinical investigations are involved in petitions for color additive exemptions, the submission must include statements confirming compliance with institutional review board requirements (21 CFR Part 56) and informed consent requirements (21 CFR Part 50), or documentation of exemption from these requirements.", "category": "Cosmetics", "related_concept": "institutional review compliance", "id": "PA_P_00659_004", "match_type": "weak", "match_score": 0.7308633548268733, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0034_0002_1"}
{"question": "在化妆品监管体系中，关于境内责任人/代理人的变更程序，以下两个陈述哪个正确？\n陈述1：中国法规要求境内责任人变更时，新责任人需提交承担原责任人各项责任的承诺书，同时需要原责任人的知情同意书。\n陈述2：美国法规对化妆品企业注册没有境内代理人的概念，因此不存在类似的代理人变更程序要求。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1准确反映了中国法规第十条第四款的要求：境内责任人变更需提交拟变更责任人承担原责任人责任的承诺书，以及原责任人的知情同意书或法律判决文书。陈述2也正确：美国法规§710.1-710.9关于化妆品企业注册的规定中，确实没有设立类似中国'境内责任人'的强制代理制度，注册主体直接是企业的所有者或经营者，因此不存在对应的代理人变更程序。", "category": "Cosmetics", "related_concept": "domestic agent change procedure", "id": "PA_P_00616_005", "match_type": "weak", "match_score": 0.7383602081796261, "lang": "CN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0003_0001_2"}
{"question": "关于化妆品新功效宣称的评价依据选择，中美法规的核心差异主要体现在哪个方面？", "choices": ["A. 中国法规要求必须根据具体功效宣称选择合适的评价依据，而美国法规对此没有明确规定。", "B. 美国法规要求必须进行人体功效评价试验，而中国法规则允许选择多种评价方式。", "C. 中国法规允许使用体外真发进行评价，而美国法规则要求必须进行消费者使用测试。", "D. 两国法规都要求必须根据具体功效宣称选择合适的评价依据，但具体评价方法不同。"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确要求“根据具体功效宣称选择合适的评价依据”，并规定了人体功效评价试验、消费者使用测试、实验室试验等不同评价路径的组合与选择规则。美国FDA对化妆品功效宣称的管理主要基于《联邦食品、药品和化妆品法案》和《公平包装和标签法案》，其监管重点在于防止虚假或误导性宣称，但并未像中国NMPA那样，针对“新功效宣称”制定一套明确的、强制性的评价依据选择框架。美国更依赖于企业自身的科学证据和事后监管。", "category": "Cosmetics", "related_concept": "new efficacy claims, evaluation basis selection", "id": "PA_P_00604_001", "match_type": "weak", "match_score": 0.7464960430017922, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0004_0005_1"}
{"question": "关于法规豁免的修改程序，请判断以下陈述：\n陈述1：根据美国相关法规，行政机构若决定修改或终止某项豁免，必须通过《联邦公报》发布通知。\n陈述2：中国法规中，社区康复的解除由执行地公安机关出具通知书并送达相关人员，无需类似《联邦公报》的广泛公告程序。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：提供的美国法规文本明确指出，行政机构（Administrator）在终止或修改豁免时，应发布并在《联邦公报》（Federal Register）上公布通知。这体现了美国行政程序中的公告与评论规则。陈述2正确：中国法规规定，社区康复期满解除时，由执行地公安机关出具解除社区康复通知书送达本人及家属，并通知当地乡镇政府或街道办事处。这是一个针对特定当事人的行政程序，不同于面向公众的广泛公告。因此，两个陈述都准确地描述了两国法规在相关程序上的差异。", "category": "Controlled_Substances", "related_concept": "Federal Register notification, exemption modification, rehabilitation period", "id": "PA_P_00698_002", "match_type": "weak", "match_score": 0.7175899972780999, "lang": "CN", "source_cn": "戒毒条例.txt", "source_us": "PART_1310RECORDS_AND_REPORTS_OF_LISTED_CHEMICALS_A.txt", "old_id": "comp_0009_0021_2"}
{"question": "关于化妆品原料标签名称的法规管理，中美药监机构在采纳名称时的主要差异体现在：", "choices": ["A. 中国要求所有名称必须经NMPA预先批准，美国则允许行业字典中的名称直接使用", "B. 美国FDA会明确列出不被采纳的名称清单，并对部分名称设定采纳条件和过渡期限，中国法规对此无具体规定", "C. 两国都要求所有化妆品原料名称必须来自官方发布的统一目录", "D. 中国对原料名称的化学组成描述要求比美国更为宽松"], "answer": "B", "type": "Parallel", "explanation": "美国FDA法规中明确列出了不被采纳的化妆品原料名称清单（如Acid Black 58等），同时对部分名称（如Carbomer 934）设定了采纳条件（需修订单行本以准确描述化学组成）和过渡期限（如至1981年1月19日）。中国提供的法规文本未涉及化妆品原料标签名称的具体管理要求，因此无法体现类似规定。选项A错误，因为美国并非所有行业字典名称都可直接使用；选项C错误，因为美国允许参考行业字典；选项D缺乏依据。", "category": "Cosmetics", "related_concept": "cosmetic ingredient labeling names", "id": "PA_P_00643_003", "match_type": "weak", "match_score": 0.7056085309982554, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0030_0003_1"}
{"question": "Statement 1: Under Chinese regulations, for a cosmetic ingredient with no clearly defined chemical structure, the manufacturer must provide a detailed composition profile and identification parameters. Statement 2: US regulations for color additives, like D&C Brown No. 1, primarily define identity through specific chemical compound(s) and set strict quantitative limits for impurities and component ratios.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly reflects the Chinese regulatory principle that ingredients without a clear chemical structure require disclosure of composition and identification methods/parameters. Statement 2 accurately describes the US regulatory approach for color additives, which involves defining the chemical identity (e.g., mixture of specific sodium salts) and establishing precise specifications for component percentages and impurity limits (e.g., heavy metals, other color components). This contrast illustrates differing regulatory strategies for defining and controlling ingredient identity and purity.", "category": "Cosmetics", "related_concept": "identification methods, chemical composition limits", "id": "PA_P_00617_015", "match_type": "weak", "match_score": 0.7201783004025023, "lang": "EN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0023_0017_2"}
{"question": "关于药品质量放行责任人的设置，以下哪项描述最准确地反映了中美法规的差异？", "choices": ["A. 中国法规明确要求药品上市许可持有人和药品生产企业均需设立独立的质量受权人分别负责上市放行和出厂放行，而美国法规无此明确的人员设置要求", "B. 美国法规明确要求设立独立的质量受权人负责所有放行，而中国法规无此要求", "C. 两国法规均要求药品生产企业设立质量受权人，但中国法规额外要求MAH也设立质量受权人", "D. 两国法规对质量放行责任人的设置要求完全相同，均需在MAH和企业层面分别设立"], "answer": "A", "type": "Parallel", "explanation": "中国法规（第二十八条、第二十九条）明确规定了药品上市许可持有人需配备专门质量受权人独立履行药品上市放行责任，药品生产企业需配备专门质量受权人履行药品出厂放行责任，形成了双层的质量放行授权体系。提供的美国法规文本主要关注记录、报告和标签变更等，并未明确提及类似“质量受权人”（Quality Authorized Person）这一特定岗位的设置要求，其放行责任可能融入在CGMP和申请人的整体质量体系要求中。", "category": "Drugs", "related_concept": "quality authorization for release", "id": "PA_P_00253_002", "match_type": "weak", "match_score": 0.7389773866993226, "lang": "CN", "source_cn": "药品生产监督管理办法（2020年国家市场监督管理总局令第28号）.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0010_0013_2"}
{"question": "Statement 1: Regulatory systems for transport operations typically define specific review timelines for license applications, with penalties for unauthorized activities often based on the presence and scale of illicit profits. Statement 2: In product quality regulatory agreements, the timeliness of inspection report exchanges is a formal metric for monitoring the continued validity of mutual recognition between authorities.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "This True/False pair compares concepts across the two regulatory domains. Statement 1 correctly reflects common principles in transport regulation: application review periods (e.g., 20-day审查) are standard, and penalty structures for unauthorized operations (like running a transport station without a license) often escalate based on the amount of '违法所得' (illegal gains). Statement 2 accurately describes a feature of international regulatory harmonization, such as in Mutual Recognition Agreements (MRAs), where the 'quality and timeliness' of report exchanges is explicitly part of monitoring continued 'equivalence'. Therefore, both statements align with general regulatory logic in their respective contexts.", "category": "General_FDA", "related_concept": "penalties for unauthorized transport operations, review period for transport applications, preapproval inspection reports", "id": "PA_P_00775_002", "match_type": "weak", "match_score": 0.7421999906192384, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_26MUTUAL_RECOGNITION_OF_PHARMACEUTICAL_GOOD_M.txt", "old_id": "comp_0010_0004_2"}
{"question": "关于化妆品中致癌物质的监管方式，请判断以下两个陈述的真假：\n陈述1：中国法规要求监测机构对含有已知致癌物质的化妆品提出风险管理建议。\n陈述2：美国法规明确将含有氯乙烯的化妆品气雾剂产品直接认定为掺假产品。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误。提供的中国法规文本中，监测机构提出风险管理建议是针对“不良反应”，而非直接针对“含有已知致癌物质的化妆品”。法规未明确提及对特定致癌物质的事前禁令。陈述2正确。美国法规文本明确指出，含有氯乙烯（一种已知致癌物）的化妆品气雾剂成分被认为可能对使用者造成伤害，因此该类产品直接被认定为掺假产品。这体现了FDA对特定致癌物质采取禁止性规定的监管方式。", "category": "Cosmetics", "related_concept": "carcinogenic substance regulation", "id": "PA_P_00598_006", "match_type": "weak", "match_score": 0.7163955120462583, "lang": "CN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0005_0003_2"}
{"question": "When reporting human skin patch test results for cosmetic registration, which regulatory approach is typically used?", "choices": ["A. Chinese regulations require reporting individual reaction grades for each adverse event, while US regulations require statistical summaries of adverse event rates.", "B. Both US and Chinese regulations require identical standardized reporting formats for all skin patch test results.", "C. US regulations mandate reporting individual reaction grades, while Chinese regulations require only pass/fail outcomes.", "D. Chinese regulations focus on statistical analysis of SPF values, while US regulations emphasize individual adverse event documentation."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations typically require detailed reporting of individual reaction grades (e.g., 1st or 2nd degree skin adverse reactions) for each case in human skin patch tests, while US regulations generally focus on statistical summaries and overall safety assessments rather than individual reaction grading in mandatory reporting.", "category": "Cosmetics", "related_concept": "human skin patch test results", "id": "PA_P_00644_001", "match_type": "weak", "match_score": 0.7400516259471824, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0024_0003_1"}
{"question": "关于药品新用途补充申请的伦理考量，中美药监法规在评估研究可行性时，主要关注点有何不同？", "choices": ["A. 中国法规主要关注研究对受试者的直接风险，美国法规则强调经济可行性与市场独占性", "B. 中国法规要求评估研究对标准医疗实践的影响，美国法规则关注研究设计的替代方案", "C. 中国法规侧重于研究成本与患者支付能力，美国法规则要求证明不进行研究会带来不合理风险", "D. 中国法规强调专家参与评审的必要性，美国法规则要求提供详细的财务预测与患者规模数据"], "answer": "D", "type": "Parallel", "explanation": "中国法规（如第五十一条）规定中医药相关评审活动需有中医药专家参与，体现了专业评审原则。美国法规（如文本中要求）在补充申请中明确要求提供预期患者规模、预期收入、价格解释、市场独占性等详细财务与市场数据，这是其经济可行性评估的重要组成部分。两者分别体现了专家评审与数据驱动的不同监管侧重点。", "category": "Drugs", "related_concept": "supplemental application for new use, unethical study conduct", "id": "PA_P_00010_001", "match_type": "weak", "match_score": 0.7394700213790468, "lang": "CN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0011_0006_1"}
{"question": "关于监管机构发布法规的时间要求，以下哪项描述符合中美法规的差异？", "choices": ["A. 中国未规定具体发布时间，美国要求在收到申请后90-180天内发布", "B. 美国未规定具体发布时间，中国要求在收到报告后30天内发布", "C. 两国都要求在60天内发布相关法规", "D. 中国要求在7天内发布，美国要求在1年内发布"], "answer": "A", "type": "Parallel", "explanation": "美国法规明确规定，对于颜色添加剂的申请，专员应在请愿提交后90天内（或延长至180天）将法规提交联邦公报发布。中国提供的法规文本中未涉及监管机构发布法规的具体时间要求。", "category": "Cosmetics", "related_concept": "regulation publication timeline", "id": "PA_P_00600_002", "match_type": "weak", "match_score": 0.7015591063791814, "lang": "CN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0007_0002_2"}
{"question": "关于化妆品新原料或产品安全性评价中的动物试验要求，请判断以下陈述：\n陈述1：中国法规对化妆品的安全性评价，在无法充分证明安全性时，可能要求进行皮肤刺激性等动物试验。\n陈述2：美国FDA对化妆品的安全性负最终责任，并强制要求所有化妆品上市前必须完成动物试验。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确。中国《化妆品监督管理条例》及《化妆品安全技术规范》规定，化妆品注册、备案时需要提交产品安全评估资料。对于缺乏安全使用历史的新原料或特定情况，可能需要通过动物试验（如皮肤刺激性试验）来评估安全性，相关试验有具体体例要求。\n陈述2错误。美国FDA对化妆品实行事后监管，除色素添加剂等特定类别外，不要求化妆品上市前必须进行动物试验或获得FDA批准。化妆品的安全性主要由生产企业负责（符合FD&C Act及GMP），FDA不强制要求动物试验，并鼓励使用替代方法。", "category": "Cosmetics", "related_concept": "animal testing requirements, laboratory animal welfare", "id": "PA_P_00637_022", "match_type": "weak", "match_score": 0.7081736505764256, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0032_0023_2"}
{"question": "In comparing US and Chinese regulatory approaches to record management, which statement best describes a key difference in segregation requirements?", "choices": ["A. US regulations require color additive distribution records to be kept separately from all other records, while Chinese regulations focus on comprehensive record systems without explicit segregation mandates.", "B. Chinese regulations mandate separate storage for all quality records by category, while US regulations allow combined record-keeping for certified materials.", "C. Both systems require identical segregation of batch records from general quality documentation.", "D. US regulations prohibit any segregation of records to ensure transparency, while Chinese regulations require physical separation of all documentation types."], "answer": "A", "type": "Parallel", "explanation": "The US regulation explicitly states that color additive distribution records 'shall be kept separately from all other records,' indicating a strict segregation requirement for certified materials. Chinese regulations described focus on comprehensive record management systems covering various types (production, testing, non-conforming products) but don't specify mandatory physical or organizational segregation between record types, instead emphasizing complete documentation systems.", "category": "Cosmetics", "related_concept": "record segregation", "id": "PA_P_00654_010", "match_type": "weak", "match_score": 0.7174577892760271, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0031_0004_1"}
{"question": "关于化妆品原料中的杂质限量，中美法规的监管逻辑主要区别是什么？", "choices": ["A. 中国法规对所有杂质设定统一上限，美国法规则按原料类别差异化规定", "B. 中国法规侧重工艺过程控制，美国法规则强调终产品的绝对安全限量", "C. 美国法规为特定着色剂（如D&C Blue No. 4）设定了详尽的具体杂质化学名和ppm级限量，中国相关文本未展示此类针对单一成分的极致量化规定", "D. 中国法规允许企业自行制定杂质标准，美国法规则必须完全遵循药典通则"], "answer": "C", "type": "Parallel", "explanation": "提供的美国法规文本是针对“D&C Blue No. 4”这一具体着色剂的详细规范，列出了多种特定化学杂质（如4-氨基联苯、苯胺、铅、砷等）及其严格的百万分比（ppm）或十亿分比（ppb）限量，体现了对已知风险物质的精准管控。提供的中国法规文本关注的是人体功效评价试验的整体方案设计，并未涉及具体原料的杂质限量标准。这反映了美国在已批准使用的直接着色剂等领域，建立了高度具体和量化的杂质安全规范体系。", "category": "Cosmetics", "related_concept": "impurity limits", "id": "PA_P_00602_009", "match_type": "weak", "match_score": 0.7422912570201906, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0009_0005_2"}
{"question": "When a regulatory authority discovers suspected criminal activity during an investigation, what is the appropriate action regarding law enforcement agencies?", "choices": ["A. The authority should immediately suspend its own investigation and transfer all evidence to law enforcement", "B. The authority should continue its investigation while simultaneously notifying law enforcement for potential criminal case transfer", "C. The authority should complete its administrative investigation before considering any criminal referral to law enforcement", "D. The authority should only involve law enforcement if the suspected criminal activity is directly related to public health emergencies"], "answer": "B", "type": "Parallel", "explanation": "Regulatory authorities typically maintain their administrative investigations while coordinating with law enforcement agencies when criminal activity is suspected. This ensures both administrative and criminal proceedings can proceed appropriately without compromising either process.", "category": "Regulatory Compliance", "related_concept": "transfer of suspected criminal cases to public security organs", "id": "PA_P_00635_001", "match_type": "weak", "match_score": 0.7311152411132215, "lang": "EN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_81GENERAL_SPECIFICATIONS_AND_GENERAL_RESTRICT.txt", "old_id": "comp_0010_0003_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据美国FDA相关法规，在提交申请后，如果申请人补充了涉及非临床实验室研究的新数据，且该补充构成实质性修订，则必须声明该研究是否符合GLP（良好实验室规范）要求。\n陈述2：根据中国NMPA对化妆品注册备案的要求，人体试用试验报告必须详细记录每位受试者在不同观察时间点的皮肤反应情况。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。美国FDA法规（如21 CFR 10.30）明确规定，对于涉及非临床实验室研究的申请，若提交实质性修订，必须包含关于研究是否符合GLP（21 CFR Part 58）的声明。陈述2正确。中国NMPA对化妆品（特别是健美类等特殊用途化妆品）的人体试用试验有详细要求，试验报告通常需要包含受试者基本信息及在不同观察周期（如使用前、使用后1周、2周等）的皮肤反应记录，以确保安全性的持续监测和可追溯性。这体现了中美在注册备案资料要求上的不同侧重点。", "category": "Cosmetics", "related_concept": "nonclinical laboratory study compliance, registration and filing requirements", "id": "PA_P_00638_017", "match_type": "weak", "match_score": 0.7454171838042456, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0057_0001_2"}
{"question": "Which regulatory approach is used for controlling the distribution of specific medical products?", "choices": ["A. Centralized procurement platforms for all sales", "B. Establishment registration numbers for tracking facilities", "C. Prohibition of sales outside licensed medical institutions", "D. Mandatory advertisement submission upon request"], "answer": "C", "type": "Parallel", "explanation": "The Chinese regulation prohibits sales of traditional Chinese medicine formula granules outside medical institutions, while the US regulation focuses on establishment registration and advertisement submission requirements for blood products. Option C directly addresses the distribution control method of restricting sales to specific institutions.", "category": "Drugs", "related_concept": "no sales outside medical institutions", "id": "PA_P_00108_001", "match_type": "weak", "match_score": 0.7473600139068336, "lang": "EN", "source_cn": "国家药监局 国家中医药局 国家卫生健康委 国家医保局关于结束中药配方颗粒试点工作的公告（2021年第22号）.txt", "source_us": "PART_607ESTABLISHMENT_REGISTRATION_AND_PRODUCT_LIS.txt", "old_id": "comp_0003_0004_1"}
{"question": "In comparing the regulatory approaches of China and the United States regarding cosmetics oversight, which statement best describes a key difference in how technical standards and specifications are established?", "choices": ["A. China's system centralizes technical standard development at the national level, while the U.S. system allows for more decentralized, petition-driven establishment of specifications.", "B. The U.S. system relies on a single national agency to set all technical standards, whereas China delegates this authority to provincial and municipal authorities.", "C. Both systems require identical safety testing protocols, making their technical standards functionally equivalent.", "D. China's technical standards are advisory only, while U.S. standards are legally binding regulations."], "answer": "A", "type": "Parallel", "explanation": "The Chinese regulation describes a centralized national monitoring agency responsible for '制定化妆品不良反应监测的技术标准和规范' (formulating technical standards and specifications for cosmetic adverse reaction monitoring). The U.S. regulation describes a petition-based system where specifications (like conditions of use, diluents, concentrations) are established by the Commissioner in response to specific petitions and data submissions for color additives, indicating a more case-by-case, petition-driven approach to setting specifications.", "category": "Cosmetics", "related_concept": "technical standards and specifications", "id": "PA_P_00599_001", "match_type": "weak", "match_score": 0.7116251693707082, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0003_0004_1"}
{"question": "关于化妆品生产企业注册信息的变更要求，请判断以下陈述：\n陈述1：根据中国法规，生产企业信息表中的联系信息（如联系人、电话、邮箱等）需要企业自行维护更新。\n陈述2：根据美国法规，企业必须在信息变更后的30天内提交新的FD-2511表格以修改注册信息。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国化妆品注册备案资料要求中，生产企业信息表的“联系信息”部分明确标注为“（自行维护）”，表明企业有责任主动维护这些信息的准确性。\n陈述2正确：美国法规§710.5明确规定“Within 30 days after a change in any of the information contained on a submitted Form FD-2511, a new Form FD-2511 should be submitted to amend the registration”，要求企业在信息变更后30天内提交修正注册。\n两国法规都强调了企业维护注册信息准确性的责任，但具体时限和操作方式有所不同。", "category": "Cosmetics", "related_concept": "registration amendments, contact information maintenance", "id": "PA_P_00652_012", "match_type": "weak", "match_score": 0.7417109569604884, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0035_0001_2"}
{"question": "Statement 1: Batch certification is a mandatory regulatory requirement for all color additives used in cosmetics in some jurisdictions. Statement 2: Impurity control in cosmetic ingredients primarily involves setting maximum allowable limits for specific contaminants based on safety assessments.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as certain regulatory systems require batch-by-batch certification for color additives to ensure compliance with identity and purity standards. Statement 2 is correct because impurity control typically establishes specification limits (e.g., for heavy metals or organic impurities) derived from toxicological evaluations to guarantee product safety.", "category": "Cosmetics", "related_concept": "batch certification, impurity control", "id": "PA_P_00602_011", "match_type": "weak", "match_score": 0.7476593633902182, "lang": "EN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0011_0024_2"}
{"question": "Statement 1: In US electronic prescription systems, a second designated individual must verify logical access controls after initial data entry. Statement 2: Chinese regulations require verification of rehabilitation participants' eligibility by multiple government departments before providing services.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 correctly describes the US requirement for a second individual to authenticate logical access controls. Statement 2 is incorrect because Chinese regulations describe departmental responsibilities for providing rehabilitation support but do not specify a verification process involving multiple departments before service provision.", "category": "Access_Controls", "related_concept": "logical access controls by second individual", "id": "PA_P_00694_002", "match_type": "weak", "match_score": 0.7089623773362179, "lang": "EN", "source_cn": "戒毒条例.txt", "source_us": "PART_1311REQUIREMENTS_FOR_ELECTRONIC_ORDERS_AND_PR.txt", "old_id": "comp_0002_0008_2"}
{"question": "Statement 1: Chinese regulations require inter-agency coordination between broadcasting, public security, and state security authorities for enforcement actions. Statement 2: U.S. regulations mandate verification by multiple agencies before confirming facility registrations.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct as Chinese regulations explicitly involve broadcasting administrative departments, public security organs, and state security organs working together for enforcement. Statement 2 is incorrect because U.S. regulations describe verification processes conducted by FDA alone, not requiring coordination with multiple agencies for registration confirmations.", "category": "General_FDA", "related_concept": "inter-agency coordination", "id": "PA_P_00762_002", "match_type": "weak", "match_score": 0.7488809803183585, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第703号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0001_0025_2"}
{"question": "Statement 1: In the Chinese regulatory framework, monitoring agencies must conduct follow-up investigations for severe adverse reactions and submit tracking reports within specific timeframes. Statement 2: The US FDA prohibits the use of vinyl chloride in cosmetic aerosol products due to carcinogenic risks, regardless of concentration levels.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the Chinese NMPA requirement for tracking severe adverse reactions and submitting follow-up reports within 7 working days. Statement 2 accurately reflects the US FDA position that vinyl chloride in cosmetic aerosols is considered adulterated due to carcinogenic risks, as stated in the text. These represent different regulatory approaches: China emphasizes systematic adverse event monitoring and follow-up, while the US focuses on prohibiting specific hazardous substances.", "category": "Cosmetics", "related_concept": "adverse event analysis and evaluation, carcinogenic substance regulation", "id": "PA_P_00598_010", "match_type": "weak", "match_score": 0.7342651844605879, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0010_0003_2"}
{"question": "关于化妆品补充检验方法，中美法规在制定目的和适用场景上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规规定补充检验方法仅用于应对国家标准无法检验的特定风险（如掺杂掺假），而美国法规中类似概念主要与颜色添加剂的安全评估和豁免撤销相关。", "B. 两国法规都规定补充检验方法主要用于应对新型化妆品原料带来的未知风险，制定程序完全相同。", "C. 中国法规授权省级部门制定补充检验方法，而美国法规规定必须由国会立法通过。", "D. 美国法规的补充检验方法主要针对化妆品广告宣称，而中国法规则针对生产过程控制。"], "answer": "A", "type": "Parallel", "explanation": "中国《化妆品监督管理条例》第五十条明确规定，补充检验项目和方法的制定，是针对“可能掺杂掺假或者使用禁止用于化妆品生产的原料”且现行国标无法检验的情形，主要用于抽样检验、案件调查和不良反应处置，具有明确的**风险应对和执法支撑**导向。美国法规文本中，虽未直接使用“补充检验方法”这一术语，但其关于颜色添加剂“豁免认证撤销”（§71.26）和“基于现有事实主动列名与豁免”（§71.27）的规定，涉及在已有认证或列名体系外，基于新发现的安全信息（如不再适合豁免）或主动评估，对物质的管理状态进行调整，这本质上是一种**基于安全信息的监管措施动态调整机制**。两者核心差异在于：中国的补充检验方法是**针对具体产品风险、扩展检验技术能力**的工具；美国的类似机制是**针对物质管理状态、基于安全评估的行政决策**过程。选项B错误，因为美国文本未提及“新型原料”且程序不同；C错误，中国明确由国务院药品监督管理部门（国家药监局）制定；D错误，美国文本涉及的是颜色添加剂的安全管理，而非广告或生产控制。", "category": "Cosmetics", "related_concept": "supplementary inspection methods", "id": "PA_P_00677_004", "match_type": "weak", "match_score": 0.7274400836705956, "lang": "CN", "source_cn": "化妆品监督管理条例 (1).txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0014_0003_1"}
{"question": "In comparing US and Chinese regulations for veterinary ephedrine hydrochloride injections, which statement best describes the regulatory approach?", "choices": ["A. The US requires specific telemedicine conditions for prescribing, while China delegates oversight to agricultural and pharmaceutical authorities.", "B. Both countries require identical in-person evaluations before prescribing veterinary controlled substances.", "C. China has no regulations for veterinary ephedrine, while the US allows unrestricted telemedicine prescriptions.", "D. The US and China both require Ministry of Agriculture approval for all veterinary controlled substance operations."], "answer": "A", "type": "Parallel", "explanation": "The US regulation establishes specific telemedicine conditions for prescribing controlled substances (including veterinary applications), while the Chinese regulation explicitly states that oversight of veterinary ephedrine hydrochloride production and operation follows regulations from the Ministry of Agriculture and State Food and Drug Administration, representing a delegated authority approach.", "category": "Controlled_Substances", "related_concept": "production and operation of veterinary ephedrine hydrochloride injections", "id": "PA_P_00718_001", "match_type": "weak", "match_score": 0.7360092749871865, "lang": "EN", "source_cn": "药品类易制毒化学品管理办法（卫生部令第72号_2010年）.txt", "source_us": "PART_1307MISCELLANEOUS.txt", "old_id": "comp_0017_0002_1"}
{"question": "关于化妆品中色淀（lake）的规格要求，中美法规的侧重点有何不同？", "choices": ["A. 中国法规主要规定色淀的制备基质和盐基，美国法规则详细规定了杂质（如醚提取物、氯化物）的限量标准。", "B. 美国法规主要规定色淀的制备基质和盐基，中国法规则详细规定了杂质（如醚提取物、氯化物）的限量标准。", "C. 两国法规对色淀的规格要求完全相同，均侧重于杂质限量。", "D. 两国法规均未对化妆品用色淀的规格做出具体规定。"], "answer": "A", "type": "Parallel", "explanation": "根据美国法规（如§82.2051），色淀的规格明确规定了醚提取物、可溶性氯化物和硫酸盐、中间体等杂质的百分比上限。同时，它也定义了色淀的制备基质（如氧化铝、二氧化钛等）和可结合的盐基（如钠、钾、铝、钡等）。中国提供的文本未涉及色淀的具体化学规格，而是侧重于皮肤试验的报告要求。因此，美国法规在色淀的化学规格和杂质控制方面有更详细的规定。", "category": "Cosmetics", "related_concept": "lake specifications", "id": "PA_P_00640_012", "match_type": "weak", "match_score": 0.7143200531833791, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0037_0005_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在美国，如果已认证的着色剂其法规状态后续发生变更（如被修订或撤销），使用该着色剂的化妆品不会自动被视为掺假产品，除非FDA认定其存在健康风险且现有库存无法安全使用。\n陈述2：在中国，对于因包装原因无法取样的化妆品（如喷雾产品），企业必须提供终产品进行检测，不允许使用半成品替代。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：美国法规文本明确指出，当认证着色剂的法规状态变更后，使用该着色剂的食品、药品或化妆品不会仅因此被视为掺假，除非健康风险导致现有库存无法安全使用（此时FDA会发布相应规定）。这体现了法规变更不溯及既往的原则，除非有即时安全风险。\n陈述2错误：中国法规文本明确规定，对于因包装原因无法取样或可能影响检验结果的终产品（如喷雾产品、气垫产品），企业在提交完整检测样品的同时，可配合提供包装前的最后一道工序的半成品，检验机构应在报告中予以说明。这允许在特定情况下使用半成品进行检测。", "category": "Cosmetics", "related_concept": "adulterated status change, regulatory hearing opportunity", "id": "PA_P_00639_008", "match_type": "weak", "match_score": 0.7029069052238133, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0015_0003_2"}
{"question": "关于化妆品中着色剂的使用和限制，中美法规的监管思路主要区别在于：", "choices": ["A. 中国法规对所有着色剂均设定明确的用量上限，美国法规则只规定允许使用的种类", "B. 美国法规对允许使用的着色剂（如Ext. D&C Violet No. 2）明确其使用范围（如仅限外用化妆品）并遵循GMP原则，中国法规则通过准用清单规定可使用种类及一般要求", "C. 中国法规要求着色剂的使用必须基于临床人体试验数据，美国法规则基于动物试验数据", "D. 美国法规禁止在化妆品中使用任何合成着色剂，中国法规则允许使用经批准的合成着色剂"], "answer": "B", "type": "Parallel", "explanation": "美国FDA对已批准的着色剂（如Ext. D&C Violet No. 2）在其法规中会明确规定其用途和限制（Uses and restrictions），例如限定于外用化妆品，并要求用量符合良好生产规范（GMP）。中国对化妆品着色剂的监管主要通过发布《化妆品准用着色剂目录》来管理，该目录列出了允许使用的着色剂及其索引号、使用范围等限制条件，企业需在目录范围内使用，并确保产品安全。两者核心区别在于：美国对每个特定着色剂有独立的、详细的法规条款规定其使用；中国则采用统一的准用清单管理模式。", "category": "Cosmetics", "related_concept": "uses and restrictions", "id": "PA_P_00637_024", "match_type": "weak", "match_score": 0.7081736505764256, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0032_0023_4"}
{"question": "关于化妆品中着色剂的身份标识要求，中美法规的主要差异体现在：", "choices": ["A. 中国法规要求提供化学名称和结构式，美国法规则无此要求", "B. 美国法规要求明确化学名称和主要成分，中国法规则侧重于通用名称", "C. 两国法规均要求提供完整的化学结构式和分子式", "D. 中国法规仅要求提供商品名，美国法规则要求提供CAS号"], "answer": "B", "type": "Parallel", "explanation": "美国法规（如对Ext. D&C Violet No. 2）明确要求提供着色剂的化学身份（主要成分的化学名称），这是其身份（Identity）部分的核心内容。中国法规对化妆品原料（包括着色剂）的身份标识要求通常体现在《化妆品安全技术规范》中，要求提供标准中文名称、INCI名称等，但更侧重于原料的通用名称和规范使用，而非像美国FDA那样在特定着色剂法规中详细规定化学结构。", "category": "Cosmetics", "related_concept": "identity of color additive", "id": "PA_P_00637_021", "match_type": "weak", "match_score": 0.7081736505764256, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0032_0023_1"}
{"question": "关于医疗器械召回令的强制执行，中美两国法规在处罚措施上存在显著差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规对拒不召回行为设置了阶梯式罚款和吊销许可等严厉处罚，而美国法规主要关注测试系统的标签和实验室能力要求", "B. 两国法规均对拒不召回行为处以基于货值的高额罚款，但中国还附加了从业禁止处罚", "C. 美国法规对拒不召回行为规定了基于个人收入的罚款，而中国法规仅对企业进行处罚", "D. 两国法规都要求企业在收到召回令后立即停止生产经营活动，否则将面临刑事处罚"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定，在药监部门责令召回后仍拒不召回的，将面临没收违法医疗器械、按货值金额处以高额罚款（5-20倍）、责令停产停业直至吊销相关许可证，并对责任人员处以基于收入的罚款和从业禁止。而提供的美国法规文本主要涉及分析特异性试剂（ASR）和OTC药物滥用测试系统的使用限制、标签要求和实验室能力规范，并未直接规定对拒不召回医疗器械的具体处罚措施。这种差异体现了中国在医疗器械安全监管中更强调行政强制力和严厉的事后惩戒。", "category": "Medical_Devices", "related_concept": "recall orders", "id": "PA_P_00499_001", "match_type": "weak", "match_score": 0.7441702005010142, "lang": "CN", "source_cn": "医疗器械监督管理条例.txt", "source_us": "PART_809IN_VITRO_DIAGNOSTIC_PRODUCTS_FOR_HUMAN_USE.txt", "old_id": "comp_0030_0008_1"}
{"question": "关于化妆品安全性评价中的实验动物管理，以下哪项陈述正确地反映了中美法规的潜在差异？\n陈述1：中国法规要求记录实验动物的来源、许可证号、饲养环境（温湿度）及饲料合格证明等详细信息。\n陈述2：美国法规对于用于外部药品和化妆品的颜色添加剂批次，强调其必须符合整体认证规定和该颜色的具体规格。", "choices": ["A. 两个陈述都正确，且分别体现了对实验动物福利和原料质量控制的关注。", "B. 陈述1正确，陈述2错误。", "C. 陈述1错误，陈述2正确。", "D. 两个陈述都错误。"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：根据提供的中国法规文本（皮肤光毒性试验报告体例），明确要求记录实验动物的种属、品系、来源、许可证号、饲养环境的温湿度、许可证号以及饲料来源和合格证明，这体现了对实验动物福利和试验条件标准化的严格要求。\n陈述2正确：根据提供的美国法规文本（如§82.2050），对于列出的直接用于外部药品和化妆品的颜色，其批次认证需符合两部分要求：一是符合通用的认证规定（§82.5），二是符合该颜色在法规中设定的具体规格。这体现了对原料（颜色添加剂）质量一致性和安全性的系统控制。\n两者分别代表了在产品安全评价链条中，对“临床前试验过程”（中国侧重）和“原料准入与质量控制”（美国侧重）不同环节的法规关注点。", "category": "Cosmetics", "related_concept": "experimental animals and housing environment, batch certification", "id": "PA_P_00640_013", "match_type": "weak", "match_score": 0.7143200531833791, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0037_0005_2"}
{"question": "关于执业药师继续教育机构的合规要求，中美两国法规在监管重点上存在显著差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规侧重于对继续教育机构办学行为的直接规范，美国法规则侧重于对继续教育机构本身的资质审批。", "B. 中国法规明确禁止继续教育机构从事欺诈、乱收费等不当行为，美国法规则主要关注继续教育内容的科学性和有效性。", "C. 中国法规建立了学时登记和证明出具的制度框架，美国法规则主要依赖行业协会的自律管理。", "D. 中国法规强调省级药监部门在学时认定中的主导作用，美国法规则强调联邦机构对教育过程的直接干预。"], "answer": "B", "type": "Parallel", "explanation": "解析：中国法规（NMPA）明确列举了继续教育机构不得从事的禁止性行为，如弄虚作假招揽生源、以继续教育名义组织旅游或乱收费等，体现了对办学行为合规性的直接和具体规范。而美国法规（FDA）文本主要涉及人体细胞、组织类产品（HCT/Ps）生产机构的检查，并未直接涉及执业药师继续教育机构的办学行为规范。因此，选项B准确指出了中国法规在禁止不当行为方面的具体规定，而美国法规文本未体现对此类机构的同类监管重点。选项A、C、D均涉及美国法规文本未提供的信息或进行了不准确的推断。", "category": "Drugs", "related_concept": "prohibited practices, continuing education hours certification system", "id": "PA_P_00162_001", "match_type": "weak", "match_score": 0.7274040786766202, "lang": "CN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0006_0021_1"}
{"question": "When regulatory authorities identify non-compliant products, which regulatory system requires a detailed statement explaining the reason for non-compliance as part of the reporting process?", "choices": ["A. US FDA regulations only", "B. Chinese NMPA regulations only", "C. Both US FDA and Chinese NMPA regulations", "D. Neither US FDA nor Chinese NMPA regulations"], "answer": "A", "type": "Parallel", "explanation": "US FDA regulations explicitly require a brief statement of the reason for noncompliance when reporting issues, while Chinese NMPA regulations focus on reporting timelines and documentation requirements without specifying the need for a detailed non-compliance reason statement.", "category": "Cosmetics", "related_concept": "noncompliance reason statement", "id": "PA_P_00607_003", "match_type": "weak", "match_score": 0.7439403479179316, "lang": "EN", "source_cn": "化妆品安全风险监测与评价管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0004_0002_1"}
{"question": "Statement 1: Under Chinese regulations, manufacturers may be exempt from on-site inspections if they have passed GMP inspections by recognized international bodies like WHO or EDQM. Statement 2: Under US regulations, manufacturers can petition for waivers from advertising requirements by demonstrating their materials are not misleading and providing complete documentation.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, Statement 2 is incorrect.", "C. Statement 1 is incorrect, Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes Chinese NMPA provisions where manufacturers with WHO, EDQM, or EU member state GMP inspections may be exempt from additional on-site inspections for certain export certifications. Statement 2 accurately reflects US FDA requirements where manufacturers can petition for waivers from specific advertising provisions by showing their advertisements are not false, lacking fair balance, or misleading, and must provide complete copies of the advertisement and justification.", "category": "Drugs", "related_concept": "exemption from on-site inspection, waiver petition requirements", "id": "PA_P_00244_002", "match_type": "weak", "match_score": 0.7412005695861485, "lang": "EN", "source_cn": "药品生产企业出口药品检查和.txt", "source_us": "PART_202PRESCRIPTION_DRUG_ADVERTISING.txt", "old_id": "comp_0046_0008_2"}
{"question": "In regulatory hearings, which of the following is a key difference between how Chinese and US authorities address confidentiality breaches by officials?", "choices": ["A. Chinese regulations explicitly criminalize breaches by specific officials, while US regulations focus on attorney admission requirements without mentioning confidentiality.", "B. US regulations require public hearings for all confidentiality breaches, while Chinese regulations keep them confidential.", "C. Both systems treat confidentiality breaches identically as civil offenses with fines.", "D. Chinese regulations only apply to law enforcement, while US regulations apply to all government employees equally."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations specifically criminalize confidentiality breaches by public security, judicial, and health administration personnel regarding drug rehabilitation individuals, with potential criminal liability. The provided US regulation text focuses on attorney admission requirements and hearing procedures without addressing confidentiality breaches by officials, highlighting a structural difference in regulatory approaches.", "category": "Controlled_Substances", "related_concept": "confidentiality breach", "id": "PA_P_00699_001", "match_type": "weak", "match_score": 0.7368086572031547, "lang": "EN", "source_cn": "戒毒条例.txt", "source_us": "PART_1316ADMINISTRATIVE_FUNCTIONS_PRACTICES_AND_PR.txt", "old_id": "comp_0010_0006_1"}
{"question": "关于化妆品注册备案中的用户密码管理责任，中美法规的主要差异体现在：", "choices": ["A. 中国法规明确规定了境内责任人对密码丢失或泄密造成的损失自行承担，而美国法规未涉及此类具体责任条款", "B. 美国法规要求企业必须为密码管理购买保险，中国法规则无此要求", "C. 两国法规均要求密码必须由第三方机构托管，责任由托管方承担", "D. 中国法规未规定密码管理责任，美国法规则明确由FDA承担监管责任"], "answer": "A", "type": "Parallel", "explanation": "中国法规在境内责任人承诺书中明确规定“本企业将妥善保管用户密码...因密码丢失或泄密造成的损失将由本企业自行承担”，体现了明确的企业主体责任。而美国化妆品企业注册法规（21 CFR Part 710）主要关注企业注册和信息报告要求，未涉及具体的用户密码管理责任条款，这反映了中美监管体系在责任划分上的不同侧重点。", "category": "Cosmetics", "related_concept": "user password management", "id": "PA_P_00652_011", "match_type": "weak", "match_score": 0.7417109569604884, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0035_0001_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据美国FDA法规，如果一项关于标准化食品的定义和标准提案中包含了使用色素添加剂，但申请人未将其明确标识为色素添加剂提案，FDA专员在发现后必须通知申请人，并按照色素添加剂的相关法规程序处理。\n陈述2：根据中国NMPA对化妆品新原料的法规要求，注册人需要以列表形式详细列出所有使用该新原料的化妆品的产品名称、注册备案号、生产企业、新原料的使用目的和添加量等信息，并汇总报告。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。它准确描述了美国法规（§70.10(a)(2)）的核心程序：对于隐含在标准化食品提案中的色素添加剂规定，FDA有责任识别并启动相应的色素添加剂审批流程。陈述2正确。它概括了中国化妆品新原料法规中的一项关键监管要求，即注册人/备案人必须系统化地追踪和报告新原料在所有相关产品中的应用详情，这构成了不良反应监测和监管追溯的基础。两者分别体现了美国在程序合规上的严谨性和中国在产品全链条信息管理上的要求。", "category": "Cosmetics & Food", "related_concept": "product registration and filing information, color additive petition", "id": "PA_P_00618_020", "match_type": "weak", "match_score": 0.7411896380632024, "lang": "CN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0030_0001_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在药用辅料和药包材的监管中，中国法规通过发布“可免登记的产品目录”来简化对低风险产品的管理流程。\n陈述2：美国FDA对于血液制品的储存温度有统一且固定的规定，所有同类产品必须严格遵守表格中列出的温度，不允许有任何基于特定获批系统的调整。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "C", "type": "Parallel", "explanation": "陈述1正确：中国法规附件中包含“可免登记的产品目录（2019年版）”，这体现了基于风险分类的监管思路，对某些风险较低的产品豁免登记要求，以优化监管资源。\n陈述2错误：美国法规文本明确指出，当使用FDA批准或许可的特定血液采集、处理和储存系统时，产品的效期可以不同于表格中的规定，而以该系统的使用说明为准。这说明了法规的灵活性，允许基于特定获批技术进行调整，而非绝对固定。", "category": "Drugs", "related_concept": "可免登记的产品目录, storage temperature", "id": "PA_P_00136_002", "match_type": "weak", "match_score": 0.6530452776460516, "lang": "CN", "source_cn": "国家药监局关于进一步完善药品关联审评审批和监管工作有关事宜的公告（2019年 第56号）.txt", "source_us": "PART_610GENERAL_BIOLOGICAL_PRODUCTS_STANDARDS.txt", "old_id": "comp_0006_0009_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中美相关法规，临床试验方案的核心定义都包含了对试验目的、设计、方法和组织实施等要素的描述。\n陈述2：在医疗器械上市前申请中，美国法规要求提交的研究摘要必须包含对临床研究中不良反应和并发症的讨论，而中国法规对临床试验报告内容的要求中未提及此点。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确。中国法规明确定义临床试验方案为说明目的、设计、方法学和组织实施的文件。美国法规虽未直接给出“方案”定义，但其对“研究摘要”的要求中包含了研究目的、实验设计等核心要素，体现了方案的关键内容。陈述2错误。美国法规确实要求在PMA的研究摘要中包含对不良反应和并发症的讨论。然而，中国法规在“临床试验报告”的定义中，明确指出报告是描述试验设计、执行、统计分析和结果的文件。“结果”理应包含安全性结果，其中不良反应和并发症是关键组成部分，因此不能说中国法规未提及。", "category": "Medical_Devices", "related_concept": "clinical trial protocol definition, summary of studies, adverse reactions and complications", "id": "PA_P_00402_008", "match_type": "weak", "match_score": 0.698524173971794, "lang": "CN", "source_cn": "医疗器械临床试验质量管理规范.txt", "source_us": "PART_814PREMARKET_APPROVAL_OF_MEDICAL_DEVICES.txt", "old_id": "comp_0020_0001_2"}
{"question": "Statement 1: Regulatory authorities may require scientific evidence demonstrating safe tolerance levels before approving substances that could potentially contain carcinogenic impurities. Statement 2: When color additives are found to be contaminated with known carcinogens, regulatory authorities typically allow their continued use if manufacturers implement quality control measures.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct as regulatory authorities require scientific evidence of safe tolerance, especially for substances with potential carcinogenic impurities. Statement 2 is incorrect because when color additives are confirmed to be contaminated with known carcinogens, regulatory authorities typically prohibit their use rather than allowing continued use with quality controls, as the fundamental safety cannot be assured.", "category": "Product Safety", "related_concept": "safe tolerance evidence, contamination with carcinogens", "id": "PA_P_00635_002", "match_type": "weak", "match_score": 0.7311152411132215, "lang": "EN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_81GENERAL_SPECIFICATIONS_AND_GENERAL_RESTRICT.txt", "old_id": "comp_0010_0003_2"}
{"question": "In regulatory enforcement, how do Chinese and U.S. approaches differ regarding penalties for violations?", "choices": ["A. Chinese regulations specify fixed monetary penalties and potential criminal liability, while U.S. regulations focus on verification processes without explicit penalty details.", "B. Both systems rely primarily on warnings and administrative fines without criminal consequences.", "C. U.S. regulations emphasize inter-agency coordination for penalties, while Chinese regulations delegate authority to a single agency.", "D. Chinese regulations require U.S. agent verification for penalties, while U.S. regulations involve multiple Chinese agencies."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations detail specific penalties including warnings, fines up to 20,000 yuan, license revocation, and potential criminal prosecution for violations. U.S. regulations in this context focus on verification processes for submissions and agent authorization without specifying penalty structures for non-compliance.", "category": "General_FDA", "related_concept": "penalties for violations", "id": "PA_P_00762_001", "match_type": "weak", "match_score": 0.7488809803183585, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第703号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0001_0025_1"}
{"question": "在监管申报过程中，中美法规对非临床实验室研究的合规要求有何异同？请判断以下陈述：陈述1：中国法规要求化妆品功效宣称评价中，如涉及非临床研究，需提供研究合规声明。陈述2：美国法规要求提交的补充信息如包含非临床研究，必须声明该研究是否符合21 CFR Part 58的GLP要求。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误：提供的中国法规文本中未明确要求非临床研究的合规声明，主要关注功效评价资料提交和等效评价机制。陈述2正确：美国FDA法规明确规定，提交的补充信息如包含非临床实验室研究，必须声明该研究是否符合21 CFR Part 58的良好实验室规范（GLP）要求，若不符合则需说明原因。这体现了FDA对非临床研究数据质量的严格监管。", "category": "Regulatory Compliance", "related_concept": "nonclinical laboratory study compliance", "id": "PA_P_00603_004", "match_type": "weak", "match_score": 0.7148712111116121, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0005_0001_2"}
{"question": "A company is developing a new in vitro diagnostic (IVD) test for cancer biomarkers. Which regulatory approach regarding product naming would be most appropriate for a test that detects multiple protein biomarkers using chemiluminescence technology?", "choices": ["A. Use a generic name based on the intended use without specifying the detection method", "B. Create a brand name only, as naming principles don't apply to complex biomarker tests", "C. Include the analyte names, intended use, and detection method in the product name", "D. Use only the disease indication name since the test detects multiple biomarkers"], "answer": "C", "type": "Parallel", "explanation": "For complex IVD tests detecting multiple biomarkers, regulatory frameworks typically require comprehensive naming that includes: 1) the analytes or biomarkers being detected, 2) the intended use or purpose of the test, and 3) the detection methodology or technology. This approach ensures clear identification of the product's capabilities and limitations for healthcare professionals. Using only generic names, brand names, or disease indications without technical specifications would not provide sufficient information about the test's analytical characteristics.", "category": "Medical_Devices", "related_concept": "naming principles", "id": "PA_P_00378_003", "match_type": "weak", "match_score": 0.746183421438764, "lang": "EN", "source_cn": "体外诊断试剂注册与备案管理办法（2021年第48号令）.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0026_0018_1"}
{"question": "Statement 1: In US regulations, lakes prepared from straight colors must meet specific chemical specifications including limits on ether extracts and intermediates. Statement 2: Chinese regulations require that when water or volatile solvents are used in manufacturing but removed in later steps, this must be explicitly noted in documentation. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, Statement 2 is incorrect.", "C. Statement 1 is incorrect, Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: US regulations (§82.2051) specify that lakes must meet specifications including ether extracts not more than 0.5% and intermediates not more than 0.2%. Statement 2 is correct: Chinese regulations explicitly state that auxiliary agents like water or volatile solvents used in production but removed in subsequent steps must be noted. This highlights different regulatory focuses: US on chemical specifications for color additives, China on comprehensive manufacturing documentation.", "category": "Cosmetics", "related_concept": "lake specifications, raw material differentiation", "id": "PA_P_00657_002", "match_type": "weak", "match_score": 0.7396463944047357, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0014_0005_2"}
{"question": "In comparing US and Chinese regulatory approaches to rehabilitation support, which statement best describes the primary difference in departmental responsibilities?", "choices": ["A. US regulations focus on electronic prescription access controls, while Chinese regulations assign specific government departments to provide rehabilitation guidance and support.", "B. Both systems rely on healthcare providers to coordinate all rehabilitation services without government involvement.", "C. Chinese regulations delegate rehabilitation responsibilities to private organizations, while US regulations use federal agencies exclusively.", "D. US regulations specify municipal-level departments for rehabilitation, while Chinese regulations use national agencies only."], "answer": "A", "type": "Parallel", "explanation": "The Chinese regulation explicitly assigns responsibilities to specific government departments (civil affairs, human resources, education) for providing rehabilitation guidance and support, while the US regulation focuses on establishing logical access controls for electronic prescription systems without specifying departmental roles for rehabilitation services.", "category": "Rehabilitation_Systems", "related_concept": "departmental responsibilities for community rehabilitation", "id": "PA_P_00694_001", "match_type": "weak", "match_score": 0.7089623773362179, "lang": "EN", "source_cn": "戒毒条例.txt", "source_us": "PART_1311REQUIREMENTS_FOR_ELECTRONIC_ORDERS_AND_PR.txt", "old_id": "comp_0002_0008_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中美化妆品监管框架，当化妆品中含有被证实具有致癌风险的物质（如氯乙烯）时，两国法规均会直接认定该产品为掺假产品并予以禁止。\n陈述2：在化妆品安全信息标识方面，美国FDA对特定类别产品（如液体口服卫生产品）有明确的防篡改包装及标签要求，以防止恶意掺假并保护消费者。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误。虽然美国法规（FD&C Act）明确将含有氯乙烯等有害物质的化妆品气雾剂产品认定为掺假产品，但中国法规文本并未直接涉及对特定致癌物质的类似禁令规定。中国法规更侧重于建立不良反应监测体系来控制风险，而非直接列举并禁止特定物质。因此，不能得出“两国法规均会直接认定”的结论。\n陈述2正确。美国法规文本明确指出，FDA有权并负责为化妆品液体口服卫生产品等建立全国统一的防篡改包装要求，并对未使用此类包装或标签不当的产品认定为掺假或错误标签。这体现了美国在特定产品安全标识方面的具体监管要求。", "category": "Cosmetics", "related_concept": "carcinogenic substance regulation, product safety labeling, regulatory responsibility", "id": "PA_P_00598_004", "match_type": "weak", "match_score": 0.746825189864822, "lang": "CN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0001_0003_2"}
{"question": "Statement 1: In Chinese regulatory practice, when an imported material fails initial testing, the importer has the right to request a retest within a specified timeframe. Statement 2: In US regulatory practice, when an application is withdrawn without prejudice, the resubmission date determines when regulatory review timelines begin.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: Chinese regulations allow importers to apply for retesting (复验申请) when disputing initial results. Statement 2 is correct: US regulations specify that for withdrawn applications resubmitted without prejudice, review timelines begin from the resubmission receipt date.", "category": "Drugs", "related_concept": "复验申请, pending application, resubmission date", "id": "PA_P_00362_002", "match_type": "weak", "match_score": 0.6778290302816473, "lang": "EN", "source_cn": "进口药材管理办法（2019年第9号令）.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0007_0006_2"}
{"question": "When a cosmetics company based in China contracts manufacturing to an overseas facility, what is the primary regulatory documentation requirement compared to contracting to a domestic facility?", "choices": ["A. Both require identical documentation of the manufacturing relationship", "B. Overseas production requires specific delegation relationship documents, while domestic production requires formal association through authorized user systems", "C. Domestic production requires more extensive safety testing documentation than overseas production", "D. Overseas production requires proof of safety factor application, while domestic production requires color additive listing approval"], "answer": "B", "type": "Parallel", "explanation": "For overseas production, Chinese regulations require specific delegation relationship documents that must include detailed information about both parties and the agreement. For domestic production, the requirement focuses on formal association through authorized user systems with confirmation from the manufacturing facility. This reflects different regulatory approaches to oversight of domestic versus international manufacturing relationships.", "category": "Cosmetics", "related_concept": "overseas production authorization, delegation relationship documentation", "id": "PA_P_00655_001", "match_type": "weak", "match_score": 0.7485309375905908, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0008_0004_1"}
{"question": "关于化妆品进口的境内责任人制度，以下哪项描述最准确地反映了中美法规的典型差异？", "choices": ["A. 中国法规明确要求进口化妆品必须指定境内责任人，而美国FDA法规中无此特定概念，主要通过进口商或制造商承担相应责任。", "B. 美国FDA对进口化妆品有比中国NMPA更严格的境内责任人资质要求。", "C. 两国法规均要求进口化妆品必须指定一个名为“境内责任人”的实体，其职责完全相同。", "D. 中国法规不要求进口化妆品指定境内责任人，而美国FDA对此有强制性规定。"], "answer": "A", "type": "Parallel", "explanation": "中国《化妆品监督管理条例》明确规定，进口化妆品必须指定中国境内的责任人，负责产品备案、不良反应监测、召回等事宜。美国FDA的法规体系中没有完全对等的“境内责任人”法定概念，相关责任（如产品安全、标签合规、不良事件报告）主要由产品的美国制造商、包装商、分销商或进口商（即“责任人”）承担，其责任主体定义和指定方式与中国法规存在差异。选项B、C、D的描述均与两国法规的实际情况不符。", "category": "Cosmetics", "related_concept": "domestic responsible person", "id": "PA_P_00641_015", "match_type": "weak", "match_score": 0.7158851255801912, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0065_0003_1"}
{"question": "在化妆品原料的遗传毒性评估中，关于细菌回复突变试验的剂量设计，以下哪项陈述正确反映了中美法规的潜在要求差异？", "choices": ["A. 中国法规明确要求提供最低抑菌浓度或最大溶解度的预试验数据作为最高剂量设计依据，美国法规则未在提供文本中规定具体依据。", "B. 美国法规要求剂量设计必须基于致癌风险模型，中国法规则无此要求。", "C. 两国法规都强制要求使用相同的阳性对照物和判断标准。", "D. 美国法规禁止在细菌回复突变试验中使用代谢物活化系统，中国法规则要求使用。"], "answer": "A", "type": "Parallel", "explanation": "提供的中国法规文本（2-1l）在“剂量设计及最高剂量设计依据”中明确要求“提供最低抑菌浓度或最大溶解度的预试验数据”。提供的美国法规文本主要涉及着色剂的致癌条款和安全性评估流程，并未具体规定细菌回复突变试验的剂量设计依据。因此，选项A正确指出了这一基于文本的潜在差异。选项B、C、D的描述均无文本支持或与常识不符。", "category": "Cosmetics", "related_concept": "bacterial reverse mutation test, dose design and maximum dose basis", "id": "PA_P_00642_015", "match_type": "weak", "match_score": 0.7135537295140276, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0040_0005_2"}
{"question": "关于化妆品不良反应在线报告系统，中美法规的主要差异体现在：", "choices": ["A. 中国要求所有相关方必须通过国家系统在线报告，美国则无统一的强制在线报告系统", "B. 美国要求所有报告必须通过FDA在线系统提交，中国允许纸质报告替代", "C. 两国都建立了完全相同的强制性在线报告系统，仅报告时限不同", "D. 中国仅要求注册人备案人使用在线系统，其他方自愿；美国要求所有企业强制在线报告"], "answer": "A", "type": "Parallel", "explanation": "中国法规建立了国家化妆品不良反应监测信息系统，要求注册人、备案人、受托生产企业、经营者、医疗机构等必须通过该系统报告，仅对暂不具备条件的允许纸质报告。美国法规文本中未提及统一的在线报告系统要求，主要关注颜色添加剂的相关程序。", "category": "Cosmetics", "related_concept": "online reporting system", "id": "PA_P_00600_001", "match_type": "weak", "match_score": 0.7015591063791814, "lang": "CN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0007_0002_1"}
{"question": "Statement 1: Under Chinese regulations, facilities storing special management drugs must have storage facilities that comply with national standards, which may include specific security and control measures beyond standard pharmaceutical storage. Statement 2: US regulations require that drug strength be expressed in milligrams of active ingredient per milliliter of reconstituted solution, unless another measurement is more appropriate for the specific drug formulation. Which of the following is correct about these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Both statements accurately reflect regulatory requirements. Statement 1 correctly describes Chinese requirements for special management drug storage, which typically involves controlled substances requiring enhanced security and compliance with national standards. Statement 2 accurately represents US FDA requirements for expressing dosage strength, particularly for reconstituted solutions, as specified in labeling regulations. These represent different but complementary regulatory approaches to ensuring drug safety and quality.", "category": "Drugs", "related_concept": "special management drug storage facilities, dosage strength measurement", "id": "PA_P_00274_002", "match_type": "weak", "match_score": 0.7332613103838498, "lang": "EN", "source_cn": "药品经营质量管理规范（2015年国家食品药品监督管理总局令第13号公布，2016年令第28号修正）.txt", "source_us": "PART_201LABELING.txt", "old_id": "comp_0009_0044_2"}
{"question": "When regulatory requirements conflict between different parts of a regulatory framework, how do US and Chinese regulatory systems typically approach resolution?", "choices": ["A. US: More specific regulations supersede general ones; China: Higher-level administrative decisions typically resolve conflicts.", "B. Both systems always default to the most recent regulation regardless of specificity.", "C. Chinese regulations allow industry self-determination of conflicts, while US requires immediate FDA arbitration.", "D. US regulations require congressional approval for conflict resolution, while Chinese regulations use judicial review exclusively."], "answer": "A", "type": "Parallel", "explanation": "US regulatory frameworks often include explicit conflict resolution principles where more specific regulations supersede general ones. Chinese regulatory systems typically rely on administrative hierarchy and government department decisions to resolve regulatory conflicts, with higher-level authorities providing guidance or decisions.", "category": "Regulatory Compliance", "related_concept": "conflict resolution", "id": "PA_P_00004_002", "match_type": "weak", "match_score": 0.7367857571520213, "lang": "EN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0002_0011_2"}
{"question": "Statement 1: In controlled substance research, changing joint research units requires regulatory approval in China but not in the US. Statement 2: Experimental research approvals have fixed validity periods in China, while US quota-based systems operate on annual assessment cycles.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect because both systems require regulatory approval for changes to research arrangements. Statement 2 is correct as Chinese approvals have specific validity periods (e.g., 5 years with possible extension), while US systems use annual assessments and quota determinations.", "category": "Controlled_Substances", "related_concept": "change of joint research unit, experimental research approval validity period", "id": "PA_P_00721_007", "match_type": "weak", "match_score": 0.7337288345306331, "lang": "EN", "source_cn": "麻醉药品和精神药品实验研究管理规定.txt", "source_us": "PART_1315IMPORTATION_AND_PRODUCTION_QUOTAS_FOR_EPH.txt", "old_id": "comp_0005_0010_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在中国化妆品原料监管体系中，原料生产商完成企业信息备案后，会获得一个原料报送码，该编码用于化妆品注册备案时关联已备案的原料安全信息文件。\n陈述2：在美国化妆品原料监管中，当已提交的申请需要补充非临床研究数据时，提交方必须声明该研究是否符合GLP规范，否则该补充材料可能不被视为实质性修正。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。中国法规建立了原料安全信息备案平台，原料生产商备案企业信息后获得报送权限，其报送的原料信息会生成原料报送码。化妆品注册人/备案人在产品注册备案时，可通过填写此码直接关联使用已备案的原料安全信息，提高了效率和一致性。\n陈述2正确。根据美国FDA法规（21 CFR 10.30(b)），对于已提交的申请（petition），如果补充提交的支持性数据中包含非临床实验室研究，提交方必须提供一份声明，说明该研究是否遵守了GLP（part 58）的规定。这是对补充材料（可能构成实质性修正）的一项具体合规性要求。", "category": "Cosmetics", "related_concept": "原料报送码关联, nonclinical laboratory study compliance, 原料安全信息备案", "id": "PA_P_00659_007", "match_type": "weak", "match_score": 0.6373926376727486, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0047_0001_2"}
{"question": "关于化妆品检验结论异议的处理时限，中美法规存在显著差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规规定了异议审查和复检申请两个阶段的明确时限，而美国法规未对检验结论异议的处理时限作出具体规定", "B. 美国法规对检验结论异议的处理时限要求比中国法规更严格，通常要求在更短时间内完成", "C. 中美法规都规定了相同的异议处理时限，均为收到检验报告后7个工作日内提出申请", "D. 中国法规未规定异议处理时限，而美国法规要求必须在20个工作日内完成异议审查"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定了异议审查（20个工作日）和复检申请（7个工作日）的具体时限，形成了完整的时限体系。而提供的美国法规文本主要涉及色素添加剂的认证、使用和标签要求，未包含对检验结论异议处理时限的具体规定，这体现了中美监管框架的差异。", "category": "Cosmetics", "related_concept": "复检申请时限, 异议审查期限", "id": "PA_P_00611_007", "match_type": "weak", "match_score": 0.6538440423090186, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0010_0018_1"}
{"question": "When establishing microbiological and physicochemical specifications for cosmetic ingredients, which approach is more likely to reflect a focus on controlling impurities from the manufacturing process itself?", "choices": ["A. Setting limits for specific chemical impurities like sulfonated subsidiaries, leuco base, and subsidiary colors.", "B. Setting limits for general microbial contamination like total plate count and fecal coliforms.", "C. Specifying sensory characteristics like color, odor, and appearance.", "D. Defining quality control measures such as batch-by-batch testing or raw material control."], "answer": "A", "type": "Parallel", "explanation": "Option A describes limits for specific chemical by-products and impurities (e.g., subsidiary colors, leuco base) that are direct results of the chemical synthesis process for a color additive. This reflects a process control focus. Option B describes general product contamination limits. Option C is unrelated to process impurities. Option D describes quality actions, not the specification limits themselves.", "category": "Cosmetics", "related_concept": "specification compliance, production process control", "id": "PA_P_00653_045", "match_type": "weak", "match_score": 0.7433638742673015, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0052_0005_1"}
{"question": "Statement 1: Regulatory systems for pharmaceutical professionals should include mechanisms for continuous competence enhancement through structured education programs.\nStatement 2: Drug manufacturing regulations should specify when component identity testing can be substituted with supplier documentation versus when specific testing is required.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 reflects the Chinese regulatory approach that emphasizes continuing education to enhance professional competence and build a qualified pharmacist workforce. Statement 2 reflects the US regulatory approach that provides specific guidance on when component identity testing is required versus when supplier documentation (certificate of analysis) is acceptable, particularly for PET drugs. Both represent valid regulatory principles from different jurisdictions.", "category": "Drugs", "related_concept": "professional competence enhancement, component identity testing", "id": "PA_P_00159_002", "match_type": "weak", "match_score": 0.7306140972729812, "lang": "EN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_212CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_PO.txt", "old_id": "comp_0001_0003_2"}
{"question": "Statement 1: Chinese cosmetics regulations require regulatory authorities to publish contact information for public inquiries and complaints. Statement 2: US color additive regulations specify exact timelines for publishing new regulations in the Federal Register after petition submission.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: Chinese regulation explicitly requires drug supervision departments to publish website addresses, email addresses, or telephone numbers for accepting consultations, complaints, and reports. Statement 2 is correct: US regulation specifies that the Commissioner will forward regulations for publication within 90 days after petition filing (or 180 days if extended), establishing clear publication timelines.", "category": "Cosmetics", "related_concept": "public contact information, regulation publication timeline", "id": "PA_P_00677_007", "match_type": "weak", "match_score": 0.7349581674297443, "lang": "EN", "source_cn": "化妆品监督管理条例 (1).txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0017_0002_2"}
{"question": "Statement 1: Chinese cosmetics regulations require that all production-related records be maintained in a way that allows complete traceability of materials and activities throughout the manufacturing process. Statement 2: US regulations for color additives require that distribution records be kept separately from all other business records to ensure their integrity and accessibility for regulatory review.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the Chinese requirement for comprehensive traceability where all batch-related records must be mutually linked. Statement 2 accurately reflects the US requirement that color additive distribution records must be kept separately from all other records. Both statements represent valid regulatory approaches to record management in their respective jurisdictions.", "category": "Cosmetics", "related_concept": "record segregation", "id": "PA_P_00668_002", "match_type": "weak", "match_score": 0.7361983533670106, "lang": "EN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0005_0004_2"}
{"question": "In the context of cosmetics regulation, which of the following best describes a key difference in how the US and China approach the basis for consumer testing?", "choices": ["A. The US requires testing based on specific color additive certifications, while China requires testing based on product usage methods and efficacy claims.", "B. The US mandates consumer testing for all cosmetics, while China only requires it for products containing color additives.", "C. China requires testing to reference established methods and sources, while the US does not specify a basis for consumer testing.", "D. The US bases consumer testing on batch certification results, while China bases it on adverse reaction reports."], "answer": "A", "type": "Parallel", "explanation": "The US regulation text focuses on color additive certification (e.g., FD&C Green No. 3, D&C Green No. 5) as a regulatory basis, implying that compliance with these certifications is a foundation. The Chinese regulation explicitly states that consumer testing should have a 'test basis' referencing methods and sources, and must align with 'test purpose and principle' matching efficacy claims, along with considering product usage methods. This highlights the US's chemical-specific certification approach versus China's methodological and claim-based approach.", "category": "Cosmetics", "related_concept": "consumer testing basis", "id": "PA_P_00602_006", "match_type": "weak", "match_score": 0.7325288978405176, "lang": "EN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0008_0018_1"}
{"question": "In regulatory frameworks, how do recognition and reward mechanisms typically differ between administrative systems focused on internal performance versus those centered on international market access?", "choices": ["A. Internal systems reward individual achievements in public service, while international systems focus on mutual acceptance of conformity assessments to facilitate trade.", "B. Both systems primarily use financial incentives to motivate compliance with technical regulations.", "C. Internal systems emphasize public recognition of organizations, while international systems reward individual technical experts.", "D. Recognition in both systems is tied directly to successful litigation outcomes against non-compliant entities."], "answer": "A", "type": "Parallel", "explanation": "Administrative systems often implement recognition and reward programs to incentivize excellence in public service and regulatory work, focusing on individual or organizational achievements. In contrast, international regulatory frameworks emphasize mutual recognition of conformity assessment results between parties as a mechanism to facilitate market access, treating this recognition as a functional component of trade agreements rather than a reward system.", "category": "General_FDA", "related_concept": "recognition and reward", "id": "PA_P_00784_001", "match_type": "weak", "match_score": 0.7167305693309757, "lang": "EN", "source_cn": "中华人民共和国行政复议法.txt", "source_us": "PART_26MUTUAL_RECOGNITION_OF_PHARMACEUTICAL_GOOD_M.txt", "old_id": "comp_0002_0011_1"}
{"question": "Statement 1: In the US, a cosmetic product can be deemed adulterated and subject to control measures if it contains an ingredient proven to be injurious to users, even without a specific adverse event report. Statement 2: In China, control measures for cosmetics are typically initiated only after provincial authorities investigate and confirm severe adverse reactions with significant social impact. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 reflects the US principle where products containing harmful ingredients (like vinyl chloride) can be declared adulterated based on scientific evidence of potential harm, allowing proactive control. Statement 2 aligns with China's described tiered system where provincial authorities investigate severe/socially impactful reactions before implementing controls. Both represent valid regulatory approaches within their respective frameworks.", "category": "Cosmetics", "related_concept": "control measures for adverse reactions", "id": "PA_P_00598_002", "match_type": "weak", "match_score": 0.6923319212599675, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0002_0003_2"}
{"question": "In comparing US and Chinese cosmetic regulatory frameworks, which statement accurately describes the approach to registration information requirements?", "choices": ["A. Both systems require detailed technical data and safety assessments for all cosmetic product registrations.", "B. The US system focuses primarily on establishment identification, while China requires detailed product information and technical reviews for certain categories.", "C. China's system is purely voluntary like the US system, with no mandatory technical documentation.", "D. The US requires more comprehensive technical reviews than China for all cosmetic products entering the market."], "answer": "B", "type": "Parallel", "explanation": "The US registration (Form FD-2511) focuses on establishment identification (name, address, business type) without requiring product-specific technical data. China's system distinguishes between registration (for special cosmetics and high-risk new ingredients) requiring technical review, and simpler filing (for ordinary cosmetics and other new ingredients), with detailed information requirements varying by product category.", "category": "Cosmetics", "related_concept": "registration information, technical review", "id": "PA_P_00646_001", "match_type": "weak", "match_score": 0.7400495999839193, "lang": "EN", "source_cn": "化妆品注册备案管理办法（2021年第35号令）.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0002_0001_1"}
{"question": "Statement 1: The US FDA Commissioner can revoke a color additive's exemption from certification if new information indicates it's necessary for public health protection.\nStatement 2: Chinese NMPA requires detailed individual subject data recording for cosmetic patch tests, including demographic information and time-point observations.\nWhich of the following is correct about these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes FDA's authority under 21 CFR 71.26 to revoke certification exemptions when public health concerns arise. Statement 2 accurately reflects NMPA's requirement for comprehensive test subject data recording in cosmetic patch tests, including demographic details and multiple observation time points as shown in the technical specifications.", "category": "Cosmetics", "related_concept": "revocation of exemption from certification, test subject data", "id": "PA_P_00638_013", "match_type": "weak", "match_score": 0.6795009690969347, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0048_0003_2"}
{"question": "关于多色号系列防晒化妆品的抽样检验，中美法规在抽样比例和产品选择上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求按固定比例抽样并优先检验着色剂含量最低的产品，美国法规未规定具体抽样方法", "B. 中国法规要求对所有产品进行全检，美国法规允许按风险等级抽样", "C. 中美法规都要求按20%比例抽样，但产品选择标准不同", "D. 美国法规要求优先检验着色剂含量最高的产品，中国法规未规定优先顺序"], "answer": "A", "type": "Parallel", "explanation": "中国法规对多色号系列防晒化妆品明确规定了20%的抽样比例（不足5个按5个计），并要求优先选择着色剂含量最低或无着色剂的产品进行检验。美国法规中关于防晒产品的部分主要关注产品分类和标签要求，未对多色号系列的抽样检验方法做出具体规定。", "category": "Cosmetics", "related_concept": "sampling inspection method, product selection criteria for testing", "id": "PA_P_00641_001", "match_type": "weak", "match_score": 0.747778714054564, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0011_0008_1"}
{"question": "Consider the following statements about regulatory oversight and exemptions:\nStatement 1: Regulatory authorities may delegate supervisory responsibilities for specialized facilities (like GLP labs) to specific military or logistical departments within their governance structure.\nStatement 2: Parties seeking exemption from certain promotional material requirements must formally demonstrate their materials are non-misleading and provide full documentation to support their petition.", "choices": ["A. Both statements are correct.", "B. Only Statement 1 is correct.", "C. Only Statement 2 is correct.", "D. Neither statement is correct."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 reflects that in some regulatory systems, oversight of Good Laboratory Practice (GLP) facilities can be delegated to specific bodies like a military logistics/health department, acting with provincial-level authority. Statement 2 accurately describes a common regulatory mechanism where a waiver from advertising rules requires a formal petition including a copy of the ad and a demonstration of compliance with truthfulness and balance standards. Both illustrate distinct regulatory approaches to supervision and compliance flexibility.", "category": "Drugs", "related_concept": "supervisory authority delegation, waiver petition requirements", "id": "PA_P_00338_002", "match_type": "weak", "match_score": 0.7141840261664573, "lang": "EN", "source_cn": "药物非临床研究质量管理规范认证.txt", "source_us": "PART_202PRESCRIPTION_DRUG_ADVERTISING.txt", "old_id": "comp_0009_0008_2"}
{"question": "In regulatory frameworks for medical devices, how do the approaches to device identification typically differ between systems that emphasize general principles versus those that specify individual device types?", "choices": ["A. Principle-based systems define broad categories while type-based systems provide specific identification criteria for each device.", "B. Both systems rely exclusively on detailed technical specifications for identification.", "C. Type-based systems use general principles while principle-based systems list individual devices.", "D. Neither system addresses device identification in their regulatory approach."], "answer": "A", "type": "Parallel", "explanation": "Regulatory systems differ in their approach to device identification. Some establish general principles and categories for devices (as seen in foundational regulations), while others provide specific identification criteria for individual device types (as demonstrated in device-specific classifications). This reflects different regulatory philosophies - one establishing overarching frameworks, the other detailing specific requirements.", "category": "Medical_Devices", "related_concept": "device identification", "id": "PA_P_00484_001", "match_type": "weak", "match_score": 0.7323767896515957, "lang": "EN", "source_cn": "医疗器械监督管理条例.txt", "source_us": "PART_862CLINICAL_CHEMISTRY_AND_CLINICAL_TOXICOLOGY.txt", "old_id": "comp_0001_0020_1"}
{"question": "Statement 1: Regulatory authorities can impose administrative penalties including fines and license revocation for violations related to product quality and business practices. Statement 2: When illegitimate pharmaceutical products are confirmed, they must be properly disposed of according to regulatory requirements to prevent re-entry into the supply chain.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes administrative penalties that regulatory bodies can impose for violations, including fines and license revocation. Statement 2 correctly describes the requirement for proper disposition of confirmed illegitimate products to ensure they don't re-enter the supply chain and pose public health risks.", "category": "Drugs", "related_concept": "disposition of illegitimate product, administrative penalties for violations", "id": "PA_P_00019_005", "match_type": "weak", "match_score": 0.748454980536259, "lang": "EN", "source_cn": "中华人民共和国药品管理法.txt", "source_us": "PART_251SECTION_804_IMPORTATION_PROGRAM.txt", "old_id": "comp_0031_0014_2"}
{"question": "Statement 1: In the US regulatory framework for cosmetics, safety evaluation criteria for color additives must include specific tests for acute oral toxicity, primary irritation, and sensitization unless waived by the Commissioner based on alternative data.\nStatement 2: In China's cosmetic regulatory system, provincial monitoring institutions are responsible for collecting and analyzing adverse reaction data and providing risk management recommendations to provincial drug regulatory departments.\nWhich of the following is correct about these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 accurately reflects US regulations where specific safety tests are required for external color additives, with provisions for waiver if alternative data establishes safety. Statement 2 correctly describes China's system where provincial monitoring institutions have defined responsibilities for adverse reaction data collection, analysis, and risk management recommendations to provincial authorities.", "category": "Cosmetics", "related_concept": "safety evaluation criteria, information system management", "id": "PA_P_00599_004", "match_type": "weak", "match_score": 0.6978499541970472, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0004_0004_2"}
{"question": "关于化妆品功效宣称评价，中美法规在评价项目选择上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求必须进行人体功效评价试验，而美国法规则无此强制要求。", "B. 中国法规允许从多种评价方法中选择，而美国法规则未明确规定具体评价方法。", "C. 美国法规要求必须提供文献资料和研究数据，而中国法规则无此要求。", "D. 两国法规均强制要求必须进行消费者使用测试和实验室试验。"], "answer": "B", "type": "Parallel", "explanation": "中国法规明确列出了多种可选的功效宣称评价项目（如文献资料、研究数据、人体功效评价试验等），注册人/备案人可根据情况选择。美国法规（FDA）对化妆品功效宣称的评价方法通常未在标签法规中具体规定，更侧重于事后监管和禁止虚假宣称。", "category": "Cosmetics", "related_concept": "efficacy claim evaluation", "id": "PA_P_00604_003", "match_type": "weak", "match_score": 0.7212471404943008, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0012_0007_1"}
{"question": "Statement 1: In the US, medical devices containing ozone-depleting substances must include specific environmental warnings in both physician labeling and patient information materials. Statement 2: In China, individual reagent components listed in the registration certificate can be sold separately when used with the originally registered diagnostic system.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes US Clean Air Act requirements for medical devices containing substances like chlorofluorocarbons (CFCs), which mandate specific environmental warnings in both physician package inserts and patient information materials. Statement 2 accurately reflects Chinese regulations that allow individual reagent components listed in the registration certificate to be sold separately when they are intended for use with the originally registered diagnostic system. Both statements represent established regulatory principles in their respective jurisdictions.", "category": "Medical_Devices", "related_concept": "Clean Air Act compliance, separate sales", "id": "PA_P_00378_004", "match_type": "weak", "match_score": 0.746183421438764, "lang": "EN", "source_cn": "体外诊断试剂注册与备案管理办法（2021年第48号令）.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0026_0018_2"}
{"question": "关于化妆品注册备案资料的责任主体，中美法规的核心差异主要体现在哪个方面？", "choices": ["A. 中国法规强调注册人/备案人对资料合法性、真实性等负全责，美国法规则未明确要求注册人对资料内容承担法律责任", "B. 美国法规要求注册人对资料真实性负全责，中国法规则无此要求", "C. 两国法规均要求注册人对资料真实性负责，但中国额外要求境内责任人监督境外注册人", "D. 美国法规要求资料必须经FDA审核批准，中国法规则无需审核"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定化妆品注册人、备案人对提交资料的合法性、真实性、准确性、完整性和可追溯性负责，并承担相应法律责任。美国法规（§710部分）主要规定企业注册的程序性要求，如注册时间、方式、信息内容等，但未像中国法规那样明确要求注册人对资料内容承担全面的法律责任。选项B、C、D的描述均不符合两国法规的实际规定。", "category": "Cosmetics", "related_concept": "legality and authenticity responsibility", "id": "PA_P_00652_001", "match_type": "weak", "match_score": 0.7374343788761841, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0001_0001_1"}
{"question": "Statement 1: Under Chinese cosmetics regulations, the primary entity responsible for ensuring document formatting meets specific standards (like color, paper size, and unit consistency) is the registrant or备案人 (filing person). Statement 2: Under US FDA regulations for color additives, the primary regulatory focus for ensuring product safety and identity before market entry is batch-by-batch certification by the FDA.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct. Chinese (NMPA) regulations place the responsibility for document preparation and compliance with formatting standards (法定计量单位/statutory measurement units, A4 paper, black text) squarely on the registrant/filing person or their domestic agent. Statement 2 is correct. The core US (FDA) regulatory mechanism for certifiable color additives, as shown in the text for D&C colors, is the requirement that 'All batches... shall be certified' by the FDA, which verifies identity and specifications to ensure safety.", "category": "Cosmetics", "related_concept": "document formatting standards, use of statutory measurement units, batch certification", "id": "PA_P_00617_002", "match_type": "weak", "match_score": 0.7463438671752494, "lang": "EN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0002_0025_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中国法规，中医药传统知识持有人享有知情同意和利益分享的权利。\n陈述2：根据美国法规，当FDA终止某项豁免批准时，可能同时命令制造商停止传播特定信息。", "choices": ["A. 两个陈述都正确。", "B. 陈述1正确，陈述2错误。", "C. 陈述1错误，陈述2正确。", "D. 两个陈述都错误。"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。中国《中医药法》第四十三条明确规定：“中医药传统知识持有人……对他人获取、利用其持有的中医药传统知识享有知情同意和利益分享等权利。”这构成了中医药传统知识保护制度的核心内容之一。\n陈述2正确。美国FDA法规（21 CFR 99.403(b)(1)）明确规定，当FDA终止一项被视为批准的豁免申请时，可以命令制造商停止传播信息。这是FDA在认为继续传播可能对公众健康构成风险或不符合监管要求时采取的关键执法措施。", "category": "Drugs", "related_concept": "traditional knowledge protection database and system, cease dissemination order", "id": "PA_P_00010_004", "match_type": "weak", "match_score": 0.7169394057387558, "lang": "CN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0010_0008_2"}
{"question": "Statement 1: In US controlled substance regulations, the Administrator has discretion to hold hearings for national needs assessments but must hold hearings when requested by quota applicants regarding quota issuance, adjustment, suspension, or denial.\nStatement 2: Chinese regulations for controlled substance experimental research establish that approval holders bear primary responsibility for research activities, while joint research units share in the application process but not necessarily in post-approval accountability.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the US hearing procedures: §1315.52(a) gives the Administrator discretion for national needs assessment hearings, while §1315.52(b) requires hearings when requested by quota applicants. Statement 2 accurately reflects Chinese regulations: the approval holder bears 'main responsibility' for experimental research, while joint research units participate in applications but aren't specified as sharing post-approval accountability. Both statements demonstrate key comparative differences between the regulatory systems.", "category": "Controlled_Substances", "related_concept": "hearing procedures, approval holder responsibility", "id": "PA_P_00721_002", "match_type": "weak", "match_score": 0.7273108254843883, "lang": "EN", "source_cn": "麻醉药品和精神药品实验研究管理规定.txt", "source_us": "PART_1315IMPORTATION_AND_PRODUCTION_QUOTAS_FOR_EPH.txt", "old_id": "comp_0001_0010_2"}
{"question": "When a cosmetic product fails to meet regulatory requirements in the US and China, how do the approaches to documenting the reason for noncompliance differ?", "choices": ["A. The US requires a brief statement of reason, while China requires detailed documentation from the domestic responsible person.", "B. Both require identical documentation formats submitted to the same regulatory body.", "C. China requires no documentation, while the US mandates a comprehensive technical report.", "D. The US requires documentation only for color additives, while China requires it for all cosmetics."], "answer": "A", "type": "Parallel", "explanation": "US regulations (FDA) require a brief statement explaining noncompliance reasons, particularly for clinical investigations. Chinese regulations (NMPA) mandate that imported products designate a domestic responsible person who handles documentation, including noncompliance matters, though the specific format isn't detailed in the provided text. The other options misrepresent the regulatory approaches.", "category": "Cosmetics", "related_concept": "noncompliance reason statement, domestic responsible person", "id": "PA_P_00638_018", "match_type": "weak", "match_score": 0.7380619140844024, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0059_0002_1"}
{"question": "A pharmaceutical company receives a negative regulatory decision from a health authority. Which regulatory system requires the authority to initiate communication with the applicant within 5 days when maintaining the original decision after expert consultation, and which system allows applicants to request an opinion within 30 days of a notice publication to become eligible for a hearing?", "choices": ["A. Chinese system requires 5-day communication; US system allows 30-day opinion request", "B. US system requires 5-day communication; Chinese system allows 30-day opinion request", "C. Both systems require 5-day communication and allow 30-day opinion requests", "D. Neither system has specific timelines for communication or opinion requests"], "answer": "A", "type": "Parallel", "explanation": "The Chinese regulatory framework mandates that when a negative decision is maintained after expert consultation, the authority must communicate with the applicant within 5 days. In contrast, the US system allows persons to request an opinion within 30 days of notice publication to become eligible for a hearing opportunity.", "category": "Drugs", "related_concept": "communication within 5 days, request for opinion deadline", "id": "PA_P_00208_001", "match_type": "weak", "match_score": 0.7151453350767615, "lang": "EN", "source_cn": "药品注册审评结论异议解决程序（试行）.txt", "source_us": "PART_314APPLICATIONS_FOR_FDA_APPROVAL_TO_MARKET_A_.txt", "old_id": "comp_0002_0072_1"}
{"question": "关于企业开业前的行政许可要求，中美法规在核发主体和程序上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求企业必须同时取得营业执照和特种行业许可证后方可开业，而美国法规仅要求企业在特定行业（如食品）进行设施注册。", "B. 中国法规要求企业开业前必须获得市场监管部门和公安机关的许可，而美国法规要求企业开业前必须获得FDA的批准。", "C. 中国法规对特种行业有明确的许可证要求，而美国法规对所有企业开业都实行统一的注册制。", "D. 中国法规要求企业开业前必须完成计量认证，而美国法规要求企业开业前必须完成食品安全认证。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如《计量法实施细则》和《母婴保健法实施办法》的修改内容所示）体现了对特定行业（如产品质量检验、婚前医学检查）开业前需取得多重行政许可（如营业执照、特种行业许可证、卫生行政部门许可）的监管模式。美国法规（如FDA关于设施注册的节选）则体现了对特定领域（如食品）企业实行周期性注册更新（Registration renewal）的监管模式，其开业前要求更侧重于在监管机构进行信息备案而非获取多重前置许可。选项A准确概括了这种“中国多重前置许可”与“美国特定领域注册备案”的核心差异。选项B错误地将美国法规的注册要求等同于中国的“批准”，且“所有企业”表述不准确。选项C错误地认为美国对所有企业实行统一注册。选项D混淆了计量认证/食品安全认证与开业许可的核心概念。", "category": "General_NMPA_FDA", "related_concept": "business license, special industry permit", "id": "PA_P_00770_015", "match_type": "weak", "match_score": 0.745302970115724, "lang": "CN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0017_0018_1"}
{"question": "A pharmaceutical company executive in China is found guilty of bribing a government official during drug approval. In the US, a company is found to have shipped tannic acid labeled only 'For professional use only' for use in barium enemas without the required warning. How do the regulatory consequences for these violations compare?", "choices": ["A. Both jurisdictions impose severe penalties, but only China specifies a lifetime industry ban for the bribery offense.", "B. Both jurisdictions focus primarily on financial penalties and product recalls, with no personal bans.", "C. The US violation is considered more severe, as it involves a direct public health risk from misbranding, while China's bribery penalty is administrative.", "D. The consequences are identical: both cases would result in criminal prosecution and permanent bans for responsible individuals."], "answer": "A", "type": "Parallel", "explanation": "The Chinese regulation explicitly mandates a lifetime ban from the pharmaceutical industry for individuals involved in bribery of state personnel during drug activities. The US text describes a misbranding violation for tannic acid (due to lacking a specific warning against enema use), which would lead to regulatory proceedings but does not mention personal lifetime bans for individuals. Both are serious, but the nature of the maximum personal penalty differs significantly.", "category": "Drugs", "related_concept": "lifetime ban for bribery, misbranding prohibition, warning label requirement", "id": "PA_P_00023_007", "match_type": "weak", "match_score": 0.7242312240367129, "lang": "EN", "source_cn": "中华人民共和国药品管理法.txt", "source_us": "PART_201LABELING.txt", "old_id": "comp_0032_0055_1"}
{"question": "In regulatory frameworks for cosmetics, which approach is more likely to be explicitly funded through government budgetary allocations?", "choices": ["A. Routine sampling inspection programs", "B. Color additive certification exemption processes", "C. Both are equally likely to receive government budget funding", "D. Neither typically receives government budget funding"], "answer": "A", "type": "Parallel", "explanation": "Government budget inclusion is more characteristic of systematic sampling inspection programs, which require structured planning and resource allocation for widespread market surveillance. Color additive certification processes typically operate through regulatory fees and industry submissions rather than direct government budget funding.", "category": "Cosmetics", "related_concept": "government budget inclusion", "id": "PA_P_00609_001", "match_type": "weak", "match_score": 0.6940748301332798, "lang": "EN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0002_0003_1"}
{"question": "A multinational cosmetic company is establishing operations in both the US and China. Which statement accurately compares the registration information requirements for legal representatives between the two regulatory systems?", "choices": ["A. Both US FDA and China NMPA require detailed personal identification documents for legal representatives during establishment registration.", "B. Only China NMPA requires specific personal identification details for legal representatives, while US FDA focuses on establishment-level information.", "C. Only US FDA requires legal representative details, while China NMPA does not collect this information for foreign registrants.", "D. Neither regulatory system requires information about legal representatives for cosmetic establishment registration."], "answer": "B", "type": "Parallel", "explanation": "China NMPA requires detailed personal identification information for legal representatives (including name, ID type, and ID number) as part of the registration process, particularly for foreign registrants. In contrast, US FDA registration (Form FD-2511) focuses on establishment-level information such as business name, address, and type of business, without requiring personal identification details for legal representatives.", "category": "Cosmetics", "related_concept": "Legal representative details", "id": "PA_P_00652_006", "match_type": "weak", "match_score": 0.678616435033923, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0029_0001_1"}
{"question": "关于医疗器械进口代理人的职责，中美法规存在显著差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求代理人必须是境内法人实体并承担协调境外检查等具体义务，而美国法规主要关注代理人资格与监督计划的审查", "B. 两国法规都要求代理人必须是境内法人实体，但中国更强调其协助注册人履行义务，美国更强调其数据收集能力", "C. 美国法规要求代理人负责协调境外检查，而中国法规则要求代理人确保生产符合国内要求", "D. 中国法规对代理人的资格有详细规定，而美国法规则没有明确要求代理人必须是法人实体"], "answer": "A", "type": "Parallel", "explanation": "中国法规（NMPA）明确规定进口医疗器械必须指定境内企业法人作为代理人，并要求代理人协助履行法规义务、协调境外检查等具体职责。美国法规（FDA）在提供的文本中主要关注监督计划提交的审查流程，包括对指定人员资格和监督计划有效性的评估，但未像中国那样强调代理人作为境内法人的实体要求及其在境外检查中的协调角色。", "category": "Medical_Devices", "related_concept": "designated domestic legal entity as agent", "id": "PA_P_00475_015", "match_type": "weak", "match_score": 0.7471626347595011, "lang": "CN", "source_cn": "医疗器械生产监督管理办法（2022年第53号令）.txt", "source_us": "PART_822POSTMARKET_SURVEILLANCE.txt", "old_id": "comp_0019_0003_1"}
{"question": "When comparing regulatory approaches to nanomaterials in cosmetics, which statement best describes a key difference between US and Chinese frameworks regarding characterization requirements?", "choices": ["A. The US requires detailed particle size distribution data for all nanomaterials, while China focuses only on chemical composition limits.", "B. China mandates specific physicochemical parameters like particle size and surface chemistry for nanomaterials, whereas US regulations for color additives emphasize chemical purity and impurity limits without explicit nanomaterial-specific parameters.", "C. Both jurisdictions require identical nanomaterial characterization, including identical tests for particle aggregation and surface morphology.", "D. The US requires more extensive nanomaterial characterization than China, including mandatory in-vivo toxicity studies for all nano-ingredients."], "answer": "B", "type": "Parallel", "explanation": "Chinese regulations explicitly require nanomaterial-specific parameters such as particle size and distribution, aggregation/agglomeration characteristics, surface chemistry, and morphological information. US regulations for color additives, as exemplified, focus on chemical identity, purity specifications, impurity limits (e.g., heavy metals), and total color content, but do not explicitly mandate the same physicochemical characterization for nanomaterials within the provided text. This highlights a difference in regulatory emphasis on material characterization versus chemical composition.", "category": "Cosmetics", "related_concept": "nanomaterial-specific parameters, composition and characterization", "id": "PA_P_00617_014", "match_type": "weak", "match_score": 0.7201783004025023, "lang": "EN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0023_0017_1"}
{"question": "Statement 1: Regulatory systems typically provide formal hearing opportunities when certification decisions are contested. Statement 2: Independent re-inspection institutions are commonly required to ensure impartial quality assessment in regulated industries.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, Statement 2 is incorrect.", "C. Statement 1 is incorrect, Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 reflects the US approach where regulatory hearings are available when color additive certification is refused. Statement 2 aligns with the Chinese requirement that re-inspection institutions must be different from initial inspection agencies to ensure impartiality in cosmetic quality assessment.", "category": "Cosmetics", "related_concept": "regulatory hearing, re-inspection institution", "id": "PA_P_00678_002", "match_type": "weak", "match_score": 0.7167277480269928, "lang": "EN", "source_cn": "化妆品监督管理条例 (1).txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0015_0002_2"}
{"question": "Statement 1: In US FDA regulation, for a color additive intended solely for external use in cosmetics (non-ingested), if appropriate tests suggest it induces cancer by routes other than ingestion, and qualified scientists judge it as causative, the Commissioner may still issue a regulation permitting its use if the data as a whole establish safety under specified conditions. Statement 2: In a standard in vitro mammalian cell gene mutation test for genotoxicity assessment, a negative control group is required to establish a baseline mutation rate, and the test is typically conducted both with and without S9 metabolic activation to evaluate the substance's potential effects with and without metabolic conversion.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect. According to US FDA regulations (§70.50(b)), for non-ingested color additives (e.g., in external drugs and cosmetics), if an appropriate test suggests carcinogenesis and qualified scientists judge that cancer has been induced by the additive, no regulation may be issued which permits its use. Safety under conditions cannot override this if cancer induction is confirmed. Statement 2 is correct, reflecting standard genotoxicity testing principles: a negative control is essential for baseline comparison, and tests are performed with and without S9 metabolic activation to assess the substance's direct and metabolically activated genotoxic potential.", "category": "Cosmetics/Toxicology", "related_concept": "non-ingested color additives, negative control, S9 metabolic activation", "id": "PA_P_00642_026", "match_type": "weak", "match_score": 0.7000097442265656, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0045_0005_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在特定医疗器械违法情形下，中国法规可对相关责任人员处以违法行为期间自本单位所获收入30%以上3倍以下的罚款。\n陈述2：美国法规对销售给体外诊断制造商的分析特异性试剂，豁免了其关于禁止做出分析或临床性能声明的限制。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规文本明确指出，对违法单位的法定代表人、主要负责人等责任人员，可没收其违法行为发生期间自本单位所获收入，并处所获收入30%以上3倍以下的罚款。这体现了对个人责任的追究。\n陈述2正确：美国法规文本规定，当符合分析特异性试剂定义的试剂销售给体外诊断制造商时，包括禁止做出分析或临床性能声明在内的多项限制均不适用。这属于对特定商业用途的豁免条款。", "category": "Medical_Devices", "related_concept": "fines based on income, prohibition on performance claims, exemptions for reagent sales", "id": "PA_P_00499_002", "match_type": "weak", "match_score": 0.7441702005010142, "lang": "CN", "source_cn": "医疗器械监督管理条例.txt", "source_us": "PART_809IN_VITRO_DIAGNOSTIC_PRODUCTS_FOR_HUMAN_USE.txt", "old_id": "comp_0030_0008_2"}
{"question": "Which statement best describes a key difference in how continuing education obligations are enforced for healthcare professionals in the US and China?", "choices": ["A. In China, continuing education is a mandatory condition for professional registration, while in the US, it is typically a voluntary requirement for maintaining licensure.", "B. In the US, continuing education is funded entirely by the government, while in China, it is funded entirely by the employer.", "C. In China, professionals have no choice in their continuing education provider, while in the US, they can select from any accredited institution.", "D. In the US, failure to complete continuing education results in immediate license revocation, while in China, it only affects promotions."], "answer": "A", "type": "Parallel", "explanation": "The Chinese regulation explicitly states that participation in continuing education is a necessary condition for registration and practice, framing it as both a right and an obligation. US regulations, particularly in contexts like drug approvals shown, focus on compliance with study timelines and orders from the FDA, but for general professional licensure (like pharmacists), continuing education is a standard mandatory requirement for license renewal, not directly tied to a single registration event as described in the Chinese text. The other options misrepresent the funding mechanisms (shared in China, not solely government in US), provider choice (explicitly allowed in China), and consequences.", "category": "Drugs", "related_concept": "continuing education rights and obligations", "id": "PA_P_00161_003", "match_type": "weak", "match_score": 0.6784612668091279, "lang": "EN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0002_0008_1"}
{"question": "在药物管制体系中，关于记录保存要求（recordkeeping requirements）的主要目的，中美法规的侧重点有何不同？", "choices": ["A. 中国法规强调记录用于政府预算和部门协调，美国法规则强调记录用于防止药物滥用和确保供应链可追溯性。", "B. 中国法规强调记录用于社区康复和职业技能培训，美国法规则强调记录用于分析实验室的化学分析。", "C. 中国法规强调记录用于强制隔离戒毒场所管理，美国法规则强调记录用于评估申请人的公共安全因素。", "D. 中国法规强调记录用于监测吸毒人员和动态管控，美国法规则强调记录用于确保注册制造商和分析实验室的合规操作与药物安全。"], "answer": "D", "type": "Parallel", "explanation": "中国法规中，记录保存要求主要体现在公安机关对吸毒人员进行登记和动态管控，以及多部门在戒毒工作中的协调，目的是维护社会秩序和提供综合矫治。美国法规则将记录保存作为注册制造商和分析实验室必须遵守的通用要求之一，核心目的是确保受控物质（如大麻）在分析、转移和销毁过程中的可追溯性，防止流入非法渠道，这与公共安全因素（如防止转移）紧密相关。选项A、B、C均存在片面或错误关联。", "category": "Controlled_Substances", "related_concept": "recordkeeping requirements", "id": "PA_P_00693_001", "match_type": "weak", "match_score": 0.7109067817344387, "lang": "CN", "source_cn": "戒毒条例.txt", "source_us": "PART_1318CONTROLS_TO_SATISFY_THE_REQUIREMENTS_OF_T.txt", "old_id": "comp_0001_0003_1"}
{"question": "Statement 1: For color additives that may be ingested, if scientific data suggests the possibility of cancer induction, regulators must determine whether the color additive was the causative substance before applying the cancer clause.\nStatement 2: Skin phototoxicity testing is required for all cosmetic products containing chemical sunscreen agents at concentrations of 0.5% or higher, regardless of product category.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 correctly describes the regulatory approach for ingested color additives: regulators must establish causation between the color additive and cancer induction before applying the cancer clause. Statement 2 is incorrect because skin phototoxicity testing requirements have exceptions; for example, certain product categories like perfumes and nail polishes are exempted even when containing chemical sunscreen agents at ≥0.5% concentrations.", "category": "Cosmetics", "related_concept": "ingested color additives, skin phototoxicity test", "id": "PA_P_00642_005", "match_type": "weak", "match_score": 0.6815427977986931, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0016_0005_2"}
{"question": "A cosmetics company wants to use a novel marketing term that consumers might not immediately understand, but it does not fall under prohibited claims. Which regulatory approach would require them to provide an explanatory note adjacent to the term?", "choices": ["A. US FDA regulations", "B. Chinese NMPA regulations", "C. Both US FDA and Chinese NMPA regulations", "D. Neither US FDA nor Chinese NMPA regulations"], "answer": "B", "type": "Parallel", "explanation": "Chinese NMPA regulations specifically require that when innovative terms not widely understood by consumers are used (but are not prohibited content), their meaning must be explained in an adjacent position. US FDA regulations, as provided, do not address this specific requirement for explanatory notes on novel marketing terms.", "category": "Cosmetics", "related_concept": "prohibited misleading descriptions", "id": "PA_P_00626_004", "match_type": "weak", "match_score": 0.7374148555739084, "lang": "EN", "source_cn": "化妆品标签管理办法.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0007_0003_1"}
{"question": "关于法规要求中提交材料的授权与准确性认证，请判断以下两个陈述：\n陈述1：根据中国法规，在特定告知承诺程序下，申请机构自愿签署承诺书并提交材料后，可简化部分审批流程。\n陈述2：根据美国FDA法规，当非企业负责人（如授权个体）提交注册更新时，必须同时提交一份声明，证明所提交信息真实准确，并指明授权人。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规文本（《计量法实施细则》修改内容）明确提到“产品质量检验机构自愿签署告知承诺书并按要求提交材料的，按照告知承诺相关程序办理”，这体现了在满足条件时简化审批流程的监管思路。陈述2正确：美国法规文本明确要求，当提交注册更新（Registration renewal）的个体不是设施的所有者、经营者或负责代理人时，该更新必须包含一份声明，用于证明信息真实准确（certifies that the information submitted is true and accurate）以及提交授权（certifies that he/she is authorized to submit the registration renewal），并需指明授权人（identifies ... the individual who authorized submission）。两者都涉及“授权提交”和“信息准确性”的核心要求，但具体应用场景和程序不同。", "category": "General_NMPA_FDA", "related_concept": "authorized individual submission, certification of accuracy", "id": "PA_P_00770_016", "match_type": "weak", "match_score": 0.745302970115724, "lang": "CN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0017_0018_2"}
{"question": "关于麻醉药品和第一类精神药品的跨区域销售审批，中美法规的主要差异体现在：", "choices": ["A. 中国法规要求事前审批，美国法规则无此要求", "B. 中国法规仅适用于区域性批发企业，美国法规则适用于所有注册制造商", "C. 中国法规明确规定了审批时限和通报义务，美国法规则侧重于采购配额和库存管理", "D. 中国法规允许因特殊地理位置原因跨省销售，美国法规则完全禁止跨州销售"], "answer": "C", "type": "Parallel", "explanation": "中国法规（如第26条）对区域性批发企业跨省销售规定了具体的事前审批流程、5日内通报等程序性要求。美国法规（如§1303.16）的核心在于通过采购配额和库存比例（如35%/50%库存津贴、50%库存上限）来控制物质流动，并未规定类似中国的事前行政审批和通报机制。选项A错误，因为美国法规通过配额制度进行控制，并非“无要求”；选项B错误，因为中国法规也涉及全国性批发企业；选项D错误，美国法规并未明文禁止跨州销售，而是通过注册和配额体系管理。", "category": "Controlled_Substances", "related_concept": "cross-regional sales approval", "id": "PA_P_00732_001", "match_type": "weak", "match_score": 0.7452378650717418, "lang": "CN", "source_cn": "麻醉药品和精神药品管理条例.txt", "source_us": "PART_1303QUOTAS.txt", "old_id": "comp_0008_0005_1"}
{"question": "Statement 1: Under Chinese regulations, pharmaceutical companies must register their medical representatives with the national drug authority and maintain updated information in a designated platform.\nStatement 2: US regulations require sponsors to promptly inform both FDA and participating investigators of significant new adverse effects discovered during drug investigations.\nWhich option correctly evaluates these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes Chinese requirements: marketing authorization holders must register representatives on the NMPA platform and maintain current information. Statement 2 correctly describes US requirements: sponsors must promptly report significant adverse effects to FDA and investigators. Both represent key regulatory responsibilities in their respective systems.", "category": "Drugs", "related_concept": "registration and management requirements, adverse effect reporting", "id": "PA_P_00099_002", "match_type": "weak", "match_score": 0.7469324812193866, "lang": "EN", "source_cn": "医药代表备案管理办法（试行）.txt", "source_us": "PART_312INVESTIGATIONAL_NEW_DRUG_APPLICATION.txt", "old_id": "comp_0001_0015_2"}
{"question": "关于新原料或色素添加剂的安全性信息提交，中美法规在触发条件上有何关键区别？", "choices": ["A. 中国法规要求所有新原料注册时都必须提交安全性信息，而美国法规仅在色素添加剂用于标准化食品或新药时，若其安全性未获证实才需提交。", "B. 美国法规要求所有新原料注册时都必须提交安全性信息，而中国法规仅在色素添加剂用于标准化食品或新药时，若其安全性未获证实才需提交。", "C. 两国法规都要求所有新原料注册时都必须提交安全性信息，没有区别。", "D. 两国法规都仅在色素添加剂用于标准化食品或新药时，若其安全性未获证实才需提交安全性信息，没有区别。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如化妆品新原料注册）通常要求注册人提交全面的安全性评估资料作为注册的必要条件。而美国法规（§70.10）明确规定，对于色素添加剂在标准化食品或新药中的应用，只有当其安全性信息此前未提交且其预期用途的安全性尚未确立时，才需要按照第71部分的规定提交安全性信息。这体现了美国法规基于风险和历史评估的灵活性。", "category": "Cosmetics & Food/Drugs", "related_concept": "safety information submission", "id": "PA_P_00618_019", "match_type": "weak", "match_score": 0.7411896380632024, "lang": "CN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0030_0001_1"}
{"question": "Consider the following statements about regulatory approaches to quality system oversight and improvement:\nStatement 1: Regulations in one major jurisdiction require companies to analyze internal audit findings and implement corresponding quality system improvement measures to ensure continuous effectiveness.\nStatement 2: Regulations in another major jurisdiction empower a regulatory agency to conduct unannounced inspections of manufacturing establishments, review records, and take samples to assess compliance.\nWhich option correctly evaluates these statements?", "choices": ["A. Both statements are correct and describe complementary regulatory approaches.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 accurately reflects the Chinese regulatory requirement for companies to perform internal audit analysis and drive continuous improvement based on the conclusions. Statement 2 accurately describes the US FDA's inspection authority as outlined in §1271.400, which allows for inspections at reasonable times, record reviews, and sample collection to determine compliance. These represent two key, complementary pillars of quality oversight: internal management systems (emphasized in China's text) and external regulatory verification (emphasized in the US text).", "category": "Drugs", "related_concept": "compliance with regulations, internal audit analysis and improvement", "id": "PA_P_00271_002", "match_type": "weak", "match_score": 0.7363228804119062, "lang": "EN", "source_cn": "药品经营质量管理规范（2015年国家食品药品监督管理总局令第13号公布，2016年令第28号修正）.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0002_0021_2"}
{"question": "In regulatory compliance for color additives, which approach best describes the difference between US and Chinese frameworks regarding batch certification and raw material tracking?", "choices": ["A. The US system requires batch certification for all color additives used in drugs and cosmetics, while China focuses on detailed sensory descriptions and raw material differentiation in product documentation.", "B. Both systems require identical batch certification processes, but China has stricter sensory indicator requirements for externally applied products.", "C. The US mandates batch certification specifically for straight colors in externally applied products, whereas China emphasizes documenting raw material usage and differentiation throughout manufacturing.", "D. China requires batch certification for lakes and straight colors, while the US only requires it for products with multiple color variations."], "answer": "C", "type": "Parallel", "explanation": "The US regulation specifically discusses batch certification for straight colors in externally applied drugs and cosmetics (§82.2050), requiring conformity to specifications. The Chinese regulation focuses on raw material differentiation in manufacturing processes and detailed sensory indicators (color, form, odor) in product documentation, without mentioning batch certification. This reflects different regulatory emphases: US on pre-market color additive certification, China on manufacturing documentation and product description.", "category": "Cosmetics", "related_concept": "batch certification, raw material differentiation", "id": "PA_P_00657_001", "match_type": "weak", "match_score": 0.7396463944047357, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0014_0005_1"}
{"question": "A pharmaceutical company discovers a batch of imported drugs in its supply chain may be counterfeit. Which regulatory approach best describes the immediate required action for securing these products?", "choices": ["A. The products must be immediately quarantined and investigated to determine legitimacy before any disposition", "B. The products should be destroyed immediately upon suspicion to prevent distribution", "C. The company must notify regulatory authorities first, then quarantine the products if instructed", "D. The products can continue through distribution while an investigation occurs in parallel"], "answer": "A", "type": "Parallel", "explanation": "When suspect products are identified in the supply chain, immediate quarantine is required to prevent potential distribution of illegitimate products while an investigation determines their legitimacy. This contrasts with immediate destruction (which might be premature) or continuing distribution during investigation (which risks public health).", "category": "Drugs", "related_concept": "suspect foreign product quarantine", "id": "PA_P_00019_004", "match_type": "weak", "match_score": 0.748454980536259, "lang": "EN", "source_cn": "中华人民共和国药品管理法.txt", "source_us": "PART_251SECTION_804_IMPORTATION_PROGRAM.txt", "old_id": "comp_0031_0014_1"}
{"question": "In comparing US and Chinese pharmaceutical quality management regulations, which statement about the establishment and authority of quality departments is most accurate?", "choices": ["A. Both require a quality department, but only Chinese regulations explicitly grant it independent authority and prohibit delegation of its duties.", "B. Both require a quality department, but only US regulations specify it must be headed by senior management with decision-making power.", "C. Chinese regulations require a quality department while US regulations do not specify such a requirement, focusing instead on inspection authority.", "D. US regulations require a more detailed organizational chart than Chinese regulations, which only mention general responsibilities."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations explicitly mandate establishing a quality management department that must perform its duties independently, with its responsibilities not to be fulfilled by other departments. They also specify that the quality head must be a senior executive with adjudicatory power. While US regulations (like §1271.400) establish FDA's inspection authority over establishments, they do not prescribe the internal organizational structure or specific authority of a quality department within the company in the provided text. The other options misrepresent the requirements.", "category": "Drugs", "related_concept": "quality department establishment, organizational structure and responsibilities", "id": "PA_P_00271_001", "match_type": "weak", "match_score": 0.7363228804119062, "lang": "EN", "source_cn": "药品经营质量管理规范（2015年国家食品药品监督管理总局令第13号公布，2016年令第28号修正）.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0002_0021_1"}
{"question": "关于药品上市后风险管理计划，中美法规在责任主体和核心要求方面存在差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规明确要求上市许可持有人制定并主动执行风险管理计划，而美国法规未对此作出强制性规定。", "B. 美国法规要求申请人必须提交风险管理计划作为申请的一部分，而中国法规则将此责任赋予医疗机构。", "C. 两国法规均要求药品生产企业作为主要责任方，持续开展上市后研究并提交年度报告。", "D. 中国法规侧重于对已识别风险采取控制措施，而美国法规则侧重于在申请阶段就预设风险管理策略。"], "answer": "A", "type": "Parallel", "explanation": "根据中国《药品管理法》第七十七条，药品上市许可持有人（MAH）被明确赋予制定并主动开展药品上市后风险管理计划的责任，这是其法定义务的核心部分。而提供的美国法规文本（§ 514.6, § 514.7）主要涉及新兽药申请的修订、撤回与重新提交的程序性规定，并未直接强制规定上市后风险管理计划的制定。因此，选项A准确地指出了中国法规的明确强制性要求与美国相关文本中未直接体现此要求的差异。选项B错误，因为美国文本未提及风险管理计划作为申请要件，且中国责任主体是MAH而非医疗机构。选项C错误，因为美国文本未涉及生产企业作为主要责任方及年度报告要求。选项D错误，因为中国法规要求的是全面、主动的风险管理，而不仅仅是事后控制。", "category": "Drugs", "related_concept": "上市后风险管理", "id": "PA_P_00018_004", "match_type": "weak", "match_score": 0.6855677237456212, "lang": "CN", "source_cn": "中华人民共和国药品管理法.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0015_0006_1"}
{"question": "关于质量保证计划的制定，中美药监法规的典型要求有何不同？", "choices": ["A. 中国法规明确要求质量保证部门制定书面计划并指定执行人员，美国法规未在提供的文本中直接规定此要求", "B. 美国法规要求质量保证计划必须包含设备清洁记录，中国法规则无此规定", "C. 两国法规均要求质量保证计划由专题负责人批准", "D. 美国法规要求质量保证计划需提交给FDA备案，中国法规则无此要求"], "answer": "A", "type": "Parallel", "explanation": "中国法规（第三十六条）明确规定质量保证部门应当制定书面的质量保证计划，并指定执行人员。美国法规在提供的文本中主要涉及记录、报告、通知程序等内容，未直接规定质量保证计划的制定要求。干扰项B错误，因为设备清洁记录是美国法规对记录的要求，并非质量保证计划的组成部分；C错误，中国法规中专题负责人批准的是总结报告的修订，而非质量保证计划；D错误，美国法规文本未提及质量保证计划需提交FDA备案。", "category": "Drugs", "related_concept": "quality assurance plan", "id": "PA_P_00347_004", "match_type": "weak", "match_score": 0.7452050897217664, "lang": "CN", "source_cn": "药物非临床研究质量管理规范（2017年第34号）.txt", "source_us": "PART_211CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_FI.txt", "old_id": "comp_0015_0013_1"}
{"question": "Statement 1: Regulatory frameworks for international agreements typically include formal consultation processes that must be exhausted before a party can exercise termination rights related to market access. Statement 2: The application of information technology in regulatory administration is primarily aimed at improving internal workflow efficiency rather than facilitating public access to procedures.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct: International regulatory agreements commonly establish mandatory consultation procedures that parties must engage in to resolve disputes before invoking termination clauses, ensuring due process. Statement 2 is incorrect: While improving internal efficiency is one goal, a key objective of implementing information technology in regulatory systems is explicitly to enhance accessibility for citizens and organizations, making it easier to apply for and participate in administrative processes, thereby serving public-facing functions.", "category": "General_FDA", "related_concept": "termination rights, information technology application, market access, consultation process", "id": "PA_P_00784_002", "match_type": "weak", "match_score": 0.7167305693309757, "lang": "EN", "source_cn": "中华人民共和国行政复议法.txt", "source_us": "PART_26MUTUAL_RECOGNITION_OF_PHARMACEUTICAL_GOOD_M.txt", "old_id": "comp_0002_0011_2"}
{"question": "关于化妆品注册备案资料的语言要求，请判断以下两个陈述：\n陈述1：中国法规要求所有注册备案资料必须使用规范汉字，仅允许少数特定情况（如注册商标、专业术语）保留原文。\n陈述2：美国法规对化妆品企业注册时提交的Form FD-2511表格有明确的语言翻译要求。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：中国法规明确规定化妆品注册备案资料应当使用国家公布的规范汉字，并详细列举了允许保留原文的例外情况（如注册商标、网址、专利名称、境外企业名称地址及约定俗成的专业术语）。陈述2错误：提供的美国法规文本（§710.3, §710.4）仅描述了Form FD-2511的获取方式、邮寄地址及表格要求填写的信息内容（如企业名称、地址、业务类型），并未提及对该表格或注册信息有任何语言或翻译方面的强制性要求。", "category": "Cosmetics", "related_concept": "Chinese translation requirement", "id": "PA_P_00652_002", "match_type": "weak", "match_score": 0.7374343788761841, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0001_0001_2"}
{"question": "A cosmetics manufacturer has a batch of products that fails initial regulatory review. Which regulatory system provides a formal opportunity for the manufacturer to contest this decision before the final determination is made?", "choices": ["A. US FDA system only", "B. Chinese NMPA system only", "C. Both US FDA and Chinese NMPA systems", "D. Neither system provides such opportunity"], "answer": "A", "type": "Parallel", "explanation": "The US FDA system explicitly provides for regulatory hearings when a batch certification is refused, allowing manufacturers to contest the decision. The Chinese NMPA text focuses on sampling, testing, and payment procedures but does not mention formal hearing procedures for contesting batch compliance decisions.", "category": "Cosmetics", "related_concept": "regulatory hearing", "id": "PA_P_00612_001", "match_type": "weak", "match_score": 0.7286812022616567, "lang": "EN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0006_0001_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：中国法规明确要求负责药品监督管理的部门对化妆品电子商务平台内经营者的经营行为开展网络监测，作为发现违法行为的途径之一。\n陈述2：美国法规中，食品药品监督管理局（FDA）局长有权针对特定包装化妆品，若现有净含量标注方式不利于消费者进行价值比较，则通过制定规章来指定应使用的适当术语。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。根据中国《化妆品监督管理条例》及配套规定，负责药品监督管理的部门对化妆品电子商务平台服务提供者（平台）有监管要求，平台需对其平台内经营者进行管理，而监管部门自身也会开展网络监测，以发现违法行为。\n陈述2正确。根据美国《联邦食品、药品和化妆品法案》及其实施条例（如21 CFR 701.13），FDA局长（Commissioner）被授权在特定情况下，若认为现有净含量标注实践（如按重量、体积等）不利于消费者进行价值比较，可以通过发布规章来指定该化妆品应使用的适当标注术语。这体现了FDA在标签管理上的灵活性和规制权。", "category": "Cosmetics", "related_concept": "network monitoring, commissioner regulation designation", "id": "PA_P_00686_002", "match_type": "weak", "match_score": 0.6892620333132327, "lang": "CN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0009_0007_2"}
{"question": "Statement 1: Both US and Chinese regulations require establishments to maintain comprehensive records for regulatory review during inspections. Statement 2: Only US regulations explicitly authorize inspectors to take samples during establishment inspections.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct as both regulatory frameworks emphasize record-keeping - US FDA explicitly mentions review and copying of required records, while China NMPA requires maintaining various records including training and self-inspection reports. Statement 2 is incorrect because while US regulations explicitly mention sample-taking authority, Chinese regulations also imply similar authority through their comprehensive inspection provisions, though the specific mention of sampling is more explicit in the US text.", "category": "Drugs", "related_concept": "record review and sampling", "id": "PA_P_00183_002", "match_type": "weak", "match_score": 0.7421787128226985, "lang": "EN", "source_cn": "药品上市许可持有人落实药品质量安全.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0009_0021_2"}
{"question": "比较中美化妆品监管中对特定物质使用的控制方式，请判断以下陈述：\n陈述1：中国法规通过规定不予复检的具体情形（如微生物项目不合格、样品超期等），间接体现了对某些检验结论的终局性认定。\n陈述2：美国法规对色素添加剂的使用主要通过规定用途限制和浓度上限（如D&C Green No. 8限重0.01%）进行直接控制，并要求所有批次获得认证。", "choices": ["A. 两个陈述都正确", "B. 只有陈述1正确", "C. 只有陈述2正确", "D. 两个陈述都不正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规列出不予复检的情形（如微生物项目不符、样品超期），这实际上限制了复检权利的行使，意味着在这些情况下初始检验结论具有决定性。陈述2正确：美国法规文本明确展示了通过对色素添加剂规定具体使用范围、限制（包括眼部使用允许性）和浓度上限，并结合批次认证要求，来直接控制其安全使用。两者分别体现了“事后救济限制”和“事前准入与使用规范”两种不同的监管逻辑。", "category": "Cosmetics", "related_concept": "复检申请限制, uses and restrictions, batch certification", "id": "PA_P_00611_008", "match_type": "weak", "match_score": 0.6538440423090186, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0010_0018_2"}
{"question": "Statement 1: The US regulation provides statutory exemptions specifically for intercity rail passenger service regarding waste discharge requirements. Statement 2: Chinese regulation exempts vehicles under 4500kg from road transport permit requirements but maintains waste discharge regulations for all transportation modes. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct as the US text explicitly references statutory exemptions for 'intercity rail passenger service' under 45 U.S.C. 546(i). Statement 2 is incorrect because while Chinese regulation exempts vehicles under 4500kg from road transport permit requirements, the provided Chinese text does not mention any waste discharge regulations for transportation modes, focusing instead on permit and licensing requirements for various transport operations.", "category": "General_FDA", "related_concept": "statutory exemptions for intercity rail passenger service, road transport permit exemption", "id": "PA_P_00774_002", "match_type": "weak", "match_score": 0.7477872903300858, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_1250INTERSTATE_CONVEYANCE_SANITATION.txt", "old_id": "comp_0009_0006_2"}
{"question": "针对注册备案资料审核制度，以下哪项正确描述了中美法规的异同？", "choices": ["A. 两国都要求质量安全负责人审核资料，但中国还要求对年度报告进行审核", "B. 美国法规要求审核所有临床研究合规性，中国法规则无类似规定", "C. 中国法规建立了动态管理机制，美国法规则以颜色添加剂认证为核心", "D. 两国均强调审核的合法性、真实性和科学性，但中国更注重完整性"], "answer": "C", "type": "Parallel", "explanation": "中国法规要求建立基于风险防控的动态管理机制，包括注册备案资料审核等制度；美国法规在提供文本中主要围绕颜色添加剂的认证和豁免流程，未涉及化妆品注册备案的动态管理机制。选项A错误，因为美国文本未提质量安全负责人角色；选项B涉及临床研究，但美国文本针对颜色添加剂请愿，非一般化妆品注册；选项D不准确，因美国文本未强调这些审核要素。", "category": "Cosmetics", "related_concept": "registration and filing data review system", "id": "PA_P_00592_002", "match_type": "weak", "match_score": 0.7422778044524491, "lang": "CN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0005_0002_2"}
{"question": "Statement 1: US regulations require documented procedures for facility cleaning and sanitation with assigned responsibilities and detailed schedules. Statement 2: Chinese regulations establish national systems for protecting and utilizing traditional medical knowledge through documentation and research support. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes US FDA requirements for documented cleaning procedures with assigned responsibilities and schedules. Statement 2 accurately reflects Chinese NMPA regulations that establish systems for protecting TCM heritage through documentation, research support, and utilization of traditional knowledge.", "category": "Drugs", "related_concept": "facility cleaning and sanitation, protection and utilization of TCM heritage", "id": "PA_P_00004_010", "match_type": "weak", "match_score": 0.7092041544582943, "lang": "EN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0009_0013_2"}
{"question": "Statement 1: Under US FDA regulations, a safety factor of 100:1 is automatically applied when extrapolating animal toxicity data to humans for color additives. Statement 2: Chinese NMPA regulations require human skin patch testing for all special use cosmetics, with additional testing only when initial results are inconclusive.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct: US FDA regulations specify a default 100:1 safety factor for color additives unless evidence justifies a different factor. Statement 2 is incorrect: Chinese NMPA regulations do not require human skin patch testing for all special use cosmetics; it's specifically required for hair growth, depilatory, breast enhancement, and body shaping products, with additional testing for spot-removing and sunscreen products only when initial results are inconclusive.", "category": "Cosmetics", "related_concept": "safety factor application, human skin patch test", "id": "PA_P_00642_007", "match_type": "weak", "match_score": 0.7296966226713631, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0017_0004_2"}
{"question": "在化妆品原料质量控制方面，中美法规对技术负责人的资质要求存在显著差异。请判断以下两个陈述：\n陈述1：中国法规要求质量管理部门负责人必须具有化妆品质量安全相关专业知识背景，并明确列出了化学、生物、医学等具体专业领域。\n陈述2：美国法规对D&C Blue No. 4着色剂的技术负责人资质未在规范中具体规定，而是通过严格的成分规格标准来确保产品质量。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国《化妆品监督管理条例》实施细则明确要求质量管理部门负责人应具备化妆品、化学、化工、生物、医学、药学等专业知识背景，并熟悉相关法规标准。\n陈述2正确：美国FDA对化妆品着色剂（如D&C Blue No. 4）的管理主要通过《联邦法规汇编》第21篇第74部分规定具体的化学成分规格、杂质限量和检测标准，而对技术负责人的具体资质要求则体现在更广泛的CGMP原则中，而非在着色剂规格条款中详细列举。这体现了中美监管思路的差异：中国更强调人员资质的具体化要求，美国更侧重通过技术标准控制产品质量。", "category": "Cosmetics", "related_concept": "quality management department head qualifications, specification compliance", "id": "PA_P_00667_005", "match_type": "weak", "match_score": 0.7454394300032434, "lang": "CN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0003_0005_2"}
{"question": "关于化妆品风险监测与评价结果的应用，中美法规在系统性风险处置上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规强调在发现系统性风险后，相关项目原则上不再纳入监测计划，转而通过抽样检验或日常监管防控风险；美国法规则侧重于对特定化学物质（如D&C Blue No. 4）设定严格的成分含量上限，作为持续合规的基础。", "B. 中国法规要求对所有风险监测项目都必须持续开展，直至风险完全消除；美国法规则允许在达到特定标准后终止监测。", "C. 中国法规仅授权药品监督管理部门开展风险监测；美国法规则强制要求所有化妆品生产企业自行开展全面的风险监测。", "D. 中美法规在系统性风险处置上完全一致，都要求立即召回产品并处以高额罚款。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如第二十七条）规定，当风险监测与评价结果提示可能存在系统性、区域性质量安全风险时，药品监督管理部门应通过抽样检验或结合日常监管防控风险，相关项目原则上不再纳入风险监测计划，这体现了从监测转向针对性防控的路径。美国法规（如提供的D&C Blue No. 4规格）则通过设定具体化学物质的严格含量限值（如铅、砷、汞等），作为产品必须持续符合的强制性标准，以预防风险，而非直接描述系统性风险的后续处置流程。选项B错误，因为中国法规允许在特定情况下（系统性风险）停止将项目纳入监测计划；选项C错误，两国法规都涉及监管机构和企业责任，但具体机制不同；选项D错误，两国法规在风险处置上存在显著差异。", "category": "Cosmetics", "related_concept": "risk monitoring and evaluation, risk control measures", "id": "PA_P_00608_006", "match_type": "weak", "match_score": 0.7386822448282998, "lang": "CN", "source_cn": "化妆品安全风险监测与评价管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0006_0005_1"}
{"question": "Statement 1: Both US and Chinese regulations explicitly authorize regulatory agencies to review establishment records and take samples during inspections to ensure compliance. Statement 2: Both regulatory frameworks have specific provisions for approving and managing usage fees for imitation products when the original is in short supply.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct: The US text explicitly authorizes FDA to 'review and copy any records' and 'take samples' during inspections. While the Chinese text doesn't detail inspection procedures in the provided excerpt, general regulatory principles imply such authority exists for compliance verification. Statement 2 is incorrect: Only the Chinese regulation specifically addresses approval and usage fees for imitation of clinically scarce traditional Chinese medicine protected varieties, requiring NMPA approval and negotiated/arbitrated fees. The US text focuses on communicable disease prevention for HCT/Ps without mentioning imitation approval or fee structures.", "category": "Drugs", "related_concept": "record review and sampling, imitation approval and usage fee", "id": "PA_P_00103_002", "match_type": "weak", "match_score": 0.7467604747081672, "lang": "EN", "source_cn": "国务院修改《中药品种保护条例》等行政法规部分条款.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0002_0021_2"}
{"question": "关于化妆品人体试用试验中皮肤不良反应的分级与记录，中美法规在核心要求上存在差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规要求按统一分级标准记录，美国法规则无此强制要求。", "B. 美国法规要求按统一分级标准记录，中国法规则无此强制要求。", "C. 两国法规都要求按统一分级标准记录，但分级标准本身不同。", "D. 两国法规都未对皮肤不良反应的分级记录做出具体规定。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如NMPA相关技术规范）通常对化妆品人体试用试验中观察到的皮肤不良反应，要求按照现行有效的、统一的分级标准进行记录和报告。美国法规（如FDA对化妆品的要求）虽然也关注安全性，但并未像药品或医疗器械那样，为化妆品的人体试用强制规定一个全国统一的皮肤不良反应分级标准；其监管重点更侧重于事后报告和市场监督。", "category": "Cosmetics", "related_concept": "skin adverse reaction grading", "id": "PA_P_00638_016", "match_type": "weak", "match_score": 0.7454171838042456, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0057_0001_1"}
{"question": "关于化妆品质量安全信息通报，中美法规在通报对象和目的上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求向产品注册人/备案人所在地监管部门通报，以启动监督检查；美国法规要求向消费者通报，以保障知情权。", "B. 中国法规要求向平台经营者所在地监管部门通报，以追究平台责任；美国法规要求向生产商总部所在地监管部门通报，以统一监管标准。", "C. 中国法规要求向违法经营者实际经营地监管部门通报，以进行属地查处；美国法规要求向食品药品监督管理局（FDA）通报，以评估产品风险。", "D. 中国法规要求向化妆品注册人/备案人/境内责任人住所地同级监管部门通报，以追溯源头并协同查处；美国法规主要涉及标签标示要求，未明确规定此类跨辖区质量安全信息通报机制。"], "answer": "D", "type": "Parallel", "explanation": "中国法规（第二十八条）明确规定，当平台内经营者违法涉及质量安全时，实际经营地监管部门应向化妆品注册人、备案人、境内责任人住所地同级部门通报信息，后者需及时开展监督检查，体现了跨辖区协同追溯源头的监管逻辑。美国提供的法规文本主要涉及标签标注（如净含量、生产商地址），并未建立类似针对质量安全问题的、强制性的跨辖区监管部门间信息通报与协同查处机制。选项A、B、C均错误描述了美国法规的相关内容或意图。", "category": "Cosmetics", "related_concept": "information sharing on quality safety, regulatory cooperation and enforcement", "id": "PA_P_00686_003", "match_type": "weak", "match_score": 0.7086082618679896, "lang": "CN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0010_0007_1"}
{"question": "关于化妆品功效宣称评价的等效评价，中美法规在适用条件上有何关键差异？", "choices": ["A. 中国法规要求多色号系列产品基础配方成分种类和含量相同，美国法规则无此等效评价机制", "B. 美国法规要求等效评价需基于非临床实验室研究合规声明，中国法规则无此要求", "C. 中国法规允许对仅作用于头发的功效宣称使用体外真发评价，美国法规则要求必须进行临床研究", "D. 美国法规要求等效评价报告需包含产品抽检信息，中国法规则要求包含着色剂含量最低产品的试验报告"], "answer": "A", "type": "Parallel", "explanation": "中国NMPA法规建立了明确的化妆品等效评价机制，要求多色号系列彩妆产品在基础配方成分种类和含量相同的情况下可共用功效评价数据。而美国FDA法规中未提及类似的化妆品等效评价概念，其关于实质性修正的规定主要针对已提交申请后补充信息的情况，不涉及产品系列间的数据共用。", "category": "Cosmetics", "related_concept": "equivalent evaluation conditions", "id": "PA_P_00603_003", "match_type": "weak", "match_score": 0.7148712111116121, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0005_0001_1"}
{"question": "A company manufacturing cigars in the United States for domestic sale and another importing roll-your-own tobacco from abroad both need to pay tobacco product user fees. Which regulatory approach is most consistent with requiring both entities to obtain permits from the same federal agency before being subject to such fees?", "choices": ["A. Both domestic manufacturers and importers must secure permits from the Alcohol and Tobacco Tax and Trade Bureau to establish their obligation to pay user fees.", "B. Domestic manufacturers require a permit from the Food and Drug Administration, while importers need authorization from U.S. Customs and Border Protection.", "C. Only domestic manufacturers are mandated to obtain a permit; importers are exempt from such a requirement for fee assessment.", "D. The permit requirement is determined by state authorities, not federal agencies, for both manufacturing and importing activities."], "answer": "A", "type": "Parallel", "explanation": "This question compares the foundational requirements for domestic manufacturers and importers regarding permit acquisition as a prerequisite for tobacco product user fee obligations. The correct answer reflects a unified regulatory approach where both entities must obtain permits from the same specific federal agency (the Alcohol and Tobacco Tax and Trade Bureau) to legitimize their operations and subsequent fee liabilities, emphasizing consistency in oversight for domestic production and importation.", "category": "General_FDA", "related_concept": "domestic manufacturer requirements, importer requirements", "id": "PA_P_00755_001", "match_type": "weak", "match_score": 0.7435104102305736, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第666号）.txt", "source_us": "PART_1150USER_FEES.txt", "old_id": "comp_0006_0002_1"}
{"question": "在化妆品监管中，中美法规对重点监管对象和抽样监测重点的设定逻辑有所不同。请判断以下两个陈述：\n陈述1：中国法规倾向于将特定责任主体（如注册人、生产企业）和特定产品类别（如儿童化妆品）明确列为重点监管对象，并加大检查频次。\n陈述2：美国法规主要通过设定通用生产规范（GMP）和具体产品成分规格来间接定义监管重点，而非明文列出特定企业或产品类别。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规（如《化妆品监督管理条例》配套规定）明确要求将化妆品注册人、备案人、受托生产企业等责任主体以及儿童化妆品经营者列为重点监管对象，并将儿童化妆品作为年度抽检和风险监测重点，体现了基于主体和产品类别的风险分级监管思路。\n陈述2正确：美国法规（如FDA对色素添加剂的规定）通常通过设定详细的成分化学规格（如杂质限量、纯度要求）并引用“良好生产规范（GMP）”作为通用标准来确保产品质量安全。其监管重点隐含在对规格符合性和GMP遵守的核查中，而非总是明文指定某类企业或产品为固定重点。", "category": "Cosmetics", "related_concept": "key supervision targets, sampling and monitoring focus, manufacturing practice standards", "id": "PA_P_00597_002", "match_type": "weak", "match_score": 0.7469867924709149, "lang": "CN", "source_cn": "儿童化妆品监督管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0006_0005_2"}
{"question": "在化妆品监管中，关于批次认证（batch certification）的要求，请判断以下两个陈述的真假：\n陈述1：美国FDA对某些化妆品颜色添加剂（如D&C Orange No. 5）要求所有批次都必须进行认证。\n陈述2：中国NMPA对化妆品原料的批次认证要求与美国FDA完全一致，均强制适用于所有化妆品。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：美国FDA法规（如21 CFR Part 74）明确规定，对于列出的颜色添加剂（如D&C Orange No. 5），所有生产批次都必须经过FDA认证，以确保其符合身份和规格要求，这是美国化妆品颜色添加剂管理的核心制度之一。\n陈述2错误：中国NMPA对化妆品原料的批次认证要求与美国FDA并不完全一致。中国法规对化妆品的监管重点可能包括原料安全性评估、产品备案或注册、生产质量管理规范（如《化妆品生产质量管理规范》）等，但对颜色添加剂或其他原料的批次认证并无与美国FDA完全相同的强制性普遍要求。中国的认证或检验要求可能针对特定高风险原料或产品，而非所有化妆品均适用统一的批次认证制度。", "category": "Cosmetics", "related_concept": "batch certification", "id": "PA_P_00637_020", "match_type": "weak", "match_score": 0.7298684217497523, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0034_0019_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在评估外部用色素添加剂的安全性时，美国FDA法规通常要求进行包括急性口服毒性、原发性刺激、致敏性、亚急性皮肤毒性（完整和破损皮肤）以及皮肤应用致癌性在内的测试，但专员有权在已有数据足以证明安全性的情况下豁免某些测试。\n陈述2：中国NMPA法规对于防晒产品测试中最小红斑剂量（MED）的测定，要求必须包括受试者皮肤不涂被测物、涂对照品、涂被测物三种情况，并在24小时后分别记录MED值。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：它准确概括了美国法规（21 CFR §70.42(b)）关于外部用色素添加剂安全性测试的常规要求（急性口服毒性、原发性刺激、致敏性、亚急性皮肤毒性、致癌性皮肤应用测试），并正确指出专员有权根据已有数据豁免不必要的测试。这体现了法规的灵活性和基于风险的原则。\n陈述2正确：它准确描述了中国法规文本中关于防晒产品测试时最小红斑剂量（MED）测定的具体要求，即需要设置三种照射情况（不涂被测物、涂对照品、涂被测物）并在24小时后观察记录各自的MED值。这体现了测试设计的严谨性和对照原则。\n两个陈述分别准确反映了中美法规在不同产品（色素添加剂 vs. 防晒产品）和不同测试环节（安全性测试套餐 vs. 功效性测试设计）的具体要求，因此两个陈述都正确。", "category": "Cosmetics", "related_concept": "MED value, color additive listing conditions", "id": "PA_P_00642_045", "match_type": "weak", "match_score": 0.668742140787648, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0073_0004_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中国法规，持有人对受托方进行药物警戒审计是强制性的定期要求。\n陈述2：根据美国法规，临床研究者（Investigator）有责任确保其所有协助研究的人员都了解并履行其在研究中的义务，包括不良事件报告。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。中国法规（如《药物警戒质量管理规范》）明确规定持有人应当定期对药物警戒受托方进行审计，以确保其活动持续符合要求。\n陈述2正确。美国FDA法规21 CFR 312.60规定了研究者的总体责任，其中隐含了对其团队的管理义务；更具体地，在研究者承诺（如Form FDA 1572的声明）中，通常包含确保所有研究助理了解其义务的条款，这直接关联到如不良事件报告等关键职责的履行。", "category": "Drugs", "related_concept": "delegated party selection, investigator responsibilities", "id": "PA_P_00324_005", "match_type": "weak", "match_score": 0.7447350911737357, "lang": "CN", "source_cn": "药物警戒质量管理规范.txt", "source_us": "PART_312INVESTIGATIONAL_NEW_DRUG_APPLICATION.txt", "old_id": "comp_0004_0018_2"}
{"question": "在药监法规中，实质性修订（substantive amendment）的处理方式，以下哪项正确描述了中美法规的异同？", "choices": ["A. 中美法规都规定，实质性修订会导致申请获得新的受理日期", "B. 只有美国法规规定实质性修订会重置受理日期，中国法规无此规定", "C. 只有中国法规规定实质性修订会重置受理日期，美国法规无此规定", "D. 中美法规都规定实质性修订不会影响原受理日期"], "answer": "B", "type": "Parallel", "explanation": "美国FDA法规明确规定，如果提交的补充信息或数据构成实质性修订，该申请将获得新的受理日期（new filing date），审评时限重新计算。中国NMPA法规对于化妆品或药品注册，虽也接受补充资料，但通常不因补充资料而自动重置受理日期；除非是重大变更或重新提交，否则原受理日期一般保持不变。这反映了美国法规在程序透明性和时限管理上的严格性。", "category": "Regulatory Procedures", "related_concept": "substantive amendment, new filing date", "id": "PA_P_00638_011", "match_type": "weak", "match_score": 0.7345130164074233, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0047_0001_2"}
{"question": "Statement 1: In US cosmetic regulation, certification requirements are primarily applied to color additives to ensure they meet specific chemical purity standards.\nStatement 2: In Chinese cosmetic regulation, registration and filing processes require detailed clinical testing protocols including MED determination and SPF calculation with statistical validation.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as the US regulation text specifically mentions certification requirements for FD&C Red No. 40 and detailed chemical specifications for FD&C Yellow No. 5, indicating certification focuses on color additive purity. Statement 2 is correct as the Chinese regulation text details clinical testing requirements including MED prediction, SPF calculation with statistical validation (95% CI requirements), and structured reporting formats, which are characteristic of registration and filing processes in China's cosmetic regulatory system.", "category": "Cosmetics", "related_concept": "certification requirement, registration and filing, minimum erythema dose, SPF calculation method", "id": "PA_P_00637_035", "match_type": "weak", "match_score": 0.6935390345348023, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0068_0003_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：中美法规均对实验研究的定义有明确规定，且定义范围基本一致。\n陈述2：美国管制物质清单中的第二类物质（Schedule II）包含阿片类物质，且这类物质在中国通常按麻醉药品进行管理。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "D", "type": "Parallel", "explanation": "陈述1错误。中国法规明确将实验研究定义为“以医疗、科学研究或者教学为目的的临床前药物研究”。美国提供的文本未涉及实验研究的定义，两者在文本呈现上不一致。陈述2正确。美国Schedule II清单详细列出了阿片（Opium）和阿片类药物（Opiates）及其多种衍生物（如吗啡、可待因、羟考酮）。中国法规虽未列出具体物质名称，但通过“含麻醉药品的复方制剂”等条款，表明阿片类物质属于其麻醉药品管理范畴，两者在将阿片类物质纳入严格管制方面具有一致性。", "category": "Controlled_Substances", "related_concept": "experimental research definition, Schedule II substances, opium and opiate derivatives", "id": "PA_P_00727_008", "match_type": "weak", "match_score": 0.7084201711341327, "lang": "CN", "source_cn": "麻醉药品和精神药品管理条例.txt", "source_us": "PART_1308SCHEDULES_OF_CONTROLLED_SUBSTANCES.txt", "old_id": "comp_0026_0001_2"}
{"question": "关于定制式医疗器械的备案责任主体，中美法规有何差异？", "choices": ["A. 中国要求生产企业和医疗机构共同备案，美国无类似共同备案要求", "B. 中美都要求生产企业和医疗机构共同备案", "C. 美国要求生产企业和医疗机构共同备案，中国无类似要求", "D. 中美都无共同备案要求，均由生产企业单独负责"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定定制式医疗器械需由医疗器械生产企业及医疗机构共同作为备案人，向省级药监部门备案。美国法规（21 CFR Part 820）主要规定生产企业的质量管理体系要求，包括控制号、包装、处理、存储、分销、安装及记录保存等，但未涉及医疗机构作为共同备案人的要求。", "category": "Medical_Devices", "related_concept": "joint filing responsibility", "id": "PA_P_00571_001", "match_type": "weak", "match_score": 0.7423353307292716, "lang": "CN", "source_cn": "定制式医疗器械监督管理规定（试行）.txt", "source_us": "PART_820QUALITY_SYSTEM_REGULATION_EFF_until_2-2-26.txt", "old_id": "comp_0002_0005_1"}
{"question": "Which regulatory approach to establishment inspections emphasizes both scheduled oversight and proactive internal monitoring?", "choices": ["A. US FDA focuses on unannounced inspections at agency discretion, while China NMPA requires regular internal audits by holders", "B. Both US FDA and China NMPA rely exclusively on announced inspections during business hours", "C. China NMPA delegates all inspection authority to provincial agencies without federal oversight", "D. US FDA requires mandatory annual self-inspections similar to China's internal audit system"], "answer": "A", "type": "Parallel", "explanation": "The US FDA approach allows for inspections at any reasonable time with or without prior notification, with frequency at agency discretion. China's NMPA requires holders to conduct regular self-inspections or internal audits to monitor GMP implementation, creating a dual system of external oversight and internal monitoring.", "category": "Drugs", "related_concept": "inspection of establishments", "id": "PA_P_00183_001", "match_type": "weak", "match_score": 0.7421787128226985, "lang": "EN", "source_cn": "药品上市许可持有人落实药品质量安全.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0009_0021_1"}
{"question": "在化妆品原料管理体系中，关于物料进货查验记录制度，中美法规的共同核心要求是什么？", "choices": ["A. 要求企业必须对关键原料进行留样并保存记录", "B. 要求企业建立并执行物料验收规程，确保物料符合质量要求", "C. 要求企业必须对供应商进行现场审核", "D. 要求企业必须使用原料的标准中文名称"], "answer": "B", "type": "Parallel", "explanation": "中国法规（如第三十条）明确要求企业建立并执行物料进货查验记录制度和物料验收规程，确保物料质量。美国法规（如§ 80.39）虽未直接使用“进货查验”一词，但其要求对色料添加剂批次的处置（包括使用）进行详细记录，这本质上是对物料进入生产环节后的追踪和确认，体现了对物料符合性（包括质量）的验证要求。两者都强调了通过制度和记录确保物料符合规定。选项A是中国法规对关键原料的特定要求；选项C是中国法规对关键供应商的审核要求；选项D是中国法规对物料标识的要求。这些并非两国法规在进货查验记录制度上的共同核心要求。", "category": "Cosmetics", "related_concept": "incoming inspection records", "id": "PA_P_00668_003", "match_type": "weak", "match_score": 0.743629626545878, "lang": "CN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0010_0004_1"}
{"question": "In regulatory frameworks for pharmaceutical quality management, how do approaches to nonconforming products typically differ between systems emphasizing corrective actions and those with reprocessing provisions?", "choices": ["A. Systems with reprocessing provisions always require destruction of nonconforming products, while corrective action systems allow conditional release.", "B. Corrective action systems focus on preventing recurrence through investigation and process fixes, while reprocessing systems may allow reworking products to meet specifications under controlled conditions.", "C. Both systems mandate identical investigation procedures but differ only in whether the product can be sold after rejection.", "D. Reprocessing is prohibited in all major regulatory systems once a product fails specifications, making corrective actions the sole permitted response."], "answer": "B", "type": "Parallel", "explanation": "Corrective action systems prioritize identifying root causes and implementing fixes to prevent future occurrences, often involving process improvements or equipment corrections. Reprocessing systems, when permitted, allow nonconforming products to be reworked under strict protocols (e.g., following approved procedures) to bring them into compliance before release, provided final specifications are met. This reflects a balance between quality assurance and resource efficiency.", "category": "Drugs", "related_concept": "correction of problems, reprocessing of nonconforming product", "id": "PA_P_00017_004", "match_type": "weak", "match_score": 0.654891903084492, "lang": "EN", "source_cn": "中华人民共和国药品管理法.txt", "source_us": "PART_212CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_PO.txt", "old_id": "comp_0019_0005_1"}
{"question": "关于实质性修订对申请日的影响，以下哪项陈述正确？\n陈述1：根据美国法规，如果提交的额外信息构成实质性修订，申请将获得新的提交日期。\n陈述2：中国法规明确规定，实质性修订会导致申请时间限制重新计算。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：美国法规明确，若额外信息构成实质性修订，修订后的请愿将获得新的提交日期，时间限制重新开始计算。陈述2错误：提供的中国法规文本未涉及实质性修订及其对申请日或时间限制的影响。", "category": "Regulatory Procedure", "related_concept": "substantive amendment, new filing date", "id": "PA_P_00638_015", "match_type": "weak", "match_score": 0.7144604136639631, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0052_0001_2"}
{"question": "关于化妆品人体试用试验中皮肤不良反应的观察与记录，中美法规在以下哪项要求上存在显著差异？", "choices": ["A. 是否要求对皮肤不良反应进行分级记录", "B. 是否要求设置最低观察时间", "C. 是否要求记录受试者个人信息（如姓名首字母、性别、年龄）", "D. 是否要求试验结果必须包含具体的不良反应发生例数和等级"], "answer": "B", "type": "Parallel", "explanation": "中国法规明确规定了人体试用试验的观察时间应不少于4周，这是一个具体的最低时间要求。而美国法规文本（涉及支持性数据提交）并未直接规定此类具体试验的观察时长，其重点在于提交数据时需声明研究是否符合伦理审查（IRB）和知情同意等监管要求。选项A和D是中美都可能涉及的原则（分级和报告结果），选项C（记录个人信息）更多是试验设计的通用实践，而非法规核心差异点。", "category": "Cosmetics", "related_concept": "observation time points, skin adverse reaction grading", "id": "PA_P_00638_020", "match_type": "weak", "match_score": 0.7337638265167562, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0060_0001_1"}
{"question": "Statement 1: Under US cosmetics regulation, batch certification is mandatory for specific color additives like D&C Green No. 8. Statement 2: Under Chinese cosmetics regulation, adverse reactions must be recorded regardless of whether they are related to product use. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: The US regulation text for D&C Green No. 8 (and others like FD&C Green No. 3) includes a 'Certification' section stating 'All batches... shall be certified,' indicating a mandatory batch certification requirement for these color additives. Statement 2 is correct: The Chinese regulation text explicitly states in the 'Adverse reactions' section that 'adverse reactions... regardless of whether they are related to product use, shall be recorded and handled.' This demonstrates a key regulatory difference: the US emphasizes batch-level chemical certification, while China mandates comprehensive adverse event monitoring.", "category": "Cosmetics", "related_concept": "batch certification, adverse reaction recording", "id": "PA_P_00602_007", "match_type": "weak", "match_score": 0.7325288978405176, "lang": "EN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0008_0018_2"}
{"question": "A cosmetics company in China receives a re-inspection notice after an initial failed test. Which of the following best describes the regulatory requirements for the re-inspection process?", "choices": ["A. The re-inspection institution is selected by the applicant from a pre-approved list, and the applicant must pay the re-inspection fee upfront regardless of outcome.", "B. The re-inspection institution is randomly assigned by the regulatory authority from a published list, and payment of fees is required before re-inspection begins, with final responsibility depending on the outcome.", "C. The re-inspection institution must be different from the initial testing institution, but the applicant can choose any certified laboratory and pay fees after receiving results.", "D. The regulatory authority assigns the same institution for re-inspection to ensure consistency, and fees are split between the applicant and the authority regardless of outcome."], "answer": "B", "type": "Parallel", "explanation": "Chinese regulations require random selection of re-inspection institutions from an official list by the regulatory authority, not by the applicant. Payment of re-inspection fees is required upfront, with final responsibility determined by whether re-inspection results match initial findings.", "category": "Cosmetics", "related_concept": "random selection of re-inspection institution, payment of re-inspection fees", "id": "PA_P_00613_001", "match_type": "weak", "match_score": 0.674469871698357, "lang": "EN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0011_0002_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在美国，获得FDA为化妆品产品成分声明分配的一个编号（如FDA reference number），意味着该产品或其生产企业已获得FDA的正式批准。\n陈述2：在中国，当化妆品拟增加新的生产场地且该场地无法提供符合要求的质量体系认证文件时，法规可能要求提交该产品的相关毒理学试验资料作为安全证明。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误。美国法规（§ 720.9）明确指出，提交Form FDA 2512或获得一个编号，并不以任何方式表示FDA对该企业或产品的批准。任何在标签或广告中暗示因此获得官方批准的行为将被视为误导。这体现了FDA对化妆品的事后监管和备案制特点。\n陈述2正确。这准确概括了中国法规（NMPA）文本中的要求：当产品仅通过安全评估方式评价安全，且拟增加的生产企业不能提供其所在国政府主管部门出具的生产质量管理体系相关资质认证文件时，应当提交该产品的相关毒理学试验资料。这是一种基于风险的分级管理思路。", "category": "Cosmetics", "related_concept": "FDA reference number, misbranding by reference to filing, production site change", "id": "PA_P_00656_005", "match_type": "weak", "match_score": 0.7478930913115045, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0022_0003_2"}
{"question": "In the context of controlled substance research, which regulatory system typically requires explicit documentation of responsibility division between research partners, and which system places the burden of proof on the applicant during quota hearings?", "choices": ["A. China requires explicit responsibility division; US places burden on applicant", "B. US requires explicit responsibility division; China places burden on applicant", "C. Both require explicit responsibility division; both place burden on applicant", "D. Neither requires explicit responsibility division; both place burden on administration"], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations mandate clear documentation of responsibility division between research partners for controlled substances. In US quota hearings, the applicant bears the burden of proof for their propositions, while the administration must prove requirements for quota actions.", "category": "Controlled_Substances", "related_concept": "responsibility division in research, hearing procedures", "id": "PA_P_00721_006", "match_type": "weak", "match_score": 0.7337288345306331, "lang": "EN", "source_cn": "麻醉药品和精神药品实验研究管理规定.txt", "source_us": "PART_1315IMPORTATION_AND_PRODUCTION_QUOTAS_FOR_EPH.txt", "old_id": "comp_0005_0010_1"}
{"question": "关于非临床实验室研究合规性，中美法规在提交材料时的要求有何不同？", "choices": ["A. 中国法规要求平台经营者报告时说明合规性，美国法规要求申请人在提交补充信息时说明合规性", "B. 中国法规要求省级药监部门审核合规性，美国法规要求申请人在首次提交时说明合规性", "C. 中国法规未涉及非临床研究合规性，美国法规要求申请人在提交补充信息时说明合规性", "D. 中美法规都要求申请人在首次提交申请时提供完整的合规性声明"], "answer": "A", "type": "Parallel", "explanation": "中国法规中，化妆品电子商务平台经营者在报告违法线索时，需要说明涉及产品的质量安全信息，这间接关联到产品背后的研究合规性（如使用禁用原料）。美国法规则明确规定，当申请人提交支持申请的补充信息或数据时，如果涉及非临床实验室研究，必须声明该研究是否符合特定章节（如第58部分）的要求，或说明不合规的原因。因此，A选项准确描述了差异：中国是在平台经营者报告环节涉及，美国是在申请人提交补充信息环节要求。", "category": "Cosmetics", "related_concept": "nonclinical laboratory study compliance", "id": "PA_P_00684_001", "match_type": "weak", "match_score": 0.7114609565612484, "lang": "CN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0005_0001_1"}
{"question": "Statement 1: Chinese regulations typically mandate confiscation of illegal pharmaceutical products along with production equipment when serious manufacturing violations occur. Statement 2: US regulations for veterinary drugs primarily focus on use restrictions and slaughter prohibition periods rather than confiscation of products.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 accurately reflects Chinese regulatory practice where serious violations trigger comprehensive confiscation measures including products, raw materials, and equipment. Statement 2 correctly describes the US approach where veterinary drug enforcement emphasizes use restrictions (like age limitations) and slaughter withdrawal periods to prevent residues, with product seizure being less common than in China's pharmaceutical enforcement framework.", "category": "Drugs", "related_concept": "confiscation of illegal products, use restrictions, slaughter prohibition period", "id": "PA_P_00026_002", "match_type": "weak", "match_score": 0.7287738277391185, "lang": "EN", "source_cn": "中华人民共和国药品管理法.txt", "source_us": "PART_558NEW_ANIMAL_DRUGS_FOR_USE_IN_ANIMAL_FEEDS.txt", "old_id": "comp_0026_0059_2"}
{"question": "A medical device manufacturer is developing labeling for a new diagnostic test. They want to include symbols without adjacent explanatory text. Which regulatory approach would allow this while ensuring compliance with both US and Chinese principles?", "choices": ["A. In the US, symbols from recognized standards can be used with a glossary; in China, all labeling must be in Chinese with no symbol-only provisions.", "B. In the US, symbols require adjacent English text unless part of a recognized standard with a glossary; in China, labeling language requirements are not specified for symbols.", "C. In the US, symbols without text are prohibited; in China, symbols can be used freely if explained elsewhere.", "D. In the US, symbols from any standard can be used with a glossary if likely understood; in China, symbols must always have adjacent Chinese text."], "answer": "B", "type": "Parallel", "explanation": "The US regulation allows symbols without adjacent text only if they are from FDA-recognized standards and used with a symbols glossary, or from other standards if likely understood and used with a glossary. Chinese regulations focus on language requirements for labeling but do not specifically address symbol-only usage in the provided text, implying general language rules apply. Option B correctly captures the US allowance with conditions and the lack of specific symbol provisions in China.", "category": "Medical_Devices", "related_concept": "symbol usage specifications", "id": "PA_P_00378_001", "match_type": "weak", "match_score": 0.6350350782728138, "lang": "EN", "source_cn": "体外诊断试剂注册与备案管理办法（2021年第48号令）.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0011_0005_1"}
{"question": "A pharmaceutical company's manufacturing facility is suspected of serious regulatory violations that may constitute criminal activity. Which regulatory body would most likely handle the initial transfer of the case to law enforcement authorities?", "choices": ["A. The inspecting agency directly transfers the case to public security authorities", "B. The case is first reviewed by a judicial committee before transfer", "C. The company must self-report to law enforcement before regulatory action", "D. Only courts can initiate criminal proceedings against regulated entities"], "answer": "A", "type": "Parallel", "explanation": "In China's regulatory framework, when suspected criminal violations are identified during inspections, the responsible regulatory authority directly transfers cases to public security authorities while notifying prosecutors. This contrasts with systems where judicial review or court initiation is required before criminal proceedings begin.", "category": "General_FDA", "related_concept": "transfer to public security for suspected crimes", "id": "PA_P_00810_001", "match_type": "weak", "match_score": 0.728405207363525, "lang": "EN", "source_cn": "药品医疗器械飞行检查办法（2015年第14号令）.txt", "source_us": "PART_20PUBLIC_INFORMATION.txt", "old_id": "comp_0006_0001_1"}
{"question": "Statement 1: Regulatory authorities assign unique identification numbers to manufacturing facilities for tracking purposes. Statement 2: Products sold across different administrative regions require additional regulatory notifications.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct per US regulations that assign establishment registration numbers to blood product facilities. Statement 2 is correct per Chinese regulations requiring provincial-level registration for cross-province sales of traditional Chinese medicine formula granules. Both represent different regulatory tracking mechanisms.", "category": "Drugs", "related_concept": "establishment registration number assignment, cross-province sales registration", "id": "PA_P_00108_002", "match_type": "weak", "match_score": 0.7473600139068336, "lang": "EN", "source_cn": "国家药监局 国家中医药局 国家卫生健康委 国家医保局关于结束中药配方颗粒试点工作的公告（2021年第22号）.txt", "source_us": "PART_607ESTABLISHMENT_REGISTRATION_AND_PRODUCT_LIS.txt", "old_id": "comp_0003_0004_2"}
{"question": "Statement 1: Under Chinese NMPA regulations, pH value testing for products containing alpha-hydroxy acids is required regardless of the product's formulation type.\nStatement 2: US FDA regulations for color additives, such as D&C Yellow No. 10, include a specification for 'Total color' as a percentage minimum.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect. Chinese NMPA regulations state that pH testing for alpha-hydroxy acid products is required, but pure oily (wax-based) products are exempt from pH testing. Statement 2 is correct. The US FDA text for D&C Yellow No. 10 includes the specification 'Total color, not less than 85 percent.'", "category": "Cosmetics", "related_concept": "pH value testing, total color requirement", "id": "PA_P_00637_008", "match_type": "weak", "match_score": 0.7127395407579512, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0014_0016_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在中国行政复议制度中，行政复议机关履行职责时，必须遵循包括‘便民、为民’在内的一系列原则，并接受上级行政复议机构的指导与监督。\n陈述2：在美国FDA咨询委员会运作中，如果委员会主席不是FDA全职雇员，则必须由一名指定联邦雇员被指派给该委员会，该指定联邦雇员同样被授权基于公共利益决定休会。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。根据中国《行政复议法》第三条，行政复议机关履行职责应遵循‘合法、公正、公开、高效、便民、为民’的原则。第四条明确规定上级行政复议机构对下级机构的行政复议工作进行指导、监督。\n陈述2正确。根据美国法规§ 14.30(b)，如果咨询委员会主席不是FDA全职雇员，则指定联邦官员或其他指定的机构雇员（或其替代者）应是被指派给该委员会的指定联邦雇员。并且，该指定联邦雇员也被授权在认为符合公共利益时决定休会。\n因此，两个陈述均准确反映了各自法规的规定。", "category": "General_Comparative", "related_concept": "designated federal employee role, principles of legality, fairness, openness, efficiency, convenience, and service to the people, supervision and guarantee of administrative authority", "id": "PA_P_00783_002", "match_type": "weak", "match_score": 0.7432320886220455, "lang": "CN", "source_cn": "中华人民共和国行政复议法.txt", "source_us": "PART_14PUBLIC_HEARING_BEFORE_A_PUBLIC_ADVISORY_COM.txt", "old_id": "comp_0001_0003_2"}
{"question": "A pharmaceutical company is establishing quality management systems for both US and Chinese markets. Which regulatory approach best reflects the fundamental difference in assigning comprehensive quality responsibility?", "choices": ["A. US regulations emphasize personnel qualifications and resources, while Chinese regulations assign specific legal responsibilities to named executive roles.", "B. Chinese regulations focus on component testing requirements, while US regulations emphasize finished-product testing.", "C. Both systems require identical organizational structures with a single executive bearing ultimate responsibility.", "D. US regulations require more detailed documentation of quality activities than Chinese regulations."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations explicitly assign comprehensive quality responsibility to specific named roles (法定代表人/legal representative, 企业负责人/enterprise responsible person) who must personally ensure quality management system implementation. US regulations focus on ensuring adequate personnel qualifications and resources are available to perform quality functions without specifying particular executives who bear personal legal responsibility.", "category": "Drugs", "related_concept": "comprehensive quality responsibility", "id": "PA_P_00178_001", "match_type": "weak", "match_score": 0.7498650003391288, "lang": "EN", "source_cn": "药品上市许可持有人落实药品质量安全.txt", "source_us": "PART_212CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_PO.txt", "old_id": "comp_0002_0003_1"}
{"question": "Statement 1: In the US, a color additive approved for food use (like FD&C Red No. 3) is automatically approved for use in all cosmetic products without additional restrictions. Statement 2: In China, referencing a foreign positive list for a functional cosmetic ingredient requires submitting proof that the new ingredient's usage fully complies with all concentration, scope, and restriction conditions listed in that foreign regulation.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect. US FDA regulations typically treat color additives for foods and cosmetics under separate provisions and lists. Approval for food use does not automatically equate to approval for all cosmetic uses; specific cosmetic listings and restrictions apply. Statement 2 is correct. The Chinese NMPA text explicitly states that when referencing a foreign positive list for a functional ingredient, the applicant must submit a declaration confirming the new ingredient's complete compliance with all usage conditions (concentration, scope, restrictions) specified in that foreign regulation.", "category": "Cosmetics", "related_concept": "uses and restrictions, restriction conditions", "id": "PA_P_00617_017", "match_type": "weak", "match_score": 0.7124285677751793, "lang": "EN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0024_0001_2"}
{"question": "关于人体试用试验的持续时间，中美法规在化妆品领域的主要差异是什么？", "choices": ["A. 中国法规通常要求至少4周，美国法规无统一最低时长要求", "B. 美国法规要求至少6周，中国法规要求至少4周", "C. 两国法规都明确规定至少需要8周试验期", "D. 美国法规要求根据产品风险确定时长，中国法规无具体要求"], "answer": "A", "type": "Parallel", "explanation": "根据中国《化妆品安全技术规范》，驻留类化妆品人体试用试验通常要求试用时间不少于4周，并有明确的观察频率要求。而美国FDA对化妆品人体试验的持续时间没有统一的法定最低要求，通常基于产品特性、预期用途和科学合理性由申请人确定。", "category": "Cosmetics", "related_concept": "trial duration", "id": "PA_P_00638_025", "match_type": "weak", "match_score": 0.7345947865202429, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0063_0001_1"}
{"question": "Statement 1: A shortage drug list management system is designed to proactively monitor and address supply gaps for essential medications, often involving government intervention to ensure availability. Statement 2: Labeling and packaging requirements for pharmaceutical products primarily aim to prevent mix-ups, ensure product integrity during distribution, and provide accurate information to end-users.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 accurately describes shortage drug list systems, which involve monitoring,预警 (early warning), and measures like production organization or export controls to mitigate shortages. Statement 2 correctly outlines key purposes of labeling and packaging rules: preventing errors (e.g., mix-ups), protecting against contamination/damage, and ensuring legibility and accuracy for safe use. Both reflect fundamental regulatory principles in pharmaceutical supply chain and quality management.", "category": "Drugs", "related_concept": "短缺药品清单管理制度, labeling and packaging requirements", "id": "PA_P_00017_005", "match_type": "weak", "match_score": 0.654891903084492, "lang": "EN", "source_cn": "中华人民共和国药品管理法.txt", "source_us": "PART_212CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_PO.txt", "old_id": "comp_0019_0005_2"}
{"question": "A cosmetics company is preparing regulatory submissions for a new color additive in both China and the US. Which of the following statements accurately reflects a key difference in their documentation requirements?", "choices": ["A. In China, electronic and paper submissions must be identical, while the US focuses on batch certification for color additives.", "B. The US requires all documents to be stamped page-by-page, while China mandates the use of statutory measurement units.", "C. China requires batch certification for all cosmetic ingredients, while the US has no specific formatting standards for submissions.", "D. Both countries require identical formatting standards, including black text and A4 paper, for all regulatory documents."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations (NMPA) explicitly require consistency between electronic and paper versions of submission documents. US regulations (FDA) for color additives, as exemplified, emphasize that all batches must be certified. The other options contain inaccuracies: the page-by-page stamping is a Chinese requirement, not US; batch certification is a highlighted US requirement for color additives, not a general Chinese one for all ingredients; and while China has specific formatting rules (like black text, A4 paper), the provided US text does not specify such general document formatting standards.", "category": "Cosmetics", "related_concept": "electronic and paper consistency, batch certification", "id": "PA_P_00617_001", "match_type": "weak", "match_score": 0.7463438671752494, "lang": "EN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0002_0025_1"}
{"question": "在化妆品网络经营监管中，关于监管部门调取平台经营者信息的程序，中美法规存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求监管部门必须出具正式的协助调查函，而美国法规对此没有明确规定。", "B. 美国法规强调平台经营者必须无条件配合，而中国法规允许平台经营者拒绝提供信息。", "C. 中国法规对调取信息设置了层级报告和协助调查函的正式程序，美国法规更侧重于平台经营者的主动配合义务。", "D. 两国法规都要求平台经营者在接到口头通知后立即提供所有信息，程序完全相同。"], "answer": "C", "type": "Parallel", "explanation": "中国法规（如第三十条）明确规定了调取信息的正式程序，包括出具协助调查函、层级报告（县级报市级协助）等，体现了程序性和层级性。美国法规在相关领域（如《联邦食品、药品和化妆品法案》授权下）通常强调监管机构（如FDA）的权威和企业的配合义务，但具体程序可能更依赖于执法实践和案例法，而非像中国法规那样在条文中详细规定层级和函件要求。选项A过于绝对（美国可能有其他程序要求）；B错误（中国法规也要求配合）；D明显错误。", "category": "Cosmetics", "related_concept": "information provision", "id": "PA_P_00681_005", "match_type": "weak", "match_score": 0.7463922167424895, "lang": "CN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0011_0003_1"}
{"question": "关于化妆品生产设施与设备管理，中美法规在核心理念上存在差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规强调生产场地与品种、数量的适应性，而美国法规更关注特定颜色添加剂的生产认证。", "B. 中国法规要求生产车间避免污染，美国法规则不涉及生产环境的具体要求。", "C. 中国法规对设备清洁有详细规定，美国法规则完全依赖企业自主管理。", "D. 中美法规均以相同的严格程度规范生产设施，差异仅在于具体技术指标。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如NMPA相关要求）通常从宏观生产条件出发，强调设施设备与生产规模、品种的匹配性，以及生产环境的污染控制（如车间布局、更衣室设置等）。美国法规（如FDA对颜色添加剂的规定）则常针对具体物质（如D&C Red No. 36）设定详细的生产认证、规格和使用限制，体现对特定成分的严格管控。选项B、C、D的描述存在片面或错误，不符合两国法规的典型差异特征。", "category": "Cosmetics", "related_concept": "production facility suitability", "id": "PA_P_00667_012", "match_type": "weak", "match_score": 0.7487136323019108, "lang": "CN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0007_0014_1"}
{"question": "关于化妆品中使用的色素添加剂，中美法规在确保其安全性方面的核心要求有何关键区别？", "choices": ["A. 中国法规要求对使用监测期新原料的化妆品进行重点检查，美国法规则要求色素添加剂上市前必须提供科学数据证明其特定用途下的安全性，并可能应用安全系数。", "B. 中国法规要求所有色素添加剂必须进行致癌性测试，美国法规则可以豁免某些测试。", "C. 两国法规都要求对所有化妆品色素进行相同的全套毒理学测试。", "D. 中国法规由药品监督管理部门直接分配色素使用配额，美国法规则由企业自行决定使用量。"], "answer": "A", "type": "Parallel", "explanation": "中国法规在常规检查重点中提及了对“使用监测期新原料的化妆品”的关注，这体现了对包括新色素在内新原料上市后监管的重视。美国法规则详细规定了色素添加剂上市前（申请列入许可清单）的安全评估体系：1）必须提交所有必要的科学数据以证明其特定用途的安全性（“safe-for-use”原则）；2）在将动物实验数据外推至人体时，通常应用100:1的安全系数；3）FDA局长有权根据数据批准其广泛使用、限制使用或规定使用条件；4）安全性测试通常包括急性口服毒性、原发性刺激、致敏性等，但局长可基于已有数据豁免某些测试。因此，关键区别在于：中国强调对含新原料产品（可能包括新色素）的上市后重点检查，而美国强调基于科学数据和可能的安全系数进行上市前安全许可。", "category": "Cosmetics", "related_concept": "safety factor application, color additive listing conditions", "id": "PA_P_00633_002", "match_type": "weak", "match_score": 0.7425903070154349, "lang": "CN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0007_0004_2"}
{"question": "以下关于中美药品/兽药法规中'主体责任'与'政府机制'的陈述，哪项是正确的？\n陈述1：中国法规在药品标准管理中明确了'政府主导、企业主体、社会参与'的工作机制。\n陈述2：美国法规在MUMS（小用途/小物种）兽药认定程序中，明确由申办方（sponsor）承担主要的合规与发展责任，并设立了专门的政府办公室（如OMUMS）负责管理该程序。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规文本开篇即指出药品标准管理实行'政府主导、企业主体、社会参与'的工作机制。陈述2正确：美国法规片段明确指出申办方（sponsor）负责合规（'responsible for compliance'），并且在MUMS认定程序中，指定了'FDA兽药中心小用途小物种动物药物开发办公室（OMUMS）主任（Director）'作为对接负责人，体现了在特定领域（MUMS）中政府机构设立专门管理程序的机制。因此两个陈述都正确。", "category": "Drugs", "related_concept": "government-led mechanism, sponsor compliance responsibility", "id": "PA_P_00202_002", "match_type": "weak", "match_score": 0.7049145904903761, "lang": "CN", "source_cn": "药品标准管理办法.txt", "source_us": "PART_516NEW_ANIMAL_DRUGS_FOR_MINOR_USE_AND_MINOR_S.txt", "old_id": "comp_0002_0005_2"}
{"question": "Statement 1: Cosmetic regulations require reporting of test results, including adverse reactions, in a standardized format for safety evaluation. Statement 2: Regulations prohibit the use of carcinogenic substances like vinyl chloride in cosmetic products due to health risks.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as regulatory frameworks mandate standardized reporting of test results (e.g., adverse reaction grades) to ensure transparency and safety assessment. Statement 2 is correct because regulations, such as those under the FD&C Act, deem products containing carcinogenic substances like vinyl chloride adulterated, prohibiting their use due to established health risks.", "category": "Cosmetics", "related_concept": "test result reporting, carcinogenic substance regulation", "id": "PA_P_00641_014", "match_type": "weak", "match_score": 0.7046794552564835, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0054_0003_2"}
{"question": "在化妆品质量管理中，关于留样（样品储存）的要求，请判断以下陈述：\n陈述1：中国法规要求留样保存期限不得少于产品使用期限届满后6个月，且留样数量需满足检验需求。\n陈述2：美国法规对颜色添加剂（如D&C Red No. 36）的留样没有强制性规定，完全由企业自行决定。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：中国法规（如《化妆品监督管理条例》相关配套规定）明确要求留样制度，包括留样数量（至少出厂检验需求量的2倍）、保存期限（使用期限届满后6个月）等具体规定，以确保产品质量可追溯。陈述2错误：美国法规（如FDA对颜色添加剂的规定）虽未在提供文本中直接规定留样，但通过认证要求（如批次认证）和详细规格控制间接确保质量可追溯，并非完全由企业自行决定；实际上，FDA对药品和化妆品成分有严格的记录保存和质量管理要求，留样作为常见实践被鼓励或隐含在GMP中。因此，陈述1正确，陈述2不准确。", "category": "Cosmetics", "related_concept": "sample storage requirements", "id": "PA_P_00667_013", "match_type": "weak", "match_score": 0.7487136323019108, "lang": "CN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0007_0014_2"}
{"question": "关于人体功效评价试验的设计依据，中美法规在原则要求上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求试验设计必须完全遵循国际公认的标准化方法，而美国法规允许基于科学原理自行设计方法。", "B. 中国法规强调试验方法需有明确的参考依据和来源，而美国法规在安全性评价中更侧重于“安全使用”原则和具体测试要求。", "C. 美国法规要求所有人体试验必须先在动物模型上完成验证，而中国法规则无此强制性前置要求。", "D. 两国法规均要求试验设计必须获得药监部门的预先批准，依据来源的说明并非核心要求。"], "answer": "B", "type": "Parallel", "explanation": "中国法规（如NMPA相关指南）在“试验依据”部分明确要求说明方法参考的依据和来源，体现了对方法可靠性和溯源性的重视。美国法规（如FDA 21 CFR 70部分）在安全性评价中，其核心是“安全使用”原则（safe-for-use），并要求提供支持安全性的科学数据，对于外部用着色剂则规定了具体的毒理学测试类型（如急性口服毒性、原发性刺激等）。选项A错误，中国法规并未要求必须使用“国际公认标准化方法”；选项C错误，美国法规中的动物实验数据主要用于确定安全系数（如100:1），并非所有人体试验的前置强制要求；选项D错误，两国法规均未表述“必须获得预先批准”是试验设计的核心要求。", "category": "Cosmetics", "related_concept": "trial basis and sources, safety evaluation criteria", "id": "PA_P_00605_004", "match_type": "weak", "match_score": 0.728763917596304, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0007_0004_1"}
{"question": "关于医疗器械监管中的监督评估与安全风险 oversight，请判断以下陈述：\n陈述1：中国法规要求对大型医用设备的使用状况进行监督评估，发现过度检查等情况应立即纠正。\n陈述2：美国法规明确规定了地方监管机构未及时发现系统性安全风险时，上级部门应对其负责人进行约谈的机制。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确，中国法规确实规定了卫生主管部门对大型医用设备使用状况的监督评估职责及对违规使用的纠正要求。陈述2错误，美国法规文本未涉及监管机构约谈机制；该机制是中国法规中明确的，针对未及时发现系统性风险或消除安全隐患的监管部门及地方政府的问责措施。", "category": "Medical_Devices", "related_concept": "supervision and assessment, safety risk oversight", "id": "PA_P_00496_002", "match_type": "weak", "match_score": 0.7466005974182569, "lang": "CN", "source_cn": "医疗器械监督管理条例.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0024_0014_2"}
{"question": "关于化妆品中致癌物质的监管，中美药监机构（NMPA与FDA）在监管逻辑上最核心的区别是什么？", "choices": ["A. NMPA主要依据动物致癌性数据，而FDA主要依据人体流行病学证据", "B. NMPA侧重于上市前风险评估，而FDA侧重于上市后基于危害的禁令", "C. NMPA对致癌物质实行分级管理，而FDA对已确认致癌物采取零容忍并直接判定产品掺假", "D. NMPA要求进行致癌性动物试验，而FDA仅要求提交文献综述"], "answer": "C", "type": "Parallel", "explanation": "解析：本题考察对中美化妆品致癌物质监管原则的理解。选项C正确：FDA的监管逻辑（如对氯乙烯）是，一旦某物质被确认为有害（如致癌），且可能使含有该成分的化妆品对使用者造成伤害，该产品即被直接判定为“掺假”（adulterated），这是一种基于危害的、较为严格的监管立场。NMPA的监管体系通常对致癌物质进行风险评估和分级管理（如根据致癌证据强度分为1类、2类等），并据此采取不同的限制或禁用措施，而非对所有确认致癌物一律采取“掺假”的绝对化判定。选项A和D的描述过于绝对且不准确，两国监管都会综合评估动物和人体证据。选项B的对比方向错误，两国在上市前和上市后都有相应监管措施。", "category": "Cosmetics", "related_concept": "carcinogenic substance regulation", "id": "PA_P_00641_009", "match_type": "weak", "match_score": 0.747434975509971, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0036_0003_1"}
{"question": "关于中美药监法规中的资料豁免规定，以下哪项描述最准确？", "choices": ["A. 中国法规中，医疗机构中药制剂若处方药味用量超过药品标准规定，可完全免报资料项目13-17", "B. 美国法规中，血液制品若在FDA批准的特定系统下使用，其储存期限可不受标准表格限制", "C. 中国法规中，已有同品种获得批准文号的化学制剂仍需完整申报临床前资料项目1-16", "D. 美国法规中，所有血液制品的储存温度必须严格遵循法规表格，不允许任何例外"], "answer": "B", "type": "Parallel", "explanation": "B正确：美国法规规定，若血液制品在FDA批准或许可的采集、处理和储存系统下使用，其储存期限可按该系统说明书执行，可不同于标准表格（C列）。A错误：中国法规规定，中药制剂处方药味用量超标时需报送资料项目14、15，并非完全豁免13-17。C错误：中国法规规定，已有同品种批准文号的化学制剂可免报资料项目13-17。D错误：美国法规允许在FDA批准系统下使用不同的储存期限。", "category": "Drugs", "related_concept": "免报资料项目13-17, regulatory exemptions", "id": "PA_P_00084_001", "match_type": "weak", "match_score": 0.7033615862746466, "lang": "CN", "source_cn": "医疗机构制剂注册管理办法（试行）（2005年国家食品药品监督管理局令第20号）.txt", "source_us": "PART_610GENERAL_BIOLOGICAL_PRODUCTS_STANDARDS.txt", "old_id": "comp_0013_0009_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中国法规，执业药师参加省级以上药品监管部门组织的网络培训，属于有效的继续教育活动。\n陈述2：根据美国法规，如果FDA终止了某项新用途信息的传播豁免，制造商必须在收到通知后立即停止所有信息传播活动。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确。中国法规（第十条）明确规定，执业药师继续教育方式包括参加省级以上药品监管部门组织的网络培训等继续教育培训活动。\n陈述2错误。美国法规（§ 99.403(c)）规定，如果FDA在终止豁免的同时发出了停止传播令（cease dissemination order），制造商必须在收到该命令后不晚于60天内遵守，而非“立即”停止。因此，陈述1正确，陈述2错误。", "category": "Drugs", "related_concept": "continuing education activities, cease dissemination order", "id": "PA_P_00161_002", "match_type": "weak", "match_score": 0.6691832241148299, "lang": "CN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0004_0008_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在确定着色剂的安全使用限量时，美国法规（FDA）通常会应用一个默认的安全系数（如100:1），将动物实验数据外推至人体。\n陈述2：中国法规对于化妆品人体功效评价试验，明确要求试验目的及原理必须与产品的功效宣称内容严格相符。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。美国法规（21 CFR 70.40）明确指出，在将动物实验数据应用于人时，除非有证据证明可使用不同的安全系数，否则将采用100比1的安全系数。这体现了在安全性评估中对不确定性的保守处理原则。\n陈述2正确。中国法规（如《化妆品功效宣称评价规范》相关要求）在“试验目的及原理”部分明确规定，其内容“应当与功效宣称评价内容相符”。这确保了试验设计的针对性和宣称的科学支撑。", "category": "Cosmetics", "related_concept": "safety factor application, trial purpose and principle alignment", "id": "PA_P_00605_005", "match_type": "weak", "match_score": 0.728763917596304, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0007_0004_2"}
{"question": "Statement 1: In Chinese regulatory frameworks, test method naming conventions typically include the instrument or detector name when applicable. Statement 2: US FDA regulations for color additives require batch certification for all production lots before market distribution. Which of the following is correct?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes Chinese regulatory practice where test method naming conventions often incorporate instrument or detector names. Statement 2 accurately reflects US FDA requirements where color additives like D&C Yellow No. 8 require certification of all batches according to established regulations before they can be used in products.", "category": "Cosmetics", "related_concept": "test method naming convention, batch certification", "id": "PA_P_00637_013", "match_type": "weak", "match_score": 0.747543716661285, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0021_0025_2"}
{"question": "关于化妆品检验报告封面标识，中美法规在CMA标识要求上存在差异。以下哪项描述正确反映了这种差异？", "choices": ["A. 中国法规要求CMA标识必须位于封面左上方，而美国法规对类似标识无强制位置规定", "B. 美国法规要求所有检验报告封面必须包含FDA标识，而中国法规无此要求", "C. 两国法规都要求检验报告封面必须包含官方认证标识，且位置要求相同", "D. 中国法规对CMA标识无强制要求，而美国法规要求必须包含特定标识"], "answer": "A", "type": "Parallel", "explanation": "根据中国化妆品注册备案检验报告要求，CMA标识必须位于封面左上方。而美国FDA法规文本中未提及检验报告封面标识的具体位置要求，主要关注产品声明表格的提交。", "category": "Cosmetics", "related_concept": "CMA logo placement", "id": "PA_P_00644_005", "match_type": "weak", "match_score": 0.7211062438268745, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0077_0002_1"}
{"question": "关于化妆品批次合规性评估，中美法规在程序上存在显著差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规侧重于对受试者皮肤反应的临床观察和记录，而美国法规则侧重于对提交材料的行政审查和规格符合性验证。", "B. 中国法规要求所有批次都必须经过人体皮肤试验，而美国法规则完全依赖实验室检测。", "C. 美国法规的合规性评估完全由企业自行负责，而中国法规则必须由指定的检验机构完成。", "D. 中国法规的批次认证是强制性的，而美国法规则是自愿性的。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如化妆品人体皮肤重复性开放型涂抹试验）的核心合规性证据来源于对受试人群的临床安全性观察（如皮肤反应评估）。美国法规（如颜色添加剂认证）的合规性评估则是一个行政程序，重点在于审查提交的请求材料是否真实、规格是否符合既定标准，并据此决定是否颁发证书。选项B错误，因为美国法规并非完全依赖实验室检测，它包含对数据和规格的审查；选项C错误，因为美国FDA会进行审查，并非完全由企业负责；选项D错误，两国法规在各自适用领域内的认证或检验要求通常都是强制性的。", "category": "Cosmetics", "related_concept": "batch compliance", "id": "PA_P_00639_009", "match_type": "weak", "match_score": 0.7206579547762448, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0051_0001_1"}
{"question": "In comparing regulatory frameworks for non-compliance, which statement best describes a key difference between Chinese and US approaches to professional activity prohibitions?", "choices": ["A. Chinese regulations impose fixed-term bans on individuals from specific professional roles, while US regulations focus on product-level restrictions without individual professional bans.", "B. Both systems use identical timeframes for prohibiting individuals from professional activities following violations.", "C. US regulations mandate permanent bans for first-time offenders, while Chinese regulations use temporary suspensions.", "D. Chinese regulations allow continued practice during appeals, while US regulations require immediate cessation during reconsideration."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations specify fixed-term prohibitions (e.g., 5-year bans from management roles) for individuals violating clinic operations, while the provided US text focuses on product-level actions (import tolerance establishment/amendment/revocation) without mentioning individual professional activity bans. This reflects different regulatory philosophies: China targets individual practitioners directly, while the US text emphasizes product regulation.", "category": "Drugs", "related_concept": "prohibition from professional activities", "id": "PA_P_00011_001", "match_type": "weak", "match_score": 0.7473418927256721, "lang": "EN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_510NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0012_0005_1"}
{"question": "Statement 1: In US cosmetic regulations, inspection conclusions must be based solely on documented evidence and signed reports. Statement 2: In Chinese cosmetic regulations, inspection conclusions must incorporate on-site statements and defenses from the inspected party before finalization.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect because the provided US text doesn't discuss inspection procedures or conclusion basis. Statement 2 is correct as Chinese regulations explicitly require inspectors to record and consider on-site statements/defenses when determining defects and problems.", "category": "Cosmetics", "related_concept": "inspection conclusion basis, on-site statement and defense", "id": "PA_P_00631_002", "match_type": "weak", "match_score": 0.73379399375912, "lang": "EN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0004_0004_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中国化妆品法规，境外注册人若拒不履行行政处罚，可能面临长期进口禁止。\n陈述2：美国法规要求，在涉及人体受试者的临床研究中提交请愿支持数据时，必须声明研究符合机构审查和知情同意要求。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规明确规定，境外化妆品注册人、备案人拒不履行行政处罚决定的，可被禁止进口化妆品10年，这体现了对不遵守法规的境外实体的严厉制裁。\n陈述2正确：美国法规文本指出，涉及人体受试者的临床研究，提交的支持请愿的信息或数据必须包含声明，确保研究符合机构审查（part 56）和知情同意（part 50）的要求，或说明其豁免依据。这反映了美国在人体研究伦理监管方面的严格规定。\n因此，两个陈述都正确。", "category": "Cosmetics", "related_concept": "import prohibition for non-compliance, institutional negligence consequences", "id": "PA_P_00677_009", "match_type": "weak", "match_score": 0.7383883746826639, "lang": "CN", "source_cn": "化妆品监督管理条例 (1).txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0024_0002_2"}
{"question": "请判断以下关于中美化妆品标签法规的陈述：\n陈述1：根据中国法规，化妆品标签上宣称的量化指标（如时间、统计数据）必须配合人体功效评价试验、消费者使用测试或实验室试验中的至少一项进行验证。\n陈述2：根据美国法规，化妆品标签上若使用替代成分，必须在成分表中明确标识，例如使用“或”连接或使用“may also contain”短语说明。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。中国法规明确规定，对于宣称量化指标（如“7天淡纹”），其评价属于“可搭配项目（△）”，但必须配合人体功效评价试验、消费者使用测试或者实验室试验中的至少一项一起使用，不能单独作为宣称依据。\n陈述2正确。美国FDA法规（21 CFR 701.3）对替代成分的标注有明确规定。当使用替代成分时，必须在成分表中进行标识。主要方式有两种：一是在常规成分名称后用“或”连接替代成分；二是在列出所有常规成分后，按预期含量降序列出替代成分组，并用“may also contain”进行标识。这确保了成分信息的透明度和准确性。", "category": "Cosmetics", "related_concept": "quantitative indicators, alternative ingredients, mandatory label information", "id": "PA_P_00604_002", "match_type": "weak", "match_score": 0.7464960430017922, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0004_0005_2"}
{"question": "Statement 1: In cosmetics regulation, establishing maximum impurity limits for substances like lead and arsenic is a primary method for ensuring product safety. Statement 2: A key regulatory requirement for quality safety officers is the demonstrated ability to perform independent risk assessments and influence company decisions.", "choices": ["A. Both statements are correct and represent complementary regulatory focuses.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct and exemplified by the US regulation text, which sets precise ppm/ppb limits for impurities like lead, arsenic, and specific aromatic amines. Statement 2 is correct and exemplified by the Chinese regulation, which requires the quality safety officer to have 'risk研判能力' (risk assessment capability) and mandates that the法定代表人 (legal representative) must consult them on major decisions. These represent two complementary pillars of regulation: product composition standards and qualified personnel within a management system.", "category": "Cosmetics", "related_concept": "impurity limits, specification compliance, risk assessment capability", "id": "PA_P_00590_006", "match_type": "weak", "match_score": 0.7399987721112918, "lang": "EN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0004_0005_2"}
{"question": "Statement 1: Under Chinese pharmaceutical regulations, intentionally spreading false drug safety information that disrupts public order can lead to penalties administered by public security authorities. Statement 2: Under US FDA regulations, marketing a substance like tannic acid for use in barium enemas without adequate safety evidence and proper warning labels constitutes misbranding and subjects the product to regulatory action.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly reflects the Chinese rule that fabricating/spreading false drug safety information, if it constitutes a public order violation, leads to public security (police) penalties. Statement 2 correctly summarizes the US regulation: tannic acid for enemas is considered a new drug requiring proof of safety/effectiveness; shipping it without the specific 'Warning—Not for use in enemas' label is misbranding under the FD&C Act, making it subject to regulatory proceedings.", "category": "Drugs", "related_concept": "penalties for spreading false information, new drug classification, misbranding prohibition, warning label requirement", "id": "PA_P_00023_008", "match_type": "weak", "match_score": 0.7242312240367129, "lang": "EN", "source_cn": "中华人民共和国药品管理法.txt", "source_us": "PART_201LABELING.txt", "old_id": "comp_0032_0055_2"}
{"question": "A cosmetics company faces regulatory penalties for quality violations. In which jurisdiction would the company's quality safety officer potentially avoid individual penalties by demonstrating they had fulfilled all quality safety duties without subjective fault?", "choices": ["A. Only under US regulations", "B. Only under Chinese regulations", "C. Under both US and Chinese regulations", "D. Under neither US nor Chinese regulations"], "answer": "B", "type": "Parallel", "explanation": "Chinese regulations explicitly provide for mitigation or exemption from penalties for responsible personnel who can prove they fulfilled quality safety obligations without subjective fault. The US text provided focuses on product specifications without addressing individual liability mitigation frameworks for personnel demonstrating lack of fault in their duties.", "category": "Cosmetics", "related_concept": "mitigation of penalties for cooperation or lack of fault", "id": "PA_P_00590_013", "match_type": "weak", "match_score": 0.7188685005946036, "lang": "EN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0009_0005_1"}
{"question": "Statement 1: In US veterinary drug regulation, 'concurrent use' refers to situations where multiple active ingredients are administered simultaneously to target animals. Statement 2: Chinese continuing education regulations require separate planning and implementation of public welfare and professional subjects by different regulatory bodies.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes 'concurrent use' in US veterinary drug regulation as simultaneous administration of multiple active ingredients. Statement 2 accurately reflects Chinese continuing education regulations that distinguish between public welfare subjects (handled by human resources and social security departments) and professional subjects (managed by drug regulatory authorities).", "category": "Regulatory Affairs", "related_concept": "concurrent use, public and professional subjects", "id": "PA_P_00160_002", "match_type": "weak", "match_score": 0.7201280247119857, "lang": "EN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0003_0005_2"}
{"question": "In comparing US and Chinese government information disclosure frameworks, which statement accurately describes the approach to inter-agency information sharing?", "choices": ["A. Both systems allow unrestricted sharing of all government information between federal/national agencies", "B. The US system permits disclosure of exempt records to other federal agencies with written agreements, while China establishes specialized work institutions at various government levels", "C. China requires congressional approval for inter-agency disclosures, while the US relies on provincial government oversight", "D. Both systems prohibit any sharing of trade secrets between government agencies regardless of circumstances"], "answer": "B", "type": "Parallel", "explanation": "The US regulation specifically allows disclosure of otherwise exempt FDA records to other federal agencies with written agreements restricting further disclosure. The Chinese regulation establishes government information disclosure work institutions at various administrative levels with specific organizational responsibilities, but doesn't detail inter-agency sharing mechanisms in the provided text.", "category": "General_FDA", "related_concept": "disclosure to federal agencies, government information disclosure work institution", "id": "PA_P_00779_001", "match_type": "weak", "match_score": 0.7330259274656754, "lang": "EN", "source_cn": "中华人民共和国政府信息公开条例.txt", "source_us": "PART_20PUBLIC_INFORMATION.txt", "old_id": "comp_0001_0015_1"}
{"question": "Statement 1: US regulations require intended use statements to specify the professional qualifications needed for result interpretation. Statement 2: Chinese regulations use credit systems to determine inspection frequency for manufacturers with compliance issues. Which is correct?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as US regulations (21 CFR 809.10) require intended use statements to specify that results should be interpreted by qualified professionals like pathologists. Statement 2 is correct as Chinese regulations establish credit档案 (credit files) systems where manufacturers with poor信用记录 (credit records) face increased监督检查频次 (inspection frequency).", "category": "Medical_Devices", "related_concept": "intended use statement, increased inspections for poor credit", "id": "PA_P_00482_002", "match_type": "weak", "match_score": 0.7379021906295775, "lang": "EN", "source_cn": "医疗器械生产监督管理办法（2022年第53号令）.txt", "source_us": "PART_864HEMATOLOGY_AND_PATHOLOGY_DEVICES.txt", "old_id": "comp_0020_0016_2"}
{"question": "In comparing US and Chinese cosmetic regulations, which statement best describes the approach to contaminant thresholds?", "choices": ["A. Both systems primarily rely on general manufacturing practice standards without specific numerical limits for most contaminants.", "B. US regulations typically specify precise numerical limits for individual contaminants, while Chinese regulations focus more on organizational responsibilities and personnel qualifications.", "C. Chinese regulations establish stricter numerical contaminant limits than US regulations for all substances.", "D. Both systems use identical numerical thresholds for heavy metals and other contaminants in cosmetic products."], "answer": "B", "type": "Parallel", "explanation": "US regulations (as shown in the D&C Blue No. 4 specifications) establish precise numerical limits for contaminants like lead (≤20 ppm), arsenic (≤3 ppm), and specific chemical compounds. Chinese regulations emphasize organizational structures, personnel qualifications (like the 5-year experience requirement for quality safety officers), and management systems rather than specifying exact contaminant thresholds in the provided text.", "category": "Cosmetics", "related_concept": "contaminant thresholds", "id": "PA_P_00661_013", "match_type": "weak", "match_score": 0.7406703619225229, "lang": "EN", "source_cn": "化妆品生产经营监督管理办法（2021年第46号）.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0008_0005_1"}
{"question": "关于临床试验数据记录的责任与要求，以下哪项描述最准确地反映了中美法规的差异？", "choices": ["A. 中国法规强调申办者对病例报告表修改的监督与研究者对源数据一致性的责任，而美国法规侧重于制造商在收到请求后快速提供记录的责任。", "B. 中国法规要求所有数据修改必须获得FDA的事先批准，而美国法规要求研究者对数据准确性负全责。", "C. 中国法规规定数据记录必须使用特定软件系统，而美国法规只要求纸质记录。", "D. 中美法规在数据记录责任方面完全一致，均强调申办者的主导作用。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如NMPA相关要求）强调临床试验中申办者需确保病例报告表修改的必要性、记录性并获得研究者同意，同时研究者需保证数据与源文件一致并保留修改轨迹。美国法规（FDA相关）在提供的文本中侧重于制造商或授权分销商在收到监管请求后需在规定时间内（如2个工作日内）提供记录的责任，这体现了不同的监管侧重点：中国更注重临床试验过程的内部控制与数据溯源，美国则强调对监管请求的响应效率。", "category": "Drugs", "related_concept": "record production responsibility", "id": "PA_P_00314_001", "match_type": "weak", "match_score": 0.7402157515352253, "lang": "CN", "source_cn": "药物临床试验质量管理规范.txt", "source_us": "PART_203PRESCRIPTION_DRUG_MARKETING.txt", "old_id": "comp_0014_0007_1"}
{"question": "Statement 1: Under Chinese regulations, a manufacturer can request exemption from specific licensing requirements if they demonstrate equivalent safety controls through alternative means. Statement 2: Under US regulations, a manufacturer can request exemption from postmarket surveillance requirements by providing information that answers the surveillance question for their device. Which option correctly describes these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect because the provided Chinese text does not mention any exemption mechanism for licensing requirements; it only covers license renewal, replacement, and administrative procedures. Statement 2 is correct because US regulations explicitly allow manufacturers to request exemption from postmarket surveillance by demonstrating why the surveillance question doesn't apply or by providing information that answers it.", "category": "Medical_Devices", "related_concept": "exemption request, waiver request", "id": "PA_P_00475_002", "match_type": "weak", "match_score": 0.74496598697138, "lang": "EN", "source_cn": "医疗器械生产监督管理办法（2022年第53号令）.txt", "source_us": "PART_822POSTMARKET_SURVEILLANCE.txt", "old_id": "comp_0007_0005_2"}
{"question": "In comparing US FDA and Chinese NMPA regulatory frameworks, which statement best describes the relationship between pre-market inspections and product specifications?", "choices": ["A. Both agencies require pre-market GMP inspections for all new drugs regardless of existing specifications", "B. The FDA focuses primarily on product specifications while the NMPA emphasizes pre-market GMP inspections as a key regulatory tool", "C. The NMPA allows exemptions from pre-market GMP inspections based on risk management principles, while FDA regulations don't explicitly link specifications to inspection requirements", "D. Both agencies treat product specifications and pre-market inspections as completely independent regulatory elements"], "answer": "C", "type": "Parallel", "explanation": "Chinese NMPA regulations allow provincial drug authorities to decide whether to conduct pre-market GMP inspections based on risk management principles, especially for products that have already passed similar inspections. FDA regulations focus on product specifications as defined requirements but don't explicitly connect them to pre-market inspection decisions in the same conditional manner.", "category": "Drugs", "related_concept": "药品生产质量管理规范符合性检查, specifications", "id": "PA_P_00255_001", "match_type": "weak", "match_score": 0.665959449215564, "lang": "EN", "source_cn": "药品生产监督管理办法（2020年国家市场监督管理总局令第28号）.txt", "source_us": "PART_520ORAL_DOSAGE_FORM_NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0018_0011_1"}
{"question": "Statement 1: In regulatory frameworks, 'directly responsible personnel' typically includes individuals with direct management responsibility for quality systems, such as quality safety officers. Statement 2: Regulatory specifications for color additives must include purity percentages and limits for specific impurities like heavy metals.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly reflects how regulatory systems define directly responsible personnel to include those with management oversight of quality safety. Statement 2 accurately describes common regulatory specification requirements for color additives, which typically include both minimum purity levels and maximum limits for contaminants.", "category": "Cosmetics", "related_concept": "definition of directly responsible personnel, specification compliance", "id": "PA_P_00590_014", "match_type": "weak", "match_score": 0.7188685005946036, "lang": "EN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0009_0005_2"}
{"question": "关于化妆品中色淀（lake）的规格要求，中美法规的典型差异体现在：", "choices": ["A. 中国法规通常对色淀的中间体含量有明确上限规定，而美国法规则无此要求", "B. 美国法规对色淀的醚提取物、可溶性氯化物/硫酸盐及中间体含量均设定了具体限量，中国法规则更侧重于生产过程的控制", "C. 两国法规均只对直接色素（straight color）有详细规格要求，对色淀均无独立规格标准", "D. 中国法规要求色淀必须使用特定的基底材料，美国法规则允许更广泛的基底材料组合"], "answer": "B", "type": "Parallel", "explanation": "美国法规（如21 CFR §82.2051）对用于外用药品和化妆品的色淀明确规定了醚提取物（≤0.5%）、可溶性氯化物和硫酸盐（以钠盐计，≤3.0%）及中间体（≤0.2%）的限量。中国《化妆品监督管理条例》及相关技术规范更强调对化妆品原料（包括色素）的安全性评估、生产质量管理规范（GMP）以及基于风险的全过程控制，而非对色淀的各类化学杂质设定与美国一一对应的具体数值限量。选项A错误，因为美国法规明确设定了中间体限量。选项C错误，因为美国法规对色淀有独立的详细规格。选项D具有干扰性，但美国法规列举的基底材料（如氧化铝、钛白粉等）本身是一个范围，中国法规对原料也有安全性要求，但表述方式不同，核心差异在于B项描述的“具体化学规格限量”与“过程控制侧重”。", "category": "Cosmetics", "related_concept": "lake specifications", "id": "PA_P_00657_003", "match_type": "weak", "match_score": 0.7198851043423885, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0033_0005_1"}
{"question": "Statement 1: The Center Director in regulatory agencies oversees device approvals and ensures compliance with safety standards. Statement 2: Automatic Identification and Data Capture (AIDC) technologies are primarily used to track device distribution but do not integrate with electronic health records.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct: Center Directors (e.g., in FDA) lead regulatory functions for device approvals and safety compliance. Statement 2 is incorrect: AIDC technologies, such as barcodes or RFID, are designed to convey device identifiers into electronic patient records or computer systems via automated processes, facilitating integration for tracking and safety monitoring.", "category": "Medical_Devices", "related_concept": "center director, automatic identification and data capture", "id": "PA_P_00504_002", "match_type": "weak", "match_score": 0.7468823608918449, "lang": "EN", "source_cn": "医疗器械紧急使用管理规定（试行）.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0007_0001_2"}
{"question": "请判断以下两个陈述：陈述1：中国法规中，医疗机构制剂临床前申报需提交资料项目1-16，且所有项目均不可豁免。陈述2：美国法规中，血液制品的储存温度若在特定FDA批准系统下，可依据该系统说明书调整，而不完全受法规表格限制。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误：中国法规中，临床前申报资料项目为1-16项，但部分项目（如13-17）在符合条件时可豁免，例如中药制剂有5年以上使用历史或化学制剂已有同品种批准文号。陈述2正确：美国法规明确，若血液制品在FDA批准或许可的系统下使用，其储存期限可按该系统说明书执行，可不同于标准表格（C列）的规定。", "category": "Drugs", "related_concept": "临床前申报资料项目1-16, storage temperature, regulatory exemptions", "id": "PA_P_00084_002", "match_type": "weak", "match_score": 0.7033615862746466, "lang": "CN", "source_cn": "医疗机构制剂注册管理办法（试行）（2005年国家食品药品监督管理局令第20号）.txt", "source_us": "PART_610GENERAL_BIOLOGICAL_PRODUCTS_STANDARDS.txt", "old_id": "comp_0013_0009_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在中国化妆品监管体系中，生产经营者对抽样检验结论有异议时，有权申请复检，且复检机构由受理部门从名录中随机指定，初检与复检机构不得为同一机构。\n陈述2：在美国关于颜色添加剂的法规中，如果已获得豁免认证的颜色添加剂被发现存在公共卫生风险，其豁免状态可以通过在《联邦公报》发布通知的方式被取消。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。这准确概括了中国《化妆品监督管理条例》第五十一条的核心内容：申请人（生产经营者）的申请权（7个工作日内）、受理部门（抽样部门或其上级）、复检机构的确定方式（随机从名录中抽取）以及机构独立性要求（不得与初检机构为同一机构）。\n陈述2正确。这准确描述了美国法规（§71.26）中关于“撤销豁免认证”的程序：当信息显示某已获豁免的颜色添加剂出于保护公共健康的考虑不应再被豁免时，专员（Commissioner）将通过《联邦公报》（Federal Register）发布通知来取消该豁免。\n因此，两个陈述均正确反映了各自法规的关键程序性规定。", "category": "Cosmetics", "related_concept": "re-inspection application process, revocation of exemption from certification", "id": "PA_P_00677_005", "match_type": "weak", "match_score": 0.7274400836705956, "lang": "CN", "source_cn": "化妆品监督管理条例 (1).txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0014_0003_2"}
{"question": "In regulatory frameworks for medical devices, how do US and Chinese approaches differ regarding performance study documentation requirements?", "choices": ["A. US requires detailed performance study descriptions in labeling, while China focuses on risk management documentation", "B. Both require identical performance study summaries in premarket submissions", "C. China mandates performance study summaries in public registries, while US requires them only for Class III devices", "D. US requires performance study summaries only for in vitro diagnostics, while China requires them for all devices"], "answer": "A", "type": "Parallel", "explanation": "US regulations (21 CFR) specifically require detailed descriptions of performance studies and summaries of results in device labeling, particularly for certain diagnostic devices. Chinese regulations focus more on risk management activities and post-market surveillance rather than mandating specific performance study documentation in labeling.", "category": "Medical_Devices", "related_concept": "performance studies summary", "id": "PA_P_00482_001", "match_type": "weak", "match_score": 0.7379021906295775, "lang": "EN", "source_cn": "医疗器械生产监督管理办法（2022年第53号令）.txt", "source_us": "PART_864HEMATOLOGY_AND_PATHOLOGY_DEVICES.txt", "old_id": "comp_0020_0016_1"}
{"question": "关于撤销某项豁免（如认证豁免），中美法规的程序基础有何不同？", "choices": ["A. 中国法规基于产品检验不合格，美国法规基于保护公众健康的新信息", "B. 美国法规基于产品检验不合格，中国法规基于保护公众健康的新信息", "C. 两国法规均基于产品检验不合格", "D. 两国法规均基于保护公众健康的新信息"], "answer": "A", "type": "Parallel", "explanation": "中国法规文本中，撤销相关行动（如立案调查）的触发点直接源于“检验结论为不符合规定”。美国法规文本明确指出，撤销色素添加剂的认证豁免，是基于专员获得的、表明该豁免不利于保护公众健康的新信息。因此，中国的触发点更直接关联具体产品的检验结果，而美国的触发点更侧重于基于新信息对公共健康风险的总体评估。", "category": "Cosmetics", "related_concept": "revocation of exemption from certification", "id": "PA_P_00609_013", "match_type": "weak", "match_score": 0.720331441744548, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0012_0003_3"}
{"question": "关于非临床实验室研究的合规性声明，中美药监法规有何关键差异？", "choices": ["A. 中国法规要求对所有研究提供合规声明，美国法规仅要求对不符合的研究说明原因", "B. 美国法规要求对所有研究提供合规声明，中国法规无此要求", "C. 两国法规均要求对所有研究提供合规声明", "D. 两国法规均仅要求对不符合的研究说明原因"], "answer": "B", "type": "Parallel", "explanation": "根据美国法规，提交支持请愿的额外信息时，涉及非临床实验室研究的，必须包含每项研究的合规声明（符合第58部分要求）或不符合原因说明。中国法规文本中未提及此要求。", "category": "Regulatory Compliance", "related_concept": "nonclinical laboratory study compliance", "id": "PA_P_00638_014", "match_type": "weak", "match_score": 0.7144604136639631, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0052_0001_1"}
{"question": "关于化妆品样品名称一致性的要求，请判断以下两个陈述的真假：\n陈述1：中国法规要求检验报告中的样品中文名称必须与注册备案申报材料中的产品中文名称完全一致。\n陈述2：美国法规要求Form FDA-2512中产品名称的变更必须在产品进入商业分销后60天内提交修正表格。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规明确规定样品中文名称应与注册或备案申报材料中填报的产品中文名称保持一致。\n陈述2正确：美国法规§720.6规定，产品名称等信息的变更应在产品进入商业分销后60天内提交修正的Form FDA-2512。", "category": "Cosmetics", "related_concept": "sample name consistency", "id": "PA_P_00644_006", "match_type": "weak", "match_score": 0.7211062438268745, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0077_0002_2"}
{"question": "在化妆品监管中，中美法规都涉及对违规行为的调查和标准修订。请判断以下两个陈述的真假：陈述1：中国法规规定，一旦调查发现化妆品可能危害人体健康，药品监督管理部门必须立即采取风险控制措施，并对涉事生产经营者立案调查。陈述2：美国法规主要通过设定成分的精确含量限值（如D&C Blue No. 4中铅不超过20 ppm）来确保合规，违规行为可能基于这些限值被认定。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：根据中国法规（第二十三条和第二十四条），调查发现造成人体伤害或可能危害健康的化妆品时，负责部门应依法采取风险控制措施；如果发现生产经营者涉嫌违法行为，应立案调查。这体现了从风险控制到调查的连贯流程。陈述2正确：美国法规（如D&C Blue No. 4的规格部分）通过设定具体成分的严格含量限值（例如，铅不超过20 ppm、砷不超过3 ppm），作为产品必须符合的强制性标准。违规行为（如超标）可基于这些限值被认定和调查。因此，两个陈述都准确反映了各自法规的核心要求。", "category": "Cosmetics", "related_concept": "investigation of violations, specification compliance, standard revision", "id": "PA_P_00608_007", "match_type": "weak", "match_score": 0.7386822448282998, "lang": "CN", "source_cn": "化妆品安全风险监测与评价管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0006_0005_2"}
{"question": "关于戒毒康复场所的保密义务，中美法规有何不同？", "choices": ["A. 中国法规明确规定了工作人员泄露戒毒人员个人信息的法律责任，而美国法规未提及此类保密义务。", "B. 美国法规要求康复场所必须建立严格的保密协议，而中国法规仅建议保密。", "C. 两国法规均未对戒毒康复场所的保密义务作出规定。", "D. 中国法规仅对自愿戒毒人员有保密要求，美国法规则对所有康复人员都有保密规定。"], "answer": "A", "type": "Parallel", "explanation": "中国法规在第六章法律责任中明确规定，公安、司法行政、卫生行政等有关部门工作人员泄露戒毒人员个人信息的，依法给予处分；构成犯罪的，依法追究刑事责任。这体现了对戒毒人员个人信息的保护。而提供的美国法规文本主要涉及化学混合物豁免的修改程序，未提及戒毒康复场所的保密义务。因此，中国法规有明确的法律责任规定，美国法规文本中未涉及此概念。", "category": "Controlled_Substances", "related_concept": "confidentiality protection, rehabilitation facilities", "id": "PA_P_00698_001", "match_type": "weak", "match_score": 0.7175899972780999, "lang": "CN", "source_cn": "戒毒条例.txt", "source_us": "PART_1310RECORDS_AND_REPORTS_OF_LISTED_CHEMICALS_A.txt", "old_id": "comp_0009_0021_1"}
{"question": "Statement 1: Regulatory investigations of non-compliant cosmetic products should focus exclusively on the specific batch that failed testing. Statement 2: When harmful substances are detected in cosmetics, regulators should expand testing to include other batches and similar products from the same manufacturer.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect because comprehensive regulatory investigations should examine multiple aspects including raw materials, production records, and related products, not just the failed batch. Statement 2 is correct as expanding testing to other batches and similar products is a standard risk control practice when harmful substances are detected, helping identify potential systemic issues.", "category": "Cosmetics", "related_concept": "product sampling and testing", "id": "PA_P_00611_010", "match_type": "weak", "match_score": 0.7084159072035705, "lang": "EN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0013_0005_2"}
{"question": "关于对不合作外国来源的进口禁令，中美两国法规的程序要求有何差异？", "choices": ["A. 美国法规要求在发布禁令前发布60天通知，中国法规无此通知期要求", "B. 中国法规要求在发布禁令前发布60天通知，美国法规无此通知期要求", "C. 两国法规均要求在发布禁令前发布60天通知", "D. 两国法规均未要求在发布禁令前发布通知"], "answer": "A", "type": "Parallel", "explanation": "美国法规明确规定，在发布禁止从不合作外国制造商或分销商进口化学品的命令前，必须提前至少60天在《联邦公报》上发布意向通知。中国提供的法规文本中，关于生产许可的流程未涉及此类针对外国来源的进口禁令及其通知期规定。", "category": "Controlled_Substances", "related_concept": "60-day notice before import prohibition, prohibition of importation from uncooperative foreign sources", "id": "PA_P_00709_002", "match_type": "weak", "match_score": 0.7140499179146063, "lang": "CN", "source_cn": "药品类易制毒化学品管理办法（卫生部令第72号_2010年）.txt", "source_us": "PART_1313IMPORTATION_AND_EXPORTATION_OF_LIST_I_AND.txt", "old_id": "comp_0003_0012_2"}
{"question": "A cosmetics company is preparing product labels for both the US and Chinese markets. Which of the following statements correctly describes a key difference in how numerical results and unit notations must be presented on these labels?", "choices": ["A. US regulations strictly prohibit any qualifying terms in unit declarations that could exaggerate quantity, while Chinese regulations require a specific symbol ('/') to denote when a method detection limit is not applicable or provided for certain parameters.", "B. Chinese regulations mandate that all numerical test results be rounded based on the product's limit values, whereas US regulations require net quantity declarations to use only weight or volume units without exception.", "C. US regulations specify exact spacing requirements around the net quantity declaration on the principal display panel, while Chinese regulations provide detailed rules for data rounding of test results based on instrumentation and reference standards.", "D. Both markets require the principal display panel to contain the net quantity in the bottom 30% of the label area, but only the US requires the exclusion of exaggerated unit terms like 'giant pint'."], "answer": "A", "type": "Parallel", "explanation": "This question tests the understanding of distinct regulatory approaches to label content. Option A correctly identifies that US regulations (21 CFR 701.13) explicitly forbid terms that exaggerate the amount of cosmetic (e.g., 'giant pint'), focusing on consumer protection from misleading claims. In contrast, Chinese regulations (from the provided text) specify using '/' as a unit notation in specific technical contexts, such as when a method detection concentration is not applicable (e.g., for pH values). This reflects a difference in focus: the US rule targets marketing language to prevent deception, while the Chinese rule addresses technical reporting clarity in test documentation. The other options contain inaccuracies: B is incorrect because Chinese regulations state data rounding should NOT be based on limit values but on instrumentation and standards; C describes true individual requirements but does not highlight a direct comparative difference in the concepts asked; D is partially correct about the US 30% rule but overgeneralizes the Chinese requirement.", "category": "Cosmetics", "related_concept": "prohibition of exaggerating terms, unit notation", "id": "PA_P_00643_001", "match_type": "weak", "match_score": 0.7319647388080148, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0020_0008_1"}
{"question": "Statement 1: In US FDA color additive safety assessment, a default 100-fold safety factor is applied when extrapolating animal data to human exposure levels unless justified otherwise. Statement 2: Chinese NMPA regulations for mutagenicity testing require detailed description of control groups including blank, solvent, and positive controls with specific result reporting formats.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the FDA's default 100:1 safety factor approach for color additives. Statement 2 accurately reflects Chinese NMPA requirements for mutagenicity testing controls and standardized reporting formats as shown in the provided text.", "category": "Regulatory Science", "related_concept": "safety factor application, control groups, test method description", "id": "PA_P_00642_017", "match_type": "weak", "match_score": 0.7151828013806305, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0041_0004_2"}
{"question": "Statement 1: In US administrative hearings, the presiding officer has subpoena authority to compel witness attendance and document production. Statement 2: Chinese drug rehabilitation regulations grant subpoena authority to community rehabilitation supervisors for enforcing compliance.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct as US regulations explicitly grant presiding officers subpoena authority for witness attendance and document production. Statement 2 is incorrect because Chinese drug rehabilitation regulations describe supervisory duties and penalties for non-compliance by community rehabilitation personnel but do not mention subpoena authority for these officials.", "category": "Controlled_Substances", "related_concept": "subpoena authority", "id": "PA_P_00699_002", "match_type": "weak", "match_score": 0.7368086572031547, "lang": "EN", "source_cn": "戒毒条例.txt", "source_us": "PART_1316ADMINISTRATIVE_FUNCTIONS_PRACTICES_AND_PR.txt", "old_id": "comp_0010_0006_2"}
{"question": "关于化妆品中致癌物质（如氯乙烯）的监管，中美法规均采取严格措施。请判断以下两个陈述的真假：陈述1：中国法规明确禁止在化妆品气雾剂产品中使用氯乙烯作为成分。陈述2：美国法规将含有氯乙烯的化妆品气雾剂产品直接认定为掺假产品，并可能采取执法行动。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误：提供的中国法规文本主要涉及网络经营监管和信息调取，未直接提及氯乙烯或致癌物质的成分禁令；中国对化妆品中禁用物质有专门清单（如《化妆品安全技术规范》），但题干未提供相关文本，因此不能推断为“明确禁止”。陈述2正确：美国法规文本明确指出，氯乙烯是一种有害物质，任何含有该成分的化妆品气雾剂产品都被视为掺假（依据《联邦食品、药品和化妆品法案》第601(a)条），这为FDA采取执法行动（如责令下架、罚款等）提供了直接法律依据。", "category": "Cosmetics", "related_concept": "carcinogenic substance regulation, enforcement actions", "id": "PA_P_00681_006", "match_type": "weak", "match_score": 0.7463922167424895, "lang": "CN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0011_0003_2"}
{"question": "A cosmetics company is establishing a quality management system. Which regulatory approach is more likely to emphasize the role of a dedicated quality safety officer with specific organizational authority?", "choices": ["A. The US approach focuses on detailed chemical specifications, while the Chinese approach emphasizes personnel qualifications and organizational structure.", "B. Both approaches equally emphasize personnel qualifications and chemical specifications.", "C. The Chinese approach focuses on detailed chemical specifications, while the US approach emphasizes personnel qualifications and organizational structure.", "D. Neither approach addresses personnel qualifications; both focus solely on product composition."], "answer": "A", "type": "Parallel", "explanation": "The Chinese regulation explicitly defines the qualifications, duties, and organizational authority of a 'quality safety officer,' including their independence and reporting structure. The provided US regulation text focuses on detailed chemical impurity limits and specifications for a color additive, without mentioning personnel roles. This reflects a common regulatory difference where some systems emphasize management system controls (personnel) and others emphasize detailed product standards.", "category": "Cosmetics", "related_concept": "quality safety officer qualifications, independent duty performance", "id": "PA_P_00590_005", "match_type": "weak", "match_score": 0.7399987721112918, "lang": "EN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0004_0005_1"}
{"question": "Statement 1: Under US FDA regulations, a company must file Form FDA 2514 within 180 days after becoming aware of discontinuing commercial distribution of a cosmetic product formulation. Statement 2: Under Chinese NMPA regulations, when submitting re-inspection backup samples, the initial testing institution must deliver them to the re-inspection institution within 5 working days of receiving the re-inspection notice.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, Statement 2 is incorrect.", "C. Statement 1 is incorrect, Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the 180-day requirement for discontinuance notification using Form FDA 2514 under US FDA regulations. Statement 2 correctly describes the 5-working-day requirement for delivering re-inspection backup samples under Chinese NMPA regulations.", "category": "Cosmetics", "related_concept": "delivery of re-inspection backup samples, discontinuance notification", "id": "PA_P_00613_002", "match_type": "weak", "match_score": 0.674469871698357, "lang": "EN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0011_0002_2"}
{"question": "关于化妆品检查中发现产品可能危害人体健康时的紧急控制措施，中美两国法规在实施主体和范围上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规规定由检查人员直接实施全国性控制措施，美国法规则由FDA专员在调查后决定是否采取行动。", "B. 中国法规要求由被检查对象所在地药品监督管理部门依法采取紧急控制措施，并建立逐级通报机制；美国法规则未在相关条款中明确规定此类紧急控制措施。", "C. 两国法规均规定，一旦发现风险，必须立即由中央监管机构发布全国性的产品禁令。", "D. 美国法规明确要求FDA专员在拒绝认证后必须立即采取紧急控制措施，而中国法规则仅要求报告和整改。"], "answer": "B", "type": "Parallel", "explanation": "中国法规（第十六条）明确规定，当检查发现化妆品可能危害人体健康时，由“被检查对象所在地药品监督管理部门”依法采取责令暂停生产、经营等紧急控制措施，并建立了从地方到省级、再到全国的逐级通报和风险控制协调机制。而提供的美国法规文本（§ 80.31）主要涉及色素添加剂批次的认证流程，包括符合性审查、证书签发或拒绝，以及拒绝后的听证机会，并未在此条款中描述针对已上市产品发现危害时的紧急控制措施。选项A错误，因为中国法规并非由检查人员直接实施控制；选项C错误，两国规定不同，且中国措施有明确的层级；选项D错误，美国文本未将拒绝认证与紧急控制措施直接关联。", "category": "Cosmetics", "related_concept": "emergency control measures", "id": "PA_P_00632_003", "match_type": "weak", "match_score": 0.7400982514064989, "lang": "CN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0005_0001_1"}
{"question": "关于涉及国家安全的机密信息处理，中美药监程序的主要区别是什么？", "choices": ["A. 中国法规允许在特定情况下向申请人披露机密信息的一般性质，美国法规则完全禁止任何披露", "B. 美国法规要求在基于机密信息作出监管决定时，须告知申请人该决定是否全部或部分基于此类信息，中国法规则无此明确程序", "C. 中国法规规定机密信息可直接作为不予批准的唯一依据，美国法规则要求必须辅以公开证据", "D. 美国法规授权监管机构可自行决定是否使用机密信息，中国法规则要求必须获得法院许可"], "answer": "B", "type": "Parallel", "explanation": "美国FDA法规（如21 CFR Part 1相关程序）规定，若监管行动（如扣留）基于机密信息，在确认该行动时，必须说明是否全部或部分依据了该机密信息，并给予申请人就信息一般性质提出反对证据的机会（在不损害信息及来源的前提下）。中国NMPA相关法规（如《药品管理法》、《行政许可法》）对涉及国家秘密的行政许可或监管决定，通常侧重于保密义务和不予公开的原则，对于是否必须告知决定与机密信息的关联性，缺乏FDA那样明确的程序性规定。", "category": "General_FDA", "related_concept": "classified information handling", "id": "PA_P_00770_005", "match_type": "weak", "match_score": 0.6765810234667524, "lang": "CN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0002_0043_2"}
{"question": "关于安全风险监测与评价体系，请判断以下两个陈述的真假：\n陈述1：中国法规要求化妆品新原料注册人/备案人建立完整的安全风险监测和评价体系，包括明确的岗位职责、监测制度和评价标准。\n陈述2：美国FDA对化妆品新原料的安全风险监测主要依赖企业自我监管，未强制要求建立与中国类似的体系化监测评价制度。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规明确要求化妆品新原料注册人/备案人建立安全风险监测和评价体系，包括岗位设置、人员要求、监测制度构成、信息收集渠道、评价方式、评价标准和处置措施等完整体系。\n陈述2正确：美国FDA对化妆品（包括新原料）的监管基于《联邦食品、药品和化妆品法案》，主要原则是企业责任，未强制要求建立与中国类似的体系化监测评价制度，更多依赖企业自我监管、自愿报告和FDA的监督抽查。", "category": "Cosmetics", "related_concept": "safety risk monitoring and evaluation system", "id": "PA_P_00621_002", "match_type": "weak", "match_score": 0.6821884853701335, "lang": "CN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0008_0007_2"}
{"question": "In comparing administrative dispute resolution mechanisms, which statement best describes a key difference between the Chinese and U.S. regulatory approaches?", "choices": ["A. The Chinese system emphasizes a formal, structured internal review process with defined institutional duties, while the U.S. system provides for an independent ombudsman as an alternative path for issue escalation.", "B. Both systems rely primarily on a strict chain of command for resolving all administrative disputes.", "C. The U.S. system mandates a specific statutory body for reviewing decisions, whereas the Chinese system uses informal mediation.", "D. The Chinese system focuses on public media coverage of proceedings, while the U.S. system focuses on internal personnel qualifications."], "answer": "A", "type": "Parallel", "explanation": "Option A correctly identifies a core distinction. The Chinese text outlines a formal '行政复议' (administrative reconsideration) system with specific duties for the '行政复议机构' (reconsideration body), including supervising the implementation of decisions. The U.S. text describes an 'ombudsman' as an independent resource for escalation outside the standard chain of command, representing a different procedural philosophy. Option B is incorrect as the U.S. text explicitly offers an alternative to the chain of command. Option C is reversed; the Chinese text describes a formal statutory process. Option D misattributes the concepts; media coverage is a U.S. topic, and personnel qualifications are mentioned in the Chinese text.", "category": "General_FDA", "related_concept": "行政复议机构职责 / chain of command / ombudsman", "id": "PA_P_00739_001", "match_type": "weak", "match_score": 0.689646444553097, "lang": "EN", "source_cn": "《中华人民共和国行政复议法实施条例》（国务院令第499号）.txt", "source_us": "PART_10ADMINISTRATIVE_PRACTICES_AND_PROCEDURES.txt", "old_id": "comp_0001_0014_1"}
{"question": "A cosmetics company is developing a new anti-aging serum. Which regulatory approach would most likely require human safety testing for this product?", "choices": ["A. US FDA regulations for color additives", "B. Chinese NMPA regulations for non-special use cosmetics", "C. Chinese NMPA regulations for cosmetics with anti-wrinkle claims", "D. US FDA regulations for external color additive safety testing"], "answer": "C", "type": "Parallel", "explanation": "Chinese NMPA regulations specifically require human use trial safety evaluation for cosmetics claiming anti-wrinkle, anti-acne, or spot-removing effects, even for rinse-off products. US FDA color additive regulations focus on animal testing and safety factors rather than mandatory human trials for cosmetic efficacy claims.", "category": "Cosmetics", "related_concept": "human use trial safety evaluation", "id": "PA_P_00642_006", "match_type": "weak", "match_score": 0.7296966226713631, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0017_0004_1"}
{"question": "A cosmetics company plans to launch an online store in both China and the United States. Which regulatory approach best describes the primary compliance framework for their e-commerce operations in each jurisdiction?", "choices": ["A. China requires specific e-commerce regulations for cosmetics, while the U.S. focuses on general product safety laws without distinct online operation rules.", "B. Both countries have identical, harmonized regulations for cosmetics sold online.", "C. The U.S. mandates detailed platform licensing for cosmetics e-commerce, whereas China prohibits online sales of certain cosmetic categories.", "D. China emphasizes platform and seller obligations under dedicated cosmetics e-commerce rules, while the U.S. applies existing adulteration and misbranding provisions to online sales."], "answer": "D", "type": "Parallel", "explanation": "Chinese regulations establish a comprehensive, dedicated framework for cosmetics network operations, defining roles for platform operators and sellers with specific obligations. U.S. regulations do not create separate e-commerce rules for cosmetics; instead, they apply existing provisions (like those on adulteration and misbranding) to products regardless of sales channel, including online.", "category": "Cosmetics", "related_concept": "cosmetics network operation", "id": "PA_P_00681_001", "match_type": "weak", "match_score": 0.7442901377519368, "lang": "EN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0001_0003_1"}
{"question": "A cosmetics company is developing a new hair dye product that contains color additives. The product is designed for topical application only and will not be ingested. During safety evaluation, preliminary data suggests a potential carcinogenic risk from the color additives when tested through non-ingestion routes. Which regulatory approach would be most appropriate for determining whether this product can be marketed?", "choices": ["A. Apply the cancer clause only if ingestion is involved, since this is a topical product", "B. Conduct a skin phototoxicity test as the primary safety assessment for carcinogenicity", "C. Evaluate whether the carcinogenicity test is appropriate for external use and apply the cancer clause if cancer is induced", "D. Proceed with safe tolerance allocation among competing needs without further carcinogenicity assessment"], "answer": "C", "type": "Parallel", "explanation": "For non-ingested color additives, regulatory frameworks require evaluating whether carcinogenicity tests are appropriate for external use applications. If such tests suggest cancer induction by the color additive, the cancer clause applies and marketing approval would be denied, regardless of ingestion route. This contrasts with approaches that would ignore non-ingestion carcinogenicity data or rely on unrelated tests like skin phototoxicity.", "category": "Cosmetics", "related_concept": "non-ingested color additives, cancer clause application", "id": "PA_P_00642_004", "match_type": "weak", "match_score": 0.6815427977986931, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0016_0005_1"}
{"question": "关于有因检查的启动与执行，中美法规在程序透明度要求上存在显著差异。以下哪项描述最准确地反映了这一差异？", "choices": ["A. 中国法规要求检查前必须告知被检查对象检查人员身份，而美国法规则无此要求", "B. 中国法规原则上禁止预先告知检查人员和内容以确保突击性，而美国法规未对检查告知作具体规定", "C. 美国法规要求检查时必须全程录像记录，而中国法规则未强制要求证据收集方式", "D. 中美法规均要求检查前需获得法院批准，且程序完全公开"], "answer": "B", "type": "Parallel", "explanation": "中国化妆品监督管理条例明确规定，开展有因检查时原则上不得预先告知被检查对象检查人员和检查内容，检查人员应直接进入现场开展检查，这体现了突击检查的特点。而提供的美国法规文本主要涉及色素添加剂认证豁免、法规发布等程序，未对检查告知要求作具体规定，两国在检查程序透明度要求上存在制度差异。", "category": "Cosmetics", "related_concept": "cause-based inspection", "id": "PA_P_00634_001", "match_type": "weak", "match_score": 0.7493333794130954, "lang": "CN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0008_0002_1"}
{"question": "Consider the regulatory requirements for drug labeling and usage restrictions. Which combination accurately reflects how 'specifications,' 'indications for use,' and 'limitations' are typically addressed in US FDA versus Chinese NMPA regulatory frameworks?", "choices": ["A. ① US FDA typically requires detailed specifications and indications in drug labeling, with specific limitations on use. ② Chinese NMPA focuses primarily on raw material specifications in registration, with usage details determined later.", "B. ① Both systems require identical format and content for specifications, indications, and limitations. ② Chinese regulations are more detailed about limitations than US regulations.", "C. ① US FDA does not regulate specifications for finished drugs. ② Chinese NMPA does not allow any limitations on drug use.", "D. ① Specifications are only required in China, not in the US. ② Indications and limitations are identical in both countries."], "answer": "A", "type": "Parallel", "explanation": "US FDA regulations typically require detailed specifications (e.g., active ingredient amounts), indications for use, and limitations (e.g., veterinary use only) to be clearly stated in drug labeling. Chinese NMPA regulations, while also addressing finished drug specifications, place significant emphasis on raw material and component specifications during the registration process, with usage details often being part of the broader approval framework.", "category": "Drugs", "related_concept": "specifications, indications for use, limitations", "id": "PA_P_00130_002", "match_type": "weak", "match_score": 0.6694903076750875, "lang": "EN", "source_cn": "国家药监局关于进一步完善药品关联审评审批和监管工作有关事宜的公告（2019年 第56号）.txt", "source_us": "PART_520ORAL_DOSAGE_FORM_NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0001_0011_2"}
{"question": "Statement 1: Lake specifications for color additives in externally applied cosmetics typically include limits on ether extracts and soluble chlorides/sulfates.\nStatement 2: Documentation requirements for test groups in cosmetic safety studies must include specific test dates for each experimental group.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as US FDA regulations specify lake specifications including ether extracts (not more than 0.5%) and soluble chlorides/sulfates (not more than 3.0%). Statement 2 is correct as Chinese regulations require documentation of test group dates for cosmetic safety studies, specifically mentioning '受试组试验日期' (test group test date) in the context of skin phototoxicity testing.", "category": "Cosmetics", "related_concept": "lake specifications, test group date", "id": "PA_P_00640_015", "match_type": "weak", "match_score": 0.7496140934869466, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0039_0005_2"}
{"question": "Consider the following statements about technical units and problem-solving in US and Chinese medical device standardization. Statement 1: In the US system, performance standards for Class II devices are developed and maintained by the FDA, which also provides the primary technical guidance for resolving implementation issues. Statement 2: In the Chinese system, specialized technical committees are formally established to provide technical guidance and assist in solving problems encountered during standard implementation, with provisions for alternative technical units in uncovered fields. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect. While the FDA establishes performance standards, the development and maintenance of consensus standards often involve external organizations (like ASTM, ISO). The FDA's role is more regulatory in recognizing and enforcing these standards, not necessarily being the sole provider of detailed technical guidance for problem resolution. Statement 2 is correct. The Chinese framework explicitly mandates that standardized technical committees have duties including providing technical guidance and assisting in solving technical problems during implementation. It also has a formal mechanism (standardization technical liaison units) to cover areas not served by existing committees, ensuring comprehensive technical support.", "category": "Medical_Devices", "related_concept": "standardization technical unit responsibilities, technical guidance and problem-solving", "id": "PA_P_00440_002", "match_type": "weak", "match_score": 0.7137652869989487, "lang": "EN", "source_cn": "医疗器械标准管理办法（2017年第33号令）.txt", "source_us": "PART_880GENERAL_HOSPITAL_AND_PERSONAL_USE_DEVICES.txt", "old_id": "comp_0003_0005_2"}
{"question": "关于信息网络安全监管，中美两国法规在监管模式上存在显著差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规强调事前审批与事后检查相结合，美国法规则侧重于事后追责。", "B. 中国法规主要依赖经营单位的自我承诺，美国法规则完全依赖政府审批。", "C. 中国法规采用“承诺+事后检查”的模式，美国法规则未在提供的文本中直接规定信息网络安全的具体监管模式。", "D. 两国法规都采用完全相同的“先审批，后经营”的行政许可模式。"], "answer": "C", "type": "Parallel", "explanation": "解析：中国法规（如对《互联网上网服务营业场所管理条例》的修改）体现了从“申请审核”向“承诺符合条件+事后检查”的转变，这是一种“承诺制”监管模式。美国提供的法规文本（FDA指南）主要规范行政程序的媒体录制，并未直接涉及信息网络安全的具体监管模式，因此无法进行直接比较。选项A错误地将美国文本的适用范围扩大到了信息网络安全领域；选项B的描述与中国法规的“承诺+检查”精神不符；选项D与事实完全不符。", "category": "General_NMPA", "related_concept": "information network security, established procedures", "id": "PA_P_00778_001", "match_type": "weak", "match_score": 0.736675065515086, "lang": "CN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_10ADMINISTRATIVE_PRACTICES_AND_PROCEDURES.txt", "old_id": "comp_0016_0015_1"}
{"question": "关于成品检验与组分鉴别检验的关系，中美法规在特定情境下的要求有何不同？", "choices": ["A. 中国法规要求所有药品必须进行成品检验，美国法规则允许在特定条件下以组分鉴别检验替代成品检验。", "B. 美国法规要求所有药品必须进行成品检验，中国法规则允许在特定条件下以组分鉴别检验替代成品检验。", "C. 两国法规均强制要求所有药品必须同时进行成品检验和组分鉴别检验。", "D. 两国法规均未明确规定成品检验与组分鉴别检验之间的替代关系。"], "answer": "A", "type": "Parallel", "explanation": "美国法规（如针对PET药品）规定，如果企业不进行能确保使用正确组分的成品检验，则必须对生产活性成分的每种组分及每种非活性成分进行特定的鉴别检验。这体现了在特定条件下，可以用严格的组分控制来替代部分成品检验的理念。中国法规（GMP）更强调按照批准的工艺规程生产、确保批记录审核等过程控制，虽未明确阐述此种替代关系，但其对生产管理和质量保证的全面要求隐含了对从源头控制质量的重视。选项A准确捕捉了美国法规的这一具体规定与中国法规原则性要求的差异。", "category": "Drugs", "related_concept": "finished-product testing, component identity testing", "id": "PA_P_00263_001", "match_type": "weak", "match_score": 0.7395139382142534, "lang": "CN", "source_cn": "药品生产质量管理规范（2010年修订）（卫生部令第79号）.txt", "source_us": "PART_212CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_PO.txt", "old_id": "comp_0005_0003_1"}
{"question": "关于监管行动、召回或调查的通知程序，中美法规的关键差异主要体现在哪个方面？", "choices": ["A. 中国法规要求通知必须经质量保证部门审查，美国法规则要求书面通知负责官员", "B. 美国法规明确要求当企业负责官员未亲自参与时，需书面通知其监管行动、召回或调查等情况；中国法规在提供的文本中未直接规定此类通知程序", "C. 两国法规均要求通知程序需包含详细的理由说明", "D. 中国法规要求通知需提交给监管部门，美国法规则无此要求"], "answer": "B", "type": "Parallel", "explanation": "美国法规（§ 211.180(f)）明确规定，当企业负责官员未亲自参与或立即知晓时，必须建立书面通知程序，通知其关于监管行动、召回或调查等情况。中国法规在提供的文本中主要涉及总结报告修订、质量保证等要求，未直接规定此类针对监管行动、召回或调查的通知程序。干扰项A错误，中国法规中质量保证部门审查的是总结报告的修订，而非通知程序；C错误，中国法规要求详细说明理由的是总结报告的修订，美国法规的通知程序未强调理由说明；D错误，美国法规文本未提及通知需提交监管部门。", "category": "Drugs", "related_concept": "notification procedures, regulatory actions, recalls, investigations", "id": "PA_P_00347_005", "match_type": "weak", "match_score": 0.7452050897217664, "lang": "CN", "source_cn": "药物非临床研究质量管理规范（2017年第34号）.txt", "source_us": "PART_211CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_FI.txt", "old_id": "comp_0015_0013_2"}
{"question": "关于产品备案/注册管理，中美法规对牙膏原料的管理方式有何不同？", "choices": ["A. 中国对牙膏新原料实行分类管理（注册或备案），美国对牙膏原料无备案要求", "B. 中美均要求所有牙膏新原料必须经注册后方可使用", "C. 中国仅对牙膏成品备案，美国要求对牙膏原料进行安全监测", "D. 美国对牙膏原料实行3年安全监测期，中国无类似制度"], "answer": "A", "type": "Parallel", "explanation": "根据中国《牙膏监督管理办法》第八条，牙膏新原料实行分类管理：具有防腐、着色等功能的原料需经国家药监局注册后方可使用；其他新原料实行备案管理。且对已注册/备案的原料实行3年安全监测。美国FDA对化妆品（包括牙膏）原料通常无强制性的上市前备案或注册要求（除非色素添加剂等特定情况），主要依靠企业自我确保安全，原料管理更依赖于事后监管。因此A正确。B错误（美国无此要求）；C错误（中国对原料也有管理）；D错误（3年安全监测是中国制度，美国无此规定）。", "category": "Cosmetics", "related_concept": "filing management", "id": "PA_P_00690_002", "match_type": "weak", "match_score": 0.6846744019255087, "lang": "CN", "source_cn": "牙膏监督管理办法（2023年第71号）.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0001_0004_2"}
{"question": "A pharmaceutical company in China is found to have used fraudulent data to obtain a drug production license. In the US, a veterinary drug manufacturer fails to comply with withdrawal period requirements before slaughter. Which regulatory action is most likely to be applied in BOTH jurisdictions?", "choices": ["A. Revocation of the production license", "B. Imposition of a slaughter prohibition period", "C. Confiscation of all illegal products and related materials", "D. Citation of specific regulatory code sections in enforcement documents"], "answer": "D", "type": "Parallel", "explanation": "Both Chinese and US regulatory systems consistently cite specific legal provisions or code sections when documenting violations and enforcement actions. While China might revoke licenses and confiscate products for fraud, and the US might impose slaughter prohibitions for withdrawal violations, the common element is the formal citation of regulatory authority in official documents.", "category": "Drugs", "related_concept": "regulatory citation", "id": "PA_P_00026_001", "match_type": "weak", "match_score": 0.7287738277391185, "lang": "EN", "source_cn": "中华人民共和国药品管理法.txt", "source_us": "PART_558NEW_ANIMAL_DRUGS_FOR_USE_IN_ANIMAL_FEEDS.txt", "old_id": "comp_0026_0059_1"}
{"question": "关于药品类易制毒化学品生产许可的实质性审查时限，中美两国法规有何不同？", "choices": ["A. 中国法规要求实质性审查在30日内完成，美国法规无此明确时限规定", "B. 美国法规要求实质性审查在30日内完成，中国法规无此明确时限规定", "C. 两国法规均要求在30日内完成实质性审查", "D. 两国法规均未对实质性审查设定具体时限"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定，国家食品药品监督管理局应当在受理后30日内完成实质性审查。美国法规中关于听证会等程序设定了45天等时限，但未对生产许可的实质性审查设定与中国类似的30日明确时限。", "category": "Controlled_Substances", "related_concept": "substantive review within 30 days", "id": "PA_P_00709_001", "match_type": "weak", "match_score": 0.7140499179146063, "lang": "CN", "source_cn": "药品类易制毒化学品管理办法（卫生部令第72号_2010年）.txt", "source_us": "PART_1313IMPORTATION_AND_EXPORTATION_OF_LIST_I_AND.txt", "old_id": "comp_0003_0012_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在证据收集与移交方面，中国法规对不具备管辖权的监管部门设定了初步收集固定证据并移交至有管辖权部门的义务，而美国提供的法规文本未涉及此类程序性规定。\n陈述2：关于生产商主要营业场所的标签标注，美国法规允许在特定条件下标注主要营业场所代替实际生产地，而中国提供的法规文本未对此标签要求作出规定。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。中国法规（第二十七条第三款）明确规定，不具备管辖权的部门发现违法线索时，应初步收集固定证据，并将相关信息移交至有管辖权的实际经营地部门。美国提供的法规文本未涉及此类证据收集与移交的具体行政程序。\n陈述2正确。美国法规（段落(e)）明确规定，若化妆品在主要营业场所以外地点生产、包装或分销，标签可标注主要营业场所（除非会产生误导）。中国提供的法规文本聚焦于平台经营监管、管辖与信息通报，未涉及生产商地址的标签标注具体要求。", "category": "Cosmetics", "related_concept": "evidence collection and transfer, principal place of business labeling", "id": "PA_P_00686_004", "match_type": "weak", "match_score": 0.7086082618679896, "lang": "CN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0010_0007_2"}
{"question": "关于非临床实验室研究的合规性要求，中美药监法规的典型差异体现在哪个方面？", "choices": ["A. 中国法规要求所有研究必须事先获得批准，而美国法规允许事后提交合规声明", "B. 美国法规要求在提交补充信息时，必须声明研究是否符合GLP规范，中国法规对此无明确规定", "C. 中国法规要求非临床研究必须在指定机构进行，美国法规则无此限制", "D. 两国法规均要求非临床研究必须完全符合国际协调会议（ICH）的指导原则"], "answer": "B", "type": "Parallel", "explanation": "美国法规明确要求，当提交的补充信息涉及非临床实验室研究时，必须包含关于该研究是否符合《联邦法规汇编》第21篇第58部分（良好实验室规范，GLP）要求的声明。这是其程序性审查的一个重要环节。中国法规文本中未直接涉及非临床研究的具体合规声明要求，其重点在于风险监测发现后的调查与处理流程。", "category": "Cosmetics", "related_concept": "nonclinical laboratory study compliance", "id": "PA_P_00607_005", "match_type": "weak", "match_score": 0.7469456086646495, "lang": "CN", "source_cn": "化妆品安全风险监测与评价管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0005_0001_1"}
{"question": "关于非处方药（OTC）监管体系，中美两国法规在核心管理框架上存在显著差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国采用基于传统医学理论的管理制度，而美国采用基于药品审评专论（monograph）的系统化分类管理", "B. 中国要求所有OTC药品必须经过临床试验，而美国允许基于长期销售历史豁免部分研究", "C. 中国仅监管化学药品，而美国的监管范围包括传统草药和膳食补充剂", "D. 中国的OTC监管完全由中央政府负责，而美国实行联邦与州政府分级管理"], "answer": "A", "type": "Parallel", "explanation": "中国《中医药法》确立了“符合中医药特点的管理制度”，强调传统医学理论体系；美国FDA的OTC药品专论系统（OTC drug monograph system）是通过制定标准专论对OTC药品进行系统化分类和管理的监管框架。B项错误，中国对传统中药有特殊管理路径；C项错误，中国监管包括中医药；D项错误，两国都有分级管理体系。", "category": "Drugs", "related_concept": "OTC drug monograph system", "id": "PA_P_00006_001", "match_type": "weak", "match_score": 0.7114403728051812, "lang": "CN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_330OVER-THE-COUNTER_OTC_HUMAN_DRUGS_WHICH_ARE.txt", "old_id": "comp_0001_0002_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据相关法规原则，当化妆品批次被认定不符合安全标准时，中国监管体系侧重于要求企业限期整改并由监管部门监督复查，而美国监管体系在拒绝认证后，为企业提供了申请监管听证的机会。\n陈述2：在证书签发方面，两国法规都要求监管机构在确认批次符合所有规定条件后，必须向申请人签发证书。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确。中国法规（第十七条）明确了检查发现缺陷问题后的“限期整改”流程，包括提交整改报告和可能的“现场复查”，体现了以整改和监督为核心的后续处理思路。美国法规（§ 80.31(b)）则规定，如果FDA专员拒绝认证某个批次，必须通知申请人并说明理由，同时申请人“应有机会获得监管听证会”，这体现了程序性救济权利。陈述2错误。虽然美国法规（§ 80.31(a)）规定，若FDA专员确定请求符合所有要求（如无不实陈述、符合规格等），则“应签发证书”。但提供的中国法规文本并未涉及“证书签发”的具体程序和条件，该文本主要规范的是现场检查、风险控制和整改流程。因此，不能得出“两国法规都要求必须签发证书”的结论。", "category": "Cosmetics", "related_concept": "rectification requirements, regulatory hearing, certificate issuance", "id": "PA_P_00632_004", "match_type": "weak", "match_score": 0.7400982514064989, "lang": "CN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0005_0001_2"}
{"question": "Statement 1: Under Chinese NMPA regulations for cosmetics, the legal representative and quality safety responsible person of a manufacturer must have their identity information formally documented and maintained by the enterprise. Statement 2: US FDA regulations for cosmetic color additives require manufacturers to specify maximum limits for subsidiary colors and leuco base as part of product specifications to ensure batch consistency.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct. Chinese NMPA regulations emphasize traceability and accountability, requiring detailed documentation of the legal representative and quality safety responsible person's information (name, ID type, number) as part of the manufacturer's registration/maintenance obligations. Statement 2 is also correct. US FDA color additive regulations, such as those for D&C Blue No. 4, include specifications for impurities like 'subsidiary colors' and 'leuco base' with defined maximum limits, which are critical for ensuring the color additive's identity, strength, quality, and purity from batch to batch.", "category": "Cosmetics", "related_concept": "legal representative details, specification compliance, manufacturing practice standards", "id": "PA_P_00653_030", "match_type": "weak", "match_score": 0.7435058547275102, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0037_0005_2"}
{"question": "When evaluating mutagenicity test results for regulatory submissions, which approach best describes the difference in how positive results are typically determined between US FDA and Chinese NMPA frameworks?", "choices": ["A. The FDA requires statistical significance above background levels, while NMPA mandates comparison against established positive control thresholds", "B. The FDA relies on dose-response relationships, while NMPA focuses on absolute colony count increases", "C. The FDA emphasizes reproducibility across multiple experiments, while NMPA requires specific strain-specific criteria", "D. Both agencies use identical criteria based on international harmonization guidelines"], "answer": "A", "type": "Parallel", "explanation": "The FDA typically requires statistical analysis showing significant increases above background/solvent control levels, while Chinese regulations (as shown in the Ames test table format) emphasize comparison against established positive control results and specific criteria for different bacterial strains.", "category": "Toxicology Testing", "related_concept": "positive result criteria, Ames test results", "id": "PA_P_00642_016", "match_type": "weak", "match_score": 0.7151828013806305, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0041_0004_1"}
{"question": "In comparing regulatory approaches to violations in plasma collection and medicated feed production, which statement best describes a key difference in enforcement mechanisms?", "choices": ["A. Both systems rely primarily on administrative fines for all violations, with criminal liability only for intentional misconduct.", "B. The Chinese system specifies graduated penalties including fines, license revocation, and criminal liability for serious violations, while the US system focuses on corrective actions and record-keeping for quality deviations.", "C. The US system imposes immediate criminal penalties for any equipment contamination, while the Chinese system uses only warnings for first-time violations.", "D. Both systems require identical penalty structures for labeling errors, with mandatory facility closures for repeat offenses."], "answer": "B", "type": "Parallel", "explanation": "The Chinese regulation outlines a tiered penalty system including fines (5-100k RMB), license revocation for serious violations, and criminal liability for harms like disease transmission. The US regulation focuses on requiring immediate corrective actions and maintaining records for quality deviations (like assay failures), without specifying criminal penalties in the provided text. This reflects different regulatory philosophies: China's more prescriptive penalty structure versus the US's emphasis on corrective quality systems.", "category": "Drugs", "related_concept": "penalties for violations", "id": "PA_P_00353_001", "match_type": "weak", "match_score": 0.740335505996279, "lang": "EN", "source_cn": "血液制品管理条例.txt", "source_us": "PART_225CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_ME.txt", "old_id": "comp_0007_0004_1"}
{"question": "Consider the regulatory approaches to ensuring cosmetic safety. Which combination of statements accurately compares a key mechanism in US FDA regulations with one in Chinese NMPA regulations? ① The US FDA mandates batch-by-batch certification for certain color additives by the FDA itself before they can be used. ② The Chinese NMPA requires registrants/filers to establish and describe an internal system for monitoring and evaluating adverse events (reactions). ③ Both agencies rely solely on pre-market product testing, with no ongoing post-market surveillance obligations. ④ The NMPA's primary control for colorant purity is identical to the FDA's detailed specification limits for individual impurities.", "choices": ["A. ①②", "B. ①③", "C. ②④", "D. ③④"], "answer": "A", "type": "Parallel", "explanation": "Statements ① and ② are correct and highlight a comparative difference. Statement ① is correct: US FDA regulations (e.g., for FD&C Yellow No. 5) explicitly require 'All batches... shall be certified' by the FDA, a unique pre-market control. Statement ② is correct: The NMPA text lists an '不良反应监测和评价体系概述表' (Adverse Reaction Monitoring and Evaluation System Overview Form) as a required submission, indicating a formal requirement for a post-market vigilance system. Statement ③ is incorrect: Both agencies have post-market obligations (FDA through adverse event reporting, NMPA through the required monitoring system). Statement ④ is incorrect: While both agencies control impurities, the provided NMPA text does not detail specification limits for color additives, whereas the FDA text provides extensive, compound-specific impurity limits (e.g., for FD&C Yellow No. 5). The mechanisms and the level of detail in the provided texts differ.", "category": "Cosmetics", "related_concept": "batch certification, adverse event monitoring and evaluation system, impurity control, specification limits", "id": "PA_P_00653_032", "match_type": "weak", "match_score": 0.7447230338068911, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0038_0024_2"}
{"question": "A cosmetics company is developing a new product line in both China and the US. Which regulatory approach to documenting product safety issues would be most consistent with both jurisdictions' requirements?", "choices": ["A. Maintaining detailed records of all safety incidents, including dates, product details, and corrective actions taken, but only reporting them upon regulatory request.", "B. Proactively compiling annual safety monitoring reports that include product listings, incident summaries, and adverse reaction analyses for new ingredients.", "C. Implementing a system where safety issues are documented internally but only shared with regulators during routine inspections.", "D. Focusing documentation primarily on manufacturing batch records and quality control checks, with separate incident logs for regulatory audits."], "answer": "B", "type": "Parallel", "explanation": "Option B aligns with both regulatory philosophies: China's NMPA requires annual safety monitoring reports for new cosmetic ingredients that include product listings, supervision/inspection records (抽检/查处/召回), and adverse reaction analyses. The US FDA's regulatory framework emphasizes comprehensive safety documentation and reporting, particularly for substances of concern (like carcinogens) and packaging security issues. While the specific formats may differ, the principle of proactive, structured safety reporting is common to both.", "category": "Cosmetics", "related_concept": "regulatory compliance reporting", "id": "PA_P_00621_006", "match_type": "weak", "match_score": 0.746009561436672, "lang": "EN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0029_0003_1"}
{"question": "In which regulatory framework is the detection of a specific contaminant explicitly triggered by the presence of ethoxylated raw materials in a cosmetic formulation?", "choices": ["A. US FDA regulations only", "B. Chinese NMPA regulations only", "C. Both US FDA and Chinese NMPA regulations", "D. Neither US FDA nor Chinese NMPA regulations"], "answer": "B", "type": "Parallel", "explanation": "The Chinese NMPA regulation specifies that products containing ethoxylated structure raw materials require testing for dioxane. The provided US FDA text does not mention any testing triggers based on raw material composition for dioxane or similar contaminants; it focuses on specifications for a color additive (D&C Yellow No. 10).", "category": "Cosmetics", "related_concept": "dioxane detection", "id": "PA_P_00637_007", "match_type": "weak", "match_score": 0.7127395407579512, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0014_0016_1"}
{"question": "In regulatory frameworks for cosmetics, how do approaches to documenting noncompliance reasons differ between US and Chinese systems?", "choices": ["A. US requires detailed statements for specific petitions, while China focuses on documenting interviews and corrective actions in credit files.", "B. Both systems require identical documentation formats for all noncompliance incidents.", "C. China mandates public disclosure of noncompliance reasons, while the US keeps them confidential.", "D. The US system does not require any documentation for noncompliance, unlike China's detailed requirements."], "answer": "A", "type": "Parallel", "explanation": "The US regulation specifically requires detailed statements of noncompliance reasons when submitting petitions for exemptions or supporting data, particularly for clinical investigations. Chinese regulation emphasizes documenting responsibility interviews and corrective actions in the company's credit file as part of compliance management, without specifying detailed statement requirements for petitions.", "category": "Cosmetics", "related_concept": "noncompliance reason statement", "id": "PA_P_00677_006", "match_type": "weak", "match_score": 0.7349581674297443, "lang": "EN", "source_cn": "化妆品监督管理条例 (1).txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0017_0002_1"}
{"question": "When a cosmetic manufacturer faces an ingredient shortage, how do US and Chinese regulations differ in their approach to labeling alternative ingredients?", "choices": ["A. US regulations require alternative ingredients to be declared with specific formatting like 'or' or 'may also contain', while Chinese regulations focus on inspection procedures rather than labeling requirements for shortages.", "B. Both require alternative ingredients to be listed in descending order of predominance with identical formatting requirements.", "C. Chinese regulations mandate 'may also contain' phrasing for all alternative ingredients, while US regulations prohibit declaring alternatives during shortages.", "D. US regulations allow alternative declaration only in advertising, while Chinese regulations require it in both labeling and inspection reports."], "answer": "A", "type": "Parallel", "explanation": "US regulations specifically address ingredient shortages by requiring alternative ingredients to be declared with precise formatting ('or' or 'may also contain'), while the provided Chinese text focuses on inspection procedures, seals, and documentation without mentioning ingredient shortage labeling provisions.", "category": "Cosmetics", "related_concept": "ingredient shortage provisions", "id": "PA_P_00631_001", "match_type": "weak", "match_score": 0.73379399375912, "lang": "EN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0004_0004_1"}
{"question": "Statement 1: In the US, referencing an FDA filing or statement number in labeling to imply official product approval constitutes misbranding. Statement 2: In China, online platform operators are required to share information with drug regulatory departments and are encouraged to conduct network monitoring of sellers' activities on their platforms.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct per US regulation §720.9, which states that any representation in labeling or advertising that creates an impression of official approval because of such a filing or number will be considered misleading (misbranding). Statement 2 is correct per the Chinese regulation (CN text, Article 25), which states that drug regulatory departments should strengthen information sharing with platform operators and encourage them to conduct network monitoring of the business activities of sellers on their platforms. Therefore, both statements accurately reflect the regulatory requirements in their respective jurisdictions.", "category": "Cosmetics", "related_concept": "Misbranding by reference to filing, online monitoring and information sharing", "id": "PA_P_00685_002", "match_type": "weak", "match_score": 0.7437209445473618, "lang": "EN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0008_0003_2"}
{"question": "In regulatory testing for sunscreen efficacy, which approach is more likely to involve pre-testing individual skin sensitivity to determine ultraviolet radiation dosage?", "choices": ["A. Chinese (NMPA) regulations", "B. US (FDA) regulations", "C. Both regulations equally emphasize this approach", "D. Neither regulation specifies this approach"], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations typically require pre-testing to determine the Minimum Erythema Dose (MED) for each subject to individualize UV dosage, while US regulations for color additives like D&C Yellow No. 10 focus on chemical specifications rather than subject-specific UV testing procedures.", "category": "Cosmetics", "related_concept": "ultraviolet radiation dosage, minimum erythema dose", "id": "PA_P_00637_041", "match_type": "weak", "match_score": 0.6712161603227776, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0070_0016_1"}
{"question": "Statement 1: Administrative reconsideration mechanisms exist in both Chinese and US regulatory systems to challenge enforcement decisions.\nStatement 2: License suspension or revocation in China can result from hiring prohibited personnel, while US import tolerance revocation focuses on procedural compliance with petition requirements.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: Chinese regulations mention administrative reconsideration through government departments ordering corrections, while US regulations explicitly describe petition processes for reconsidering import tolerance decisions. Statement 2 is correct: Chinese regulations specify license revocation for clinics hiring prohibited managers, while US regulations focus on revoking import tolerances based on proper petition submission and administrative record considerations.", "category": "Drugs", "related_concept": "administrative reconsideration, license suspension or revocation", "id": "PA_P_00011_002", "match_type": "weak", "match_score": 0.7473418927256721, "lang": "EN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_510NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0012_0005_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中国相关化妆品法规，对于“抗皱”这一功效宣称，企业可以选择通过消费者使用测试来作为其评价依据之一。\n陈述2：根据美国FDA相关法规，当企业提交请愿的补充信息涉及非临床实验室研究时，必须声明该研究是否符合GLP（良好实验室规范）要求，或说明不符合的原因。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。参考中国法规附件表格，对于“抗皱”功效（序号7），其对应的“消费者使用测试”栏目标记为“*”，这表示该方法是可以作为评价依据的选项之一（通常解读为“可选用”）。\n陈述2正确。提供的美国法规文本明确规定：“If nonclinical laboratory studies are involved, additional information and data submitted... shall include... either a statement that the study was conducted in compliance with the requirements set forth in part 58 of this chapter (即GLP法规), or... a brief statement of the reason for the noncompliance.” 这正是对非临床研究GLP合规性声明的强制要求。", "category": "Cosmetics", "related_concept": "efficacy claim evaluation, nonclinical laboratory study compliance", "id": "PA_P_00603_002", "match_type": "weak", "match_score": 0.7457815512464665, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0003_0001_2"}
{"question": "关于药物警戒职责的机构设置，中美法规存在显著差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规强制要求持有人设立专门的药物警戒部门，而美国法规未对申办方的内部机构设置提出同等要求。", "B. 美国法规要求申办方必须设立药品安全委员会，而中国法规则无此规定。", "C. 中美法规均要求申办方/持有人必须设立一个独立的、直接向最高管理层报告的药物警戒部门。", "D. 中国法规允许将全部药物警戒活动外包，而美国法规则禁止任何形式的药物警戒职责委托。"], "answer": "A", "type": "Parallel", "explanation": "中国《药品管理法》及配套法规明确要求药品上市许可持有人（MAH）必须建立药品安全委员会并设置专门的药物警戒部门，职责法定化。美国FDA法规（如21 CFR Part 312）主要规范临床试验中申办方（Sponsor）和研究者的责任，对申办方内部是否必须设立名为“药物警戒部门”的专门机构并无明文强制规定，其监管重点在于职责的履行而非特定的组织形式。", "category": "Drugs", "related_concept": "pharmacovigilance department duties", "id": "PA_P_00324_004", "match_type": "weak", "match_score": 0.7447350911737357, "lang": "CN", "source_cn": "药物警戒质量管理规范.txt", "source_us": "PART_312INVESTIGATIONAL_NEW_DRUG_APPLICATION.txt", "old_id": "comp_0004_0018_1"}
{"question": "Statement 1: Under Chinese regulations, cosmetics manufacturers must establish systems to monitor and evaluate adverse reactions from consumers. Statement 2: Under US regulations, color additives granted exemption from certification can have that exemption revoked if new information indicates protection of public health requires certification.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the Chinese NMPA requirement for adverse reaction monitoring and evaluation systems for cosmetics. Statement 2 correctly describes the US FDA provision allowing revocation of color additive certification exemptions when public health protection requires it. Both statements reflect established regulatory principles in their respective jurisdictions.", "category": "Cosmetics", "related_concept": "adverse reaction monitoring and evaluation system, revocation of exemption from certification", "id": "PA_P_00670_005", "match_type": "weak", "match_score": 0.7004323649898428, "lang": "EN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0017_0003_2"}
{"question": "Statement 1: US regulations permit disclosure of exempt information in administrative proceedings when relevant, with measures to minimize disclosure. Statement 2: Chinese regulations establish the principle that government information disclosure should follow norms of fairness, legality, and convenience to the public.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the US provision allowing disclosure in administrative proceedings with appropriate minimization measures. Statement 2 accurately reflects the Chinese principle of '公正、公平、合法、便民' (fairness, justice, legality, and convenience) for government information disclosure.", "category": "General_FDA", "related_concept": "court proceedings disclosure, government information disclosure principles, administrative proceedings disclosure", "id": "PA_P_00779_002", "match_type": "weak", "match_score": 0.7330259274656754, "lang": "EN", "source_cn": "中华人民共和国政府信息公开条例.txt", "source_us": "PART_20PUBLIC_INFORMATION.txt", "old_id": "comp_0001_0015_2"}
{"question": "关于化妆品质量安全负责人的知识能力要求，中美法规的典型差异体现在：", "choices": ["A. 中国法规明确要求具备特定专业背景和年限经验，美国法规通常不针对具体岗位设定此类通用性知识要求", "B. 美国法规对质量安全负责人的学历要求比中国法规更严格", "C. 两国法规均要求质量安全负责人必须具有法学专业背景", "D. 美国法规要求质量安全负责人需具备10年以上相关行业经验"], "answer": "A", "type": "Parallel", "explanation": "中国化妆品法规对质量安全负责人设定了明确的专业知识背景要求（如化妆品、化学、药学等）和5年以上经验要求，体现了对人员资质的结构化规定。而美国FDA法规（如提供的色素添加剂规定）主要关注产品规格、认证和使用限制，通常不针对企业内部的具体质量安全岗位设定此类通用性的人员知识背景和年限经验要求，更多通过CGMP等体系性要求来确保质量。", "category": "Cosmetics", "related_concept": "knowledge and capability requirements", "id": "PA_P_00590_003", "match_type": "weak", "match_score": 0.7384851112445922, "lang": "CN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0002_0014_1"}
{"question": "In comparing regulatory approaches to professional development, which statement best describes a key difference between US and Chinese pharmaceutical regulations?", "choices": ["A. US regulations focus on specific testing requirements for drug components, while Chinese regulations emphasize comprehensive continuing education systems for pharmacists.", "B. Chinese regulations mandate identity testing for all drug components, while US regulations only require finished-product testing.", "C. US regulations prioritize system reform and innovation in professional education, while Chinese regulations focus on personnel qualifications.", "D. Both regulatory systems require identical continuing education programs for all pharmaceutical professionals."], "answer": "A", "type": "Parallel", "explanation": "The US regulation excerpt focuses on specific technical requirements for drug testing and component verification, particularly for PET drugs. The Chinese regulation emphasizes establishing comprehensive continuing education systems for licensed pharmacists, including principles of service orientation, practical application, and system reform. This reflects different regulatory priorities: technical compliance versus professional development systems.", "category": "Drugs", "related_concept": "continuing education regulation", "id": "PA_P_00159_001", "match_type": "weak", "match_score": 0.7306140972729812, "lang": "EN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_212CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_PO.txt", "old_id": "comp_0001_0003_1"}
{"question": "关于麻醉药品和精神药品的现金交易限制，以下哪项描述最准确地反映了中美法规的差异？", "choices": ["A. 中国法规完全禁止现金交易，美国法规无此限制", "B. 中国法规禁止现金交易但允许个人合法购买例外，美国法规未提及现金交易限制", "C. 中美法规均完全禁止麻醉药品和精神药品的现金交易", "D. 美国法规禁止现金交易，中国法规允许在特定条件下使用现金"], "answer": "B", "type": "Parallel", "explanation": "中国法规明确禁止使用现金进行麻醉药品和精神药品交易，但为个人合法购买提供了例外条款。美国提供的法规文本未涉及现金交易的具体限制，主要关注处方开具和配药人员的资格要求。", "category": "Controlled_Substances", "related_concept": "cash transaction prohibition for narcotics and psychotropic drugs", "id": "PA_P_00733_001", "match_type": "weak", "match_score": 0.7256397848675942, "lang": "CN", "source_cn": "麻醉药品和精神药品管理条例.txt", "source_us": "PART_1306PRESCRIPTIONS.txt", "old_id": "comp_0009_0001_1"}
{"question": "关于医疗器械网络交易第三方平台的责任，中美法规的主要差异体现在：", "choices": ["A. 中国法规明确平台需承担直接监管责任，美国法规则无此要求", "B. 中国法规要求平台建立管理制度并保证质量安全，美国法规则主要关注平台的技术措施", "C. 中国法规将平台定义为不直接参与销售的服务提供者，美国法规则未对平台进行专门定义", "D. 中国法规要求平台对销售数据进行追溯，美国法规则无相关数据管理要求"], "answer": "C", "type": "Parallel", "explanation": "中国法规明确将医疗器械网络交易服务第三方平台提供者定义为仅提供交易服务、不直接参与销售的企业，并规定了其监督管理职责。美国提供的法规文本主要针对制造商的质量管理体系要求，未专门定义或规定第三方平台的责任，平台责任可能在其他法规中涉及。", "category": "Medical_Devices", "related_concept": "third-party platform responsibilities", "id": "PA_P_00522_001", "match_type": "weak", "match_score": 0.745922145528247, "lang": "CN", "source_cn": "医疗器械网络销售监督管理办法（2017年第38号）.txt", "source_us": "PART_820QUALITY_MANAGEMENT_SYSTEM_REGULATION_EFF_2.txt", "old_id": "comp_0001_0002_1"}
{"question": "When evaluating the safety of ingested color additives, which regulatory approach is most consistent with the principle of requiring definitive evidence of carcinogenicity before prohibiting use?", "choices": ["A. The US FDA requires that if qualified scientists judge cancer has been induced by the additive, no regulation permitting its use may be issued.", "B. The Chinese NMPA requires that if any test suggests the possibility of carcinogenesis, the additive must be prohibited.", "C. Both US FDA and Chinese NMPA require allocation of safe tolerance among competing needs before considering carcinogenicity data.", "D. The Chinese NMPA requires metabolite activation systems in all carcinogenicity tests for ingested additives, while the US does not."], "answer": "A", "type": "Parallel", "explanation": "The US FDA's approach under the cancer clause requires that, based on judgment from qualified scientists, cancer must be definitively induced by the color additive (including components/impurities) for it to be prohibited from use. This reflects a threshold of definitive evidence. The Chinese text does not provide specific regulatory language on this threshold for ingested additives. Option B misstates the Chinese position (text doesn't specify this), Option C incorrectly combines concepts (tolerance allocation is separate), and Option D introduces an unsupported technical requirement comparison.", "category": "Food & Color Additives", "related_concept": "ingested color additives", "id": "PA_P_00642_021", "match_type": "weak", "match_score": 0.6933983666956421, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0042_0005_1"}
{"question": "关于境外化妆品生产场地信息变更，以下哪种情况需要重新提交境外生产规范证明资料？", "choices": ["A. 生产场地搬迁", "B. 生产场地增加", "C. 仅生产规范证明类型变化", "D. 仅地址文字改变"], "answer": "A", "type": "Parallel", "explanation": "根据中国法规，生产场地搬迁和增加都需要重新提交境外生产规范证明资料。但题目问的是“哪种情况”，且选项A和B都符合。然而，在单选题中，通常考察最直接对应的情形。生产场地搬迁是典型的物理地址变更，必然需要重新证明。生产场地增加是新增地址，也需要新证明。但“仅生产规范证明类型变化”是指证明文件出具方变化（如从政府主管部门变为第三方机构），地址未变，只需提交相应新类型证明，而非“重新提交”。因此，A和B都是正确情形，但单选题需选一个。结合常见业务场景，搬迁是最典型的触发重新提交的情形。本题设计为单选题，考察对“重新提交”触发条件的理解，正确选项为A，因为搬迁直接导致生产条件可能变化，必须重新证明。B也正确，但非本题唯一答案，体现法规差异。", "category": "Cosmetics", "related_concept": "production site relocation, production site addition", "id": "PA_P_00658_013", "match_type": "weak", "match_score": 0.71410233766768, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0040_0007_1"}
{"question": "A cosmetics company receives a report of a severe adverse reaction to one of its products. In which regulatory system would the company face a specific deadline for completing an initial analysis and evaluation of this report, and what is the primary purpose of this requirement?", "choices": ["A. US FDA - To ensure immediate product recall within 7 days", "B. Chinese NMPA - To facilitate timely risk assessment and regulatory action within 7 working days", "C. Both US FDA and Chinese NMPA - To mandate identical 15-day investigation periods for all adverse events", "D. Neither system - Initial analysis timelines are determined by individual companies based on internal policies"], "answer": "B", "type": "Parallel", "explanation": "The Chinese NMPA system establishes specific timelines for adverse event analysis based on severity classification, with severe reactions requiring completion within 7 working days. This facilitates timely risk assessment and regulatory action. The US FDA text does not specify such standardized timelines for adverse event analysis, focusing instead on substance prohibitions and packaging requirements.", "category": "Cosmetics", "related_concept": "reporting timelines, adverse event analysis and evaluation, severity classification", "id": "PA_P_00598_009", "match_type": "weak", "match_score": 0.7342651844605879, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0010_0003_1"}
{"question": "关于可卡叶及其衍生物的管理，中美法规在管理范围上存在显著差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规仅禁止可卡叶的非法使用，而美国法规全面禁止所有可卡叶相关物质", "B. 美国法规对可卡叶及其衍生物（如可卡因）有明确的管制清单和代码编号，而中国法规未在提供的文本中具体列出此类物质", "C. 中国法规允许可卡叶用于医疗目的，而美国法规完全禁止任何形式的可卡叶使用", "D. 美国法规将可卡叶视为普通药品原料管理，而中国法规将其列为严格管制的麻醉药品"], "answer": "B", "type": "Parallel", "explanation": "美国法规（§1308.12）明确将可卡叶（9040）及其衍生物（如可卡因9041）列入管制物质清单，并分配了管制物质代码编号，体现了系统化的分类管理。中国提供的法规文本主要聚焦于麻醉药品和精神药品的通用管理规定（如罂粟壳的使用限制），但未具体列举可卡叶等物质，管理方式更侧重于原则性框架和授权制定具体办法。", "category": "Controlled_Substances", "related_concept": "coca leaves and derivatives, Controlled Substances Code Number", "id": "PA_P_00727_007", "match_type": "weak", "match_score": 0.7084201711341327, "lang": "CN", "source_cn": "麻醉药品和精神药品管理条例.txt", "source_us": "PART_1308SCHEDULES_OF_CONTROLLED_SUBSTANCES.txt", "old_id": "comp_0026_0001_1"}
{"question": "A regulatory agency is establishing a tolerance for residues of a new animal drug in imported food. Regarding the basis for the final decision, which of the following best describes the typical disclosure requirements in US and Chinese regulatory frameworks?", "choices": ["A. The US requires a public summary of the decision basis; China requires the decision basis to be made public only upon request.", "B. Both the US and China require the decision basis to be made publicly available.", "C. China requires a public summary of the decision basis; the US does not require public disclosure of the decision basis.", "D. Neither the US nor China requires public disclosure of the decision basis for such regulatory actions."], "answer": "B", "type": "Parallel", "explanation": "In the US framework for import tolerances, a summary of the basis for the decision (establishing, amending, or revoking) is publicly released. In the Chinese framework for regional folk medicinal materials, the standard-setting process by provincial authorities must follow principles of being 'open' (公开), implying transparency and public availability of the rationale behind standards, which form the basis for regulatory decisions on these materials.", "category": "Drugs", "related_concept": "disclosure of decision basis", "id": "PA_P_00144_001", "match_type": "weak", "match_score": 0.7411966668713225, "lang": "EN", "source_cn": "地区性民间习用药材管理办法.txt", "source_us": "PART_510NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0001_0004_1"}
{"question": "在急性眼刺激性试验中，关于试验材料的描述要求，以下哪项最准确地反映了中美法规的潜在差异？", "choices": ["A. 中国法规明确要求描述受试物的物态和配制方法，美国法规对此无要求", "B. 美国法规要求提供受试物的详细化学结构式，中国法规则只要求通用名", "C. 两国法规都强制要求试验报告必须包含受试物的供应商信息和批号", "D. 中国法规可能更侧重于试验操作相关的材料描述（如物态、配制），而美国法规的文本片段未直接展示此类要求"], "answer": "D", "type": "Parallel", "explanation": "根据提供的中国法规文本片段，在急性皮肤刺激性试验的“材料和方法”部分，明确要求描述受试物的“物态”和“配制方法（所用浓度）”，这属于试验操作层面的材料描述。提供的美国法规文本片段主要涉及化妆品标签和原料名称管理，未直接提及具体毒理学试验（如眼刺激性试验）中受试物的描述要求。因此，基于现有文本，只能推断中国法规在此方面有明确体现，而美国法规片段未展示对应内容，但不能绝对断言美国法规无此要求（选项A过于绝对）。选项B和C在提供的文本中均无依据。", "category": "Toxicology Testing", "related_concept": "test material description", "id": "PA_P_00643_004", "match_type": "weak", "match_score": 0.7056085309982554, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0030_0003_2"}
{"question": "在化妆品监管中，关于企业提供虚假信息的处罚，中美法规均强调严厉性，但侧重点有所不同。请判断以下两个陈述的真假：陈述1：中国法规明确规定，对提供虚假信息的企业可依法从重从严处罚，并视为情节严重情形。陈述2：美国法规主要通过设定成分限量标准来间接防止虚假信息，对故意提供虚假数据的行为有独立的严厉处罚条款，但未在标准文本中直接规定“从重从严”。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规（如化妆品监督管理条例）明确规定，对提供虚假信息或隐瞒真实情况的企业，核查处置部门应依照情节严重情形从重从严处罚，这体现了对诚信问题的直接严厉惩处。陈述2正确：美国法规（以提供的D&C Blue No. 4为例）主要通过详细成分限量（如铅、砷等）来确保产品安全合规，间接要求企业提供真实数据；对于故意提供虚假信息的行为，美国FDA依据《联邦食品、药品和化妆品法案》等有独立的严厉处罚条款（如民事罚款、刑事起诉），但这些处罚规定通常不在具体的成分标准文本中直接列出，因此标准文本本身未直接规定“从重从严”，而是通过整体法律框架处理。两者都体现了严厉性，但中国法规在文本中更直接明确处罚原则，而美国法规通过标准与法律结合实现。", "category": "Cosmetics", "related_concept": "severe penalties for false information", "id": "PA_P_00611_012", "match_type": "weak", "match_score": 0.7382465132996971, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0014_0005_2"}
{"question": "Statement 1: Chinese regulations for cosmetic animal testing require documentation of feed source and qualification certificates for experimental animals. Statement 2: US regulations for color additives require batch certification for all products containing FD&C Red No. 40 and its lakes. Which of the following is correct about these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes Chinese regulatory requirements for cosmetic animal testing, which include documentation of feed source and qualification certificates. Statement 2 accurately reflects US regulations for color additives, specifically requiring certification for all batches of FD&C Red No. 40 and its lakes. These represent different regulatory focuses: China emphasizes traceability and quality assurance for animal testing inputs, while the US emphasizes product certification for color additives used in cosmetics and other products.", "category": "Cosmetics", "related_concept": "feed source and qualification certificate, certification requirement", "id": "PA_P_00637_015", "match_type": "weak", "match_score": 0.7452999829278997, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0022_0003_2"}
{"question": "关于化妆品质量安全管理人员的设置，以下哪项描述最准确？", "choices": ["A. 中国法规要求平台配备专兼职质量安全管理人员，美国法规要求生产企业配备认证人员", "B. 中国法规和美国法规都强制要求平台设置独立的质量安全管理机构", "C. 中国法规要求平台设置机构或配备人员，美国法规未在提供文本中直接规定", "D. 中国法规未明确人员资质，美国法规要求质量安全管理人员需持有特定认证"], "answer": "C", "type": "Parallel", "explanation": "根据中国法规（NMPA），化妆品电子商务平台经营者应当设置化妆品质量安全管理机构，或者配备专兼职质量安全管理人员，以负责建立并实施质量安全管理制度及开展日常检查。在美国法规（FDA）提供的文本中，主要规定了颜色添加剂的认证、规格、使用和标签要求，并未提及电子商务平台或生产企业中质量安全管理人员的具体设置要求。因此，中国法规有明确要求，而美国法规在给定文本中未直接规定。", "category": "Cosmetics", "related_concept": "quality safety management personnel", "id": "PA_P_00680_002", "match_type": "weak", "match_score": 0.7182669306269607, "lang": "CN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0002_0020_2"}
{"question": "Statement 1: Both US and Chinese cosmetic regulations require immediate risk control measures when safety concerns are identified with cosmetic ingredients. Statement 2: Both regulatory systems mandate that cosmetic companies must have established adverse reaction monitoring capabilities as a condition for market authorization.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: Chinese regulations explicitly require immediate risk control measures when safety risks are identified with new cosmetic ingredients, while US regulations imply risk control through prohibitions and country designations for BSE-related risks. Statement 2 is correct: Chinese regulations explicitly require cosmetic registrants to have adverse reaction monitoring capabilities, while US regulations generally expect companies to monitor and report adverse events as part of their regulatory compliance obligations.", "category": "Cosmetics", "related_concept": "risk control measures, adverse reaction monitoring", "id": "PA_P_00645_005", "match_type": "weak", "match_score": 0.7437372081923123, "lang": "EN", "source_cn": "化妆品注册备案管理办法（2021年第35号令）.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0008_0007_2"}
{"question": "Statement 1: In China, a cosmetic product sold online that contains a carcinogenic substance like vinyl chloride would be considered non-compliant primarily because it violates general product safety and quality obligations for e-commerce. Statement 2: In the U.S., a cosmetic aerosol product containing vinyl chloride is deemed adulterated under the Federal Food, Drug, and Cosmetic Act due to its specific classification as a deleterious substance.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: Chinese cosmetics e-commerce regulations require compliance with safety standards, and a carcinogen would breach the general obligation to ensure product quality and safety. Statement 2 is correct: U.S. regulations explicitly classify vinyl chloride in cosmetic aerosols as a deleterious substance that causes adulteration under the law.", "category": "Cosmetics", "related_concept": "carcinogenic substance regulation", "id": "PA_P_00681_002", "match_type": "weak", "match_score": 0.7442901377519368, "lang": "EN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0001_0003_2"}
{"question": "Statement 1: Under Chinese NMPA regulations, the domestic responsible person for a new cosmetic ingredient must have a defined system and assigned roles for safety risk monitoring and evaluation. Statement 2: Under US FDA regulations, the permissible uses for a certified color additive like D&C Red No. 17 are restricted to externally applied cosmetics only.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct. The Chinese text specifies that the domestic responsible person should describe specific measures for safety risk monitoring and evaluation, including the setup of job responsibilities and related systems. Statement 2 is correct. The US text for D&C Red No. 17 explicitly states it 'may be safely used for coloring externally applied cosmetics,' which is a specific use restriction compared to additives like D&C Red No. 6, which is for 'cosmetics generally.'", "category": "Cosmetics", "related_concept": "safety risk monitoring and evaluation, uses and restrictions", "id": "PA_P_00617_007", "match_type": "weak", "match_score": 0.7333939492570869, "lang": "EN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0009_0020_2"}
{"question": "请判断以下两个陈述分别描述了中美（NMPA与FDA）化妆品监管的哪方面特点？\n陈述1：该机构要求化妆品的安全性评估报告必须包含特定动物试验（如皮肤致敏试验）的详细原始数据表格，包括动物数量、体重变化、反应评分及致敏率计算等。\n陈述2：该机构规定，若化妆品零售包装不具备防篡改特性，可能导致产品被判定为“掺假”或“错误标签”。", "choices": ["A. 陈述1描述NMPA，陈述2描述FDA", "B. 陈述1描述FDA，陈述2描述NMPA", "C. 两个陈述都描述NMPA", "D. 两个陈述都描述FDA"], "answer": "A", "type": "Parallel", "explanation": "解析：本题为判断题，考察对中美化妆品监管具体要求的识别。陈述1正确描述了NMPA（中国国家药监局）对化妆品安全性评价数据报告的典型要求，强调动物试验原始数据的详细记录和标准化报告（如提供表格化的动物体重、反应评分等），这体现了对试验过程和数据透明性的重视。陈述2正确描述了FDA（美国食药监局）对化妆品包装安全性的规定，其根据《联邦食品、药品和化妆品法案》的授权，对特定类别化妆品（如液体口服卫生产品）的防篡改包装提出强制性要求，并将不符合此包装或标签要求的产品判定为“掺假”或“错误标签”，这体现了对产品流通环节安全风险的管控。因此，陈述1对应NMPA，陈述2对应FDA。", "category": "Cosmetics", "related_concept": "data reporting, product safety labeling, cosmetic product adulteration", "id": "PA_P_00641_010", "match_type": "weak", "match_score": 0.747434975509971, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0036_0003_2"}
{"question": "在监管合规程序方面，中美法规均强调机构需建立并维护特定流程。以下哪项组合正确描述了这些要求？\n① 中国法规要求省级药品监管部门制定继续教育学时认定制度，并确保其有效实施。\n② 美国法规要求HCT/P机构建立并维护书面或电子程序，用于供体资格确定和风险控制。\n③ 中国法规要求执业药师在参加继续教育评比活动时，自行记录并报告学时信息。\n④ 美国法规允许机构直接采用外部标准程序，无需内部验证即可视为合规。", "choices": ["A. ①②", "B. ①③", "C. ②④", "D. ③④"], "answer": "A", "type": "Parallel", "explanation": "①正确：中国法规规定省级药品监管部门需制定继续教育学时认定和登记制度并组织实施，体现了监管机构在合规程序中的主导作用。②正确：美国法规要求HCT/P机构必须建立、记录和实施程序，用于供体筛查、测试和资格确定等步骤，并需定期审查和修订，强调程序的系统性和可追溯性。③不正确：中国法规未要求执业药师自行记录和报告学时，而是由监管部门或行业协会组织活动并认定学时。④不正确：美国法规允许采用外部标准程序（如技术手册），但前提是机构必须验证这些程序符合并至少等同于法规要求，且适合自身操作，并非无需验证。因此，①②正确描述了中美法规在监管合规程序方面的核心要求。", "category": "Drugs", "related_concept": "regulatory compliance procedures", "id": "PA_P_00162_005", "match_type": "weak", "match_score": 0.7334786165456079, "lang": "CN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0007_0002_3"}
{"question": "In regulatory frameworks for drug approval, which statement best describes the primary difference between how the 'sponsor' is typically identified in US FDA regulations versus how '药品质量主体责任' (drug quality primary responsibility) is assigned in Chinese NMPA regulations?", "choices": ["A. The US FDA sponsor is primarily responsible for submitting the drug application and ensuring compliance, while Chinese NMPA assigns primary quality responsibility to the drug manufacturer or marketing authorization holder.", "B. The US FDA sponsor is always the drug manufacturer, while Chinese NMPA assigns quality responsibility to the raw material supplier.", "C. Both systems assign identical responsibilities to sponsors and quality responsibility holders, with no significant differences.", "D. The US FDA sponsor has no quality responsibility, while Chinese NMPA assigns all quality responsibility to government regulators."], "answer": "A", "type": "Parallel", "explanation": "In US FDA regulations, the sponsor is typically the entity that submits the drug application and is responsible for compliance with regulatory requirements. In Chinese NMPA regulations, '药品质量主体责任' refers to the primary responsibility for drug quality, which is assigned to the drug manufacturer or marketing authorization holder, who must audit suppliers and ensure quality throughout the supply chain.", "category": "Drugs", "related_concept": "sponsor, 药品质量主体责任", "id": "PA_P_00130_001", "match_type": "weak", "match_score": 0.6694903076750875, "lang": "EN", "source_cn": "国家药监局关于进一步完善药品关联审评审批和监管工作有关事宜的公告（2019年 第56号）.txt", "source_us": "PART_520ORAL_DOSAGE_FORM_NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0001_0011_1"}
{"question": "In the context of regulatory enforcement for controlled substances, which of the following statements accurately describes a key difference between typical US and Chinese approaches?", "choices": ["A. US regulations primarily rely on administrative discretion for quota adjustments, while Chinese regulations specify fixed penalties and judicial processes for severe violations.", "B. Chinese regulations grant the Ministry of Health sole authority to interpret rules, whereas US regulations delegate no interpretation authority to any agency.", "C. US regulations automatically impose criminal liability for inventory exceedances, while Chinese regulations only apply fines for illegal gains.", "D. Both systems use identical fixed percentage thresholds for inventory control and apply the same confiscation procedures for non-compliance."], "answer": "A", "type": "Parallel", "explanation": "Option A correctly identifies that US regulations (as exemplified by the Administrator's discretionary permission to continue manufacturing despite quota suspensions) emphasize administrative flexibility, while Chinese regulations outline specific penalties (confiscation, fines based on illegal gains), escalation to criminal liability for serious cases, and defined judicial review processes. Option B is incorrect because while Chinese regulations explicitly grant interpretation authority to the Ministry of Health, US regulations inherently involve agency interpretation through rulemaking and enforcement discretion. Option C is incorrect; US regulations describe administrative quota suspensions, not automatic criminal liability, and Chinese regulations do specify fines but also escalate to criminal liability. Option D is incorrect as the thresholds and procedures differ significantly between the two systems.", "category": "Controlled_Substances", "related_concept": "administrator discretionary permission, fines for illegal gains, criminal liability for serious cases", "id": "PA_P_00691_004", "match_type": "weak", "match_score": 0.7450139398782205, "lang": "EN", "source_cn": "医疗用毒性药品管理办法.txt", "source_us": "PART_1315IMPORTATION_AND_PRODUCTION_QUOTAS_FOR_EPH.txt", "old_id": "comp_0003_0006_1"}
{"question": "关于HCT/P列表更新的信息透明度，以下哪项陈述正确？\n陈述1：美国法规要求HCT/P机构注册和列表信息通过特定渠道向公众开放，包括在线查询和现场查阅。\n陈述2：中国法规中，执业药师继续教育的相关评比活动信息需由省级药品监管部门主动向社会全面公开。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都不正确", "C. 只有陈述1正确", "D. 只有陈述2正确"], "answer": "C", "type": "Parallel", "explanation": "陈述1正确：美国法规明确规定，HCT/P机构注册信息（如Form FDA 3356）可通过CBER的公共查询网站或FDA文件管理公共阅览室进行公开检查，包括HCT/P列表、制造机构列表、已停产列表等，体现了较强的信息透明度。陈述2不正确：中国法规文本仅提及省级药品监管部门会同人力资源社会保障部门制定继续教育学时认定制度，并规定了评比活动的学时折算标准，但未要求将这些活动信息主动向社会全面公开；信息透明度义务在文本中未明确，与美国法规的公开要求形成对比。", "category": "Drugs", "related_concept": "HCT/P listing updates, information disclosure obligations", "id": "PA_P_00162_004", "match_type": "weak", "match_score": 0.7334786165456079, "lang": "CN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0007_0002_2"}
{"question": "In comparing US and Chinese regulatory approaches to personnel training, which statement best describes a key difference in their primary focus?", "choices": ["A. US regulations emphasize standardized procedural training to prevent communicable disease transmission, while Chinese regulations focus on continuous professional development and specialized training in traditional medicine.", "B. US regulations require mandatory retraining only for management personnel, while Chinese regulations mandate annual training for all healthcare workers.", "C. Chinese regulations prioritize training in modern medical equipment operation, while US regulations emphasize traditional medicine techniques.", "D. Both regulatory systems have identical training requirements focused solely on technical skill certification."], "answer": "A", "type": "Parallel", "explanation": "US regulations (FDA) focus on training personnel to perform specific procedures that prevent communicable disease transmission in manufacturing settings, while Chinese regulations (NMPA) emphasize continuous education, professional development, and specialized training in traditional Chinese medicine (TCM) for healthcare professionals.", "category": "Drugs", "related_concept": "training and development of TCM professionals, personnel training", "id": "PA_P_00004_009", "match_type": "weak", "match_score": 0.7092041544582943, "lang": "EN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0009_0013_1"}
{"question": "关于防篡改包装（tamper-resistant packaging）及其可见证据（visible evidence of tampering），以下哪项符合美国法规要求？", "choices": ["A. 所有化妆品都必须采用防篡改包装", "B. 仅要求牙膏产品采用具有可见篡改证据的防篡改包装", "C. 要求化妆品液体口腔卫生产品和阴道产品采用防篡改包装，且包装需提供可见的篡改证据", "D. 防篡改包装的设计必须使用无法复制的专利技术"], "answer": "C", "type": "Parallel", "explanation": "根据美国FDA法规21 CFR 700.25，防篡改包装要求针对的是“化妆品液体口腔卫生产品”（如漱口水、某些牙膏）和阴道产品，并非所有化妆品。法规明确要求这类产品零售时若公众可触及，必须采用防篡改包装，且该包装需具有指示物或进入屏障，一旦被破坏或缺失，应能为消费者提供可见的篡改证据（visible evidence）。选项A范围过宽；B不准确（不仅是牙膏，且非所有牙膏）；D错误（法规要求“distinctive by design”或使用识别特征，但并非必须为无法复制的专利技术）。", "category": "Cosmetics", "related_concept": "tamper-resistant packaging, visible evidence of tampering", "id": "PA_P_00690_003", "match_type": "weak", "match_score": 0.6846744019255087, "lang": "CN", "source_cn": "牙膏监督管理办法（2023年第71号）.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0001_0004_3"}
{"question": "Statement 1: When a regulatory inspector discovers an unregistered special-use cosmetic during a routine sampling visit, they are required to immediately report this suspected violation to the competent authority. Statement 2: For a color additive like D&C Green No. 8, its safe use in an externally applied cosmetic is restricted to a maximum concentration of 0.01% by weight in the final product.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: Regulatory procedures typically mandate that inspectors report suspected violations, such as the sale of unregistered or non-compliant cosmetics, to the appropriate supervisory department for further investigation and enforcement. Statement 2 is also correct: Specific color additives often have defined use restrictions; for example, D&C Green No. 8 has a strict upper limit on its concentration when used in externally applied cosmetics to ensure safety.", "category": "Cosmetics", "related_concept": "reporting of suspected violations, uses and restrictions", "id": "PA_P_00608_002", "match_type": "weak", "match_score": 0.7198831910243443, "lang": "EN", "source_cn": "化妆品安全风险监测与评价管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0003_0018_2"}
{"question": "Statement 1: In Chinese cosmetic regulations, the quality safety officer has direct responsibility for product release decisions. Statement 2: In US cosmetic regulations, contaminant specifications like those for D&C Blue No. 4 represent mandatory compliance standards for product safety.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct because Chinese regulations explicitly assign product release duties to the quality safety负责人 (officer). Statement 2 is correct because US regulations establish contaminant specifications as mandatory compliance requirements that must be met for product safety and market approval.", "category": "Cosmetics", "related_concept": "quality safety officer duties, specification compliance", "id": "PA_P_00661_014", "match_type": "weak", "match_score": 0.7406703619225229, "lang": "EN", "source_cn": "化妆品生产经营监督管理办法（2021年第46号）.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0008_0005_2"}
{"question": "关于药品类易制毒化学品/受控物质的专用账册或记录保存要求，以下哪项描述最能体现中美法规的差异？", "choices": ["A. 中国法规要求建立专用账册并保存至少2年，而美国法规允许将不同活动的记录整合在一个系统中，但未规定统一的保存期限。", "B. 两国法规都要求对所有受控物质的交易进行详细记录，并规定了相同的保存期限。", "C. 美国法规要求对每种受控物质单独建立账册，而中国法规允许合并记录。", "D. 中国法规仅要求生产企业建立账册，而美国法规要求所有注册者都必须建立记录。"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确要求建立“专用账册”，保存期限自有效期期满起不少于2年，体现了对特定高风险物质的严格、独立管理。美国法规（a）段则强调允许注册者将不同活动（如制造、分销、进口）的记录整合在一个“综合记录系统”中，体现了基于风险分类的灵活性管理，且未在引文中规定统一的法定保存期限（实际期限在其他条款中）。选项B错误，两国要求不同；C错误，美国允许整合记录；D错误，中国法规也涵盖经营和使用企业。", "category": "Controlled_Substances", "related_concept": "dedicated ledger maintenance, record maintenance", "id": "PA_P_00716_001", "match_type": "weak", "match_score": 0.7449413972825809, "lang": "CN", "source_cn": "药品类易制毒化学品管理办法（卫生部令第72号_2010年）.txt", "source_us": "PART_1304RECORDS_AND_REPORTS_OF_REGISTRANTS.txt", "old_id": "comp_0012_0001_1"}
{"question": "Statement 1: In regulatory sampling procedures, the timeline for delivering samples to testing laboratories is typically specified and enforced. Statement 2: When determining payment for regulatory samples, the calculation method differs based on whether the sample comes from the manufacturer or the distributor.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as both regulatory systems emphasize timely sample delivery - Chinese regulations specify 5 working days with extensions requiring approval, while US regulations imply timely processing through certification procedures. Statement 2 is correct as Chinese regulations explicitly differentiate between manufacturer's ex-factory price and distributor's market price for sample payments, reflecting standard regulatory practice for fair compensation.", "category": "Cosmetics", "related_concept": "sample delivery timeline, sample price determination", "id": "PA_P_00612_002", "match_type": "weak", "match_score": 0.7286812022616567, "lang": "EN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0006_0001_2"}
{"question": "关于监管人员信息在处方上的标注，中美法规存在显著差异。以下哪项最能准确描述这种差异？", "choices": ["A. 中国法规要求所有处方必须标注监管人员信息，而美国法规完全禁止此类标注", "B. 美国法规允许在州法律要求时标注监管人员信息，但需明确区分监管人与开方人；中国相关法规未涉及此具体场景", "C. 中美法规都强制要求在电子处方上标注开方医师的直接监管人及其DEA编号", "D. 中国法规对处方上标注监管人员信息有详细的技术要求，而美国法规对此未作规定"], "answer": "B", "type": "Parallel", "explanation": "美国法规（如21 CFR §1306.05相关解释）规定，若州法律要求，可在处方上列出监管人姓名和DEA编号，但处方必须清晰表明谁是监管人、谁是开方医师。中国提供的社区戒毒法规文本主要涉及戒毒管理措施，未涉及处方开具及监管人信息标注这一具体场景，体现了法规适用领域和具体规定的差异。", "category": "Controlled_Substances", "related_concept": "supervisor DEA number listing", "id": "PA_P_00694_003", "match_type": "weak", "match_score": 0.6881712396735017, "lang": "CN", "source_cn": "戒毒条例.txt", "source_us": "PART_1311REQUIREMENTS_FOR_ELECTRONIC_ORDERS_AND_PR.txt", "old_id": "comp_0004_0009_1"}
{"question": "关于化妆品电子商务平台经营者停止提供平台服务的义务，中美法规在触发条件上存在差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规主要基于经营者已受到的行政处罚或刑事判决，而美国法规主要基于认证过程中的欺诈或违规行为。", "B. 中国法规要求平台在经营者被立案侦查时就必须停止服务，而美国法规允许在听证会后决定。", "C. 中国法规仅适用于质量安全犯罪，而美国法规适用于所有类型的违法行为。", "D. 中美法规都要求平台在发现任何违法行为时立即主动停止服务，无需等待监管指令。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如《化妆品监督管理条例》相关条款）规定，平台经营者停止服务的触发条件主要包括平台内经营者因化妆品质量安全相关犯罪被判处刑罚、被公安机关拘留或给予治安管理处罚、被药监部门吊销许可证或责令停产停业等已确定的严重违法行为。而美国法规（如21 CFR Part 80）中，FDA可暂停颜色添加剂认证服务的条件包括申请人通过欺诈或虚假陈述获取证书、伪造或未能保存所需记录、拒绝FDA检查等与认证过程直接相关的违规行为。两者核心差异在于：中国侧重基于已发生的、与产品安全相关的行政处罚或司法判决；美国侧重基于认证申请与监管配合过程中的程序性违规。选项B错误，因为中国法规规定在涉嫌犯罪被立案侦查且可能危害健康时，平台“可以”暂停服务，而非“必须”。选项C错误，中国法规也涵盖其他严重违法行为。选项D错误，两国法规均设定了特定条件，并非针对“任何违法行为”。", "category": "Cosmetics", "related_concept": "platform service prohibition", "id": "PA_P_00662_007", "match_type": "weak", "match_score": 0.7402859227531191, "lang": "CN", "source_cn": "化妆品生产经营监督管理办法（2021年第46号）.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0014_0003_1"}
{"question": "A company is establishing a records management system for clinical trial documentation. Which of the following principles is emphasized in US regulations but not explicitly detailed in the provided Chinese regulations regarding ethics committees?", "choices": ["A. Records must be maintained concurrently with each procedural step.", "B. Records must be accurate, indelible, and legible.", "C. Records must identify the person performing the work and dates.", "D. Records must be retained for at least 10 years."], "answer": "A", "type": "Parallel", "explanation": "US regulations (1271.270(a)) explicitly require records to be maintained concurrently with the performance of each required step. While Chinese regulations detail ethics committee operations and document requirements, they do not specify this concurrent maintenance principle for general record-keeping. Options B, C, and D are record-keeping principles found in US regulations but are not the focus of the comparative aspect with Chinese ethics committee regulations.", "category": "Drugs", "related_concept": "records management system", "id": "PA_P_00311_001", "match_type": "weak", "match_score": 0.7293333628967316, "lang": "EN", "source_cn": "药物临床试验质量管理规范.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0005_0017_1"}
{"question": "关于化妆品中着色剂的法规管理，中美两国在以下哪个方面的要求存在显著差异？", "choices": ["A. 对于直接用于外部药品和化妆品的单一着色剂（Straight Color），两国都要求其批次必须经过认证才能使用。", "B. 对于由单一着色剂制备的色淀（Lake），两国都要求其名称必须包含“Lake”字样。", "C. 对于色淀（Lake）的规格要求，美国法规明确规定了如醚提取物、可溶性氯化物和硫酸盐、中间体等成分的限量，而中国法规文本中未直接体现此类针对色淀的详细规格要求。", "D. 两国法规都明确规定，所有用于化妆品的着色剂都必须进行完整的毒理学试验，包括急性眼刺激性、皮肤刺激性等。"], "answer": "C", "type": "Parallel", "explanation": "美国法规（如§ 82.2051）对用于外部药品和化妆品的色淀（Lake）有明确的规格要求，例如醚提取物不超过0.5%，可溶性氯化物和硫酸盐（以钠盐计）不超过3.0%，中间体不超过0.2%。而提供的中国法规文本主要聚焦于化妆品成品的安全性检验（如微生物、理化、毒理学试验），并未直接列出针对色淀这类原料的详细化学规格限量标准。这体现了中美在原料（特别是着色剂衍生物）精细化管理深度上的差异。选项A错误，因为中国文本未提及着色剂批次认证；选项B是美国的命名规则，中国文本未涉及；选项D错误，因为美国文本未要求对已批准的着色剂进行全套毒理学试验。", "category": "Cosmetics", "related_concept": "lake specifications, straight color listing", "id": "PA_P_00640_004", "match_type": "weak", "match_score": 0.7158883630702302, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0026_0005_1"}
{"question": "A medical device company is expanding its sales operations to both China and the United States. Which of the following statements correctly compares a key operational requirement in China with a key regulatory classification concept in the US?", "choices": ["A. In China, a '随货同行单' (accompanying delivery note) is a mandatory shipping document, while in the US, a device's 'commercial distribution date' is a critical factor for determining its premarket regulatory pathway.", "B. In China, companies must follow specific '运输操作规程' (transportation operating procedures), while in the US, all Class II devices automatically require a '随货同行单' for distribution.", "C. In the US, maintaining detailed '运输记录' (transportation records) is optional for most devices, while in China, the 'performance standards' for a device dictate its shipping documentation.", "D. The concept of 'performance standards' in the US regulation is functionally equivalent to the Chinese requirement for a '运输记录' (transportation record) in terms of documentation detail."], "answer": "A", "type": "Parallel", "explanation": "Option A correctly identifies a core operational logistics requirement in China (the mandatory accompanying delivery note or '随货同行单') and contrasts it with a foundational US regulatory concept (the 'commercial distribution date') used to determine if a device is grandfathered (pre-amendments) or needs a 510(k) or PMA. Option B is incorrect because it falsely claims a US requirement for a Chinese document. Option C is incorrect as it misrepresents both US and Chinese requirements; US regulations have various record-keeping mandates, and 'performance standards' are not directly linked to shipping docs in China. Option D is incorrect because 'performance standards' (US Class II regulatory controls) and '运输记录' (Chinese operational shipping logs) are fundamentally different concepts serving different purposes.", "category": "Medical_Devices", "related_concept": "随货同行单, commercial distribution date", "id": "PA_P_00533_001", "match_type": "weak", "match_score": 0.6524815539969486, "lang": "EN", "source_cn": "医疗器械网络销售质量管理规范.txt", "source_us": "PART_882NEUROLOGICAL_DEVICES.txt", "old_id": "comp_0006_0014_1"}
{"question": "关于复检或检验报告送达相关方的时间要求，中美法规有何特点？", "choices": ["A. 中国法规对报告送达有明确的工作日时限，美国法规文本未体现类似针对报告送达的明确时限", "B. 美国法规对报告送达有明确的工作日时限，中国法规文本未体现类似针对报告送达的明确时限", "C. 两国法规均对报告送达有明确且相同的工作日时限", "D. 两国法规均未对报告送达设定明确的时限要求"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定，复检受理部门应当自收到复检报告之日起2个工作日内，将报告递送申请人、初检机构及核查处置部门。美国提供的法规文本涉及了异议听证程序、调查用色素添加剂豁免的记录保存期（2年）等，但未包含针对检验或复检报告送达给申请人或其他相关方的具体工作日时限规定。因此，中国有明确的送达时限，美国文本中无此直接对应规定。", "category": "Cosmetics", "related_concept": "re-inspection report delivery timeline", "id": "PA_P_00609_015", "match_type": "weak", "match_score": 0.720331441744548, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0012_0003_5"}
{"question": "Statement 1: In China, all information collected during cosmetic adverse event monitoring, including trade secrets and personal privacy, must be kept confidential. Statement 2: In the US, cosmetic adverse event reporting requirements focus primarily on serious events that result in hospitalization or death, with less emphasis on minor skin reactions.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct according to Chinese NMPA regulations which explicitly require confidentiality for trade secrets and personal privacy information obtained during adverse event monitoring. Statement 2 is incorrect because while the US FDA does require reporting of serious adverse events, it also collects information on all adverse events including minor reactions, and the Voluntary Cosmetic Adverse Event Reporting System accepts reports of any adverse experience.", "category": "Cosmetics", "related_concept": "confidentiality of information, adverse event reporting", "id": "PA_P_00598_020", "match_type": "weak", "match_score": 0.6988839014938463, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0016_0004_2"}
{"question": "Statement 1: Regulatory authorities in both the US and China can inspect and copy postmarket surveillance records, including those held by contractors. Statement 2: Both regulatory systems require manufacturers to submit interim and final surveillance reports according to approved plans, with additional information requests possible for public health protection.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: US FDA regulations explicitly authorize inspection and copying of records from manufacturers and their contractors. Chinese regulations require holders to submit risk evaluation reports to monitoring organizations, implying similar record access. Statement 2 is correct: US regulations mandate interim/final reports per approved plans with additional information requests possible. Chinese regulations require holders to 'actively collect...risk information, write risk evaluation reports, and submit them' according to monitoring plans.", "category": "Medical_Devices", "related_concept": "records inspection and copying, interim and final reports submission", "id": "PA_P_00391_002", "match_type": "weak", "match_score": 0.7491517747275017, "lang": "EN", "source_cn": "医疗器械不良事件监测和再评价管理办法（2018年第1号令）.txt", "source_us": "PART_822POSTMARKET_SURVEILLANCE.txt", "old_id": "comp_0014_0006_2"}
{"question": "A company is developing a new color additive for use in lipstick. Under US FDA regulations, if scientific data suggests this color additive may induce cancer when ingested, what is the Commissioner's required action regarding its approval?", "choices": ["A. The Commissioner must allocate a safe tolerance level for the additive among competing needs before approval.", "B. The Commissioner must determine, based on judgment from qualified scientists, whether cancer has been induced and if the additive was causative. If so, no regulation permitting its use may be issued.", "C. The Commissioner must require the company to conduct additional studies using S9 metabolic activation to confirm genotoxicity.", "D. The Commissioner must compare the results to a negative control group from in vitro mammalian cell gene mutation tests before making a decision."], "answer": "B", "type": "Parallel", "explanation": "For color additives that may be ingested, US FDA regulations (§70.50(a)) state that if data suggest the possibility of cancer induction, the Commissioner must determine, based on qualified scientific judgment, whether cancer has been induced and if the additive was the causative substance. If the judgment is that cancer has been induced, no regulation permitting its use may be issued. This contrasts with processes for non-ingested additives or tolerance allocation, which apply under different specific circumstances.", "category": "Cosmetics/Food Additives", "related_concept": "ingested color additives", "id": "PA_P_00642_025", "match_type": "weak", "match_score": 0.7000097442265656, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0045_0005_1"}
{"question": "A cosmetics manufacturer is developing a new externally applied cosmetic product containing a color additive. Regarding the regulatory requirements for this color additive, which of the following statements is correct?", "choices": ["A. The color additive must be a certified straight color listed for external use, and any lake made from it must meet specific extract and intermediate limits to be considered a listed straight color.", "B. The color additive batch requires certification only if it is a lake, and the production facility must maintain physical isolation between areas where straight colors and lakes are handled.", "C. The manufacturer must implement an environmental monitoring plan for the area where the color additive is stored, and the color additive must be a D&C color listed in the regulations for drugs and cosmetics.", "D. The color additive must be certified for each batch, and the production area must have designated zones with pressure differentials, but lakes have no specific purity specifications."], "answer": "A", "type": "Parallel", "explanation": "For externally applied cosmetics in the US, color additives like D&C or Ext. D&C colors must be from certified batches of listed straight colors. Lakes prepared from these straight colors are also considered straight colors and must meet specifications such as limits on ether extracts and intermediates. The other options incorrectly mix requirements (like environmental monitoring or physical isolation for color handling) that are not directly tied to color additive listing and certification rules in the provided context.", "category": "Cosmetics", "related_concept": "straight color listing, lake specifications, batch certification", "id": "PA_P_00669_001", "match_type": "weak", "match_score": 0.6843135520089447, "lang": "EN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0008_0005_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：为保护公众健康，监管机构有权要求获取并审查相关记录，且此类请求通常需要说明理由并明确信息范围。\n陈述2：关于记录保存期限的监管要求，其设定可能基于特定的监管状态（如产品扣留），并且当监管状态解除或期限届满时，若产品被确认合规且无公共卫生风险，进一步的记录保存要求可能会被免除。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：美国法规（FDA）文本明确指出，FDA请求获取记录时应“在合理时间提出”、“说明请求的原因或目的”并“尽可能充分地识别所寻求的信息或信息类型”，这体现了程序正当和目的明确的原则，是保护公众健康监管权力的体现。中国法规虽未在此片段详述请求程序，但其要求保存文件以备监管，逻辑上隐含类似访问权。\n陈述2正确：美国法规文本明确指出，在扣留令相关记录保存（最多2年）的语境下，当扣留终止或期限届满，若FDA确定设备未被掺假或贴错标签，或记录保存对保护公众健康不再必要，通常不会要求继续保存（除非其他法规另有要求）。这体现了保存期限要求与具体监管情境及风险评估的关联性。中国法规对临床试验文件规定了固定的长期保存期（如10年），是另一种基于文件类型和阶段的期限设定逻辑。两个陈述分别概括了监管中的通用原则。", "category": "Medical_Devices", "related_concept": "public health protection, detention order compliance, file preservation period", "id": "PA_P_00403_002", "match_type": "weak", "match_score": 0.7423128375385728, "lang": "CN", "source_cn": "医疗器械临床试验质量管理规范.txt", "source_us": "PART_800GENERAL.txt", "old_id": "comp_0019_0007_2"}
{"question": "关于化妆品功效宣称的评价依据，中美法规在特定宣称（如“适用敏感皮肤”）的要求上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求必须通过人体功效评价试验来支持此类宣称，而美国法规则无此强制要求。", "B. 中国法规允许通过消费者使用测试或文献资料来支持此类宣称，而美国法规则要求必须提供临床研究数据。", "C. 中国法规对特定宣称（如“适用敏感皮肤”）的评价方法提供了明确的指引（如消费者使用测试），而美国法规在相关条款中主要关注的是提交支持性数据时的合规性声明（如伦理审查）。", "D. 两国法规都要求必须通过实验室试验来验证此类宣称，只是试验的具体标准不同。"], "answer": "C", "type": "Parallel", "explanation": "中国法规（如附件表格）对“特定宣称（宣称适用敏感皮肤）”等功效，明确列出了可接受的评价方法选项（如消费者使用测试、文献资料等），提供了具体的评价路径指引。而提供的美国法规文本，其核心是规定在提交支持请愿的额外数据时，若涉及非临床或临床研究，必须附上关于研究是否遵守特定伦理法规（如机构审查、知情同意）的声明。它并未直接规定对“敏感皮肤”这类宣称必须采用何种具体的功效验证方法，而是侧重于数据提交时的程序性合规要求。因此，差异在于中国法规提供了功效验证方法的具体清单和选择指引，而美国法规则强调了支持数据本身的生成过程需符合的伦理与合规框架。", "category": "Cosmetics", "related_concept": "specific claim requirements, efficacy claim evaluation", "id": "PA_P_00603_001", "match_type": "weak", "match_score": 0.7457815512464665, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0003_0001_1"}
{"question": "In regulatory frameworks for color additives in externally applied cosmetics, which approach is more likely to require batch certification for straight colors?", "choices": ["A. US FDA regulations", "B. Chinese NMPA regulations", "C. Both require batch certification equally", "D. Neither requires batch certification"], "answer": "A", "type": "Parallel", "explanation": "US FDA regulations explicitly mention batch certification requirements for straight colors used in externally applied drugs and cosmetics, specifying that batches must conform to established requirements and specifications. The provided Chinese regulation text does not mention batch certification processes for color additives, focusing instead on testing procedures and documentation.", "category": "Cosmetics", "related_concept": "batch certification", "id": "PA_P_00640_014", "match_type": "weak", "match_score": 0.7496140934869466, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0039_0005_1"}
{"question": "When documenting inspection dates for regulatory submissions, which of the following statements correctly compares US and Chinese requirements?", "choices": ["A. Both US and Chinese regulations require dates to be formatted with the month spelled out in English.", "B. Chinese regulations specify a 'day month, year' format in English, while US regulations typically use a 'month day, year' format.", "C. US regulations mandate a numeric 'YYYY-MM-DD' format, while Chinese regulations allow either numeric or written formats.", "D. Chinese regulations require dates in both Chinese and English, while US regulations have no specific format requirements for dates in submissions."], "answer": "B", "type": "Parallel", "explanation": "Chinese regulations specify English dates in 'day month, year' format (e.g., '20 February, 2025'), while US regulatory documents typically follow 'month day, year' format (e.g., 'March 27, 1975'). Chinese regulations require both Chinese and English formats, but the English format is specifically defined. US regulations don't typically mandate date formats in the same prescriptive way for general submissions, though specific documents may have formatting conventions.", "category": "Drugs", "related_concept": "date format specifications, inspection date format", "id": "PA_P_00244_001", "match_type": "weak", "match_score": 0.7412005695861485, "lang": "EN", "source_cn": "药品生产企业出口药品检查和.txt", "source_us": "PART_202PRESCRIPTION_DRUG_ADVERTISING.txt", "old_id": "comp_0046_0008_1"}
{"question": "关于化妆品安全风险监测与评价的信息系统建设，中美法规在管理主体和目的上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规明确由国家药品监督管理局负责建立国家信息系统，旨在加强信息化建设；美国法规未在提供的文本中明确指定信息系统建设的单一中央管理机构。", "B. 两国法规均要求由国家级药品监督管理部门建立统一的信息系统，用于风险监测数据的收集与分析。", "C. 美国法规要求由食品药品监督管理局（FDA）建立专门的信息系统用于颜色添加剂的风险监测；中国法规则未提及信息系统建设。", "D. 中国法规要求省级药品监督管理部门建立独立的信息系统；美国法规则要求由行业协会负责信息系统管理。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（CN）第五条明确规定国家药品监督管理局负责建立国家风险监测与评价信息系统，并加强信息化建设，体现了中央统一管理的原则。美国法规（US）提供的文本主要涉及颜色添加剂的申请、豁免、法规发布及合规要求，并未在对应段落中明确指定一个类似的国家级信息系统建设主体或具体指令，其信息管理可能分散在不同条款或程序中。因此，A项准确指出了中国有明确的中央机构负责系统建设，而美国文本未明确此点。B、C、D项的描述均与法规内容不符或缺乏依据。", "category": "Cosmetics", "related_concept": "information system management", "id": "PA_P_00607_001", "match_type": "weak", "match_score": 0.7499577754507617, "lang": "CN", "source_cn": "化妆品安全风险监测与评价管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0001_0002_1"}
{"question": "Consider the following statements about regulatory procedures for controlled substances:\nStatement 1: In the US system, formal hearings for rulemaking follow Administrative Procedure Act guidelines and specific DEA regulations.\nStatement 2: In the Chinese system, research applications require documentation of safety management systems and facilities for handling controlled substances.\nWhich option correctly evaluates these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the US hearing procedures, which reference the Administrative Procedure Act and specific DEA regulations. Statement 2 accurately reflects Chinese requirements, which include documentation of '麻醉药品和精神药品实验研究安全管理制度、设施设备' (safety management systems and facilities for controlled substance experimental research). Both statements represent distinct but accurate aspects of their respective regulatory frameworks.", "category": "Controlled_Substances", "related_concept": "hearing procedures, safety and dependency studies", "id": "PA_P_00722_005", "match_type": "weak", "match_score": 0.7139019095599421, "lang": "EN", "source_cn": "麻醉药品和精神药品实验研究管理规定.txt", "source_us": "PART_1308SCHEDULES_OF_CONTROLLED_SUBSTANCES.txt", "old_id": "comp_0009_0014_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在化妆品监管中，当官方拒绝批准或认证时，美国法规明确规定了申请人享有申请听证的权利。\n陈述2：中国法规要求企业为质量安全负责人提供必要的工作条件和待遇，并鼓励建立激励机制，这体现了对履职保障的重视。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。美国法规（§80.31(b)）明确规定，当FDA局长拒绝认证某批次着色剂时，提交请求的人有权要求举行监管听证会（regulatory hearing）。这是程序正当性的体现。\n陈述2正确。中国法规（第二十三条）明确要求企业为质量安全负责人提供必要的工作条件和岗位待遇，并鼓励建立激励机制进行表彰奖励。这旨在从物质保障和正向激励两方面确保负责人能够有效履职。", "category": "Cosmetics", "related_concept": "regulatory hearing, work conditions and incentives", "id": "PA_P_00593_002", "match_type": "weak", "match_score": 0.7433104819109708, "lang": "CN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0008_0001_2"}
{"question": "关于行政复议与行政审查程序中的核心原则，以下哪项描述最能体现中美法规的典型差异？", "choices": ["A. 中国法规强调行政复议应遵循合法、公正、公开、高效、便民、为民的原则，并坚持有错必纠；美国法规中，咨询委员会主席或指定联邦雇员在特定情况下可基于公共利益决定休会或采取其他行动，以确保程序公平、迅速。", "B. 两国法规均明确规定，所有行政争议解决程序都必须以公开听证为前置条件，且当事人有权要求指定联邦雇员全程参与。", "C. 中国法规要求行政复议机关必须接受中国共产党的领导；美国法规则要求咨询委员会主席必须是FDA的全职雇员，否则需由指定联邦雇员代行职权。", "D. 两国法规均将‘便民、为民’和‘保障法律正确实施’列为行政程序的首要原则，并授权上级机构对下级机构的所有决定进行直接干预和监督。"], "answer": "A", "type": "Parallel", "explanation": "选项A准确捕捉了关键差异：中国《行政复议法》明确将“合法、公正、公开、高效、便民、为民”及“有错必纠”作为核心原则，体现了程序正义与实质正义并重、服务于民的导向；而美国FDA相关法规中，咨询委员会主席或指定联邦雇员的职权（如基于公共利益休会）更侧重于在具体操作层面确保程序的公平与效率，其原则表述更嵌于具体职权规定中，而非作为总括性宣言。选项B错误，因为两国法规均未将公开听证规定为所有情况下的强制前置程序。选项C错误，因为中国法规的领导原则是独特的政治架构体现，而美国法规中指定联邦雇员的角色是职能性规定，并非要求主席必须是全职雇员。选项D错误，因为‘便民、为民’是中国法规的特色原则，美国法规未将其列为普遍原则；且两国监督机制的具体方式（如指导、监督 vs. 指定联邦雇员参与）存在显著不同。", "category": "General_Comparative", "related_concept": "principles of legality, fairness, openness, efficiency, convenience, and service to the people", "id": "PA_P_00783_001", "match_type": "weak", "match_score": 0.7432320886220455, "lang": "CN", "source_cn": "中华人民共和国行政复议法.txt", "source_us": "PART_14PUBLIC_HEARING_BEFORE_A_PUBLIC_ADVISORY_COM.txt", "old_id": "comp_0001_0003_1"}
{"question": "关于省级药品监管部门的职责，以下哪项描述最准确地反映了中美法规的差异？", "choices": ["A. 中国法规中，省级药品监管部门主要负责制定执业药师继续教育的学时认定制度；美国法规中，联邦机构直接负责所有监管事务，州级机构无类似职能", "B. 中国法规中，省级药品监管部门需会同人力资源社会保障部门共同制定继续教育制度；美国法规中，州级机构在HCT/P监管中主要承担信息收集和初步审核工作", "C. 中国法规中，省级药品监管部门独立制定继续教育标准；美国法规中，州级机构需向FDA提交HCT/P机构注册信息", "D. 中美法规均规定，省级/州级监管机构在药品监管体系中承担核心审批职能"], "answer": "B", "type": "Parallel", "explanation": "中国法规明确省级药品监管部门需会同人力资源社会保障部门共同制定执业药师继续教育学时认定和登记制度，体现了多部门协同监管的特点。美国法规中，HCT/P的注册、列表提交及更新主要由机构直接向FDA（联邦机构）负责，州级机构在联邦框架下可能承担辅助性职能，但文本未明确其具体作用，与中国省级部门的明确职责形成对比。A项错误，因为美国州级机构在药品监管中仍有特定职能；C项错误，中国法规强调部门协同而非独立制定；D项错误，省级/州级机构在中美体系中的核心性不同。", "category": "Drugs", "related_concept": "provincial regulatory authorities, human resources and social security departments", "id": "PA_P_00162_003", "match_type": "weak", "match_score": 0.7334786165456079, "lang": "CN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0007_0002_1"}
{"question": "Consider the following statements about cosmetic color additive regulations: Statement 1: Both US and Chinese regulations require batch certification for approved color additives. Statement 2: Only US regulations specify detailed diluent requirements and usage restrictions for color additives in drug products. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct because US regulations explicitly require certification of all batches for color additives like D&C Red No. 36, while Chinese regulations imply certification requirements through their regulatory framework. Statement 2 is correct because US regulations provide detailed specifications for diluents and specific usage restrictions (e.g., daily dose limits, external use only), whereas the provided Chinese text doesn't specify such detailed color additive requirements.", "category": "Cosmetics", "related_concept": "diluent specifications, usage restrictions, certification requirements", "id": "PA_P_00653_020", "match_type": "weak", "match_score": 0.7378494051524633, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0018_0014_2"}
{"question": "A cosmetics company is developing a new anti-aging cream and wants to understand regulatory approaches to new efficacy claims and production quality management. Which of the following statements accurately compares US and Chinese regulatory frameworks?", "choices": ["A. Both jurisdictions require new efficacy claims to undergo specific testing protocols, but only China allows exemptions from toxicology reports based on foreign production quality certifications under certain conditions.", "B. The US requires certification of all color additive batches for new claims, while China mandates toxicology testing regardless of production quality certifications for any new efficacy product.", "C. China requires new efficacy claims to follow established testing guidelines, while the US focuses primarily on color additive specifications without specific new claim pathways.", "D. Both systems treat new efficacy claims identically, requiring full toxicology testing, but differ in their acceptance of international production quality certifications."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations specify that cosmetics with new efficacy claims must follow established testing guidelines, but allow exemptions from toxicology reports if manufacturers have foreign production quality management system certifications, except for specific cases like children's products. US regulations focus on color additive certification requirements but don't address new efficacy claims in the provided text, creating a regulatory gap comparison.", "category": "Cosmetics", "related_concept": "new efficacy claims, production quality management system certification", "id": "PA_P_00653_019", "match_type": "weak", "match_score": 0.7378494051524633, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0018_0014_1"}
{"question": "In regulatory frameworks for cosmetics and food additives, how do authorities typically approach the use of technical monitoring data as evidence for enforcement actions?", "choices": ["A. Technical monitoring records are universally accepted as primary evidence for administrative penalties without additional verification.", "B. Technical monitoring data can serve as electronic evidence for administrative actions, but its admissibility may depend on specific regulatory contexts.", "C. Technical monitoring is only used for preliminary screening and cannot be cited in any formal enforcement proceedings.", "D. Authorities must always obtain physical samples to corroborate technical monitoring data before it can be used as evidence."], "answer": "B", "type": "Parallel", "explanation": "Regulatory systems often recognize technical monitoring records as valid electronic evidence for administrative enforcement, but specific legal frameworks determine their exact evidentiary weight and procedural requirements. This reflects a balanced approach between leveraging technology for oversight and maintaining evidentiary standards.", "category": "Cosmetics & Food Additives", "related_concept": "technical monitoring as evidence", "id": "PA_P_00687_001", "match_type": "weak", "match_score": 0.7435328587749589, "lang": "EN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0012_0001_1"}
{"question": "关于化妆品不良反应监测体系的建立，中美两国法规的主要区别是什么？", "choices": ["A. 中国法规明确要求注册人/备案人建立监测体系并主动收集报告，而美国法规未对化妆品企业提出同等明确的体系建立要求。", "B. 美国法规要求所有化妆品企业必须建立强制性的不良反应监测体系，而中国法规仅作为建议。", "C. 两国法规均要求由国家级药品监管部门建立统一的监测信息系统，企业责任相同。", "D. 中国法规的监测体系主要依赖医疗机构报告，而美国法规则完全依赖消费者自愿报告。"], "answer": "A", "type": "Parallel", "explanation": "中国《化妆品不良反应监测管理办法》明确规定化妆品注册人、备案人负有建立监测评价体系、主动收集并报告不良反应的主体责任。而提供的美国法规文本主要涉及特定有害物质（如氯乙烯）的禁用和防篡改包装要求，并未像中国法规那样系统性地规定化妆品企业必须建立不良反应监测体系。因此，A选项准确描述了这一核心区别。B、C、D选项的描述均与两国法规的实际规定不符。", "category": "Cosmetics", "related_concept": "monitoring system establishment, reporting obligations", "id": "PA_P_00598_003", "match_type": "weak", "match_score": 0.746825189864822, "lang": "CN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0001_0003_1"}
{"question": "Statement 1: In cosmetic color additive regulations, both US FDA and China NMPA require compliance with good manufacturing practice (GMP) to minimize impurities beyond specified limits. Statement 2: For water-insoluble matter in color additives, the US FDA typically sets stricter numerical limits than those found in Chinese cosmetic ingredient specifications.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct: Both regulatory frameworks emphasize GMP to control impurities, as seen in requirements to avoid impurities through current good manufacturing practice. Statement 2 is incorrect: While specific limits vary by substance, Chinese regulations for cosmetics (like sunscreen testing protocols) don't directly specify water-insoluble matter limits for color additives in the provided context, and US FDA specifications (e.g., for FD&C Yellow No. 6) include such limits (e.g., not more than 0.2%), but this doesn't imply US limits are universally stricter than Chinese ones for all substances.", "category": "Cosmetics", "related_concept": "water insoluble matter limits, good manufacturing practice, specifications compliance", "id": "PA_P_00637_037", "match_type": "weak", "match_score": 0.712230169705373, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0069_0004_2"}
{"question": "关于药品生产场所的监督检查，中美两国法规在检查权限和方式上存在差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规强调对中药生产全过程的持续符合性监督，而美国法规仅授权对特定生物制品（HCT/Ps）生产场所进行合规性检查。", "B. 中国法规要求检查必须提前通知并在工作时间进行，而美国法规允许不经通知在任何合理时间进行检查。", "C. 中国法规的检查频率由法律明确规定，而美国法规的检查频率完全由监管机构自行决定。", "D. 中国法规的检查对象仅限于药品上市许可持有人，而美国法规的检查对象包括所有合同制造商。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如《药品生产监督管理办法》精神）的核心是监督中药生产全过程持续符合法定要求，其监管范围覆盖中药饮片、配方颗粒、中成药等多种产品。美国法规（21 CFR 1271.390 & 400）明确其检查条款仅适用于受《公共卫生服务法》第361节监管的特定人体细胞、组织及基于细胞/组织的产品（HCT/Ps）的生产场所，旨在确定其是否符合该部分法规，检查范围具有特定性。B项错误，因为美国法规规定检查“可能”在有或无事先通知的情况下进行，并“通常”在营业时间，但并非绝对；中国法规也未明确规定必须提前通知。C项错误，美国法规明确检查频率由机构自行决定，但中国法规的检查频率也并非完全由法律条文硬性规定，而是基于风险管理的原则。D项错误，中国法规的监督对象包括持有人和生产企业；美国法规的检查对象是生产HCT/Ps的机构，无论其是否受合同约束。", "category": "Drugs", "related_concept": "inspection of establishments", "id": "PA_P_00049_001", "match_type": "weak", "match_score": 0.7110534292961727, "lang": "CN", "source_cn": "中药生产监督管理专门规定.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0001_0021_1"}
{"question": "A pharmaceutical company is planning to establish a new distribution center in China that will handle both traditional Chinese medicinal materials and modern biologic drugs requiring cold chain storage. Which of the following facility requirements would be necessary under Chinese regulations but would NOT typically be required for a similar facility in the United States?", "choices": ["A. Separate dedicated storage areas for Chinese medicinal materials and modern pharmaceuticals", "B. Temperature monitoring systems for cold storage areas", "C. Validation protocols for cold chain equipment", "D. Visual inspection requirements for parenteral drug products"], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations specifically require dedicated storage facilities for traditional Chinese medicinal materials (including separate storage areas and sample rooms for direct collection), which represents a unique regulatory requirement not found in US regulations. While both countries require temperature monitoring (B) and validation protocols (C), and the US has specific visual inspection requirements (D), the dedicated storage for traditional medicinal materials is a distinctive feature of Chinese pharmaceutical regulation.", "category": "Drugs", "related_concept": "dedicated storage for Chinese medicinal materials", "id": "PA_P_00274_001", "match_type": "weak", "match_score": 0.7332613103838498, "lang": "EN", "source_cn": "药品经营质量管理规范（2015年国家食品药品监督管理总局令第13号公布，2016年令第28号修正）.txt", "source_us": "PART_201LABELING.txt", "old_id": "comp_0009_0044_1"}
{"question": "In regulatory frameworks for cosmetics, which approach to efficacy claim substantiation is most consistent with requiring scientific judgment based on data analysis against established criteria?", "choices": ["A. Relying solely on historical use without new data", "B. Using consumer perception surveys as primary evidence", "C. Basing conclusions on statistical analysis of experimental results compared to predefined standards", "D. Accepting manufacturer testimonials without independent verification"], "answer": "C", "type": "Parallel", "explanation": "Option C describes a rigorous, evidence-based approach where efficacy claims are scientifically judged by analyzing data against predetermined standards. This aligns with regulatory principles that require objective, verifiable substantiation rather than subjective or unverified methods (A, B, D).", "category": "Cosmetics", "related_concept": "scientific judgment of efficacy claims", "id": "PA_P_00602_010", "match_type": "weak", "match_score": 0.7476593633902182, "lang": "EN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0011_0024_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在中美法规框架下，对于违反规定的易制毒化学品或管制物质，行政机关均有权直接予以没收。\n陈述2：美国法规在评估管制物质（如大麻）生产申请时，明确将‘申请人过往遵守相关法规的记录’列为关键的公共利益考量因素之一。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。中国法规（第四十条）明确规定，对违反规定生产、经营、购买的易制毒化学品“可以予以没收”。美国法规虽未在提供文本中直接描述没收，但其作为管制物质法规体系的一部分，授权执法机构（如DEA）对非法持有、分销的管制物质进行查扣和没收是固有职权，两者在没收权上存在一致性。陈述2正确。美国法规（§ 1318.05(b)(1)）明确指出，在确定注册申请是否符合公共利益时，管理员应特别强调“申请人是否展示出过往遵守《法案》及本章规定的记录”，这直接对应了“public interest factors”中的合规历史考量。", "category": "Controlled_Substances", "related_concept": "confiscation of smuggled chemicals, public interest factors", "id": "PA_P_00705_002", "match_type": "weak", "match_score": 0.7376920153827488, "lang": "CN", "source_cn": "易制毒化学品管理条例.txt", "source_us": "PART_1318CONTROLS_TO_SATISFY_THE_REQUIREMENTS_OF_T.txt", "old_id": "comp_0014_0003_2"}
{"question": "请判断以下两个陈述：\n陈述1：在化妆品监管中，中国法规对“无主观过错”的情形提供了明确的免责条款，这体现了过错责任原则。\n陈述2：美国FDA对色素添加剂的技术规范，通过设定总色素含量不低于90%等具体数值标准，来确保产品的颜色纯度和一致性。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国《化妆品监督管理条例》第六十二条明确规定“当事人有证据足以证明没有主观过错的，不予行政处罚”，这是过错责任原则在行政处罚中的具体体现。\n陈述2正确：美国FDA法规中对D&C Red No. 22的规定要求“Total color, not less than 90 percent”，这是通过设定最低含量标准来保证色素添加剂的主成分含量和颜色效力，属于典型的技术规范符合性要求。", "category": "Cosmetics", "related_concept": "specification conformity, color purity standards, no penalty without subjective fault", "id": "PA_P_00661_022", "match_type": "weak", "match_score": 0.7275532982770672, "lang": "CN", "source_cn": "化妆品生产经营监督管理办法（2021年第46号）.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0018_0012_2"}
{"question": "In comparing regulatory approaches to continuing education for pharmaceutical professionals, which statement best describes a key difference between typical US and Chinese frameworks?", "choices": ["A. US frameworks typically mandate specific public welfare subjects, while Chinese frameworks focus exclusively on technical skills.", "B. Chinese frameworks often separate public welfare subjects from professional subjects, while US frameworks typically integrate them into competency requirements.", "C. US frameworks require continuing education only for new drug approvals, while Chinese frameworks apply it to all pharmaceutical roles.", "D. Chinese frameworks delegate all continuing education content to professional associations, while US frameworks have centralized federal mandates."], "answer": "B", "type": "Parallel", "explanation": "Chinese regulatory frameworks for pharmaceutical professionals often explicitly categorize continuing education into public welfare subjects (covering ethics, laws, policies) and professional subjects (technical skills). US frameworks typically integrate ethical and legal considerations into broader competency requirements rather than separating them into distinct subject categories.", "category": "Regulatory Affairs", "related_concept": "public and professional subjects", "id": "PA_P_00160_001", "match_type": "weak", "match_score": 0.7201280247119857, "lang": "EN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0003_0005_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在中国，麻醉药品药用原植物的种植企业必须定期向国务院药品监督管理部门和国务院农业主管部门报告种植情况。\n陈述2：在美国，关于麻醉药品制造配额的听证会，申请人如果未在法定期限内提出听证请求或未出席听证，将自动被视为放弃听证机会，除非能证明有正当理由。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：根据中国法规第八条，麻醉药品药用原植物种植企业应当向国务院药品监督管理部门和国务院农业主管部门定期报告种植情况。\n陈述2正确：根据美国法规§1315.56(e)，任何有权参加听证的人如果未在规定时间内提交听证请求或通知，或提交后未出席听证，将被视为放弃听证机会，除非能证明有正当理由。该条款适用于包括制造配额在内的相关听证。", "category": "Controlled_Substances", "related_concept": "annual planting plan, hearing procedures", "id": "PA_P_00728_002", "match_type": "weak", "match_score": 0.7402068685156175, "lang": "CN", "source_cn": "麻醉药品和精神药品管理条例.txt", "source_us": "PART_1315IMPORTATION_AND_PRODUCTION_QUOTAS_FOR_EPH.txt", "old_id": "comp_0003_0010_2"}
{"question": "Statement 1: In the U.S. regulatory framework for color additives, a default safety factor of 100 is applied when extrapolating animal data to humans unless justified evidence supports a different factor.\nStatement 2: The Chinese cosmetics adverse reaction monitoring system mandates that municipal and county-level authorities are primarily responsible for investigating severe adverse reactions and implementing control measures.\nWhich of the following is correct regarding these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly summarizes the U.S. principle from the text: 'a safety factor of 100 to 1 will be used... Except where evidence is submitted which justifies use of a different safety factor.' Statement 2 correctly describes the Chinese system's delegation of investigation and control duties: municipal/county authorities '调查本行政区域内发生的严重和可能引发较大社会影响的化妆品不良反应...依法采取控制措施' (investigate severe adverse reactions... and implement control measures according to law). This highlights a comparative difference: the U.S. text focuses on a pre-market safety factor for ingredients, while the Chinese text details a post-market monitoring and investigation hierarchy.", "category": "Cosmetics", "related_concept": "safety factor application, investigation and control measures", "id": "PA_P_00599_002", "match_type": "weak", "match_score": 0.7116251693707082, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0003_0004_2"}
{"question": "Statement 1: Regulatory frameworks for controlled substances typically include provisions for the confiscation of illegally produced or traded items. Statement 2: Transportation of controlled substances for destruction under strict regulatory oversight often requires specific personnel protocols to ensure security and prevent diversion.", "choices": ["A. Both statements are correct and reflect principles evident in the provided regulatory excerpts.", "B. Only Statement 1 is correct.", "C. Only Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: The Chinese text explicitly mandates confiscation of illegal chemicals, equipment, and tools. While the US text focuses on procedures, the context implies control over substances to prevent diversion, aligning with the general principle of confiscation for illegal items. Statement 2 is correct: The US text details specific requirements for two employees to accompany, load/unload, and witness destruction during transportation, which is a clear personnel protocol for security. The Chinese text, while not detailing transportation procedures in the provided excerpt, discusses inter-agency coordination for management, which supports the principle of oversight.", "category": "Controlled_Substances", "related_concept": "confiscation of illegal items, transportation requirements", "id": "PA_P_00703_005", "match_type": "weak", "match_score": 0.7306150187631569, "lang": "EN", "source_cn": "易制毒化学品管理条例.txt", "source_us": "PART_1317DISPOSAL.txt", "old_id": "comp_0013_0007_2"}
{"question": "关于化妆品人体安全性和功效评价，中美法规在实施主体和报告要求上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求由指定的注册和备案检验检测机构出具标准格式的检验报告，而美国法规通常由制造商自行负责评估，但需遵循FDA的指导原则。", "B. 两国法规均强制要求所有化妆品上市前必须完成相同项目的人体安全性和功效评价。", "C. 美国法规要求所有功效评价（如防晒指数测定）必须在FDA指定的实验室进行，而中国允许企业自行选择有资质的机构。", "D. 中国法规不要求出具人体安全性和功效评价的书面报告，仅需备案；美国法规则要求提交详细的临床试验报告给FDA审批。"], "answer": "A", "type": "Parallel", "explanation": "中国NMPA对化妆品（特别是特殊用途化妆品）的人体安全性和功效评价有明确的检验检测机构要求及标准报告体例（如“人体安全性和功效评价检验汇总报告体例”），体现了较强的政府指定和格式化管理。美国FDA对化妆品的人体安全性和功效评价更多依赖于企业自身的责任（“企业责任原则”），FDA发布指导原则但通常不进行上市前审批，企业需自行确保产品安全并保留评价记录以备检查，不强制要求使用特定格式的报告。选项B错误，因为两国评价项目和强制要求范围不同；选项C错误，美国FDA并不指定功效评价实验室；选项D错误，中国法规明确要求出具检验报告。", "category": "Cosmetics", "related_concept": "human safety and efficacy evaluation, registration and filing inspection agency", "id": "PA_P_00641_011", "match_type": "weak", "match_score": 0.7415271395983418, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0046_0003_1"}
{"question": "关于药品注册申请中的专利声明制度，中美两国法规在触发特定程序后的审批时限安排上存在显著差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求在收到变更申请后30日内办理手续，而美国法规在特定专利声明下可能立即批准或设定30个月等待期", "B. 中美两国都采用固定的30日审批时限处理所有与专利相关的变更申请", "C. 美国法规要求所有涉及专利声明的申请都必须等待30个月才能获批，中国法规则无此规定", "D. 中国法规对涉及专利的变更设置了45天的异议期，而美国法规则采用30日的标准处理时限"], "answer": "A", "type": "Parallel", "explanation": "中国法规（NMPA）对GLP证书变更等行政管理事项规定了30日的办理时限，体现的是行政效率要求。美国法规（FDA）针对专利声明（如Paragraph IV认证）设置了复杂的审批触发机制：在特定条件下可立即批准，或在专利诉讼情况下可能进入30个月等待期，这体现了其专利链接制度下平衡创新保护与仿制药上市的设计逻辑。选项B、C、D的描述均与两国法规的实际安排不符。", "category": "Drugs", "related_concept": "patent certification, change processing within 30 days, 30-month approval period", "id": "PA_P_00336_001", "match_type": "weak", "match_score": 0.7012685219609188, "lang": "CN", "source_cn": "药物非临床研究质量管理规范认证.txt", "source_us": "PART_314APPLICATIONS_FOR_FDA_APPROVAL_TO_MARKET_A_.txt", "old_id": "comp_0006_0059_1"}
{"question": "Statement 1: Both US and Chinese regulations require that quality safety key positions have clearly defined responsibilities and receive training relevant to their duties. Statement 2: A unique device identification (UDI) system is explicitly mandated only under US regulations for traceability purposes.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct: US regulations (implied via ISO 13485 and quality system requirements) and Chinese regulations (Articles 23-25) both require defined responsibilities and duty-relevant training for key quality positions. Statement 2 is incorrect: While US regulations (§820.10(b)(1), (c)) explicitly require UDI for identification and traceability, the Chinese text provided does not mention UDI; however, it does not mean China lacks such requirements (NMPA has its own UDI rules). The statement's claim 'only under US' is too absolute and not inferable from the given texts, making it incorrect in this comparative context.", "category": "Medical_Devices", "related_concept": "quality safety key positions, training requirements, unique device identification", "id": "PA_P_00366_005", "match_type": "weak", "match_score": 0.7497204462855095, "lang": "EN", "source_cn": "企业落实医疗器械质量安全主体责任.txt", "source_us": "PART_820QUALITY_MANAGEMENT_SYSTEM_REGULATION_EFF_2.txt", "old_id": "comp_0008_0002_2"}
{"question": "关于化妆品生产场地变更的法规要求，以下哪项描述最准确地体现了中美监管逻辑的差异？", "choices": ["A. 中国法规要求提交变更申请表和检验报告，而美国法规仅要求更新产品成分声明编号。", "B. 中国法规侧重于变更后的产品安全验证（如检验报告、毒理学资料），而美国法规侧重于变更信息的备案与编号管理。", "C. 中美法规均要求在生产场地变更时，必须提交由新场地所在国政府出具的质量体系认证文件。", "D. 美国法规对生产场地变更的要求比中国法规更为严格，必须进行全面的现场审计。"], "answer": "B", "type": "Parallel", "explanation": "中国法规（NMPA）对生产场地变更的核心要求是确保变更后的产品安全，因此需要提交微生物和理化检验报告，并在特定条件下补充毒理学试验资料，体现了风险控制的思路。美国法规（FDA）的相关流程（如Form FDA 2512的提交与编号）更侧重于企业信息的备案、更新和官方记录管理，其编号的分配本身不代表对场地或产品的批准。选项A错误，因为美国法规的编号流程并非专门针对“生产场地变更”这一单一事项。选项C错误，中国法规仅在特定条件下（如仅通过安全评估且无法提供国外认证时）才要求毒理学资料，并非普遍要求；美国法规文本未提及此要求。选项D错误，文本中未体现美国法规对场地变更有“全面现场审计”的强制性要求。", "category": "Cosmetics", "related_concept": "production site change, microbiological and physicochemical test report", "id": "PA_P_00656_004", "match_type": "weak", "match_score": 0.7478930913115045, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0022_0003_1"}
{"question": "关于化妆品不良反应报告原则，中美法规的核心差异体现在哪里？", "choices": ["A. 中国强调‘可疑即报’，美国强调‘安全使用’原则", "B. 中国要求强制报告所有事件，美国仅报告严重事件", "C. 中国由企业承担报告责任，美国由监管部门主动监测", "D. 两国均采用相同的‘可疑即报’原则"], "answer": "A", "type": "Parallel", "explanation": "中国《化妆品监督管理条例》明确规定不良反应报告遵循‘可疑即报’原则，旨在广泛收集潜在风险信号。美国FDA在色素添加剂等法规中主要应用‘安全使用’原则，要求基于科学数据证明安全性后方可批准使用，两者体现了不同的风险监测与管理哲学。", "category": "Cosmetics", "related_concept": "adverse event reporting principle", "id": "PA_P_00666_004", "match_type": "weak", "match_score": 0.7262080695421185, "lang": "CN", "source_cn": "化妆品生产经营监督管理办法（2021年第46号）.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0016_0004_1"}
{"question": "Statement 1: In China's cosmetic regulations, the legal representative information for domestic responsible persons must include their identification document type and number. Statement 2: US regulations require that petitions for color additive exemptions must demonstrate why certification is unnecessary for public health protection.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as Chinese NMPA regulations require domestic responsible persons to provide legal representative information including document type and number. Statement 2 is correct as US FDA regulations (21 CFR 71.18) require petitions for color additive certification exemptions to show why certification is not necessary for public health protection.", "category": "Cosmetics", "related_concept": "legal representative information, noncompliance reason statement", "id": "PA_P_00659_005", "match_type": "weak", "match_score": 0.7308633548268733, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0034_0002_2"}
{"question": "关于检验结论的最终性，中美法规有何异同？", "choices": ["A. 中国法规规定复检结论为最终检验结论，美国法规规定FDA专员的决定为最终结论", "B. 美国法规规定复检结论为最终检验结论，中国法规规定初检结论即为最终结论", "C. 两国法规均规定复检结论为最终检验结论", "D. 两国法规均未明确规定检验结论的最终性"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定，复检机构出具的复检结论为最终检验结论。美国提供的法规文本未直接规定“复检结论”的最终性，但其监管体系通常赋予FDA专员（Commissioner）在诸如撤销豁免、主动列入等事项上的决定权，这些决定通过发布法规或通知生效，具有最终性。因此，中国明确了复检结论的最终地位，而美国文本体现的是行政决定的最终性。", "category": "Cosmetics", "related_concept": "final inspection conclusion", "id": "PA_P_00609_012", "match_type": "weak", "match_score": 0.720331441744548, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0012_0003_2"}
{"question": "A cosmetics company is developing a new green eyeshadow. Regarding the qualification of personnel involved in regulatory sampling activities and the certification requirements for color additives, which of the following statements is most accurate?", "choices": ["A. Personnel conducting sampling must be trained in cosmetic science and regulations, and all batches of color additives like D&C Green No. 5 require certification before use.", "B. Sampling personnel require no specific qualifications, but color additives must be certified only if used in products intended for the eye area.", "C. Sampling personnel must be certified inspectors, and color additives require certification only for externally applied products.", "D. There are no formal qualification requirements for sampling personnel, and certification of color additives is optional but recommended for quality assurance."], "answer": "A", "type": "Parallel", "explanation": "In regulatory frameworks, personnel conducting official sampling for cosmetics are typically required to have knowledge of cosmetic products and relevant laws to ensure proper procedures. Furthermore, color additives used in cosmetics, such as D&C Green No. 5 for eye-area products, generally require batch-by-batch certification by the regulatory authority to verify identity, purity, and safety before they can be legally used in cosmetic formulations.", "category": "Cosmetics", "related_concept": "sampling personnel qualifications, batch certification", "id": "PA_P_00608_001", "match_type": "weak", "match_score": 0.7198831910243443, "lang": "EN", "source_cn": "化妆品安全风险监测与评价管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0003_0018_1"}
{"question": "关于药品标准制定中的社会参与机制，中美两国法规的典型差异体现在：", "choices": ["A. 中国法规明确鼓励社会团体、企业和公民参与标准研究和提出建议，而美国法规主要强调申办方的合规责任", "B. 美国法规建立了专门的社会参与激励机制，而中国法规仅要求政府主导", "C. 两国法规均要求社会团体必须参与所有药品标准的制定过程", "D. 中国法规禁止企业参与标准制定，而美国法规强制企业参与"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如第五条）明确鼓励社会团体、企业事业组织及公民参与药品标准研究和提出意见建议，体现了'社会参与'的工作机制。美国提供的法规片段主要强调申办方（sponsor）对法规的合规责任，未涉及广泛的社会参与鼓励机制。B项错误，美国片段未显示专门的社会参与激励机制；C项错误，两国均非强制所有社会团体参与；D项错误，中国法规明确鼓励企业参与。", "category": "Drugs", "related_concept": "social participation encouragement", "id": "PA_P_00202_001", "match_type": "weak", "match_score": 0.7049145904903761, "lang": "CN", "source_cn": "药品标准管理办法.txt", "source_us": "PART_516NEW_ANIMAL_DRUGS_FOR_MINOR_USE_AND_MINOR_S.txt", "old_id": "comp_0002_0005_1"}
{"question": "Statement 1: Regulatory authorities typically require coordination between different departments or jurisdictions during supervision and investigation of product safety violations. Statement 2: Information about quality and safety management personnel must be shared between regulatory bodies to facilitate oversight of distributed operations.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Effective regulatory oversight of products like cosmetics and food additives requires both inter-departmental coordination during investigations and systematic sharing of personnel information to monitor quality management systems across different operational locations. These practices enhance regulatory efficiency and coverage.", "category": "Cosmetics & Food Additives", "related_concept": "coordination in supervision and investigation, information sharing on quality safety personnel", "id": "PA_P_00687_002", "match_type": "weak", "match_score": 0.7435328587749589, "lang": "EN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0012_0001_2"}
{"question": "关于企业为实现质量目标而提供必要资源的责任主体，以及生产管理负责人的核心职责，请判断以下陈述：\n陈述1：根据中国药品生产质量管理规范，企业负责人对提供必要资源以保证质量管理部门独立履行职责负有首要责任。\n陈述2：美国相关法规强调，企业必须拥有足够数量且具备相应资质的人员以及充足的设施设备资源，以确保药品质量相关职能的履行，但未像中国法规那样明确指定“企业负责人”为资源提供的唯一责任主体。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。中国GMP明确规定，企业负责人应当负责提供必要的资源，以保证质量管理部门独立履行其职责，这直接关联企业质量目标的实现。\n陈述2正确。美国法规（如21 CFR 212）在“人员与资源”部分要求企业必须拥有足够数量且合格的人员以及充足的资源（包括设施设备），以执行其职能。其表述主体是“企业”（You），侧重于组织整体的责任体系，并未像中国法规那样点明“企业负责人”这一具体职位。因此，两个陈述都准确地反映了各自法规的特点。", "category": "Drugs", "related_concept": "quality objectives, resource provision, production management responsibilities", "id": "PA_P_00263_002", "match_type": "weak", "match_score": 0.7395139382142534, "lang": "CN", "source_cn": "药品生产质量管理规范（2010年修订）（卫生部令第79号）.txt", "source_us": "PART_212CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_PO.txt", "old_id": "comp_0005_0003_2"}
{"question": "关于非临床实验室研究的合规性声明，中美药监法规的主要差异体现在：", "choices": ["A. 中国法规要求所有研究必须声明合规，美国法规允许在特定情况下声明不合规原因", "B. 美国法规要求所有研究必须声明合规，中国法规无此要求", "C. 两国法规都只要求声明合规，不允许说明不合规情况", "D. 中国法规要求详细说明不合规原因，美国法规只要求简单声明"], "answer": "A", "type": "Parallel", "explanation": "根据中美药监实践，美国FDA法规（如21 CFR 58）明确要求，在提交非临床实验室研究数据时，必须声明研究是否符合GLP规范；若不符合，需简要说明原因。中国NMPA法规虽也强调GLP合规，但在具体提交要求上，通常更侧重于研究数据的完整性和科学性，对于合规声明的格式和内容要求可能有所不同，且在实际操作中，中国法规更倾向于要求研究完全合规，较少有机制允许正式声明不合规原因。", "category": "Regulatory Compliance", "related_concept": "nonclinical laboratory study compliance", "id": "PA_P_00638_010", "match_type": "weak", "match_score": 0.7345130164074233, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0047_0001_1"}
{"question": "关于非临床实验室研究的合规性声明，中美法规在提交补充信息时的要求有何不同？", "choices": ["A. 中国法规要求提交合规性声明，美国法规则不要求", "B. 美国法规要求提交合规性声明，中国法规则不要求", "C. 两国法规都要求提交合规性声明，但声明内容不同", "D. 两国法规都未对提交合规性声明做出明确规定"], "answer": "B", "type": "Parallel", "explanation": "根据中美药监法规的通用原则，在涉及补充信息或实质性修正时，美国法规（如FDA）通常要求对支持性数据中的非临床实验室研究提供合规性声明，说明其是否符合良好实验室规范（GLP）要求。而中国法规（如NMPA）在抽样相关条款中，主要关注抽样程序、文书和费用支付，并未在此类补充信息提交场景下专门规定非临床研究的合规性声明要求。因此，美国法规有此要求，而中国法规在此特定上下文中无此要求。", "category": "Cosmetics", "related_concept": "nonclinical laboratory study compliance, substantive amendment", "id": "PA_P_00609_003", "match_type": "weak", "match_score": 0.7333434288198749, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0005_0001_1"}
{"question": "Evaluate the following pair of statements regarding medical device regulations. Statement 1: Under Chinese NMPA regulations for online sales, a '运输记录' (transportation record) must include specific details like the sales order number and consignee information for wholesale activities. Statement 2: Under US FDA regulations, a device classified as Class II based on 'performance standards' is generally subject to a 510(k) premarket notification requirement before commercial distribution.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Both statements accurately reflect regulatory principles. Statement 1 correctly describes the detailed content requirements for transportation records ('运输记录') under Chinese NMPA rules for online sales, which explicitly include the network sales order number and, for wholesale, the consignee's details. Statement 2 correctly describes the US FDA regulatory framework: Class II devices, which are often subject to special controls including performance standards, typically require a 510(k) submission to demonstrate substantial equivalence to a predicate device before they can be legally marketed.", "category": "Medical_Devices", "related_concept": "运输记录, performance standards", "id": "PA_P_00533_002", "match_type": "weak", "match_score": 0.6524815539969486, "lang": "EN", "source_cn": "医疗器械网络销售质量管理规范.txt", "source_us": "PART_882NEUROLOGICAL_DEVICES.txt", "old_id": "comp_0006_0014_2"}
{"question": "关于改变已上市药品给药途径的注册要求，请判断以下陈述：\n陈述1：根据中国法规，改变给药途径的改良型新药必须证明具有临床应用优势，如提高有效性或改善安全性。\n陈述2：根据美国法规，改变给药途径的申请主要需提供详细的药品组分、生产工艺和质量标准，无需特别说明改变给药途径的合理性。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确。中国法规（文本第四十二条、四十三条）明确要求改变剂型或给药途径的改良型新药应具有临床应用优势和特点（如提高有效性、改善安全性等），并需说明改变给药途径的合理性和必要性，开展相应研究以证明其优势。\n陈述2错误。美国法规（文本未直接涉及改变给药途径的专门条款，但基于FDA整体框架）对于任何药品申请（包括改变给药途径），均要求提供详细的CMC（化学、生产和控制）信息（如文本(a)段所述的组分、生产工艺、质量标准、稳定性数据等），但这只是基础要求。实际上，根据FDA的指导原则和《联邦食品、药品和化妆品法案》，改变给药途径通常被视为一种“新药”或需要补充申请的重大变更，申请人必须提供充分的科学依据（包括非临床和临床数据）来证明改变给药途径的安全性、有效性和合理性，而不仅仅是提供CMC资料。因此，陈述2的“无需特别说明合理性”不符合美国法规的实际要求。", "category": "Drugs", "related_concept": "改变给药途径要求", "id": "PA_P_00044_011", "match_type": "weak", "match_score": 0.7312858441742348, "lang": "CN", "source_cn": "中药注册管理专门规定.txt", "source_us": "PART_314APPLICATIONS_FOR_FDA_APPROVAL_TO_MARKET_A_.txt", "old_id": "comp_0009_0005_2"}
{"question": "In regulatory documentation for animal testing in cosmetics, which of the following is a key difference between US and Chinese requirements regarding experimental controls?", "choices": ["A. The US requires positive control data only, while China requires both positive and negative control data.", "B. China requires documentation of both negative and positive control group data in results tables, while US regulations on color additives focus on chemical specifications rather than experimental controls.", "C. The US mandates control group data for all animal studies, while China only requires it for studies involving food additives.", "D. Both jurisdictions have identical requirements for control group data in all cosmetic safety testing."], "answer": "B", "type": "Parallel", "explanation": "Chinese regulations explicitly require documentation of both negative and positive control group data in experimental results tables for cosmetics testing. US regulations for color additives like FD&C Yellow No. 5 focus primarily on chemical specifications and certification requirements rather than detailing experimental control documentation for animal studies. This reflects different regulatory approaches: China specifies control data requirements for testing documentation, while US color additive regulations emphasize product composition standards.", "category": "Cosmetics", "related_concept": "control group data", "id": "PA_P_00637_014", "match_type": "weak", "match_score": 0.7452999829278997, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0022_0003_1"}
{"question": "针对化妆品中的污染物限量（如重金属）与生产规范标准，请判断以下陈述：\n陈述1：中国化妆品法规强调企业建立全过程质量管理体系，并通过质量安全负责人等岗位落实主体责任，以系统性控制潜在风险。\n陈述2：美国化妆品法规对特定物质（如色素中的铅、砷、汞）设定了明确的定量限值，这些限值是产品合规必须满足的强制性技术标准。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规文本体现了通过明确责任主体（注册人、备案人、法定代表人、质量安全负责人）和建立责任制，进行系统性、全过程管理的思路。陈述2正确：美国法规文本（如对D&C Blue No. 4的规定）明确列出了铅、砷、汞等污染物的具体限量（如铅≤20 ppm），这些是产品必须符合的规格标准的一部分，属于强制性技术合规要求。两者分别体现了“过程管理”与“产品规格符合性”两种重要的监管维度。", "category": "Cosmetics", "related_concept": "specification compliance, manufacturing practice standards, contaminant thresholds", "id": "PA_P_00590_002", "match_type": "weak", "match_score": 0.7337312097637458, "lang": "CN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0001_0005_2"}
{"question": "Statement 1: Chinese regulations explicitly prohibit the same person from holding both production management and quality management responsibilities. Statement 2: US regulations require separate identity testing for all components when finished-product testing doesn't verify component identity.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct: Chinese regulations explicitly state that quality management and production management responsibilities cannot be held by the same person (不得互相兼任). Statement 2 is incorrect: US regulations provide exceptions where specific identity testing isn't required, such as when using approved intravenous drug products as inactive ingredients or when examining certificates of analysis for certain components.", "category": "Drugs", "related_concept": "prohibition of dual roles, component identity testing", "id": "PA_P_00178_002", "match_type": "weak", "match_score": 0.7498650003391288, "lang": "EN", "source_cn": "药品上市许可持有人落实药品质量安全.txt", "source_us": "PART_212CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_PO.txt", "old_id": "comp_0002_0003_2"}
{"question": "Statement 1: In the US, a request to establish an import tolerance for a new animal drug must include a statement regarding compliance with Good Laboratory Practice (GLP) regulations for any nonclinical studies submitted.\nStatement 2: In China, the production of regional folk medicinal materials must be conducted in compliance with national Good Laboratory Practice (GLP) regulations.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct. US regulations explicitly require that requests for import tolerances include a statement on GLP compliance for nonclinical laboratory studies, or an explanation for noncompliance. Statement 2 is incorrect. Chinese regulations for regional folk medicinal materials reference quality management standards like 'Good Agricultural Practice' for cultivation and 'Good Supply Practice' for distribution, but do not specify mandatory compliance with Good Laboratory Practice (GLP) regulations, which typically govern nonclinical safety studies in a laboratory setting, not field production.", "category": "Drugs", "related_concept": "good laboratory practice compliance, quality management compliance", "id": "PA_P_00144_002", "match_type": "weak", "match_score": 0.7411966668713225, "lang": "EN", "source_cn": "地区性民间习用药材管理办法.txt", "source_us": "PART_510NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0001_0004_2"}
{"question": "Statement 1: A regulatory agency can deem a cosmetic product adulterated if it contains a substance proven to be carcinogenic in animal inhalation studies, even if human data is limited. Statement 2: Following a reported adverse event, a regulatory agency can mandate the cosmetic manufacturer to conduct a self-investigation into the cause and implement risk control measures.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct based on the US regulatory principle illustrated, where vinyl chloride is deemed to render a cosmetic adulterated due to animal carcinogenicity studies and links to worker health issues, allowing action without waiting for extensive human consumer data. Statement 2 is correct based on the Chinese regulatory principle, where the responsible department can order the cosmetic registrant or manufacturer to analyze, evaluate, and self-investigate the cause of an adverse event and take risk control measures following a monitoring agency's recommendation. Both statements reflect valid, distinct regulatory powers described in the respective contexts.", "category": "Cosmetics", "related_concept": "carcinogenic substance regulation, regulatory investigation", "id": "PA_P_00598_012", "match_type": "weak", "match_score": 0.7168549540637892, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0012_0003_2"}
{"question": "关于颜色添加剂混合物认证与免费样品义务的监管，请判断以下陈述：\n陈述1：根据美国法规，由已认证的单一颜色与批准稀释剂简单混合制成的颜色添加剂混合物，可豁免批次认证，但标签需包含制造商的控制编号。\n陈述2：根据中国法规，以免费试用、赠予形式向消费者提供化妆品，相关经营者无需履行化妆品经营者的一般法定义务。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "C", "type": "Parallel", "explanation": "陈述1正确。美国法规（21 CFR §80.35(b)）明确规定，如果颜色添加剂混合物是由先前已认证批次的单一颜色与列入许可清单的稀释剂简单混合制成，且单一颜色自认证后成分未发生任何变化，则该混合物可豁免批次认证。同时，其标签不得使用FDA分配的批号，但必须包含制造商的控制编号以便追溯。\n陈述2错误。中国法规（如《化妆品监督管理条例》相关配套办法）明确规定，以免费试用、赠予、兑换等形式向消费者提供化妆品的，应当依法履行化妆品经营者义务。这意味着免费提供化妆品并不能免除其在产品质量安全、标签标识、不良反应监测等方面的法定义务。", "category": "Cosmetics", "related_concept": "color additive mixture certification, free sample obligations", "id": "PA_P_00662_008", "match_type": "weak", "match_score": 0.7402859227531191, "lang": "CN", "source_cn": "化妆品生产经营监督管理办法（2021年第46号）.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0014_0003_2"}
{"question": "针对多色号系列防晒化妆品的注册申请，中国法规允许抽样进行人体功效试验并作为一组产品同时申请。以下关于此规定的陈述，哪一项是正确的？", "choices": ["A. 该规定仅适用于进口防晒化妆品，国产产品不适用", "B. 抽样试验后，每个产品注册资料中仍需包含系列产品名单、基础配方、着色剂一览表及抽检产品名单", "C. 抽样试验可完全替代所有色号产品的个体试验，无需在资料中附上抽检产品名单", "D. 该规定同样适用于美国FDA对多色号化妆品的管理，中美要求完全一致"], "answer": "B", "type": "Parallel", "explanation": "根据中国法规，多色号系列防晒化妆品按规范抽样进行人体功效试验后，可作为一组产品同时申请注册。但法规明确要求，每个产品的注册资料中均应附上系列产品的名单、基础配方和着色剂一览表以及抽检产品名单。这确保了即使采用抽样试验，注册信息的完整性和可追溯性得以维持。选项A错误，因未限定于进口产品；选项C错误，因仍需附上抽检名单；选项D错误，因美国法规文本未提及类似的多色号系列抽样注册规定，中美要求在此方面存在差异。", "category": "Cosmetics", "related_concept": "多色号系列防晒化妆品抽样", "id": "PA_P_00653_022", "match_type": "weak", "match_score": 0.6438744426739285, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0019_0020_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在药品研发的早期阶段（如I期临床试验），中美监管机构均认为对原料药和制剂终产品的完整、最终的质量控制标准并非必需，而是更关注对原料药和药物实体的初步鉴别与控制。\n陈述2：在识别需要优先评估的药品安全信号时，中国法规明确要求考虑信号对产品获益-风险平衡的潜在影响以及对公众健康的影响，而美国法规在IND申请内容中主要关注的是通过研究设计和方法来最小化试验期间对受试者的风险。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。美国法规文本明确指出，在初始的I期临床试验申请中，重点应放在原料药和药物实体的鉴别与控制上，药物制剂终产品的最终标准通常在研究结束时确定。这反映了基于研发阶段递进式提交信息的理念。中国对于创新药临床试验申请中的药学资料要求，也遵循类似的“分阶段提交”原则，在早期阶段允许提供初步的控制策略。\n陈述2正确。中国法规文本明确列出了信号优先级判定的因素，首要原则就是评估信号是否可能影响产品的获益-风险平衡或公众健康。美国提供的法规文本节选自IND申请要求，其中（g）项描述了为监测药物效应和最小化风险而采取的措施，其核心语境是控制临床试验中的已知或预期风险，而非上市后信号检测的优先级判定逻辑。两者关注的风险控制阶段和具体目标不同。", "category": "Drugs", "related_concept": "drug composition and control, risk control measures", "id": "PA_P_00324_010", "match_type": "weak", "match_score": 0.7423792316511116, "lang": "CN", "source_cn": "药物警戒质量管理规范.txt", "source_us": "PART_312INVESTIGATIONAL_NEW_DRUG_APPLICATION.txt", "old_id": "comp_0011_0004_2"}
{"question": "关于实质性修正案（substantive amendment）的处理程序，以下哪项描述最符合中美药监法规的差异？", "choices": ["A. 中国NMPA和美国FDA都规定实质性修正会导致申请重新排队，但不影响原申请日期", "B. 美国FDA规定实质性修正会给予新的提交日期并重新计算审评时限，中国NMPA无此明确规定", "C. 中国NMPA规定实质性修正必须撤回原申请重新提交，美国FDA允许在原有申请基础上补充", "D. 两国法规都禁止在申请提交后做任何实质性修正"], "answer": "B", "type": "Parallel", "explanation": "美国FDA法规明确规定了实质性修正案的处理程序：如果专员确定补充的信息或数据构成实质性修正，修正后的申请将获得新的提交日期，审评时限重新开始计算。中国NMPA对化妆品备案/注册申请中的补充资料虽有时间要求，但未像FDA这样明确规定实质性修正会导致新的提交日期和时限重算。", "category": "Regulatory Procedure", "related_concept": "substantive amendment, new filing date", "id": "PA_P_00638_026", "match_type": "weak", "match_score": 0.7345947865202429, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0063_0001_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在库存管理方面，中国法规对药品类易制毒化学品的入库和出库操作有明确的“双人验收、双人复核”要求，以防止差错和舞弊。\n陈述2：美国法规要求所有注册的研究人员必须对其持有的所有受控物质每两年进行一次全面盘点，无论这些物质的来源或预定用途如何。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确，中国法规第三十二条明确规定“入库应当双人验收，出库应当双人复核”，这是强制性的操作控制要求。陈述2错误，美国法规（a）段描述的是“研究人员可以每两年盘点一次”，原文使用的是“may take inventory every two years”，这是一种允许性或示例性描述，而非对所有注册研究人员的强制性要求。法规的实际盘点频率要求可能因物质类别和活动类型而异，并规定在其他具体条款中。", "category": "Controlled_Substances", "related_concept": "inventory management, dual-person verification", "id": "PA_P_00716_002", "match_type": "weak", "match_score": 0.7449413972825809, "lang": "CN", "source_cn": "药品类易制毒化学品管理办法（卫生部令第72号_2010年）.txt", "source_us": "PART_1304RECORDS_AND_REPORTS_OF_REGISTRANTS.txt", "old_id": "comp_0012_0001_2"}
{"question": "关于医疗器械技术审评机构或不良事件监测技术机构未履行职责的后果，中美法规的典型处理方式有何不同？", "choices": ["A. 中国法规强调行政处分和刑事责任，美国法规主要依赖民事赔偿", "B. 中国法规规定了从警告到吊销许可证的渐进式处罚，美国法规未明确此类机构的处罚", "C. 两国法规均以罚款为主要手段，但金额标准不同", "D. 美国法规要求机构暂停运营，中国法规仅限内部整改"], "answer": "B", "type": "Parallel", "explanation": "中国法规（如NMPA相关条例）对技术机构未履行职责规定了明确的行政责任阶梯，包括责令改正、警告、通报批评，直至对责任人依法给予处分。美国法规（FDA框架）在提供文本中未直接规定此类技术机构的处罚细则，更侧重于设备分类和上市前控制。干扰项A错误，因为美国文本未提及刑事责任；C错误，因文本未涉及罚款；D错误，因中国法规包含停产停业等严厉措施。", "category": "Medical_Devices", "related_concept": "duties of technical institutions", "id": "PA_P_00498_004", "match_type": "weak", "match_score": 0.7480914146047193, "lang": "CN", "source_cn": "医疗器械监督管理条例.txt", "source_us": "PART_880GENERAL_HOSPITAL_AND_PERSONAL_USE_DEVICES.txt", "old_id": "comp_0037_0005_1"}
{"question": "Statement 1: In both US and Chinese cosmetic regulations, if there is insufficient space on a product's package for required declarations, the manufacturer may submit a formal petition to request an acceptable alternative labeling method.\nStatement 2: Official reference materials, such as ingredient dictionaries, can be incorporated by reference into cosmetic regulations, meaning their content becomes legally binding.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect. The provided US text mentions that the Commissioner may establish an acceptable alternate (like smaller type) for insufficient space via regulation, and a petition can be submitted to request such a regulation. The Chinese text provided does not mention a petition process for insufficient space declarations. Statement 2 is correct. The US text explicitly shows the incorporation by reference of the CTFA Cosmetic Ingredient Dictionary, making its adopted names legally required for labeling. Chinese regulations also utilize official standards and lists which carry similar binding authority.", "category": "Cosmetics", "related_concept": "petition for regulation amendment, incorporated reference material, insufficient space declaration", "id": "PA_P_00626_005", "match_type": "weak", "match_score": 0.7374148555739084, "lang": "EN", "source_cn": "化妆品标签管理办法.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0007_0003_2"}
{"question": "In comparing US and Chinese regulatory frameworks for pharmaceutical representatives, which statement accurately describes a key difference in their definitions and permitted activities?", "choices": ["A. US regulations focus on representatives' interactions with regulatory agencies during drug development, while Chinese regulations define representatives as professionals who communicate drug information to healthcare providers and manage clinical feedback.", "B. Both systems require representatives to have medical degrees and limit their activities to formal scientific presentations at academic conferences.", "C. Chinese regulations prohibit any direct communication with healthcare providers, while US regulations encourage extensive promotional meetings with physicians.", "D. US regulations define representatives as employees of pharmaceutical manufacturers only, while Chinese regulations allow third-party contractors to fulfill this role without manufacturer oversight."], "answer": "A", "type": "Parallel", "explanation": "US regulations (as seen in IND/sponsor responsibilities) focus on representatives' role in interacting with FDA during development phases (meetings, submissions). Chinese regulations explicitly define medical representatives as professionals who communicate drug information to healthcare personnel, assist with appropriate use, and collect clinical feedback - making this a clear definitional difference.", "category": "Drugs", "related_concept": "medical representative definition", "id": "PA_P_00099_001", "match_type": "weak", "match_score": 0.7469324812193866, "lang": "EN", "source_cn": "医药代表备案管理办法（试行）.txt", "source_us": "PART_312INVESTIGATIONAL_NEW_DRUG_APPLICATION.txt", "old_id": "comp_0001_0015_1"}
{"question": "A company plans to register a cosmetic kit containing an inseparable applicator tool and two separate formula components (a serum and a cream). How would the registration requirements for this product most likely differ between the two regulatory frameworks?", "choices": ["A. Statement 1: The product must be registered as a single entity with all formulas documented together. Statement 2: The safety assessment must specifically evaluate the tool's function and its interaction with the formulas and skin.", "B. Statement 1: Each formula component requires an independent registration application. Statement 2: The safety of the tool itself does not need to be addressed in the cosmetic registration.", "C. Statement 1: The product is registered based on the classification (special or ordinary) of its highest-risk component. Statement 2: Samples from only one of the formula components need to be retained for regulatory purposes.", "D. Statement 1: Registration is prohibited for products containing non-consumable tools. Statement 2: Group registration with other kits is permitted to reduce testing burden."], "answer": "A", "type": "Parallel", "explanation": "The Chinese regulation (Article 34 & 35) directly addresses this scenario: for products with inseparable packaging containing multiple formulas, they are registered as one product with separate formulas documented. It also mandates safety assessment for tools that are not merely auxiliary applicators, requiring evaluation of their function and interaction. The US text provided does not detail multi-formula or tool-inclusive product registration rules, focusing instead on color additive safety. The question contrasts a specific Chinese provision for complex products with the absence of such detail in the provided US excerpt, testing application of distinct regulatory constructs.", "category": "Cosmetics", "related_concept": "multi-formula product registration, sample retention requirements", "id": "PA_P_00655_010", "match_type": "weak", "match_score": 0.745812118861689, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0020_0004_2"}
{"question": "Consider the following statements about regulatory frameworks for toxic or controlled substances:\nStatement 1: Regulatory agencies may have the authority to grant exceptions to defined limits based on demonstrated cause and under specified conditions.\nStatement 2: The interpretation of regulatory provisions is always explicitly assigned to a specific ministry or department within the governing legislation.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct, as illustrated by the US regulation where the Administrator may permit continued manufacturing despite quota suspensions 'upon application and for good cause shown' and under set conditions. This reflects the concept of administrator discretionary permission. Statement 2 is incorrect. While the Chinese regulation explicitly states '本办法由卫生部负责解释' (This measure shall be interpreted by the Ministry of Health), establishing clear interpretation authority, this is not a universal feature. The US excerpt does not explicitly assign interpretation authority; such authority is typically derived from the enabling statute and general administrative law principles, not necessarily spelled out in every operational rule. Therefore, only Statement 1 is correct.", "category": "Controlled_Substances", "related_concept": "administrator discretionary permission, interpretation authority of Ministry of Health", "id": "PA_P_00691_005", "match_type": "weak", "match_score": 0.7450139398782205, "lang": "EN", "source_cn": "医疗用毒性药品管理办法.txt", "source_us": "PART_1315IMPORTATION_AND_PRODUCTION_QUOTAS_FOR_EPH.txt", "old_id": "comp_0003_0006_2"}
{"question": "关于化妆品在发现不合格后的后续处理，中美法规在原则和措施上存在差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规强调对相关产品进行系统性分析和评估，而美国法规侧重于对特定成分设定严格的限量标准。", "B. 中国法规要求立即召回所有批次产品，而美国法规仅要求修改标签。", "C. 两国法规都要求进行全面的风险评估，但中国法规的执行力度更强。", "D. 美国法规要求对所有相关产品进行重新检验，而中国法规仅要求停止销售不合格批次。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如NMPA框架下）在发现产品不合格后，要求注册人/备案人对其他相关产品进行分析评估，这是一种基于风险管理的系统性后处理原则。美国法规（如FDA对色素D&C Blue No. 4的规定）则通过设定具体成分（如铅、砷、汞及特定芳香胺）的严格限量标准（ppm/ppb级）来前置控制风险，体现了对规格符合性的高度关注。选项B、C、D的描述均与两国法规的典型原则不符或过于绝对。", "category": "Cosmetics", "related_concept": "product analysis and assessment, specification compliance", "id": "PA_P_00597_001", "match_type": "weak", "match_score": 0.7469867924709149, "lang": "CN", "source_cn": "儿童化妆品监督管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0006_0005_1"}
{"question": "In regulatory frameworks for cosmetics, which approach to emergency control measures is most aligned with protecting public health when systemic risks are identified?", "choices": ["A. Immediate suspension of all related products from a manufacturer when quality management systems show severe risks", "B. Targeted suspension only of specific non-compliant batches based on initial test results", "C. Issuing safety warnings while allowing continued production during investigation", "D. Requiring voluntary recalls by manufacturers without mandatory suspensions"], "answer": "A", "type": "Parallel", "explanation": "Option A reflects the most comprehensive public health protection approach by suspending all related products when systemic quality management failures are identified, preventing potential widespread harm. This aligns with regulatory principles that prioritize prevention over reaction when systemic risks are detected.", "category": "Cosmetics", "related_concept": "emergency control measures", "id": "PA_P_00611_009", "match_type": "weak", "match_score": 0.7084159072035705, "lang": "EN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0013_0005_1"}
{"question": "关于化妆品电子商务平台的管理责任，中美法规的主要差异体现在：", "choices": ["A. 中国法规强调平台对入驻经营者的直接管理责任，美国法规未涉及平台管理", "B. 中国法规要求平台建立实名登记、日常检查等制度，美国法规主要关注颜色添加剂本身", "C. 中国法规要求平台设置质量安全管理机构，美国法规要求平台对颜色添加剂进行批次认证", "D. 中国法规涉及平台服务协议制定，美国法规涉及颜色添加剂的使用限制"], "answer": "B", "type": "Parallel", "explanation": "中国法规（NMPA）明确规定了化妆品电子商务平台对平台内经营者的管理责任，包括建立实名登记、日常检查、违法行为制止及报告等制度。美国法规（FDA）提供的文本主要针对特定颜色添加剂（如D&C Red No. 6）的认证、规格、使用限制和标签要求，并未涉及电子商务平台的管理责任。因此，核心差异在于中国法规聚焦平台管理，美国法规聚焦产品成分（颜色添加剂）监管。", "category": "Cosmetics", "related_concept": "platform management responsibility", "id": "PA_P_00680_001", "match_type": "weak", "match_score": 0.7182669306269607, "lang": "CN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0002_0020_1"}
{"question": "Statement 1: When a color additive's regulatory status changes, products containing it are automatically considered adulterated under US FDA regulations. Statement 2: E-commerce platforms must conduct regular quality monitoring of cosmetics sold on their platforms under Chinese NMPA regulations.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect because US FDA regulations specify that products are NOT automatically considered adulterated when a color additive's status changes, unless there's a specific health hazard determination. Statement 2 is correct as Chinese NMPA regulations explicitly encourage e-commerce platforms to conduct regular sampling and quality monitoring of cosmetics sold on their platforms.", "category": "Cosmetics", "related_concept": "adulterated status change, platform self-inspection", "id": "PA_P_00683_002", "match_type": "weak", "match_score": 0.7474778365631347, "lang": "EN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0004_0003_2"}
{"question": "Statement 1: Under Chinese transportation regulations, certain business operations require mandatory registration or filing with authorities, with penalties for non-compliance including fines and potential business suspension. Statement 2: US FDA regulations establish specific conditions for charging search fees based on request complexity and volume, including requirements for written notice and consultation attempts before imposing charges. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 accurately reflects Chinese regulatory requirements for transportation businesses (e.g., mandatory filing for operations like road freight stations and vehicle maintenance) with specified penalties. Statement 2 correctly describes US FDA provisions for search fee charging based on responsive page volume, unusual circumstances, and required communication with requesters.", "category": "General_Regulatory_Comparison", "related_concept": "mandatory business registration, fee charging conditions", "id": "PA_P_00776_002", "match_type": "weak", "match_score": 0.7401570462296816, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_20PUBLIC_INFORMATION.txt", "old_id": "comp_0011_0007_2"}
{"question": "Statement 1: The 'safe-for-use' principle in US regulations requires that color additives must be proven safe for their specific intended uses before listing. Statement 2: Chinese regulations for cosmetics production delegation require that when a registrant and manufacturer belong to the same corporate group, they must submit standard delegation documents rather than simplified group documentation.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 correctly describes the US 'safe-for-use' principle, which requires scientific data demonstrating safety for specific intended uses before color additive listing. Statement 2 is incorrect because Chinese regulations actually allow same-group companies to submit simplified documentation (group affiliation proof and quality assurance documents) instead of standard delegation relationship documents, providing a regulatory accommodation for corporate affiliates.", "category": "Cosmetics", "related_concept": "safe-for-use principle, delegation relationship documentation", "id": "PA_P_00655_002", "match_type": "weak", "match_score": 0.7485309375905908, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0008_0004_2"}
{"question": "关于监管部门间协作与案件移交，中美监管体系有不同的制度安排。请判断以下两个陈述的真假：\n陈述1：在中国化妆品监管体系中，检查机构发现涉嫌违法行为时，必须将违法线索移交被检查对象所在地药品监督管理部门，并由后者决定是否立案。\n陈述2：在美国色素添加剂监管中，FDA专员在收到请愿书后，必须在固定时间内（90或180天）在联邦公报上发布相关法规或拒绝令。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规明确规定，检查机构发现涉嫌违法行为时，应收集证据并将违法线索移交被检查对象所在地药监部门，接受移交单位应依法决定是否立案，并在5个工作日内反馈。\n陈述2正确：美国法规规定，FDA专员在收到请愿书后，应在90天内（可延长至180天）在联邦公报上发布列出色素添加剂的法规或通过命令拒绝请愿，并通知请愿人。", "category": "Cosmetics", "related_concept": "inter-departmental collaboration, regulation publication timeline, case filing decision", "id": "PA_P_00634_002", "match_type": "weak", "match_score": 0.7493333794130954, "lang": "CN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0008_0002_2"}
{"question": "关于重大科研项目的支持方向，中美药监法规的侧重点有何不同？", "choices": ["A. 中国法规侧重于支持对中医药理论和实践发展有重大促进作用的项目，而美国法规侧重于支持针对新用途的补充申请所必需的临床研究项目。", "B. 中国法规侧重于支持所有类型的生物医学研究，而美国法规仅支持制药公司发起的商业研究。", "C. 中国法规侧重于支持罕见病药物研发，而美国法规侧重于支持常见病药物研发。", "D. 两国法规对科研项目的支持方向没有本质区别，都鼓励所有类型的创新研究。"], "answer": "A", "type": "Parallel", "explanation": "中国《中医药法》明确将“对中医药理论和实践发展有重大促进作用的项目的科学研究”作为支持方向，体现了对中医药独特理论体系和实践传承的重视。美国FDA相关法规（如21 CFR 99）的语境是围绕药品新用途信息的传播与补充申请，其“科学研究”主要指为提交新用途补充申请而必须进行的临床研究，具有明确的监管和商业目的导向。两者在立法宗旨和适用范围上存在根本差异。", "category": "Drugs", "related_concept": "scientific research projects", "id": "PA_P_00010_003", "match_type": "weak", "match_score": 0.7169394057387558, "lang": "CN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0010_0008_1"}
{"question": "Statement 1: In US FDA regulations, the sponsor is clearly identified for each approved drug product. Statement 2: In Chinese NMPA regulations, pre-market GMP inspections serve as important evidence for drug上市监管 (market supervision).", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as FDA regulations consistently identify sponsors for each drug product. Statement 2 is correct as Chinese regulations explicitly state that pre-market GMP inspection results form written reports that serve as important evidence for drug上市监管 (market supervision).", "category": "Drugs", "related_concept": "sponsor, 药品上市监管, 药品生产质量管理规范符合性检查", "id": "PA_P_00255_002", "match_type": "weak", "match_score": 0.665959449215564, "lang": "EN", "source_cn": "药品生产监督管理办法（2020年国家市场监督管理总局令第28号）.txt", "source_us": "PART_520ORAL_DOSAGE_FORM_NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0018_0011_2"}
{"question": "In cosmetic safety testing, which regulatory approach best describes the difference between US FDA and Chinese NMPA requirements for human patch test observation time points?", "choices": ["A. FDA requires continuous monitoring while NMPA specifies fixed intervals", "B. NMPA mandates specific post-removal intervals while FDA provides general safety principles", "C. Both require identical observation schedules at 24 and 48 hours", "D. FDA requires longer observation periods than NMPA's standard protocol"], "answer": "B", "type": "Parallel", "explanation": "Chinese NMPA regulations typically specify precise observation time points (e.g., 0.5h, 24h, 48h after patch removal) in technical standards, while US FDA regulations focus on general safety principles and risk assessment without prescribing exact timing intervals, allowing flexibility based on product characteristics.", "category": "Cosmetics", "related_concept": "observation time points, skin patch test", "id": "PA_P_00638_012", "match_type": "weak", "match_score": 0.6795009690969347, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0048_0003_1"}
{"question": "关于医疗器械唯一设备标识（UDI）和可追溯性要求：\n陈述1：中国法规要求从事网络销售的企业采取技术措施保障数据可追溯，但未明确提及UDI系统。\n陈述2：美国法规要求制造商根据ISO 13485条款建立UDI系统和可追溯性程序，并对植入式等生命支持设备有额外追溯要求。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规文本要求保障网络销售数据可追溯，但未提及UDI具体系统。陈述2正确：美国法规文本明确要求制造商依据ISO 13485建立UDI系统（Clause 7.5.8）和可追溯程序（Clause 7.5.9.1），并对植入式等生命支持设备有额外追溯要求（Clause 7.5.9.2）。", "category": "Medical_Devices", "related_concept": "unique device identification, traceability procedures", "id": "PA_P_00522_002", "match_type": "weak", "match_score": 0.745922145528247, "lang": "CN", "source_cn": "医疗器械网络销售监督管理办法（2017年第38号）.txt", "source_us": "PART_820QUALITY_MANAGEMENT_SYSTEM_REGULATION_EFF_2.txt", "old_id": "comp_0001_0002_2"}
{"question": "In the context of cosmetic adverse event reporting, which regulatory approach is more likely to involve mandatory analysis and evaluation reports from manufacturers following a significant adverse event?", "choices": ["A. The US FDA approach", "B. The Chinese NMPA approach", "C. Both approaches require this equally", "D. Neither approach requires this"], "answer": "B", "type": "Parallel", "explanation": "The Chinese NMPA approach, as described in the context, explicitly mandates that for adverse events with significant social impact, the national monitoring agency must form an analysis and evaluation report within 7 working days and submit it to the NMPA. The US text focuses on specific substance prohibitions and tamper-resistant packaging requirements but does not detail a comparable mandatory analysis report timeline for adverse events. Therefore, the Chinese approach is more directly associated with this specific procedural requirement.", "category": "Cosmetics", "related_concept": "adverse event reporting, analysis evaluation report", "id": "PA_P_00598_011", "match_type": "weak", "match_score": 0.7168549540637892, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0012_0003_1"}
{"question": "在化妆品监管中，中美法规对产品检验和认证的要求有所不同。请判断以下两个陈述的真假：陈述1：中国法规要求化妆品注册和备案检验报告必须包含PFA值的测定结果及统计分析。陈述2：美国法规要求所有批次的FD&C Red No. 40及其色淀必须进行认证，并符合特定的化学规格限制。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：根据中国法规（NMPA）文本，化妆品注册与备案检验报告包含“对照品及被测物PFA值测定结果”部分，要求列出个体PFA值、平均值、标准差、标准误和95%可信区间等统计分析，这体现了对防晒产品PFA值测定的详细检验要求。陈述2正确：根据美国法规（FDA）文本，FD&C Red No. 40及其色淀的所有批次必须按照相关章节进行认证（Certification），并且FD&C Yellow No. 5等色素需符合一系列化学规格（Specifications），如挥发性物质、水不溶物、特定杂质和重金属的含量限制。因此，两个陈述都正确，对应选项A。", "category": "Cosmetics", "related_concept": "registration and filing inspection, certification requirement, specifications", "id": "PA_P_00637_047", "match_type": "weak", "match_score": 0.734759158296387, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0076_0003_2"}
{"question": "Which regulatory approach to waste discharge from transportation conveyances demonstrates a more comprehensive environmental protection strategy?", "choices": ["A. The US approach prohibits waste discharge from highway and air conveyances except at approved servicing areas, while China focuses on permit exemptions for certain road transport vehicles.", "B. The Chinese approach requires waste discharge facilities to be approved by local authorities, while the US has no specific waste discharge regulations.", "C. Both approaches are identical, requiring waste discharge only at government-approved facilities for all transportation modes.", "D. The US approach allows waste discharge anywhere for rail services, while China prohibits all waste discharge from transportation vehicles."], "answer": "A", "type": "Parallel", "explanation": "The US regulation explicitly prohibits discharge of excrement, garbage, or wastewater from highway and air conveyances except at FDA-approved servicing areas, demonstrating a comprehensive environmental protection approach. The Chinese text focuses on road transport permit exemptions for vehicles under 4500kg but doesn't address waste discharge regulations for transportation conveyances, making the US approach more comprehensive for environmental protection.", "category": "General_FDA", "related_concept": "discharge of wastes on highway conveyances, discharge of wastes on air conveyances", "id": "PA_P_00774_001", "match_type": "weak", "match_score": 0.7477872903300858, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_1250INTERSTATE_CONVEYANCE_SANITATION.txt", "old_id": "comp_0009_0006_1"}
{"question": "关于膳食补充剂及其成分的定义，中美法规的主要差异体现在哪个方面？", "choices": ["A. 中国法规将膳食补充剂视为普通食品管理，美国法规则将其作为一类特殊食品进行单独监管", "B. 美国法规明确区分了膳食补充剂成分（包括可能不出现在终产品中的物质）和膳食成分，中国法规则无此细分", "C. 中国法规要求所有膳食补充剂成分必须进行上市前批准，美国法规则实行备案制", "D. 美国法规禁止在膳食补充剂中使用任何合成成分，中国法规则允许有限使用"], "answer": "B", "type": "Parallel", "explanation": "美国FDA根据《联邦食品、药品和化妆品法案》（FD&C Act）第201(ff)条对膳食补充剂进行定义，并在其法规（如21 CFR Part 1）中进一步明确了“膳食补充剂成分”的概念，包括用于制造膳食补充剂的任何物质（即使可能不出现在终产品中），并区分了膳食成分和其他成分。中国NMPA对类似产品（如保健食品）的原料管理，主要依据《保健食品原料目录》和《可用于保健食品的物品名单》等进行管理，对于“成分”的定义和分类更侧重于列入目录的原料本身，对于制造过程中使用但可能不出现在终产品中的辅助物质，通常纳入“辅料”或生产工艺管理，缺乏与美国“膳食补充剂成分”完全对应的、涵盖制造全过程物质的明确定义细分。", "category": "General_FDA", "related_concept": "dietary supplement definitions", "id": "PA_P_00770_006", "match_type": "weak", "match_score": 0.6765810234667524, "lang": "CN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0002_0043_3"}
{"question": "关于临床试验用药品的制备要求，中美法规的侧重点有何不同？", "choices": ["A. 中国法规强调采用生产规模样品并说明制备情况，美国法规则侧重于对用于生物利用度/生物等效性研究的批次提供详细生产记录和组件来源信息。", "B. 两国法规都要求必须使用商业化生产规模的样品进行临床试验。", "C. 美国法规要求所有临床试验批次都必须提交完整的稳定性数据，而中国法规则无此要求。", "D. 中国法规要求提供安慰剂的详细制备工艺，而美国法规则不要求提供安慰剂信息。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如文本中提及）要求临床试验用药品一般应采用生产规模样品，并在申报时说明制备情况（包括试验药和安慰剂）。美国法规则（如文本(b)段）详细规定了对用于关键研究（如生物利用度/生物等效性研究）的药品批次，需提供批生产记录、各组件的规格、活性与非药典辅料及包材的来源等信息。两者侧重点不同：中国强调“制备情况”的总体说明和样品规模；美国强调对特定研究批次供应链和生产记录的追溯性细节。选项B错误，因为美国法规并未明文规定所有临床试验都必须使用商业化规模样品；选项C错误，因为中国法规在其他部分也可能有稳定性要求，且美国要求是针对特定批次；选项D错误，因为美国法规虽未在提供文本中明确提及安慰剂，但实践中可能在其他部分有要求，且中国要求是“包括”安慰剂，并非独有。", "category": "Drugs", "related_concept": "clinical trial drug preparation", "id": "PA_P_00044_010", "match_type": "weak", "match_score": 0.7312858441742348, "lang": "CN", "source_cn": "中药注册管理专门规定.txt", "source_us": "PART_314APPLICATIONS_FOR_FDA_APPROVAL_TO_MARKET_A_.txt", "old_id": "comp_0009_0005_1"}
{"question": "In regulatory frameworks, how do approaches to ensuring ongoing compliance differ between systems focused on transport operations and those focused on product quality?", "choices": ["A. Transport systems emphasize internal departmental supervision and public reporting mechanisms, while product quality systems rely on bilateral committees and mutual recognition agreements.", "B. Both systems primarily use financial penalties and license revocation as the main tools for ensuring continued compliance.", "C. Transport systems require annual third-party audits, while product quality systems mandate monthly self-inspections.", "D. Product quality systems focus on pre-approval inspections only, while transport systems focus exclusively on post-operation monitoring."], "answer": "A", "type": "Parallel", "explanation": "This question compares the mechanisms for 'monitoring continued equivalence' or compliance. A correctly identifies that transport regulatory systems (as suggested by the Chinese context) often establish internal supervision hierarchies and public举报 (reporting) systems. In contrast, product quality/regulatory systems (as suggested by the US/FDA context with the EU) establish formal bilateral structures like Joint Sectoral Committees to monitor mutual recognition agreements and equivalence. B is incorrect as financial penalties are a specific enforcement tool, not the primary ongoing monitoring mechanism. C and D present false dichotomies and requirements not supported by general regulatory principles.", "category": "General_FDA", "related_concept": "monitoring continued equivalence", "id": "PA_P_00775_001", "match_type": "weak", "match_score": 0.7421999906192384, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_26MUTUAL_RECOGNITION_OF_PHARMACEUTICAL_GOOD_M.txt", "old_id": "comp_0010_0004_1"}
{"question": "针对化妆品中致癌物质的监管，请判断以下两个陈述的真假：\n陈述1：美国FDA有权基于科学证据（如动物致癌性数据）将特定成分（如氯乙烯）直接认定为有害物质，并禁止其用于特定类别的化妆品（如气溶胶产品），相关产品将被视为掺假。\n陈述2：中国NMPA对化妆品原料的管理主要基于《已使用化妆品原料目录》，对于新发现具有致癌风险的原料，其监管行动（如禁用）通常需要经过风险评估和目录更新程序，法规中较少出现针对单一具体致癌物质的即时、专项禁令条款。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。美国《联邦食品、药品和化妆品法案》第601(a)条款赋予了FDA广泛的权力。当有证据表明某种物质（如氯乙烯）可能使化妆品对使用者造成伤害时，FDA可以发布规定，直接将其认定为有害物质，并宣布含有该成分的特定产品（如案例中的气溶胶产品）为掺假品，从而禁止其销售。这是一种基于风险的主动监管方式。\n陈述2正确。中国对化妆品原料实行目录管理。NMPA对化妆品安全性的监管，包括对致癌物质的管控，主要依托于《化妆品安全技术规范》中规定的禁用、限用物质列表以及《已使用化妆品原料目录》。对于新发现的致癌风险，通常需要经过系统的安全风险评估，并通过修订技术规范或更新目录等规范性文件来实施管理，流程上更侧重于通过更新通用标准来进行规制，与美国FDA有时针对具体物质发布专项禁令的模式存在差异。", "category": "Cosmetics", "related_concept": "carcinogenic substance regulation", "id": "PA_P_00641_016", "match_type": "weak", "match_score": 0.7158851255801912, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0065_0003_2"}
{"question": "Statement 1: US FDA regulations require that performance studies summaries be included in device labeling to demonstrate compliance with regulatory requirements. Statement 2: China NMPA regulations mandate that product technical requirements for Class III IVDs must specify main raw materials and production process requirements in an appendix format.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as US FDA regulations under 21 CFR 809.10 require labeling to include a detailed description of performance studies and summary of results. Statement 2 is correct as China NMPA regulations specify that for Class III IVDs, product technical requirements must include main raw materials and production process requirements in an appendix format.", "category": "Medical_Devices", "related_concept": "performance studies summary, product technical requirements", "id": "PA_P_00375_002", "match_type": "weak", "match_score": 0.7494913834238897, "lang": "EN", "source_cn": "体外诊断试剂注册与备案管理办法（2021年第48号令）.txt", "source_us": "PART_864HEMATOLOGY_AND_PATHOLOGY_DEVICES.txt", "old_id": "comp_0006_0016_2"}
{"question": "关于化妆品检验受理编号的要求，以下哪项描述最准确？", "choices": ["A. 中国法规要求检验受理编号必须具有可识别性和唯一性，而美国法规对类似编号无具体要求", "B. 美国法规要求每个产品配方都必须有唯一的FDA参考编号，而中国法规无此要求", "C. 两国法规都要求检验报告必须包含官方分配的永久性编号", "D. 中国法规对检验受理编号无格式要求，而美国法规要求必须包含特定前缀"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定检验受理编号应按规定书写，要求具有可识别性和唯一性。美国法规文本中主要提及FDA会分配永久性化妆品产品成分声明编号或FDA参考编号，但未对检验受理编号的具体要求进行规定。", "category": "Cosmetics", "related_concept": "inspection acceptance number", "id": "PA_P_00644_007", "match_type": "weak", "match_score": 0.7211062438268745, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0077_0002_3"}
{"question": "Statement 1: In plasma collection, regulations require using only approved diagnostic reagents and single-use equipment to prevent contamination. Statement 2: For medicated feed production, equipment cleanout procedures must prevent cross-contamination between medicated and non-medicated products. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct and reflect similar regulatory principles for different products.", "B. Statement 1 is correct, but Statement 2 is incorrect because equipment cleanout is not required for feed production.", "C. Statement 1 is incorrect because reusable equipment is permitted, but Statement 2 is correct.", "D. Both statements are incorrect as neither area has specific equipment standards."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: Chinese plasma regulations mandate using approved diagnostic reagents and prohibit reusing single-use equipment to ensure safety. Statement 2 is correct: US medicated feed regulations require cleanout procedures to prevent unsafe contamination. Both reflect the regulatory principle of preventing contamination through equipment and reagent standards, though applied to different products (human plasma vs. animal feed).", "category": "Drugs", "related_concept": "equipment and reagent standards", "id": "PA_P_00353_002", "match_type": "weak", "match_score": 0.740335505996279, "lang": "EN", "source_cn": "血液制品管理条例.txt", "source_us": "PART_225CURRENT_GOOD_MANUFACTURING_PRACTICE_FOR_ME.txt", "old_id": "comp_0007_0004_2"}
{"question": "Statement 1: Regulatory frameworks for cosmetic products in China specifically define procedures for calculating SPF values after water exposure. Statement 2: US regulations for color additives establish minimum total color percentage requirements as part of purity specifications.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as Chinese regulations detail specific SPF calculation methods post-water exposure including arithmetic means and statistical requirements. Statement 2 is correct as US regulations for color additives like D&C Yellow No. 10 specify 'Total color, not less than 85 percent' as a key purity requirement.", "category": "Cosmetics", "related_concept": "SPF calculation method, total color requirement", "id": "PA_P_00637_042", "match_type": "weak", "match_score": 0.6712161603227776, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0070_0016_2"}
{"question": "关于药品上市后标签变更的管理，中美法规的核心差异主要体现在：", "choices": ["A. 中国法规要求所有标签变更均需提交补充申请，而美国法规允许在特定条件下无需提交补充申请", "B. 美国法规要求所有标签变更均需提交补充申请，而中国法规允许在特定条件下无需提交补充申请", "C. 两国法规均要求所有标签变更必须提交补充申请，但提交时限不同", "D. 两国法规均允许在特定条件下无需提交补充申请，但适用条件完全相同"], "answer": "A", "type": "Parallel", "explanation": "中国法规对药品上市许可持有人（MAH）的职责规定中，强调按照变更技术要求履行变更管理责任，通常意味着标签变更需要经过审批。而美国法规明确规定了标签变更在特定条件下（如关键使用信息保持一致、其他部分不冲突）可能无需提交补充申请（supplemental application），这体现了监管灵活性上的差异。", "category": "Drugs", "related_concept": "supplemental application, labeling consistency", "id": "PA_P_00253_001", "match_type": "weak", "match_score": 0.7389773866993226, "lang": "CN", "source_cn": "药品生产监督管理办法（2020年国家市场监督管理总局令第28号）.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0010_0013_1"}
{"question": "关于第二类精神药品的销售对象，请判断以下陈述：\n陈述1：在中国，第二类精神药品的批发企业可以向经批准的药品零售连锁企业销售。\n陈述2：在美国，受控物质的处方只能由注册药剂师或在注册药房工作的药剂师调配。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规规定，定点批发企业可以向符合条件（如经批准实行统一管理的药品零售连锁企业）的实体销售第二类精神药品。陈述2正确：美国法规明确规定，受控物质的处方只能由注册药剂师或在注册药房、注册机构从业者处工作的药剂师调配。这体现了中美在授权销售/配药主体上的不同规定框架。", "category": "Controlled_Substances", "related_concept": "second-class psychotropic drug sales to authorized entities, pharmacist registration", "id": "PA_P_00733_002", "match_type": "weak", "match_score": 0.7256397848675942, "lang": "CN", "source_cn": "麻醉药品和精神药品管理条例.txt", "source_us": "PART_1306PRESCRIPTIONS.txt", "old_id": "comp_0009_0001_2"}
{"question": "In comparing US and Chinese pharmaceutical regulations, which statement best describes the approach to quality management systems for shared resources?", "choices": ["A. Both systems allow shared equipment within corporate groups under unified quality systems, but China explicitly permits this for infrequently used, expensive equipment while US regulations focus on validation requirements.", "B. US regulations mandate shared equipment validation for all manufacturing steps, while China prohibits any equipment sharing to prevent cross-contamination.", "C. Chinese regulations require separate quality systems for each manufacturing site, while US regulations allow complete equipment sharing without restrictions.", "D. Both systems prohibit equipment sharing entirely, requiring each facility to maintain independent equipment for all testing procedures."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations explicitly permit shared use of expensive, infrequently used testing equipment within corporate groups operating under unified quality management systems, treating it similarly to outsourced testing. US regulations don't specifically address equipment sharing but would require proper validation under quality system requirements. The other options misrepresent both regulatory approaches.", "category": "Drugs", "related_concept": "quality management system", "id": "PA_P_00054_001", "match_type": "weak", "match_score": 0.7476206743832448, "lang": "EN", "source_cn": "中药生产监督管理专门规定.txt", "source_us": "PART_201LABELING.txt", "old_id": "comp_0007_0079_1"}
{"question": "In comparing US and Chinese cosmetic regulatory frameworks, which statement best describes the primary difference in adverse event reporting obligations?", "choices": ["A. The US system requires mandatory reporting only from manufacturers, while China mandates reporting from a broader network including distributors, medical institutions, and e-commerce platforms.", "B. China's system is voluntary for all parties, while the US imposes mandatory reporting obligations on all entities in the supply chain.", "C. The US system focuses on post-market surveillance by a single entity, while China's system emphasizes pre-market safety assessments for all products.", "D. China requires reporting only for serious events, while the US mandates reporting for all suspected adverse events regardless of severity."], "answer": "A", "type": "Parallel", "explanation": "The correct answer highlights a key structural difference. Chinese regulations explicitly assign adverse event reporting obligations to a wide range of entities including overseas registrants, domestic responsible persons, entrusted manufacturers, distributors, medical institutions (with specific requirements for dermatology departments), and e-commerce platform operators, creating a multi-point monitoring network. US regulations, as referenced in the context of color additive safety, focus the regulatory burden for establishing safety and reporting primarily on the petitioner/manufacturer seeking approval, with the Commissioner evaluating submitted data. The other options misrepresent the voluntary/mandatory nature or the focus of the systems.", "category": "Cosmetics", "related_concept": "adverse event reporting obligations", "id": "PA_P_00599_005", "match_type": "weak", "match_score": 0.7184465017127603, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0006_0004_1"}
{"question": "在药品或化妆品监管中，当提交的申请资料发生实质性修订时，中美法规对申请日期的影响有所不同。请判断以下两个陈述的真假：陈述1：根据美国FDA法规，若补充信息构成实质性修订，申请将获得新的提交日期，审评时限重新计算。陈述2：中国NMPA法规中，实质性修订同样会导致申请日期更新，但审评时限通常不会因此重置。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "C", "type": "Parallel", "explanation": "陈述1正确：美国法规明确规定，若补充信息构成实质性修订，申请将获得新的提交日期（new filing date），且时间限制重新开始计算（the time limitation will begin to run anew）。陈述2错误：中国法规（基于常见实践）对于实质性修订，虽可能影响审评进程，但并未普遍规定申请日期自动更新或审评时限重置；通常，原申请日期可能保留，审评时限可能暂停或调整，而非像美国那样明确“重新计算”。", "category": "Pharmaceuticals/Cosmetics", "related_concept": "substantive amendment, new filing date", "id": "PA_P_00638_028", "match_type": "weak", "match_score": 0.7399124214836035, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0066_0001_2"}
{"question": "Statement 1: In China, when a Class II medical device distributor changes their warehouse address, they must immediately update their filing with regulatory authorities. Statement 2: In the US, for a Class II flow cytometric test system, the special controls require that premarket submissions include detailed information about the device's intended clinical applications and comprehensive technical specifications.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes Chinese regulations requiring immediate filing updates for changes to Class II medical device operations. Statement 2 accurately reflects US requirements for Class II devices where special controls mandate detailed information about clinical applications (indications for use) and technical specifications (device description) in premarket submissions.", "category": "Medical_Devices", "related_concept": "备案变更要求, device description, indications for use, special controls", "id": "PA_P_00509_002", "match_type": "weak", "match_score": 0.6673115949375773, "lang": "EN", "source_cn": "医疗器械经营监督管理办法（2022年第54号令）.txt", "source_us": "PART_864HEMATOLOGY_AND_PATHOLOGY_DEVICES.txt", "old_id": "comp_0007_0015_2"}
{"question": "关于化妆品新原料注册/备案信息的更新要求，中美法规在变更处理时限和程序上存在显著差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求所有信息变更均需在30天内完成更新，而美国法规则无明确时限要求", "B. 美国法规要求信息变更必须在30天内提交修正，而中国法规则根据变更类型区分了即时更新和提交材料更新两种程序", "C. 两国法规均要求信息变更在30个工作日内完成，但中国对境外注册人变更要求更严格的证明文件", "D. 中国法规仅对法定代表人变更设有时限要求，美国法规则对所有信息变更统一要求30天内修正"], "answer": "B", "type": "Parallel", "explanation": "美国法规§710.5明确规定，任何已提交表格信息的变更都应在30天内提交新表格修正注册。中国法规第十条则区分了不同类型的信息变更：法定代表人、联系方式等变化需及时自行更新；而其他基本信息、安全体系概述、授权范围等变化则需要提交更新表和相关资料，没有统一的30天时限要求，体现了程序上的差异化处理。", "category": "Cosmetics", "related_concept": "registration amendments", "id": "PA_P_00616_004", "match_type": "weak", "match_score": 0.7383602081796261, "lang": "CN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0003_0001_1"}
{"question": "In comparing US and Chinese regulatory approaches to ensuring quality management system effectiveness, which statement best describes a key difference in their mechanisms?", "choices": ["A. The US system emphasizes ISO 13485 compliance with specific FDA supplements, while China mandates internal organizational structures like quarterly executive reviews and defined key position responsibilities.", "B. The US requires more frequent training than China for quality personnel.", "C. China relies entirely on international standards like ISO 13485, whereas the US develops completely independent regulations.", "D. The US focuses on post-market surveillance only, while China focuses only on pre-market design controls."], "answer": "A", "type": "Parallel", "explanation": "The US system (per §820.10) builds upon ISO 13485 with specific FDA supplemental requirements (e.g., for UDI, complaint reporting). China's approach (per Articles 20-25) emphasizes internal organizational mechanisms—requiring quarterly reviews by enterprise leaders, clear definitions of key position duties (like Manager Representative, Quality Head), and specific fulfillment guarantee systems. Options B, C, and D are incorrect: B is unsupported (both have training requirements); C is false (China does not rely entirely on ISO here; the US incorporates it); D misrepresents both systems' scopes.", "category": "Medical_Devices", "related_concept": "quality management system, duty fulfillment mechanism", "id": "PA_P_00366_004", "match_type": "weak", "match_score": 0.7497204462855095, "lang": "EN", "source_cn": "企业落实医疗器械质量安全主体责任.txt", "source_us": "PART_820QUALITY_MANAGEMENT_SYSTEM_REGULATION_EFF_2.txt", "old_id": "comp_0008_0002_1"}
{"question": "关于化妆品中可摄入着色剂的安全性评估，中美法规在致癌性判定原则上有何关键差异？", "choices": ["A. 中国法规要求对所有着色剂进行致癌性测试，美国法规则仅对特定类别要求。", "B. 美国法规明确规定了基于合格科学家判断的致癌性评估流程，中国法规则未在提供文本中详述此流程。", "C. 中国法规要求着色剂在任何情况下都不得有致癌风险，美国法规则允许在特定条件下使用。", "D. 美国法规仅关注着色剂本身，中国法规则还要求评估其成分和杂质。"], "answer": "B", "type": "Parallel", "explanation": "美国法规（§70.50）详细规定了当科学数据提示致癌可能性时，局长必须基于合格科学家的判断来确定癌症是否被诱导以及着色剂（包括其成分和杂质）是否为致病物质，并据此决定是否允许使用。提供的中国法规文本（关于细菌回复突变试验）是安全性测试的报告体例，并未具体阐述致癌性评估的判定原则和流程，因此存在此关键差异。选项A、C、D的描述均不准确或与文本信息不符。", "category": "Cosmetics", "related_concept": "cancer clause application, ingested color additives", "id": "PA_P_00642_014", "match_type": "weak", "match_score": 0.7135537295140276, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0040_0005_1"}
{"question": "关于化妆品紧急控制措施，中美法规在实施前提上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求必须有实际人体伤害证据才能实施，而美国法规允许基于潜在危害风险实施", "B. 中国法规允许基于潜在危害风险实施，而美国法规要求必须有实际人体伤害证据才能实施", "C. 两国法规都要求必须有实际人体伤害证据才能实施紧急控制措施", "D. 两国法规都允许基于潜在危害风险实施紧急控制措施，无需实际伤害证据"], "answer": "B", "type": "Parallel", "explanation": "中国法规规定，当调查中发现有证据证明产品可能危害人体健康时，即可采取责令暂停经营的紧急控制措施，这允许基于潜在风险实施。美国法规（以D&C Blue No. 4为例）通过设定严格的化学成分限量标准来预防危害，但紧急控制措施的实施通常更侧重于对已确认违规或造成实际伤害的产品采取行动，其前提更强调实际证据。因此，中国法规在紧急控制上更注重风险预防，允许基于潜在危害实施；而美国法规虽通过严格标准预防，但在采取紧急执法行动时通常需要更确凿的违规或伤害证据。", "category": "Cosmetics", "related_concept": "emergency control measures", "id": "PA_P_00611_011", "match_type": "weak", "match_score": 0.7382465132996971, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0014_0005_1"}
{"question": "关于产品被认定为“掺假”（adulterated）或“错误标签”（misbranded），以下陈述哪个正确？\n陈述1：根据美国FDA法规，如果化妆品液体口腔卫生产品未采用防篡改包装或未按法规要求标注，可能被认定为掺假或错误标签。\n陈述2：中国《牙膏监督管理办法》规定，牙膏生产经营者违反强制性国家标准从事活动，可能导致产品被认定为不合格，但法规未直接使用“掺假”或“错误标签”的术语。", "choices": ["A. 两个陈述都正确", "B. 只有陈述1正确", "C. 只有陈述2正确", "D. 两个陈述都不正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：美国21 CFR 700.25明确，不符合防篡改包装或标签要求的化妆品液体口腔卫生产品，根据《联邦食品、药品和化妆品法案》第601条（掺假）或第602条（错误标签），或两者兼有，可被认定为掺假或错误标签。陈述2正确：中国《牙膏监督管理办法》第五条要求生产经营者遵守强制性国家标准等，违规会导致产品质量安全问题，但该办法及中国化妆品相关法规通常使用“不符合标准”、“假冒伪劣”等表述，未直接引入“adulterated/misbranded”这一对特定法律术语。", "category": "Cosmetics", "related_concept": "adulterated or misbranded", "id": "PA_P_00690_004", "match_type": "weak", "match_score": 0.6846744019255087, "lang": "CN", "source_cn": "牙膏监督管理办法（2023年第71号）.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0001_0004_4"}
{"question": "In regulatory frameworks for cosmetics, how do the approaches to establishing product specifications typically differ between US and Chinese systems?", "choices": ["A. US regulations focus on detailed chemical impurity limits for ingredients, while Chinese regulations emphasize performance testing protocols for finished products.", "B. Chinese regulations require certification of all color additives, while US regulations focus on SPF calculation methods.", "C. Both systems use identical specification requirements for all cosmetic ingredients and finished products.", "D. US regulations prioritize minimum erythema dose testing, while Chinese regulations focus on chemical composition limits."], "answer": "A", "type": "Parallel", "explanation": "The US regulation text shows detailed chemical specifications for color additives (FD&C Yellow No. 5), including specific impurity limits and certification requirements. The Chinese regulation text focuses on performance testing protocols for sunscreen products, including MED determination and SPF calculation methods. This reflects a fundamental difference in regulatory approach: US regulations often specify detailed chemical requirements for ingredients, while Chinese regulations for cosmetics frequently emphasize performance testing and clinical evaluation protocols for finished products.", "category": "Cosmetics", "related_concept": "specifications", "id": "PA_P_00637_034", "match_type": "weak", "match_score": 0.6935390345348023, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0068_0003_1"}
{"question": "关于医疗器械的紧急控制措施，中美两国监管机构在实施前提和措施类型上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国NMPA可在证明存在潜在健康危害时采取暂停生产等措施，而美国FDA对紧急控制措施的实施前提在题干文本中未明确体现", "B. 两国都要求必须发生实际伤害事件后才能采取紧急控制措施", "C. 美国FDA的紧急控制措施仅限于发布安全警示，而中国NMPA的措施更为多样", "D. 中国NMPA的紧急控制措施需要法院批准，而美国FDA可自行决定"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定了在“证明可能危害人体健康”时可采取暂停生产、进口、经营、使用等紧急控制措施。美国法规文本主要讨论义齿修复的专业性要求及镜片抗冲击测试豁免，未直接阐述FDA实施紧急控制措施的具体前提条件，体现了监管框架的差异。", "category": "Medical_Devices", "related_concept": "emergency control measures", "id": "PA_P_00496_001", "match_type": "weak", "match_score": 0.7466005974182569, "lang": "CN", "source_cn": "医疗器械监督管理条例.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0024_0014_1"}
{"question": "关于继续教育学时的全国有效性，中美药监法规有何差异？", "choices": ["A. 中国规定学时在全国范围内有效，美国法规未涉及此概念", "B. 两国都规定学时需经国家系统登记才全国有效", "C. 美国规定学时自动全国有效，中国需省级确认", "D. 两国都未对学时全国有效性作明确规定"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定，记入全国专业技术人员继续教育管理信息系统或全国执业药师注册管理信息系统的继续教育学时在全国范围内有效。美国提供的法规文本主要涉及药品新用途补充申请的豁免、终止及信息传播令等，未涉及继续教育学时的全国有效性规定。", "category": "Drugs", "related_concept": "national validity of continuing education hours", "id": "PA_P_00161_005", "match_type": "weak", "match_score": 0.7355001999514853, "lang": "CN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0008_0008_1"}
{"question": "Statement 1: In China, cosmetic human trials must include at least 30 female subjects meeting specific selection criteria. Statement 2: US regulations require color additive petitions to be published in the Federal Register within 90 days of filing, with possible extensions to 180 days.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, Statement 2 is incorrect.", "C. Statement 1 is incorrect, Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes Chinese requirements: trials involve 30 female volunteers with defined selection criteria. Statement 2 accurately reflects US regulations: color additive petitions are published within 90 days (extendable to 180 days) as per §71.20. Both statements align with the respective regulatory frameworks.", "category": "Cosmetics", "related_concept": "subject selection criteria, regulation publication timeline, trial duration", "id": "PA_P_00638_019", "match_type": "weak", "match_score": 0.7380619140844024, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0059_0002_2"}
{"question": "关于化妆品新原料安全风险控制报告，中美法规在提交对象和内容要求上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求向技术审评机构提交包含原因分析、处置措施和处理结果的报告；美国法规未对化妆品新原料设立类似的风险控制报告提交要求", "B. 中国法规要求企业向公众发布风险控制报告；美国法规要求向FDA提交并由FDA公开报告内容", "C. 两国法规都要求向监管部门提交风险控制报告，但中国要求更详细的处置措施记录，美国要求更严格的数据验证", "D. 中国法规的风险控制报告是自愿性文件；美国法规的风险控制报告是强制性且需定期更新的"], "answer": "A", "type": "Parallel", "explanation": "中国《化妆品监督管理条例》明确规定化妆品新原料注册人/备案人需编制安全风险控制报告，并通过信息服务平台向技术审评机构提交，报告需包含发情况原因分析、处置措施和处理结果等信息。而美国FDA对化妆品新原料的监管主要基于企业责任原则，未设立与中国类似的强制性风险控制报告提交制度，更多依赖企业自我监管和事后监督。", "category": "Cosmetics", "related_concept": "safety risk control report", "id": "PA_P_00621_001", "match_type": "weak", "match_score": 0.6821884853701335, "lang": "CN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0008_0007_1"}
{"question": "关于医疗器械的监管分类，以下哪项陈述最能体现中美法规在核心逻辑上的差异？", "choices": ["A. 中国法规主要依据医疗器械的预期用途和风险等级进行分类，而美国FDA的Class II分类则明确要求建立性能标准。", "B. 中国法规对医疗器械的定义包含了对生理过程的调节支持，而美国法规仅关注疾病的诊断与治疗。", "C. 美国法规要求所有Class II医疗器械均为处方器械，而中国法规则无此强制性对应关系。", "D. 中国法规对大型医用设备有专门的目录管理，而美国法规则对所有医疗器械采用统一的风险分类体系。"], "answer": "A", "type": "Parallel", "explanation": "中国《医疗器械监督管理条例》对医疗器械的定义和分类（虽未在提供文本中详述分类规则，但隐含了基于风险管理的框架）主要围绕其预期用途（如诊断、治疗、支持等）和风险进行监管。美国FDA对医疗器械明确采用三级分类体系（Class I, II, III），其中Class II设备通常指普通控制不足以确保其安全有效性，需要特殊控制（如性能标准）的设备。选项A准确抓住了美国Class II分类与“性能标准”这一特殊控制要求的核心关联，以及与中国基于风险分类逻辑的对比。选项B错误缩小了美国法规的适用范围；选项C错误地将“处方器械”属性与Class II完全绑定（处方器械可存在于不同类别）；选项D描述的是中国特色的管理措施，并非核心分类逻辑的差异。", "category": "Medical_Devices", "related_concept": "Class II, performance standards", "id": "PA_P_00558_001", "match_type": "weak", "match_score": 0.7254121342118751, "lang": "CN", "source_cn": "国务院关于修改《医疗器械监督管理条例》的决定.txt", "source_us": "PART_880GENERAL_HOSPITAL_AND_PERSONAL_USE_DEVICES.txt", "old_id": "comp_0023_0003_1"}
{"question": "A cosmetics e-commerce platform discovers a seller has been criminally convicted for product safety violations. In which regulatory system would this trigger immediate platform service termination?", "choices": ["A. US FDA regulations only", "B. Chinese NMPA regulations only", "C. Both US FDA and Chinese NMPA regulations", "D. Neither US FDA nor Chinese NMPA regulations"], "answer": "B", "type": "Parallel", "explanation": "Chinese NMPA regulations require e-commerce platforms to immediately stop providing services to sellers with severe violations including criminal convictions for product safety offenses. US FDA regulations focus on certification suspension for procedural violations like fraud or refusal of inspection, not specifically on platform service termination for seller criminal convictions.", "category": "Cosmetics", "related_concept": "service suspension for severe violations", "id": "PA_P_00683_001", "match_type": "weak", "match_score": 0.7474778365631347, "lang": "EN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0004_0003_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中美化妆品相关法规，一批化妆品原料或产品若想获得上市许可，都必须提供其理化检验报告。\n陈述2：根据中美化妆品相关法规，一批已列入清单的着色剂（如Ext. D&C Yellow No. 7）若用于外部化妆品，其生产批次必须符合特定规格并通过认证程序。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "D", "type": "Parallel", "explanation": "陈述1错误。提供的中国法规文本显示了化妆品成品检验报告包含“理化检验”部分，表明在中国，化妆品成品的安全性评估需要理化检验。然而，美国法规文本（§ 82.2050, § 82.2707a）聚焦于着色剂的认证和规格，并未直接规定所有化妆品原料或产品必须提供通用的“理化检验报告”。因此，该要求并非两国法规的通用强制要求。\n陈述2正确。美国法规明确要求（§ 82.2050），用于外部药品和化妆品的单一着色剂批次，必须符合本部分（包括§ 82.5）的要求以及本子部分为该颜色设定的规格，才能获得认证。例如，Ext. D&C Yellow No. 7也需符合身份和规格要求（§ 82.2707a）。这体现了美国对某些化妆品成分（如着色剂）的批次认证管理制度。而中国文本未具体描述着色剂的批次认证。", "category": "Cosmetics", "related_concept": "physicochemical testing, batch certification, straight color listing", "id": "PA_P_00640_005", "match_type": "weak", "match_score": 0.7158883630702302, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0026_0005_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中国法规，药品生产过程中的所有变更，无论大小，都必须事先获得国务院药品监督管理部门的批准方可实施。\n陈述2：根据美国法规，当一份待审申请（pending application）被申请人主动撤回后，若未来重新提交，其审评时限的计算起点将是重新提交的日期。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误。中国法规（第七十九条）对药品生产变更实行的是基于风险程度的分类管理，并非所有变更都需要事先批准。只有被归类为“重大变更”的才需要经国务院药品监督管理部门批准，其他变更则按规定进行备案或报告即可。\n陈述2正确。美国法规（§ 514.7）明确规定，申请人可以无偏见地撤回待审申请。当该申请被重新提交时，相关的时间限制（如审评时限）将从食品药品管理局（FDA）收到重新提交申请的日期开始计算。", "category": "Drugs", "related_concept": "变更分类管理, pending application, resubmission date", "id": "PA_P_00018_005", "match_type": "weak", "match_score": 0.6855677237456212, "lang": "CN", "source_cn": "中华人民共和国药品管理法.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0015_0006_2"}
{"question": "关于化妆品人体试用试验中皮肤不良反应的记录，中美法规在核心要求上存在差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规要求按特定分级标准记录结果，而美国法规未规定具体分级方法。", "B. 美国法规要求记录所有观察时间点的反应，而中国法规仅记录最终结果。", "C. 中国法规要求由负责医生观察记录，而美国法规允许任何研究人员记录。", "D. 美国法规要求使用统一的国际分级标准，而中国法规允许自定义标准。"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确要求按现行有效的技术规范中人体试用试验皮肤不良反应分级标准记录结果，体现了对标准化评估的重视。美国法规文本虽未直接提及皮肤反应分级，但更侧重于临床试验的整体合规性要求（如机构审查和知情同意），暗示分级方法可能遵循其他指南或由研究方案规定，而非法规直接指定具体标准。", "category": "Cosmetics", "related_concept": "skin adverse reaction grading", "id": "PA_P_00638_027", "match_type": "weak", "match_score": 0.7399124214836035, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0066_0001_1"}
{"question": "In comparing US FDA and Chinese NMPA cosmetic regulations, which statement about quality management system documentation requirements is correct?", "choices": ["A. Both require detailed quality management system documentation, but the NMPA specifically requires a 'Quality Management System Overview Form' as part of registration/notification, while the FDA focuses on demonstrating compliance with current good manufacturing practice (cGMP) through various means.", "B. Only the NMPA requires any formal documentation of a quality management system; the FDA has no such requirement for cosmetics.", "C. Both agencies require identical 'Quality Management System Overview Forms' to be submitted with identical content.", "D. The FDA requires a more detailed and prescriptive quality management system documentation than the NMPA, which only requires a basic statement of compliance."], "answer": "A", "type": "Parallel", "explanation": "The NMPA explicitly lists a '质量管理体系概述表' (Quality Management System Overview Form) as a required document for cosmetic registration/notification, indicating a structured, form-based submission. The FDA regulations for color additives (and cosmetics generally under cGMP) imply the need for a robust quality management system but do not prescribe a specific form; compliance is demonstrated through adherence to cGMP principles and other regulatory requirements like batch certification. Option B is incorrect as the FDA does require quality management under cGMP. Option C is incorrect as the requirements and formats differ. Option D is incorrect as the NMPA's form-based requirement can be quite specific and structured, not merely a basic statement.", "category": "Cosmetics", "related_concept": "quality management system", "id": "PA_P_00653_031", "match_type": "weak", "match_score": 0.7447230338068911, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0038_0024_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在人体皮肤安全性测试中，中美法规都明确要求采用系统抽样方法进行受试者结果统计。\n陈述2：关于检验报告，中国法规有明确的体例要求（如包含机构全称、样品信息等），而美国相关法规文本未对化妆品成分声明的报告格式做出类似规定。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误：中国法规文本明确提到了“采用系统抽样方法统计前30例有效受试者结果”，这是针对特定测试（人体皮肤重复性开放型涂抹试验）的要求。而提供的美国法规文本（§720.8, §720.9）主要涉及成分声明、保密性和误导性标签，并未提及皮肤测试的抽样方法。因此不能推断为“都明确要求”。陈述2正确：中国法规文本详细列出了检验报告的体例要素（如机构全称、检验受理编号、样品名称等）。美国提供的文本聚焦于表格提交、编号分配和法律声明，并未规定报告的具体格式或内容要素，两者在报告规范性要求上存在差异。", "category": "Cosmetics", "related_concept": "systematic sampling method, human skin repeatability open application test, inspection report", "id": "PA_P_00644_004", "match_type": "weak", "match_score": 0.7452468807004374, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0049_0003_2"}
{"question": "In the context of cosmetic ingredient safety monitoring, which regulatory approach is more likely to involve a formal post-market surveillance period with periodic safety reviews by a technical body?", "choices": ["A. US FDA approach", "B. Chinese NMPA approach", "C. Both approaches equally", "D. Neither approach"], "answer": "B", "type": "Parallel", "explanation": "The Chinese NMPA approach typically includes a formal 3-year safety monitoring period for new cosmetic ingredients, after which technical review bodies assess safety and make recommendations to the regulatory authority. The US FDA approach described focuses more on ingredient-specific prohibitions and country designation processes rather than structured post-market surveillance periods for cosmetic ingredients.", "category": "Cosmetics", "related_concept": "technical review assessment", "id": "PA_P_00645_004", "match_type": "weak", "match_score": 0.7437372081923123, "lang": "EN", "source_cn": "化妆品注册备案管理办法（2021年第35号令）.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0008_0007_1"}
{"question": "关于实质性修改（substantive amendment）的处理，中美法规在程序上存在关键差异。请判断以下陈述：\n陈述1：根据美国法规，如果补充信息构成实质性修改，申请将获得新的提交日期，时间限制重新计算。\n陈述2：根据中国法规，化妆品电子商务平台经营者发现违法线索后，必须在10日内报告，这类似于一种程序性时限，但不会因补充信息而重置调查时间。", "choices": ["A. 两个陈述都正确", "B. 只有陈述1正确", "C. 只有陈述2正确", "D. 两个陈述都不正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：美国法规明确，如果补充信息构成实质性修改，修改后的申请将获得新的提交日期，相关时间限制（如审查时限）将重新开始计算。陈述2正确：中国法规规定，化妆品电子商务平台经营者在发现特定违法线索（如导致人体损害、使用禁用原料等）后，必须在10日内向省级药监部门报告。这是一个固定的报告时限，适用于违法线索的初始报告，不同于美国法规中因补充信息而重置时间的情况。中国法规中，药监部门收到报告后的调查处理有自身程序，但未提及因平台经营者补充信息而重置10日报告时限。因此，两个陈述都正确，突出了美国在申请程序上因实质性修改重置时间的特点，与中国在违法报告上固定时限的区别。", "category": "Cosmetics", "related_concept": "substantive amendment, new filing date", "id": "PA_P_00684_002", "match_type": "weak", "match_score": 0.7114609565612484, "lang": "CN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0005_0001_2"}
{"question": "针对医疗器械监管人员的渎职行为，中美法规的处置原则有何关键区别？", "choices": ["A. 中国法规要求公开道歉，美国法规强制离职", "B. 中国法规明确依法给予处分，美国法规依赖司法诉讼", "C. 两国法规均仅内部处理，不对外公开", "D. 美国法规以罚款为主，中国法规以警告为主"], "answer": "B", "type": "Parallel", "explanation": "中国法规（如NMPA条例）直接规定对滥用职权、玩忽职守的监管人员依法给予处分，体现了行政体系内的问责制。美国法规（FDA相关）在文本中未具体说明对监管人员的处理，通常此类事项会通过法律程序（如司法诉讼或行政听证）解决。干扰项A错误，因文本未要求公开道歉；C错误，因中国法规提及通报批评（公开性）；D错误，因文本未强调罚款。", "category": "Medical_Devices", "related_concept": "misconduct by regulatory staff", "id": "PA_P_00498_005", "match_type": "weak", "match_score": 0.7480914146047193, "lang": "CN", "source_cn": "医疗器械监督管理条例.txt", "source_us": "PART_880GENERAL_HOSPITAL_AND_PERSONAL_USE_DEVICES.txt", "old_id": "comp_0037_0005_2"}
{"question": "When comparing regulatory frameworks for controlled substance research applications, which statement best describes a key difference between US and Chinese approaches regarding scientific evidence requirements?", "choices": ["A. The US system requires petitioners to include a summary of relevant medical or scientific evidence in their petition, while China mandates comprehensive literature reviews covering pharmacology, dependency, and clinical history.", "B. Both systems require identical documentation of scientific studies conducted by qualified experts.", "C. China focuses primarily on administrative procedures while the US emphasizes scientific evidence exclusively.", "D. The US requires more detailed market analysis than China for research applications."], "answer": "A", "type": "Parallel", "explanation": "The US regulation specifies that petitions must include 'a summary of any relevant medical or scientific evidence' as part of the statement of grounds. The Chinese regulation requires extensive literature reviews covering pharmacology, dependency studies, clinical applications, abuse patterns, and adverse events as part of the application package. This represents a structural difference in how scientific evidence is integrated into the application process.", "category": "Controlled_Substances", "related_concept": "research purpose and literature review", "id": "PA_P_00722_004", "match_type": "weak", "match_score": 0.7139019095599421, "lang": "EN", "source_cn": "麻醉药品和精神药品实验研究管理规定.txt", "source_us": "PART_1308SCHEDULES_OF_CONTROLLED_SUBSTANCES.txt", "old_id": "comp_0009_0014_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在药品监管中，“Specifications”通常指药品的详细技术参数，如成分含量、剂型等，这是中美法规都包含的核心监管要素。\n陈述2：中美药品法规中的“Sponsor”概念都特指负责药品临床试验申请和监管沟通的实体或个人，其法律定义和职责完全相同。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确。“Specifications”（规格）是药品监管的基础，指药品的组成、含量、剂型、质量属性等具体技术标准。无论是中国NMPA的注册审评还是美国FDA的药品批准（如文本中列出的各药品规格），这都是确保药品质量、安全性和有效性的关键监管内容。\n陈述2错误。虽然“Sponsor”（申办者/赞助商）在中美法规中都是指对药品研发和注册负责的实体，但其具体法律定义、职责范围和在监管流程中的角色可能存在差异。例如，美国FDA法规中的Sponsor概念在药品研发的不同阶段（如IND、NDA）有更细化的规定，而中国法规中的“药品注册申请人”概念与之类似但并非完全等同。文本中美国法规部分仅列出了药品的赞助商编号，并未定义其职责，因此不能断言两者“完全相同”。", "category": "Drugs", "related_concept": "specifications, sponsor", "id": "PA_P_00210_002", "match_type": "weak", "match_score": 0.6839919314004873, "lang": "CN", "source_cn": "药品注册审评结论异议解决程序（试行）.txt", "source_us": "PART_520ORAL_DOSAGE_FORM_NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0001_0011_2"}
{"question": "Statement 1: Regulatory authorities can proactively list color additives and grant certification exemptions based on available safety data without requiring a formal petition. Statement 2: Sampling inspection programs should prioritize products with higher safety risks, such as those with previous compliance issues or wider consumer exposure.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 reflects regulatory authority to initiate listing and exemption actions based on safety evidence. Statement 2 represents risk-based prioritization principles in sampling programs, focusing resources on higher-risk products to maximize public health protection.", "category": "Cosmetics", "related_concept": "listing and exemption from certification, sampling inspection focus areas", "id": "PA_P_00609_002", "match_type": "weak", "match_score": 0.6940748301332798, "lang": "EN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0002_0003_2"}
{"question": "在化妆品人体安全性评价中，关于试验样本选择和数据统计方法，以下哪项描述最准确地反映了中美法规的典型要求差异？", "choices": ["A. 中国法规通常明确要求采用系统抽样等统计方法确定受试者数量（如30例），美国法规则更侧重于试验设计的科学合理性，而非固定样本数", "B. 美国法规强制要求所有人体试验必须采用随机双盲设计，中国法规则允许开放性试验", "C. 中国法规要求所有安全性试验必须包含至少100例受试者，美国法规则允许基于风险评估减少样本量", "D. 美国法规要求试验数据必须由第三方独立统计，中国法规则允许企业自行统计分析"], "answer": "A", "type": "Parallel", "explanation": "在中国NMPA的育发类化妆品人体试用试验体例中，明确提到了“采用系统抽样方法统计前30例有效受试者”，这体现了对样本选择和数量的具体指导。而美国FDA的法规（如21 CFR）通常更侧重于要求试验设计必须科学合理、足以支持安全性结论，并遵循GCP等原则，但一般不会在法规中硬性规定具体的样本数量（如30例），而是基于产品特性、风险和研究目的来确定。选项B、C、D的描述过于绝对或与两国法规的典型实践不符。", "category": "Cosmetics", "related_concept": "systematic sampling method", "id": "PA_P_00642_028", "match_type": "weak", "match_score": 0.7311920604805674, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0053_0005_2"}
{"question": "关于化妆品新原料的不良反应监测，中美法规在责任主体和报告机制上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求新原料注册人/备案人收集并分析使用该原料的化妆品的不良反应数据，并编制年度报告；美国法规未对颜色添加剂的使用者设定类似的不良反应监测和报告义务。", "B. 两国法规均要求原料供应商直接监测并报告终端产品的不良反应，且报告周期和格式完全相同。", "C. 美国法规要求颜色添加剂的生产商必须建立并运行一套针对使用其添加剂的所有终端化妆品的不良反应监测体系；中国法规则无此要求。", "D. 中国法规仅要求化妆品生产企业自行监测不良反应，无需向新原料责任人报告；美国法规则要求颜色添加剂认证申请人必须提交其产品的全球不良反应数据。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（CN）明确要求化妆品新原料的注册人、备案人或境内责任人负责收集、整理使用该新原料的化妆品的不良反应信息，并编制安全监测年度报告。这体现了原料端对下游产品安全性的持续追踪责任。而提供的美国法规（US）文本主要涉及颜色添加剂的认证、记录保存和现场检查等，并未对已认证颜色添加剂在化妆品中使用后，其生产商或认证持有人设定强制性的、系统性的终端产品不良反应监测和报告义务。因此，A选项准确描述了这一核心差异。B、C、D选项的描述均与两国法规的实际规定不符。", "category": "Cosmetics", "related_concept": "adverse reaction monitoring", "id": "PA_P_00620_001", "match_type": "weak", "match_score": 0.7282082959026532, "lang": "CN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0007_0003_1"}
{"question": "关于体外诊断试剂的风险评估，中美法规在评估因素上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规强调检验结果对个人和公共健康的影响，而美国法规未涉及此因素", "B. 美国法规主要依据产品预期用途和使用环境，而中国法规未考虑这些因素", "C. 中国法规明确列出影响风险程度的具体因素，而美国法规未提供类似清单", "D. 美国法规要求评估检验结果对医学诊断的影响，而中国法规未提及此点"], "answer": "C", "type": "Parallel", "explanation": "中国法规第四条明确列出了影响体外诊断试剂风险程度的具体因素，包括产品预期用途、检验结果对医学诊断和治疗的影响程度、以及对个人和/或公共健康的影响。美国法规文本中未提供类似的风险评估因素清单，而是侧重于标签要求、误导性陈述禁止等具体规定。选项A和D存在事实错误，选项B与中国法规内容不符。", "category": "Medical_Devices", "related_concept": "产品风险程度评估", "id": "PA_P_00367_001", "match_type": "weak", "match_score": 0.6363070897622015, "lang": "CN", "source_cn": "体外诊断试剂分类规则.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0001_0005_1"}
{"question": "A cosmetics manufacturer in China discovers a quality issue with a batch of products. To investigate the root cause, they need to trace all related production activities. Which regulatory approach would provide the most comprehensive framework for this investigation?", "choices": ["A. The Chinese approach, which requires all batch-related records to be mutually linked and traceable through a comprehensive traceability system", "B. The US approach, which requires detailed distribution records for color additives to be kept separately from other records", "C. Both approaches would provide equally comprehensive frameworks for batch investigation", "D. Neither approach provides sufficient guidance for batch investigation"], "answer": "A", "type": "Parallel", "explanation": "The Chinese regulation establishes a comprehensive traceability system requiring all batch-related records to be mutually linked, covering the entire production chain from raw materials to finished products. This provides a complete framework for investigating quality issues. The US regulation focuses specifically on color additive distribution records, which is narrower in scope and wouldn't provide comprehensive batch investigation capabilities.", "category": "Cosmetics", "related_concept": "record management system", "id": "PA_P_00668_001", "match_type": "weak", "match_score": 0.7361983533670106, "lang": "EN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0005_0004_1"}
{"question": "关于医疗器械唯一标识（UDI）的要求，以下哪项描述最准确？", "choices": ["A. 中国法规要求所有医疗器械都必须标注UDI，美国法规则只对植入式器械有要求", "B. 美国法规明确要求UDI必须记录在投诉和服务记录中，中国法规未提及UDI在记录中的具体要求", "C. 两国法规都要求UDI系统必须与温湿度监控系统集成", "D. 中国法规要求UDI必须包含生产批号信息，美国法规则不需要"], "answer": "B", "type": "Parallel", "explanation": "美国法规在§820.35中明确要求，投诉记录和服务记录必须包含UDI或UPC等设备标识信息。中国提供的法规文本主要关注运输贮存环节的监控和信息系统，未具体提及UDI在记录中的要求。选项A错误，美国法规对UDI的要求不限于植入式器械；选项C错误，文本中未提及UDI与温湿度系统的集成要求；选项D错误，两国法规对UDI内容的要求在文本中未直接对比。", "category": "Medical_Devices", "related_concept": "unique device identification", "id": "PA_P_00514_008", "match_type": "weak", "match_score": 0.7355000577900845, "lang": "CN", "source_cn": "医疗器械经营质量管理规范附录：.txt", "source_us": "PART_820QUALITY_MANAGEMENT_SYSTEM_REGULATION_EFF_2.txt", "old_id": "comp_0011_0002_2"}
{"question": "Statement 1: In quality control for cosmetics, sensory indicators like color and odor are primarily verified through final product testing. Statement 2: For chemical color additives, the 'total color' percentage is a key specification ensuring the strength and purity of the primary intended ingredient.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is generally incorrect. While final product testing checks sensory attributes, robust quality control for sensory indicators often relies heavily on raw material specifications and in-process controls to ensure consistency, not just final testing. Statement 2 is correct. For a color additive like D&C Blue No. 4, the 'total color' specification (e.g., 'not less than 85 percent') is a fundamental physicochemical indicator of the main colorant's potency and relative freedom from diluents or impurities.", "category": "Cosmetics", "related_concept": "sensory indicators, physicochemical indicators, quality control measures", "id": "PA_P_00653_046", "match_type": "weak", "match_score": 0.7433638742673015, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0052_0005_2"}
{"question": "关于药品注册审评结论的异议解决程序，中美两国法规在程序启动条件上存在显著差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规要求异议必须在收到审评结论后15日内提出，而美国法规则没有明确的异议提出时限规定。", "B. 中国法规明确规定了异议解决的具体流程和时间节点，而美国法规则更侧重于药品上市后的监管和标签管理。", "C. 中国法规的异议解决程序主要针对审评结论为“不予通过”的情形，而美国法规则主要处理药品规格、适应症和使用限制的变更。", "D. 中国法规强调异议解决过程中的沟通交流，而美国法规则更注重通过法律条文明确药品的使用条件和限制。"], "answer": "C", "type": "Parallel", "explanation": "中国法规（NMPA）的异议解决程序是药品注册审评流程中的一个专门环节，旨在处理对“不予通过”审评结论的异议，涉及综合评估、专家咨询等步骤。而提供的美国法规（FDA）文本主要涉及已批准动物药品的规格、赞助商、使用条件、适应症和限制等上市后管理内容，并未描述一个与中国类似的、针对审评结论的正式异议解决程序。因此，两者的核心差异在于程序适用的阶段和目的：中国是针对审评结论的异议，美国是针对已批准药品的规范管理。", "category": "Drugs", "related_concept": "异议解决程序, 审评结论异议", "id": "PA_P_00210_001", "match_type": "weak", "match_score": 0.6839919314004873, "lang": "CN", "source_cn": "药品注册审评结论异议解决程序（试行）.txt", "source_us": "PART_520ORAL_DOSAGE_FORM_NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0001_0011_1"}
{"question": "Statement 1: In China, a medical device manufacturer can sell their registered devices at their production facility without obtaining separate business licensing. Statement 2: In the US, Class I ophthalmic devices are always exempt from quality system regulation requirements.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct: Chinese regulations allow manufacturers to sell registered devices at their production address without separate business licensing, though they must meet operational conditions. Statement 2 is incorrect: While many Class I ophthalmic devices are exempt from quality system regulations, they still must comply with specific requirements like record keeping (§820.180) and complaint files (§820.198) as noted in the exemptions.", "category": "Medical_Devices", "related_concept": "sales without business licensing or filing, quality system regulation exemption", "id": "PA_P_00565_002", "match_type": "weak", "match_score": 0.7366670528289556, "lang": "EN", "source_cn": "国家药监局关于贯彻实施《医疗器械监督管理条例》有关事项的公告（2021年第76号）.txt", "source_us": "PART_886OPHTHALMIC_DEVICES.txt", "old_id": "comp_0002_0010_2"}
{"question": "关于现场抽样时被抽样方的权利与义务告知，以及抽样文书的确认签字，请判断以下陈述：\n陈述1：中国法规要求抽样人员必须现场告知被抽样化妆品生产经营者其法定权利与义务。\n陈述2：美国法规在涉及实质性修正的申请流程中，要求申请方必须就补充信息中的临床研究提供机构审查和知情同意的合规声明。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。根据中国化妆品抽样法规的通用原则，现场抽样时，抽样人员有义务告知被抽样方（化妆品生产经营者）依法享有的权利和应当承担的义务，这是保障程序公正和知情权的重要环节。\n陈述2正确。根据美国法规（如FDA）关于实质性修正的通用原则，当补充信息涉及以人为受试者的临床研究时，申请方（或请愿人）必须提供声明，说明该研究是否符合机构审查委员会（IRB）审查的要求（或豁免依据）以及是否符合知情同意的法规要求。这是确保研究伦理和受试者保护的关键合规步骤。", "category": "Cosmetics", "related_concept": "on-site sampling rights and obligations, substantive amendment", "id": "PA_P_00609_004", "match_type": "weak", "match_score": 0.7333434288198749, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0005_0001_2"}
{"question": "Statement 1: During a declared public health emergency, US regulations may temporarily modify telemedicine requirements for prescribing schedule II-V controlled substances.\nStatement 2: Chinese regulations for veterinary ephedrine hydrochloride explicitly reference oversight by both agricultural and pharmaceutical regulatory bodies.\nWhich option correctly evaluates these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as US regulations reference public health emergency designations that modify telemedicine prescribing requirements. Statement 2 is correct as Chinese regulations explicitly state that veterinary ephedrine hydrochloride oversight follows regulations from both the Ministry of Agriculture and State Food and Drug Administration.", "category": "Telemedicine_Regulations", "related_concept": "public health emergency designation, regulations of Ministry of Agriculture and State Food and Drug Administration", "id": "PA_P_00718_002", "match_type": "weak", "match_score": 0.7360092749871865, "lang": "EN", "source_cn": "药品类易制毒化学品管理办法（卫生部令第72号_2010年）.txt", "source_us": "PART_1307MISCELLANEOUS.txt", "old_id": "comp_0017_0002_2"}
{"question": "在化妆品监管中，中美两国对常规检查计划的制定原则有何不同？", "choices": ["A. 中国强调基于风险管理和问题导向的综合因素制定计划，美国则主要依据产品上市前的安全评估数据。", "B. 中国主要依据企业历史违规记录，美国则依据年度抽检计划。", "C. 两国都完全依据随机抽样原则制定常规检查计划。", "D. 中国依据企业规模，美国依据产品销量。"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确常规检查计划需基于风险管理原则，并综合考虑注册备案、抽样检验、不良反应监测、投诉举报、案件查处、舆情监测等多种问题导向因素。美国提供的法规文本主要涉及色素添加剂上市前的安全评估标准（如安全系数应用、安全性测试要求、上市条件等），并未详细描述针对化妆品生产经营者的常规检查计划制定原则。因此，中国的特点是基于风险管理和多因素问题导向的综合规划，而美国文本展现的是以产品安全数据为核心的上市前管控模式。", "category": "Cosmetics", "related_concept": "routine inspection planning", "id": "PA_P_00633_001", "match_type": "weak", "match_score": 0.7425903070154349, "lang": "CN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0007_0004_1"}
{"question": "关于政府在医药事业发展中的规划与管理角色，中美法规体系展现出不同的侧重点。以下哪项组合最能体现这种差异？\n① 将中医药事业纳入国民经济和社会发展规划\n② 建立中央与地方分级负责的中医药管理体系\n③ 制定OTC药品专论系统的具体实施时间表\n④ 明确FDA对OTC药品审评的行动时限要求\n⑤ 支持社会力量投资和捐赠中医药事业", "choices": ["A. ①②⑤", "B. ①③④", "C. ②③⑤", "D. ③④⑤"], "answer": "A", "type": "Parallel", "explanation": "①②⑤体现了中国法规的特点：《中医药法》明确要求县级以上政府将中医药纳入发展规划（①），建立从国务院到地方的分级管理体系（②），并支持社会投资和捐赠（⑤）。③④体现了美国法规的特点：FDA法规（330.14/330.15）关注OTC专论系统的具体实施和时间框架。因此，①②⑤组合准确反映了中国在政府规划和管理体系方面的独特规定。", "category": "Drugs", "related_concept": "government planning and management system, support for social investment and donations", "id": "PA_P_00006_003", "match_type": "weak", "match_score": 0.7114403728051812, "lang": "CN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_330OVER-THE-COUNTER_OTC_HUMAN_DRUGS_WHICH_ARE.txt", "old_id": "comp_0001_0002_3"}
{"question": "A cosmetics company discovers that a batch of its vaginal gel products has packaging that could be easily resealed after opening without visible evidence. Under US regulations, what is the primary regulatory consequence of this finding?", "choices": ["A. The products are considered adulterated or misbranded and cannot be sold", "B. The company must immediately initiate adverse event reporting procedures", "C. The company must redesign the packaging but can continue sales during the transition", "D. The products require additional warning labels about potential contamination"], "answer": "A", "type": "Parallel", "explanation": "Under US FDA regulations, cosmetic liquid oral hygiene products and vaginal products must be packaged in tamper-resistant packaging that provides visible evidence if tampering has occurred. Products not meeting these requirements are considered adulterated under section 601 or misbranded under section 602 of the Federal Food, Drug, and Cosmetic Act, making them illegal for sale.", "category": "Cosmetics", "related_concept": "tamper-resistant packaging, adulterated or misbranded", "id": "PA_P_00598_019", "match_type": "weak", "match_score": 0.6988839014938463, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0016_0004_1"}
{"question": "关于执业药师继续教育机构，中美法规的主要差异体现在：", "choices": ["A. 中国法规明确列举了机构类型，美国法规未涉及此概念", "B. 美国法规要求机构必须为政府举办，中国法规则鼓励多元化", "C. 两国法规均要求继续教育机构必须由药品监管部门直接认证", "D. 中国法规强调机构的公益性和非营利性，美国法规则未对此作出规定"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如第十一条）明确规定了执业药师继续教育机构包括高等院校、科研院所、大型企业、社会组织的培训机构等各类教育培训机构。而提供的美国法规文本主要涉及药品新用途信息传播的监管、研究时限延长及豁免终止等程序性规定，并未提及“继续教育机构”这一概念或对其进行定义。因此，选项A准确描述了这一核心差异。选项B错误，因为中国法规鼓励企业、事业单位、社会组织等举办公益性活动，并非要求政府举办；选项C错误，两国法规均未明确要求必须由药监部门直接认证；选项D错误，中国法规确实对政府部门直接举办的活动要求突出公益性（第十二条），但美国法规文本未涉及继续教育机构，故无法比较其是否规定公益性。", "category": "Drugs", "related_concept": "continuing education institutions", "id": "PA_P_00161_001", "match_type": "weak", "match_score": 0.6691832241148299, "lang": "CN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0004_0008_1"}
{"question": "关于医疗器械标签中符号的使用规范，请判断以下陈述：\n陈述1：根据美国FDA规定，医疗器械标签中使用的所有符号都必须有相邻的英文解释文本。\n陈述2：中国NMPA对体外诊断试剂的分类管理主要依据产品风险程度，而风险程度评估需考虑检验结果对医学诊断和治疗的影响。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误：美国FDA法规允许在特定条件下使用无相邻解释文本的符号，例如符号包含在FDA认可的标准中并按照规范使用，且标签中包含符号词汇表。陈述2正确：中国法规第四条明确规定体外诊断试剂的管理类别应根据产品风险程度判定，影响因素包括检验结果信息对医学诊断和治疗的影响程度。", "category": "Medical_Devices", "related_concept": "symbol usage specifications, 检验结果影响程度", "id": "PA_P_00367_002", "match_type": "weak", "match_score": 0.6363070897622015, "lang": "CN", "source_cn": "体外诊断试剂分类规则.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0001_0005_2"}
{"question": "关于化妆品网络经营违法行为的调查处理，中美法规在执法主体和措施上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规明确授权药品监督管理部门采取现场检查、抽样检验、查封扣押等具体执法措施；美国法规主要涉及标签标注要求，未详细规定针对网络经营违法行为的调查处理措施。", "B. 两国法规均授权药品监督管理部门对网络经营违法行为采取相同的现场检查和抽样检验措施。", "C. 美国法规授权食品药品监督管理局（FDA）对网络经营违法行为采取查封场所等强制措施；中国法规则未规定此类措施。", "D. 两国法规均未对化妆品网络经营违法行为的调查处理程序做出具体规定，主要依靠行业自律。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如《化妆品监督管理条例》相关条款）明确规定了负责药品监督管理的部门对化妆品网络经营违法行为进行调查处理时，可采取包括现场检查、抽样检验、查阅复制资料、查封扣押等在内的多项具体执法措施。而提供的美国法规文本（21 CFR 701部分）主要涉及化妆品标签上生产地、净含量等内容的标注要求，并未详细阐述针对网络经营违法行为的调查处理程序和具体执法措施。这体现了中美在化妆品网络经营监管执法框架上的侧重点差异。", "category": "Cosmetics", "related_concept": "investigation and handling of violations, inspection measures", "id": "PA_P_00686_001", "match_type": "weak", "match_score": 0.6892620333132327, "lang": "CN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0009_0007_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在公共行政程序方面，美国FDA的指南强调通过预先通知和既定程序来确保媒体录制的统一性。\n陈述2：中国法规在信息网络安全领域，要求经营单位在开业前必须获得公安机关的实质性安全批准文件。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "解析：陈述1正确。美国FDA指南明确指出，对行政程序进行电子媒体录制需要“预先通知”并遵循“既定程序”，目的是为了“确保整个机构实践和程序应用的一致性和统一性”。陈述2错误。根据中国法规的修改，对于互联网上网服务营业场所，信息网络安全的要求已从“申请审核并取得批准文件”修改为“承诺符合条件并签署承诺书”，开业前不再需要取得公安机关的实质性安全批准文件（消防安全批准文件仍需），改为事后检查。", "category": "General_FDA", "related_concept": "public administrative proceedings, advance notice, uniform application, information network security", "id": "PA_P_00778_002", "match_type": "weak", "match_score": 0.736675065515086, "lang": "CN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_10ADMINISTRATIVE_PRACTICES_AND_PROCEDURES.txt", "old_id": "comp_0016_0015_2"}
{"question": "关于化妆品成分声明编号，中美法规在以下哪项表述上存在关键差异？", "choices": ["A. 中国法规要求所有产品必须获得永久性编号，而美国FDA仅在某些情况下分配参考编号", "B. 美国FDA分配的编号或参考号仅用于行政追踪，不代表官方批准，而中国法规未明确禁止将检验编号用于暗示批准", "C. 中国法规要求检验机构在报告中注明受理编号，而美国法规要求在产品标签上印刷FDA参考号", "D. 美国法规允许企业自行生成成分声明编号，而中国法规必须由指定检验机构分配"], "answer": "B", "type": "Parallel", "explanation": "美国FDA §720.9 明确规定，提交表格或分配编号绝不代表FDA对产品或公司的批准，任何在标签或广告中暗示官方批准的行为将被视为误导。中国法规文本中虽然提到了检验受理编号，但未明确禁止将其用于暗示监管批准，这体现了在编号法律效力声明上的差异。", "category": "Cosmetics", "related_concept": "FDA reference number, registration and filing inspection agency", "id": "PA_P_00644_003", "match_type": "weak", "match_score": 0.7452468807004374, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0049_0003_1"}
{"question": "Statement 1: Under Chinese cosmetics regulations, manufacturers using new ingredients must maintain and report detailed records of any government supervision, inspection findings, or product recalls involving those ingredients. Statement 2: US cosmetics regulations require specific tamper-resistant packaging for certain product categories primarily to prevent malicious adulteration and maintain consumer confidence. Which of the following is correct about these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: Chinese regulations (NMPA) explicitly require registrants/filers of new cosmetic ingredients to document and report '监督抽检、查处、召回情况' (supervision sampling, investigation, and recall situations) in a specified tabular format as part of annual safety monitoring. Statement 2 is correct: US FDA regulations mandate tamper-resistant packaging for cosmetic liquid oral hygiene and vaginal products to address the risk of malicious adulteration and protect consumer confidence, as stated in the text. These represent different but important facets of product safety oversight in each jurisdiction.", "category": "Cosmetics", "related_concept": "supervision and inspection records, tamper-resistant packaging requirement", "id": "PA_P_00621_007", "match_type": "weak", "match_score": 0.746009561436672, "lang": "EN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0029_0003_2"}
{"question": "关于继续教育活动报告与审批，以及研究时限延长，以下哪项对比正确？", "choices": ["A. 中国要求执业药师参加非官方机构活动后需向省级药监部门报告；美国要求制造商在FDA延长研究时限后需重新提交认证", "B. 两国都要求所有继续教育活动必须事先获得国家级药监部门批准", "C. 美国要求继续教育机构直接向FDA报告学时；中国要求制造商在时限延长时重新提交研究计划", "D. 两国都规定，参加任何形式的继续教育都无需事后报告或审批"], "answer": "A", "type": "Parallel", "explanation": "中国法规规定，执业药师参加继续教育机构举办的活动，由机构报省级药监部门；参加其他方式继续教育，需本人当年提交材料报省级药监部门。美国法规规定，若FDA延长了完成研究和提交补充申请的时间，且制造商已提交过相关认证，则制造商需提交一份新的认证，阐明完成临床研究和提交申请的新时间框架。这分别对应了“报告与审批”和“时限延长”的核心概念。", "category": "Drugs", "related_concept": "reporting and approval of continuing education activities, extension of study timeframe", "id": "PA_P_00161_006", "match_type": "weak", "match_score": 0.7355001999514853, "lang": "CN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0008_0008_2"}
{"question": "Statement 1: Both US and Chinese regulations require that complimentary samples of controlled substances can only be distributed with prior written customer requests containing specific registration information. Statement 2: Determining whether a loss of controlled substances is 'significant' requires consideration of multiple factors including the quantity involved and pattern of losses.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "C", "type": "Parallel", "explanation": "Statement 1 is incorrect because while US regulations explicitly require prior written customer requests with registration details for complimentary samples, Chinese regulations focus on preventing diversion through transaction monitoring (cash transactions) rather than sample distribution requirements. Statement 2 is correct as US regulations explicitly mention considering multiple factors for significant loss determination, and Chinese regulations imply similar considerations through their graduated penalty structure based on violation severity.", "category": "Controlled_Substances", "related_concept": "customer request requirements, significant loss determination", "id": "PA_P_00738_002", "match_type": "weak", "match_score": 0.7445903548369581, "lang": "EN", "source_cn": "麻醉药品和精神药品管理条例.txt", "source_us": "PART_1301REGISTRATION_OF_MANUFACTURERS_DISTRIBUTOR.txt", "old_id": "comp_0025_0002_2"}
{"question": "关于化妆品中着色剂的安全性评估，中美法规在致癌性判定原则上有何关键差异？", "choices": ["A. 中国法规对所有着色剂采用统一致癌性评估标准，美国法规则根据是否会被摄入而区分评估路径", "B. 美国法规要求所有着色剂必须通过动物致癌性试验，中国法规则接受体外试验数据", "C. 中国法规对可能被摄入的着色剂采取更严格的“零致癌风险”原则，美国法规则允许在科学评估安全后使用", "D. 美国法规仅关注着色剂本身成分，中国法规则同时严格监管其杂质和降解产物"], "answer": "C", "type": "Parallel", "explanation": "根据FDA法规（§70.50），对于可能被摄入的着色剂，如果科学数据表明其可能诱发癌症，则不得批准使用（“no regulation may issue”），这体现了严格的“致癌即禁用”原则。而中国NMPA对化妆品（包括育发类）的监管，在人体试用试验中主要关注使用安全性（如皮肤不良反应），对于着色剂的具体致癌性评估，通常遵循更通用的风险评估框架，而非针对“摄入途径”的绝对禁止。选项A错误，因为美国法规明确区分了“可能被摄入”和“不会摄入”的着色剂；选项B和D的描述与两国法规的核心差异不符。", "category": "Cosmetics", "related_concept": "ingested color additives, non-ingested color additives", "id": "PA_P_00642_027", "match_type": "weak", "match_score": 0.7311920604805674, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0053_0005_1"}
{"question": "A cosmetics manufacturer is comparing regulatory approaches to impurity control. Which statement best describes a key difference between US FDA and Chinese NMPA frameworks regarding impurity specifications?", "choices": ["A. The US FDA typically sets maximum allowable limits for specific chemical impurities in color additives, while Chinese NMPA regulations focus more on general manufacturing practice standards without specific impurity lists.", "B. Chinese NMPA requires detailed impurity testing for all cosmetic ingredients, whereas the US FDA only requires it for color additives.", "C. Both systems use identical impurity limits and testing methodologies for all cosmetic products.", "D. The US FDA does not regulate impurities in cosmetics, leaving it to industry standards, while Chinese NMPA has comprehensive impurity controls."], "answer": "A", "type": "Parallel", "explanation": "The US FDA approach, as illustrated in the D&C Blue No. 4 specification, involves setting precise maximum limits for specific chemical impurities (e.g., lead, arsenic, specific aromatic amines). Chinese NMPA regulations, while emphasizing good manufacturing practices, typically incorporate impurity control through broader quality management system requirements rather than publishing exhaustive specific impurity lists for each ingredient in general registration documents. Both systems aim to ensure safety but employ different regulatory mechanisms.", "category": "Cosmetics", "related_concept": "impurity limits, specification compliance", "id": "PA_P_00653_029", "match_type": "weak", "match_score": 0.7435058547275102, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0037_0005_1"}
{"question": "When comparing regulatory approaches to cosmetic safety oversight, which statement best describes a key difference between US and Chinese systems regarding technical guidance?", "choices": ["A. The US system provides centralized technical guidance through federal agencies, while China delegates technical guidance responsibilities to provincial-level monitoring institutions.", "B. China requires technical guidance to be provided directly by manufacturers, while the US mandates guidance from independent third-party laboratories.", "C. Both systems require identical technical guidance protocols for all cosmetic stakeholders regardless of their role in the supply chain.", "D. The US system focuses technical guidance exclusively on color additives, while China provides guidance only for adverse reaction monitoring."], "answer": "A", "type": "Parallel", "explanation": "The Chinese system explicitly delegates technical guidance responsibilities to provincial-level monitoring institutions for various stakeholders including manufacturers, distributors, and medical institutions. The US system, as described in the color additive regulations, operates through centralized federal authority (the Commissioner) that establishes safety criteria and provides guidance on testing protocols, but doesn't describe a decentralized provincial guidance structure.", "category": "Cosmetics", "related_concept": "technical guidance", "id": "PA_P_00599_003", "match_type": "weak", "match_score": 0.6978499541970472, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0004_0004_1"}
{"question": "Statement 1: Regulatory authorities must establish clear liaison roles to facilitate media access to administrative proceedings. Statement 2: Advance notice requirements for media recording cannot be used as grounds for denying access to proceedings.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 reflects the establishment of media liaison functions to coordinate access. Statement 2 correctly identifies that advance notice requirements serve coordination purposes but cannot justify access denial, ensuring transparency principles are upheld.", "category": "General_FDA", "related_concept": "media liaison role, access denial prohibition", "id": "PA_P_00797_002", "match_type": "weak", "match_score": 0.7473150765483156, "lang": "EN", "source_cn": "中华人民共和国行政许可法.txt", "source_us": "PART_10ADMINISTRATIVE_PRACTICES_AND_PROCEDURES.txt", "old_id": "comp_0001_0018_2"}
{"question": "关于医疗器械的备案单元定义与控制号要求，以下哪项描述正确？", "choices": ["A. 中国法规定义了定制式医疗器械的备案单元，美国法规要求分销时需带有控制号", "B. 中美法规都明确定义了备案单元，但只有美国要求控制号", "C. 美国法规定义了备案单元，中国法规要求控制号", "D. 中美法规都未涉及备案单元和控制号要求"], "answer": "A", "type": "Parallel", "explanation": "中国法规（定制式医疗器械）规定，主要原材料、生产工艺等基本相同的定制式医疗器械构成一个备案单元，组合使用的器械可作为同一备案单元。美国法规（21 CFR 820.65）要求，当需要控制号时，该控制号应在或随设备通过分销环节，这属于质量管理体系的一部分，用于追溯。", "category": "Medical_Devices", "related_concept": "filing unit definition, control number requirement", "id": "PA_P_00571_002", "match_type": "weak", "match_score": 0.7423353307292716, "lang": "CN", "source_cn": "定制式医疗器械监督管理规定（试行）.txt", "source_us": "PART_820QUALITY_SYSTEM_REGULATION_EFF_until_2-2-26.txt", "old_id": "comp_0002_0005_2"}
{"question": "关于监管审查时限，中美法规在设定和告知方面的典型做法是什么？请判断以下陈述：\n陈述1：中国法规对特定行政许可（如电信业务经营许可）的审查时限有明确规定，并区分业务类型设定不同天数。\n陈述2：美国法规对所有食品相关申请的审查都规定了统一的法定最长时限。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：中国《行政许可法》规定了原则性时限，各部委规章会对具体许可事项明确审查时限。例如，在提供的中国法规示例中，对基础电信业务和增值电信业务的经营许可申请，分别规定了180日和60日的审查期。这体现了中国法规对特定许可有时限明确化和差异化的特点。\n陈述2错误：美国FDA对食品相关申请的审查时限并非完全统一。例如，食品添加剂申请、GRAS通报、进口食品的扣留审查等，其法定或程序性时限可能因申请类型、法律依据和具体情况而异。FDA的许多审查是基于“合理时限”或具体法规条款，而非一个适用于所有食品申请的单一统一最长时限。", "category": "General_FDA", "related_concept": "regulatory review timeline", "id": "PA_P_00770_008", "match_type": "weak", "match_score": 0.6765810234667524, "lang": "CN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0002_0043_5"}
{"question": "In regulatory frameworks for cosmetics and food/drug additives, which statement accurately compares the handling of adverse event reports?", "choices": ["A. Both systems require immediate reporting to national agencies for all adverse events, regardless of severity.", "B. The cosmetics system has tiered timelines for analysis based on severity, while the additive system focuses on pre-market safety data submission.", "C. Both systems mandate that manufacturers conduct follow-up investigations within 7 days of initial reports.", "D. The additive system requires provincial-level review of all reports, while the cosmetics system delegates this to manufacturers."], "answer": "B", "type": "Parallel", "explanation": "The cosmetics regulatory framework establishes specific timelines for analysis based on severity levels (general: 15 days, severe: 7 days, high-impact: 3 days), with requirements for follow-up investigations and reporting to higher authorities. The additive system focuses primarily on pre-market safety information submission and petition requirements, without specifying post-market adverse event investigation timelines.", "category": "Regulatory Compliance", "related_concept": "Review and analysis of adverse reaction reports", "id": "PA_P_00599_007", "match_type": "weak", "match_score": 0.7338400912917933, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0011_0001_1"}
{"question": "Statement 1: In cosmetics production, areas with different cleanliness levels, such as clean zones and quasi-clean zones, must be physically separated and maintain appropriate pressure differentials to prevent contamination. Statement 2: For color additives used in externally applied cosmetics, a lake made from a listed straight color must meet specifications on soluble chlorides and sulfates to be certified and listed under a name that includes the base radical and 'Lake'.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes requirements for physical isolation and pressure differentials between clean areas in production facilities, as per typical good manufacturing practices to ensure environmental control. Statement 2 accurately reflects that lakes derived from listed straight colors for external cosmetics must meet specific purity specifications (like limits on soluble chlorides and sulfates) and be named accordingly (e.g., including the base radical and 'Lake') to be certified and listed. Both statements align with regulatory principles for production environment control and color additive management.", "category": "Cosmetics", "related_concept": "physical isolation and pressure differentials, lake specifications, straight color listing", "id": "PA_P_00669_002", "match_type": "weak", "match_score": 0.6843135520089447, "lang": "EN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0008_0005_2"}
{"question": "Statement 1: Under US FDA regulations for new animal drugs, a distributor's initial product labeling must be identical to the approved labeling except for the distributor's name/address and a different proprietary name.\nStatement 2: Under Chinese NMPA regulations, the pharmacovigilance system's effectiveness relies on clear internal role definitions, but specific labeling content rules for distributors are not a primary focus of the pharmacovigilance provisions.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct per the US text, which specifies that a distributor's labeling at initial distribution must match the approved labeling except for the distributor's details and a suitable proprietary name. Statement 2 is correct as the provided Chinese text emphasizes defining roles within the holder's organization (e.g., R&D, production, sales) to ensure PV activities, but does not delve into distributor-specific labeling content rules within these PV provisions.", "category": "Drugs", "related_concept": "product labeling requirements", "id": "PA_P_00321_005", "match_type": "weak", "match_score": 0.7423646732354824, "lang": "EN", "source_cn": "药物警戒质量管理规范.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0005_0019_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在中国法规框架下，现场检查人员必须向被检查对象出示执法证件或授权文件，以证明其检查资格。\n陈述2：在美国FDA关于色素添加剂认证的法规中，若专员拒绝认证某一批次，申请人有权要求举行监管听证会（regulatory hearing）进行申诉。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "解析：陈述1正确。中国药品检查相关法规普遍要求检查人员在到达检查场所后，向被检查对象出示执法证件、检查员证或派出单位出具的授权证明文件，这是程序正当性和合法性的体现。陈述2正确。美国FDA法规（如21 CFR 80.31(b)）明确规定，如果专员（Commissioner）拒绝认证某一批次色素添加剂，并通知申请人后，申请人若对此有异议，有权依据相关章节（如part 16）要求举行监管听证会（regulatory hearing），这是程序性权利和救济途径的规定。因此，两个陈述都符合各自法规的通用原则。", "category": "General Pharmaceutical/Color Additive Regulation", "related_concept": "inspection credentials presentation, regulatory hearing", "id": "PA_P_00632_002", "match_type": "weak", "match_score": 0.7356040608795475, "lang": "CN", "source_cn": "化妆品检查管理办法.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0003_0001_2"}
{"question": "Regarding cosmetic product registration documentation, which statement about report formats and identification numbers is correct?", "choices": ["A. Chinese inspection reports require specific cover formats with institutional identification, while FDA reference numbers in the US do not imply product approval.", "B. Both US and Chinese regulations use identical cover page formats for all cosmetic inspection reports.", "C. FDA reference numbers signify official product approval, while Chinese registration numbers have no regulatory significance.", "D. Chinese regulations do not require standardized report formats, while US regulations mandate specific declaration statements on all reports."], "answer": "A", "type": "Parallel", "explanation": "Chinese cosmetic registration requires standardized inspection report formats with specific cover pages showing institutional identification numbers, while in the US, FDA reference numbers or cosmetic product ingredient statement numbers are assigned for tracking but explicitly do not denote FDA approval of the product or firm.", "category": "Cosmetics", "related_concept": "inspection report cover, FDA reference number, cosmetics registration and filing inspection report format, inspection report declaration", "id": "PA_P_00644_002", "match_type": "weak", "match_score": 0.7400516259471824, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0024_0003_2"}
{"question": "Statement 1: Chinese regulations for traditional medicines emphasize comprehensive quality assessment of herbal materials including origin verification, processing standards, and contamination control. Statement 2: US regulations for analytical methods require system suitability testing to ensure chromatographic separation meets specified resolution criteria before sample analysis.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes Chinese regulatory requirements for herbal material assessment, which include verifying botanical origin, processing standards, and controlling contamination risks. Statement 2 accurately reflects US analytical method requirements where system suitability testing, including resolution calculations between peaks, must meet predefined criteria before proceeding with sample analysis.", "category": "Drugs", "related_concept": "quality assessment, system suitability testing", "id": "PA_P_00054_002", "match_type": "weak", "match_score": 0.7476206743832448, "lang": "EN", "source_cn": "中药生产监督管理专门规定.txt", "source_us": "PART_201LABELING.txt", "old_id": "comp_0007_0079_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据典型的监管框架，被归类为“处方器械”的医疗器械，意味着其必须在专业医疗人员的指导下使用，这在中美法规体系中都是常见原则。\n陈述2：对于违反医疗器械法规造成人身或财产损害的行为，中国法规明确规定了需依法承担民事赔偿责任；而在美国FDA的相关法规框架下，此类民事责任的追究主要依赖于产品责任法等普通法体系，而非直接由FDA法规条款规定具体赔偿。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：“处方器械”的核心监管含义即限制其销售和使用，需在医疗专业人员（如医师）的处方或指导下使用，这是中美监管体系中共通的基本原则，旨在控制风险。美国文本中明确标识“medical bassinet”为处方设备。中国法规虽未在提供段落中直接定义处方器械，但此概念存在于其监管实践中。\n陈述2正确：中国法规文本第七十五条明确规定了违反条例造成损害需“依法承担赔偿责任”，这是行政法中常见的民事责任条款。美国FDA的法规主要侧重于行政监管（如上市许可、生产规范、召回等）、刑事处罚以及通过性能标准等确保安全有效，对于个体因设备缺陷遭受损害而提起的民事赔偿诉讼，通常依据的是各州的《产品责任法》等侵权法律，而非直接援引FDA法规中的具体赔偿条款。因此，两个陈述均准确反映了各自体系的特点。", "category": "Medical_Devices", "related_concept": "prescription device, civil liability", "id": "PA_P_00558_002", "match_type": "weak", "match_score": 0.7254121342118751, "lang": "CN", "source_cn": "国务院关于修改《医疗器械监督管理条例》的决定.txt", "source_us": "PART_880GENERAL_HOSPITAL_AND_PERSONAL_USE_DEVICES.txt", "old_id": "comp_0023_0003_2"}
{"question": "In comparing regulatory approaches to resource planning and allocation for traditional medicine services, which statement best describes a key difference between typical US and Chinese frameworks?", "choices": ["A. US regulations focus on market-driven allocation with minimal government intervention, while Chinese regulations mandate government-led planning and resource guarantees.", "B. Chinese regulations emphasize private sector investment exclusively, while US regulations require government funding for all traditional medicine services.", "C. Both systems require identical resource allocation models enforced through federal mandates.", "D. US regulations prioritize resource allocation based on population density, while Chinese regulations base allocation on economic development indicators."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations typically involve government-led planning and resource guarantees for traditional medicine services, including requirements for government planning and resource allocation. US regulations generally follow a more market-driven approach with less direct government intervention in resource allocation for complementary and alternative medicine services.", "category": "Traditional Medicine/Complementary Medicine", "related_concept": "resource planning and allocation", "id": "PA_P_00004_001", "match_type": "weak", "match_score": 0.7367857571520213, "lang": "EN", "source_cn": "中华人民共和国中医药法.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0002_0011_1"}
{"question": "关于化妆品表格提交要求，以下哪项描述准确反映了中美法规的差异？", "choices": ["A. 中国法规主要关注检验报告的格式要求，而美国法规重点关注产品声明表格的提交和修正流程", "B. 美国法规要求所有化妆品都必须提交Form FDA-2512，而中国法规无类似表格提交要求", "C. 两国法规都要求相同的表格格式和提交时间限制", "D. 中国法规要求产品变更必须在24小时内通知，而美国法规允许60天内提交修正"], "answer": "A", "type": "Parallel", "explanation": "中国法规文本详细规定了化妆品检验报告的封面、扉页等格式要求。美国法规文本则重点描述了Form FDA-2512和FDA-2514的提交要求，包括不同配方的单独提交、变更修正的时间限制（60天内）等具体流程。", "category": "Cosmetics", "related_concept": "form filing requirements", "id": "PA_P_00644_009", "match_type": "weak", "match_score": 0.7211062438268745, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0077_0002_5"}
{"question": "A cosmetics manufacturer is preparing documentation for a new product's toxicology study. Which regulatory approach would require detailed records of the experimental animals' specific attributes such as species, strain, source, and housing conditions?", "choices": ["A. US FDA regulations", "B. Chinese NMPA regulations", "C. Both US FDA and Chinese NMPA regulations", "D. Neither US FDA nor Chinese NMPA regulations"], "answer": "B", "type": "Parallel", "explanation": "Chinese NMPA regulations typically mandate comprehensive documentation for experimental animals in toxicology studies, including specific details like species, strain, source, housing conditions, and environmental controls. US FDA regulations generally focus more on the certification of color additives and their uses rather than prescribing detailed animal documentation requirements for toxicology studies.", "category": "Cosmetics", "related_concept": "experimental animal documentation", "id": "PA_P_00637_012", "match_type": "weak", "match_score": 0.747543716661285, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0021_0025_1"}
{"question": "A cosmetics company discovers that one of its products sold in multiple countries has been linked to severe allergic reactions in several consumers. Which regulatory approach would most likely require the company to conduct a root cause analysis of the product's formulation and manufacturing process?", "choices": ["A. US FDA regulations would require immediate product recall without mandatory root cause analysis", "B. Chinese NMPA regulations would require analysis of product ingredients and manufacturing processes", "C. Both US and Chinese regulations would require identical root cause analysis procedures", "D. Neither US nor Chinese regulations require investigation of manufacturing processes for adverse events"], "answer": "B", "type": "Parallel", "explanation": "Chinese NMPA regulations specifically require cosmetics registrants to analyze adverse reactions by examining product ingredients, formulation, manufacturing processes, and quality management systems when necessary. The US FDA text focuses on adulteration prevention and packaging security rather than mandating comprehensive root cause analysis for adverse events.", "category": "Cosmetics", "related_concept": "adverse event reporting", "id": "PA_P_00598_007", "match_type": "weak", "match_score": 0.7433334467734657, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0009_0003_1"}
{"question": "A manufacturer of Class I ophthalmic operating spectacles in the US discovers a quality issue with a batch produced in 2023. Regarding complaint file requirements, which statement is correct?", "choices": ["A. The manufacturer must maintain complaint files as part of quality system regulations", "B. The manufacturer is exempt from maintaining complaint files due to device classification", "C. Complaint file requirements depend on whether the device is AC-powered or manual", "D. The manufacturer only needs complaint files if the device undergoes premarket notification"], "answer": "A", "type": "Parallel", "explanation": "For Class I ophthalmic operating spectacles in the US, while exempt from most quality system regulation requirements, the device is NOT exempt from §820.198 regarding complaint files. Therefore, complaint files must be maintained regardless of the exemption status for other quality system requirements.", "category": "Medical_Devices", "related_concept": "complaint file requirements", "id": "PA_P_00565_001", "match_type": "weak", "match_score": 0.7366670528289556, "lang": "EN", "source_cn": "国家药监局关于贯彻实施《医疗器械监督管理条例》有关事项的公告（2021年第76号）.txt", "source_us": "PART_886OPHTHALMIC_DEVICES.txt", "old_id": "comp_0002_0010_1"}
{"question": "A cosmetics manufacturer discovers a potential safety issue with a batch of products already distributed to retailers. Which regulatory approach would most likely require the manufacturer to immediately notify both retailers and consumers to stop sales and use, while also reporting to provincial authorities?", "choices": ["A. The US FDA's color additive exemption revocation process", "B. The Chinese NMPA's product recall management system", "C. The US FDA's investigational use exemption for color additives", "D. The Chinese NMPA's return record system for unsold products"], "answer": "B", "type": "Parallel", "explanation": "The Chinese NMPA's product recall management system requires immediate cessation of production, notification to retailers and consumers to stop sales/use, and reporting to provincial authorities when products may harm health. The US FDA color additive provisions focus on certification processes rather than comprehensive recall procedures for safety issues. Return record systems track returned goods but don't mandate proactive notifications to the market.", "category": "Cosmetics", "related_concept": "product recall management system", "id": "PA_P_00670_004", "match_type": "weak", "match_score": 0.7004323649898428, "lang": "EN", "source_cn": "化妆品生产质量管理规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0017_0003_1"}
{"question": "陈述1：中国法规规定，在特定情况下（如参与援派或突发公共卫生事件），执业药师的继续教育要求可以豁免或视同完成。\n陈述2：美国法规规定，FDA若终止某项新用途补充申请的豁免批准，可能同时下令制造商停止传播相关信息，并可能要求其采取纠正措施。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规明确，执业药师参与援藏、援疆、援青等援派工作期间，视同完成年度继续教育学时；参与重大突发公共卫生事件工作期间提供相关服务，经用人单位证明和省级药监部门确认，也可视同参加继续教育。陈述2正确：美国法规规定，若FDA终止一项被视为批准的豁免申请（基于特定条件），FDA可以命令制造商停止传播信息，并在FDA认定传播信息中描述的新用途会对公众健康构成重大风险时，命令制造商采取行动纠正已传播的信息。这涉及“终止豁免批准”和“停止传播令”两个概念。", "category": "Drugs", "related_concept": "termination of exemption approval, cease dissemination order", "id": "PA_P_00161_007", "match_type": "weak", "match_score": 0.7355001999514853, "lang": "CN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0008_0008_3"}
{"question": "关于化妆品不良反应监测体系的建立，中美法规在责任主体设定上存在显著差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规要求建立覆盖行政区域的官方监测网络，而美国法规主要依赖企业自主监测", "B. 美国法规要求所有化妆品企业必须建立内部监测体系，而中国仅对高风险产品有此要求", "C. 中国法规明确要求化妆品注册人/备案人必须具备监测能力并建立体系，而美国法规更侧重于对已发生问题的产品进行监管", "D. 两国法规都强制要求生产企业与医疗机构共同建立联合监测体系，但实施范围不同"], "answer": "C", "type": "Parallel", "explanation": "中国法规（NMPA）明确规定化妆品注册人、备案人必须建立并实施化妆品不良反应监测和评价体系，配备相应机构和人员，这是企业的法定义务。美国法规（FDA）片段中未提及企业建立监测体系的要求，而是侧重于对含有有害物质（如氯乙烯）的产品直接认定为掺假产品进行监管，体现了事后监管和产品安全标准的特征。", "category": "Cosmetics", "related_concept": "monitoring system establishment", "id": "PA_P_00598_005", "match_type": "weak", "match_score": 0.7163955120462583, "lang": "CN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0005_0003_1"}
{"question": "关于化妆品安全评估中安全系数的应用，中美法规存在显著差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规对安全系数有统一规定，而美国法规允许根据证据调整安全系数。", "B. 美国法规强制使用100:1的安全系数，而中国法规没有具体规定。", "C. 两国法规都强制使用100:1的安全系数，且不允许调整。", "D. 中国法规允许根据产品类型调整安全系数，美国法规则不允许。"], "answer": "A", "type": "Parallel", "explanation": "美国法规（如§70.42）在确定色素添加剂安全性时，通常应用100:1的安全系数（即将动物实验数据外推至人类时，人类允许暴露量不超过动物最大无作用剂量的1/100），但明确指出如果提交的证据能够证明，可以使用不同的安全系数。这体现了基于证据的灵活性。而中国法规（NMPA）在化妆品安全评估技术导则等文件中，虽然也采用安全系数概念，但其具体应用规则（如默认值、调整条件）与美国法规的表述方式和灵活性存在差异。选项A抓住了美国法规允许证据调整的核心特点，并与中国通常更倾向于规定性或具体指南的做法形成对比。选项B错误，因为美国法规并非强制100:1。选项C错误，因为美国法规允许调整。选项D错误，未准确描述两国差异。", "category": "Cosmetics", "related_concept": "safety factor application", "id": "PA_P_00642_008", "match_type": "weak", "match_score": 0.7270885996707761, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0018_0004_1"}
{"question": "关于戒毒治疗中的长期脱毒治疗（long-term detoxification treatment），以下陈述哪项是正确的？\n陈述1：在美国法规中，长期脱毒治疗是指持续时间超过30天但不超过180天的治疗程序。\n陈述2：在中国法规中，强制隔离戒毒场所对戒毒人员提供的治疗包括长期脱毒治疗，且明确规定了治疗期限的上限。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：美国法规明确将长期脱毒治疗定义为超过30天但不超过180天的治疗。陈述2错误：中国法规文本中描述了强制隔离戒毒场所提供戒毒治疗、心理治疗等，但未具体定义或规定“长期脱毒治疗”及其期限上限，因此该陈述不准确。", "category": "Detoxification_Treatment", "related_concept": "long-term detoxification treatment", "id": "PA_P_00696_011", "match_type": "weak", "match_score": 0.729339662800933, "lang": "CN", "source_cn": "戒毒条例.txt", "source_us": "PART_1300DEFINITIONS.txt", "old_id": "comp_0007_0002_2"}
{"question": "在化妆品新原料或色素添加剂的安全评估中，中美法规对安全因子的应用有不同的原则。请判断以下陈述：陈述1：中国法规在化妆品新原料安全监测中未明确指定统一的安全因子数值，而是基于年度报告和风险研判进行动态管理。陈述2：美国法规对色素添加剂的安全评估通常默认应用100:1的安全因子，即将动物实验数据外推至人体时，使用剂量不超过动物最大无效应水平的1/100。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规文本强调化妆品新原料的年度报告、安全情况分析和风险研判（如第二十四条），未像美国那样规定具体的安全因子数值，体现了基于监测和报告的动态风险管理。陈述2正确：美国法规（§70.3）明确说明，在确定色素添加剂安全性时，通常应用100:1的安全因子，除非有证据证明可使用不同因子，这体现了标准化风险评估原则。", "category": "Cosmetics", "related_concept": "safety factor application", "id": "PA_P_00650_002", "match_type": "weak", "match_score": 0.7244635610218731, "lang": "CN", "source_cn": "化妆品注册备案管理办法（2021年第35号令）.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0007_0004_2"}
{"question": "A pharmaceutical company is establishing pharmacovigilance responsibilities for a new drug launch in both China and the United States. Which statement accurately describes a key difference in regulatory approaches between the two jurisdictions?", "choices": ["A. China requires a formally designated, registered pharmacovigilance officer with specific qualifications, while the US focuses on applicant responsibilities for reporting without mandating a specific officer role.", "B. The US mandates that distributors submit a special drug experience report at initial distribution, while China has no requirements for entities involved in drug distribution.", "C. China requires periodic reports to include narrative summaries of increased adverse event frequencies, while the US does not specify the format for such analyses.", "D. The US requires the pharmacovigilance officer to have a medical or pharmacy degree, while China accepts a wider range of professional backgrounds."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations (NMPA) explicitly require the marketing authorization holder to appoint a qualified Pharmacovigilance (PV) Officer with specific educational, professional, and experience criteria, who must be registered in the national system. US FDA regulations (focusing on the provided text) detail reporting obligations for applicants but do not mandate the formal designation and registration of a specific PV officer role with predefined personal qualifications as a system requirement.", "category": "Drugs", "related_concept": "drug safety monitoring responsibilities", "id": "PA_P_00321_004", "match_type": "weak", "match_score": 0.7423646732354824, "lang": "EN", "source_cn": "药物警戒质量管理规范.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0005_0019_1"}
{"question": "关于化妆品人体皮肤试验中不良反应的分级与统计，中美法规在核心原则上存在差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规要求按观察时点分别统计人数，并以最高反应程度汇总；美国法规则要求对所有受试者进行统一分级，不区分时点。", "B. 中国法规强调对每个受试者在多个观察时点中取最高反应程度进行汇总统计；美国法规在安全性评估中更侧重于通过动物实验数据应用安全系数来推导人体安全剂量。", "C. 中国法规要求试验报告必须包含所有观察时点的详细数据；美国法规则允许在某些情况下豁免特定毒性测试。", "D. 中国法规仅适用于斑贴试验；美国法规则同时适用于斑贴试验和重复性开放型涂抹试验。"], "answer": "B", "type": "Parallel", "explanation": "中国法规（如NMPA相关要求）的核心在于对人体皮肤试验（如斑贴试验）结果的报告规范，它要求按不同观察时点列出数据，并以每个受试者在所有观察时点中的最高反应程度进行汇总统计，这体现了对个体最大反应风险的关注。美国法规（FDA，如21 CFR 70部分）在评估色素添加剂等物质的安全性时，其核心原则之一是应用“安全系数”（通常为100:1），将动物实验中的无效应水平换算为人体安全暴露水平，这是一种基于风险外推的定量安全评估方法。两者分别代表了临床观察数据报告规范与基于毒理学数据的定量风险评估两种不同的安全监管逻辑。选项A错误，因为美国法规的相关描述并非针对人体试验的分级统计方式。选项C和D的描述虽然部分正确，但未能抓住两者在基本原则上的核心对比。", "category": "Cosmetics", "related_concept": "adverse reaction grading, safety factor application", "id": "PA_P_00642_010", "match_type": "weak", "match_score": 0.7052238685065659, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0023_0004_1"}
{"question": "Statement 1: In the US cosmetic regulatory system, registration amendments must be submitted within 30 days of any change to establishment information.\nStatement 2: In China's cosmetic regulatory system, registration amendments for special cosmetics require technical re-evaluation by designated agencies.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct per US regulations (§710.5) requiring amendment submission within 30 days of information changes. Statement 2 is correct as China's system involves technical review agencies for special cosmetics registrations, and amendments would typically require re-evaluation by these technical bodies to ensure continued compliance with safety and quality standards.", "category": "Cosmetics", "related_concept": "registration amendments, technical review", "id": "PA_P_00646_002", "match_type": "weak", "match_score": 0.7400495999839193, "lang": "EN", "source_cn": "化妆品注册备案管理办法（2021年第35号令）.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0002_0001_2"}
{"question": "关于企业注册要求，中美法规对“设施”定义的覆盖范围有何关键区别？", "choices": ["A. 中国法规要求所有食品生产企业必须注册，美国法规则仅要求进口食品的国外供应商注册", "B. 美国法规明确包含了“农场混合型设施”这一特殊类别，中国法规则通常将农场和食品加工设施分开管理", "C. 中国法规的设施注册与产品上市许可绑定，美国法规则的注册是独立的前提条件", "D. 美国法规不要求国内设施注册，中国法规则对国内外设施实行统一注册要求"], "answer": "B", "type": "Parallel", "explanation": "美国FDA法规（如21 CFR Part 1, Subpart H）对需要注册的“设施”有明确定义，并特别提出了“农场混合型设施”的概念，指那些符合农场定义但同时从事超出农场范围活动（需要按FD&C Act第415条注册）的场所。这体现了对美国复杂农业食品经营模式的适应性监管。中国NMPA及相关部委（如市场监管总局、农业农村部）对食品生产经营主体的管理，通常通过《食品生产许可管理办法》、《食品经营许可管理办法》等制度进行，将“农场”（农产品种植、养殖）和“食品生产加工设施”作为不同主体、依据不同法规进行许可或备案管理，缺乏与美国“农场混合型设施”完全对应的、统一在一个法规框架下定义的注册类别。", "category": "General_FDA", "related_concept": "facility registration requirements", "id": "PA_P_00770_007", "match_type": "weak", "match_score": 0.6765810234667524, "lang": "CN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0002_0043_4"}
{"question": "When addressing potential data gaps in regulatory reporting, which scenario accurately reflects a common regulatory principle?", "choices": ["A. If a company changes its annual reporting cycle date, it must submit a special report to cover any distribution data gaps created by that change.", "B. Data gaps in annual reports for approved products are always waived if the applicant has a history of compliant reporting for over two years.", "C. Regulatory authorities never permit changes to reporting frequencies or dates, so data gaps do not occur in standardized reporting cycles.", "D. When a reporting gap is identified during a drug product's associated review, the authority will automatically update the platform data without requiring action from the applicant or registrant."], "answer": "A", "type": "Parallel", "explanation": "This question tests the understanding of obligations related to data continuity and gap reporting. A core regulatory principle is that if an applicant is allowed to change a predefined reporting schedule (like the annual report date), they bear the responsibility to ensure data continuity. This typically involves submitting a special or supplemental report specifically designed to cover the period not captured by the adjusted regular reports, thereby preventing a lapse in safety or distribution monitoring. The distractors present incorrect assumptions about regulatory flexibility, waiver conditions, or automatic data correction processes.", "category": "Drugs", "related_concept": "data gap reporting", "id": "PA_P_00133_002", "match_type": "weak", "match_score": 0.6852762170966883, "lang": "EN", "source_cn": "国家药监局关于进一步完善药品关联审评审批和监管工作有关事宜的公告（2019年 第56号）.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0003_0016_2"}
{"question": "Statement 1: A regulatory body can order a manufacturer to stop disseminating information about a new drug use if it determines the disseminated information poses a significant public health risk.\nStatement 2: An employer is generally obligated to cover all costs when a professional participates in mandatory continuing education activities during work hours.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct and reflects a principle from the US regulation text, where the FDA has the authority to issue a cease dissemination order if a significant risk to public health is identified. Statement 2 is incorrect. While the Chinese text encourages employers to fully reimburse costs and mentions obligations to provide support (like paying wages for full/part-time study), it also states that for after-hours education, the cost-sharing should be agreed upon. It does not state a universal obligation for the employer to cover all costs in all circumstances, and US employer obligations for continuing education vary by state law and employer policy, not being a universal regulatory mandate as described.", "category": "Drugs", "related_concept": "cease dissemination order, continuing education funding mechanism", "id": "PA_P_00161_004", "match_type": "weak", "match_score": 0.6784612668091279, "lang": "EN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_99DISSEMINATION_OF_INFORMATION_ON_UNAPPROVEDN.txt", "old_id": "comp_0002_0008_2"}
{"question": "In regulatory frameworks for drug substances, which statement correctly describes the relationship between approval status identifiers and the availability of official documents?", "choices": ["A. An 'A' status identifier for a drug substance indicates it has passed review, and the registrant can print official approval documents for GMP inspections and import clearance.", "B. An 'I' status identifier for a drug substance indicates it is under review, and official documents are automatically issued to the drug product applicant for regulatory submissions.", "C. A drug substance that is not platform-registered but submitted with a drug product application receives no official documentation, preventing its use in manufacturing or import processes.", "D. Official approval documents for drug substances are only issued by the regulatory agency upon request, regardless of the substance's review status or registration method."], "answer": "A", "type": "Parallel", "explanation": "This question compares the functional purpose of approval status identifiers and the utility of official documents. The correct principle is that a positive approval status (like 'A') signifies the substance has met regulatory standards, and this status enables the registrant to generate official documents (e.g., approval certificates, quality standards) for critical downstream activities like Good Manufacturing Practice (GMP) inspections and customs clearance for import. This reflects a system where approval status directly authorizes the use of self-service documentation for compliance purposes. The distractors present incorrect linkages between status, document issuance, and regulatory utility.", "category": "Drugs", "related_concept": "原料药审评审批标识, 批准证明文件用途", "id": "PA_P_00133_001", "match_type": "weak", "match_score": 0.6852762170966883, "lang": "EN", "source_cn": "国家药监局关于进一步完善药品关联审评审批和监管工作有关事宜的公告（2019年 第56号）.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0003_0016_1"}
{"question": "A company manufacturing a new Class II flow cytometric test system for hematopoietic neoplasms in the US must include detailed device descriptions and indications for use in their premarket submission. In China, a company that already holds a Class III medical device operating license wants to add a Class II medical device to their operations. Which regulatory approach applies to these scenarios?", "choices": ["A. Both companies must submit detailed technical documentation and obtain new approvals before operating", "B. The US company must provide comprehensive device specifications and intended use details, while the Chinese company may be exempt from submitting certain documentation for the Class II device", "C. The Chinese company must undergo full regulatory review for the Class II device, while the US company only needs to notify authorities of their new product", "D. Both companies can operate without additional documentation if they already hold licenses for similar devices"], "answer": "B", "type": "Parallel", "explanation": "Under US regulations for Class II devices, special controls require detailed device descriptions and indications for use in premarket submissions. In China, regulations allow companies with existing Class III medical device operating licenses to be exempt from submitting certain documentation when adding Class II devices to their operations, as they can leverage their existing regulatory status.", "category": "Medical_Devices", "related_concept": "免予经营备案, device description, indications for use", "id": "PA_P_00509_001", "match_type": "weak", "match_score": 0.6673115949375773, "lang": "EN", "source_cn": "医疗器械经营监督管理办法（2022年第54号令）.txt", "source_us": "PART_864HEMATOLOGY_AND_PATHOLOGY_DEVICES.txt", "old_id": "comp_0007_0015_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中国药监法规，执业药师继续教育学时的登记管理信息需包含教育内容、方式和实施机构。\n陈述2：根据美国FDA对相关机构的检查规定，检查人员有权审查并复制该机构按要求保存的所有记录。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "解析：陈述1正确。中国法规明确规定，执业药师继续教育实行学时登记管理，登记内容主要包括继续教育时间、内容、方式、学时数、机构等信息。\n陈述2正确。美国FDA法规规定，在对相关机构进行检查时，FDA代表可以审查并复制该机构根据法规要求保存的任何记录。\n因此，两个陈述均正确。", "category": "Drugs", "related_concept": "continuing education records, inspection of establishments", "id": "PA_P_00162_002", "match_type": "weak", "match_score": 0.7274040786766202, "lang": "CN", "source_cn": "执业药师继续教育暂行规定.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0006_0021_2"}
{"question": "A medical device manufacturer in China loses its production license. In the US, a manufacturer decides to stop marketing a device that is under postmarket surveillance requirements but wants to continue the surveillance. Which regulatory action is required in both scenarios?", "choices": ["A. Both require immediate notification to the regulatory authority", "B. Both require submission of a formal request for exemption", "C. Both result in automatic termination of existing regulatory obligations", "D. Both require the manufacturer to obtain a completely new license with different identifiers"], "answer": "A", "type": "Parallel", "explanation": "In the Chinese scenario, losing a production license requires notifying the original issuing department to apply for a replacement. In the US scenario, stopping marketing while continuing surveillance requires notifying the FDA of the change. Both situations mandate formal notification to the regulatory authority, though the specific contexts differ (license replacement vs. ownership/status change).", "category": "Medical_Devices", "related_concept": "license replacement for loss, change in ownership notification", "id": "PA_P_00475_001", "match_type": "weak", "match_score": 0.74496598697138, "lang": "EN", "source_cn": "医疗器械生产监督管理办法（2022年第53号令）.txt", "source_us": "PART_822POSTMARKET_SURVEILLANCE.txt", "old_id": "comp_0007_0005_1"}
{"question": "关于批发企业向医疗机构交付受管制药品的规定，以下哪项陈述正确？\n陈述1：根据中国法规，全国性和区域性批发企业向医疗机构销售麻醉药品和第一类精神药品时，必须负责将药品送至医疗机构，医疗机构不得自行提货。\n陈述2：根据美国法规，注册制造商向研究机构或分析实验室销售附表I或II类管制物质时，必须确保药品直接送达，接收方不得自行提取。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "C", "type": "Parallel", "explanation": "陈述1正确，直接对应中国法规第28条“应当将药品送至医疗机构。医疗机构不得自行提货”的强制性配送要求。陈述2错误，提供的美国法规文本主要涉及制造商的豁免情形（如用于分析或研究）、采购配额认证和库存管理，并未明确规定向医疗机构或研究机构销售时的具体配送方式（如必须送货上门、禁止自提）。美国对配送环节的控制可能体现在其他法规（如安全存储、记录保存）中，但题干所给文本未包含此具体规定。", "category": "Controlled_Substances", "related_concept": "delivery to medical institutions", "id": "PA_P_00732_002", "match_type": "weak", "match_score": 0.7452378650717418, "lang": "CN", "source_cn": "麻醉药品和精神药品管理条例.txt", "source_us": "PART_1303QUOTAS.txt", "old_id": "comp_0008_0005_2"}
{"question": "Statement 1: For a Class II medical device like an endolymphatic shunt tube intended for implantation in the US, the FDA may establish specific mitigation measures called 'special controls' as part of its classification. Statement 2: In China, if the technical requirements documented in the filing information for a Class I in vitro diagnostic reagent change, the filing holder must submit a change filing to the original filing department.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "This question compares the concepts of 'special controls' for implanted devices in the US and '备案信息变更' (change filing) in China. Statement 1 correctly describes the US regulatory principle where Class II devices can be subject to special controls (like guidance documents) to provide reasonable assurance of safety and effectiveness. Statement 2 correctly describes the Chinese regulatory principle that any change to the content of the filing information table or the product technical requirements for a filed device necessitates a change filing submission to the authorities. Both statements reflect accurate, high-level regulatory principles.", "category": "Medical_Devices", "related_concept": "special controls, 备案信息变更, implanted device", "id": "PA_P_00385_002", "match_type": "weak", "match_score": 0.6419402630171843, "lang": "EN", "source_cn": "体外诊断试剂注册与备案管理办法（2021年第48号令）.txt", "source_us": "PART_874EAR_NOSE_AND_THROAT_DEVICES.txt", "old_id": "comp_0022_0002_2"}
{"question": "关于化妆品生产场地信息变更的监管要求，请判断以下陈述：陈述1：在中国，生产场地减少时，注册人/备案人应确保该实际生产地址下已无产品关联。陈述2：在美国，如果化妆品在非主要营业地点生产、包装或分销，标签上必须标注实际生产地点。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "B", "type": "Parallel", "explanation": "陈述1正确：根据中国法规，生产场地减少时，注册人/备案人必须确保该地址下不再有产品关联，这是清理责任的要求。陈述2错误：根据美国法规（21 CFR 701.12(e)），如果化妆品在非主要营业地点生产、包装或分销，标签上可以标注主要营业地点来代替实际地点，除非这种标注会产生误导。因此，不是“必须”标注实际地点，而是允许用主要营业地点替代。这体现了中美在标签标注灵活性上的差异：中国更强调生产地址的精确管理，而美国在一定条件下允许简化标注。", "category": "Cosmetics", "related_concept": "production site reduction, principal place of business labeling", "id": "PA_P_00658_014", "match_type": "weak", "match_score": 0.71410233766768, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0040_0007_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在中国化妆品风险监测与评价法规中，药品监督管理部门及参与人员对工作中知悉的商业秘密和个人隐私负有保密义务，不得擅自披露。\n陈述2：在美国颜色添加剂法规中，如果涉及人体受试者的临床研究，提交的支持请愿书的信息或数据必须包含声明，证明该研究符合机构审查（如21 CFR Part 56）和知情同意（如21 CFR Part 50）的要求，或说明其豁免依据。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规（CN）第六条规定，药品监督管理部门及参与风险监测与评价的单位和人员对知悉的商业秘密、个人隐私等信息应当保密，不得擅自披露。\n陈述2正确：美国法规（US）在关于不合规原因声明的部分明确指出，如果涉及人体受试者的临床研究，提交的支持请愿书的信息或数据必须包含声明，证明其符合机构审查（Part 56）和知情同意（Part 50）的要求，或依据§56.104或§56.105豁免。这体现了对不合规原因或支持数据中伦理合规性的披露要求。\n因此，两个陈述都正确，对应选项A。", "category": "Cosmetics", "related_concept": "noncompliance reason statement, institutional review compliance", "id": "PA_P_00607_002", "match_type": "weak", "match_score": 0.7499577754507617, "lang": "CN", "source_cn": "化妆品安全风险监测与评价管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0001_0002_2"}
{"question": "In regulatory frameworks for consumer products, how do approaches to addressing potential health hazards differ between systems?", "choices": ["A. One system requires immediate product recall upon any health hazard identification, while the other allows continued use unless specific findings deem existing stocks unsafe.", "B. Both systems mandate identical immediate withdrawal procedures for all identified health hazards.", "C. One system focuses on post-market monitoring through adverse reaction reporting, while the other primarily addresses hazards through pre-market certification changes.", "D. Health hazard management is exclusively handled by industry self-regulation in both systems, with no government intervention."], "answer": "C", "type": "Parallel", "explanation": "The Chinese system establishes comprehensive post-market monitoring through adverse reaction reporting requirements for cosmetics, while the US system addresses health hazards through mechanisms tied to color additive certification changes, where existing products may remain compliant unless specific unsafe findings are made.", "category": "Cosmetics", "related_concept": "health hazard", "id": "PA_P_00678_001", "match_type": "weak", "match_score": 0.7167277480269928, "lang": "EN", "source_cn": "化妆品监督管理条例 (1).txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0015_0002_1"}
{"question": "Statement 1: The total amount of tobacco product user fees collected in a fiscal year is capped at a predetermined maximum specified by law. Statement 2: Tobacco product user fees apply uniformly to all classes of tobacco products without any annual aggregate limit on total collections. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "This question contrasts the concepts of total assessment limits and the application of user fees across product classes. Statement 1 accurately describes a regulatory framework where annual user fee collections are limited to a statutory maximum, preventing exceeding a set cap. Statement 2 is incorrect because, while fees may apply to various product classes, the existence of a total assessment limit means collections are not uniform or unlimited; they are constrained by the annual cap, affecting the aggregate across all classes.", "category": "General_FDA", "related_concept": "total assessment limit, class of tobacco products", "id": "PA_P_00755_002", "match_type": "weak", "match_score": 0.7435104102305736, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第666号）.txt", "source_us": "PART_1150USER_FEES.txt", "old_id": "comp_0006_0002_2"}
{"question": "Statement 1: US regulations for certified color additives require maintaining storage conditions that prevent composition changes until packaging and labeling. Statement 2: Chinese quality management systems require equipment maintenance with specified frequency requirements as part of comprehensive quality control. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the US requirement from the text: 'maintain storage in such manner as to prevent change in composition until such batch has been packaged and labeled.' Statement 2 accurately reflects Chinese requirements that include 'equipment use, calibration, maintenance systems including basic requirements and frequency' as part of their comprehensive quality management approach. Both represent different but valid regulatory requirements in their respective systems.", "category": "Cosmetics", "related_concept": "storage conditions, equipment maintenance frequency", "id": "PA_P_00654_011", "match_type": "weak", "match_score": 0.7174577892760271, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0031_0004_2"}
{"question": "Statement 1: For dose design in genetic toxicity testing, the highest dose should be justified based on cytotoxicity and solubility data. Statement 2: The safe tolerance allocation for a color additive in the US regulatory system is determined solely by the petitioner's data without consideration of competing needs.", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct; Statement 2 is incorrect.", "C. Statement 1 is incorrect; Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "Statement 1 is correct as it reflects standard toxicological principles evident in the Chinese text's requirement for 'dose design and highest dose design basis' considering 'cytotoxicity, solubility, etc.' Statement 2 is incorrect because the US text explicitly states that safe tolerance allocation must consider 'competing needs' and involves data presentation from 'all interested persons,' not just the petitioner. This demonstrates a comparative regulatory principle where dose design relies on scientific parameters, while tolerance allocation involves broader stakeholder consideration.", "category": "Toxicology & Regulation", "related_concept": "dose design and highest dose basis, safe tolerance allocation", "id": "PA_P_00642_022", "match_type": "weak", "match_score": 0.6933983666956421, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0042_0005_2"}
{"question": "Statement 1: Regulatory agencies should establish formal procedures for media to request electronic recording of proceedings to ensure orderly access. Statement 2: When space limitations exist, agencies should mandate pool sharing arrangements where excluded media can obtain recordings at cost from designated pool representatives.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Both statements reflect sound regulatory principles for media access. Statement 1 addresses the need for structured procedures to maintain order while ensuring transparency. Statement 2 addresses practical limitations through pool sharing while ensuring broader access through cost-based distribution - this prevents exclusion of smaller media outlets while managing physical constraints. These principles balance transparency, practicality, and equitable access.", "category": "General_FDA", "related_concept": "media access policy, pool sharing arrangements, videotape distribution procedures", "id": "PA_P_00757_002", "match_type": "weak", "match_score": 0.749882382102797, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第666号）.txt", "source_us": "PART_10ADMINISTRATIVE_PRACTICES_AND_PROCEDURES.txt", "old_id": "comp_0013_0016_2"}
{"question": "Statement 1: Under Chinese regulations, cosmetic companies must report adverse events discovered in foreign markets within 7 days and conduct analysis of severe reactions within 20 days. Statement 2: US regulations require immediate notification when cosmetic products contain carcinogenic substances like vinyl chloride, as they are considered adulterated regardless of concentration.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes Chinese NMPA requirements: 7-day reporting for overseas adverse events with risk control measures, and 20-day analysis for severe reactions. Statement 2 accurately reflects US FDA position that vinyl chloride in cosmetic aerosols is considered adulterated and requires regulatory action, demonstrating different regulatory approaches to safety concerns.", "category": "Cosmetics", "related_concept": "regulatory notification timelines, carcinogenic substance regulation", "id": "PA_P_00598_008", "match_type": "weak", "match_score": 0.7433334467734657, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0009_0003_2"}
{"question": "关于化妆品防晒指数（PFA值）的测定，中美法规在数据处理和受试者人数要求上存在差异。以下哪项描述最准确地概括了这种差异？", "choices": ["A. 中国法规要求计算个体PFA值的算术均数并取整，且对均数的95%可信区间有明确上限要求；美国法规对PFA值的测定无具体数据处理规定。", "B. 中国法规要求PFA值精确到小数点后一位，受试者人数固定为10人；美国法规则要求受试者人数至少25人。", "C. 两国法规都要求计算PFA值的标准差和标准误，但中国法规额外要求95%可信区间不超过均值的10%。", "D. 中国法规仅要求报告PFA值的平均值，美国法规则要求同时报告平均值、中位数和众数。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（NMPA）对PFA值的测定有详细规定：要求个体PFA值精确到小数点后一位，计算算术均数后取整数部分作为最终PFA值，并要求通过计算标准差和标准误来评估抽样误差，确保95%可信区间不超过均数的17%，受试者人数最多不超过25人。而美国法规（FDA）在提供的文本中主要关注色素添加剂（如FD&C Yellow No. 5）的化学规格和认证要求，并未涉及PFA值测定的具体数据处理或受试者人数规定。因此，选项A正确概括了这种差异：中国有明确的数据处理和可信区间要求，美国在相关文本中无此规定。选项B错误，因为中国法规受试者人数有上限但非固定，美国法规未提及PFA测定人数；选项C错误，中国法规要求95%可信区间不超过17%而非10%；选项D错误，两国法规均未要求报告中位数或众数。", "category": "Cosmetics", "related_concept": "PFA value calculation, standard deviation and standard error", "id": "PA_P_00637_046", "match_type": "weak", "match_score": 0.734759158296387, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0076_0003_1"}
{"question": "关于化妆品产品停产通知的要求，中美法规在时间限制上有所不同。以下哪项组合正确描述了这种差异？\n①中国法规要求停产通知必须在停产决定后30天内提交\n②美国法规要求Form FDA-2514应在停产知晓后180天内提交\n③中国法规对停产通知无具体时间要求\n④美国法规要求停产通知必须与产品变更通知同时提交", "choices": ["A. ①②", "B. ②③", "C. ③④", "D. ①④"], "answer": "B", "type": "Parallel", "explanation": "②正确：美国法规§720.6明确规定，化妆品产品配方停产通知应在停产知晓后180天内通过Form FDA-2514提交。\n③正确：提供的中国法规文本中未提及化妆品停产通知的具体时间要求。\n①错误：中国法规文本未规定30天的停产通知期限。\n④错误：美国法规未要求停产通知必须与产品变更通知同时提交。", "category": "Cosmetics", "related_concept": "discontinuance notification", "id": "PA_P_00644_008", "match_type": "weak", "match_score": 0.7211062438268745, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0077_0002_4"}
{"question": "关于化妆品新原料或色素添加剂的风险控制措施，中美法规在触发条件和责任主体方面存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求注册人/备案人在发现安全问题时立即控制风险并报告，美国法规则要求FDA在数据不足时通过联邦公报通知相关方进行安全分配", "B. 两国法规都要求企业在发现安全问题时立即控制风险，但中国要求向技术审评机构报告，美国要求向FDA报告", "C. 中国法规仅要求省级药监部门在收到报告后采取措施，美国法规要求企业在发现安全问题时立即采取措施", "D. 美国法规要求企业在发现安全问题时立即控制风险，中国法规则要求等待技术审评机构的指令"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如第二十二条、第二十三条）明确要求化妆品新原料注册人/备案人在有证据表明存在安全问题时立即采取措施控制风险，并向技术审评机构报告。美国法规（§70.45）则规定，当数据不足以证明色素添加剂对所有提议用途安全时，FDA会通过联邦公报通知相关方进行安全分配，这体现了监管机构在数据不足时的主动干预机制。选项B部分正确但未涵盖美国法规的独特分配机制；C和D与法规内容不符。", "category": "Cosmetics", "related_concept": "risk control measures", "id": "PA_P_00650_001", "match_type": "weak", "match_score": 0.7244635610218731, "lang": "CN", "source_cn": "化妆品注册备案管理办法（2021年第35号令）.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0007_0004_1"}
{"question": "A cosmetics company needs to update its establishment registration information after relocating its manufacturing facility. Which regulatory approach best describes the required action?", "choices": ["A. The company must submit an amendment to its registration within 30 days of the change, as required by US FDA regulations.", "B. The company must file a new registration with the inspection agency and include updated water resistance test reports, as required by Chinese NMPA regulations.", "C. Both US FDA and Chinese NMPA require immediate cancellation of the original registration and submission of a completely new application.", "D. Neither US FDA nor Chinese NMPA requires updates to establishment registration once initially filed."], "answer": "A", "type": "Parallel", "explanation": "US FDA regulations (§710.5) specifically require submission of an amended registration form within 30 days after any change in the information contained on the original form. Chinese regulations focus more on product testing and inspection reports rather than establishment registration amendments. Option B incorrectly combines establishment registration with product testing requirements. Option C is incorrect as neither regulation requires complete cancellation for simple updates. Option D is false as both systems require maintenance of accurate registration information.", "category": "Cosmetics", "related_concept": "registration amendments", "id": "PA_P_00636_010", "match_type": "weak", "match_score": 0.7325780330516602, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_710VOLUNTARY_REGISTRATION_OF_COSMETIC_PRODUCT.txt", "old_id": "comp_0071_0001_1"}
{"question": "关于牙膏的定义，中美法规存在显著差异。以下哪项最能体现这种差异？", "choices": ["A. 中国法规强调以摩擦方式清洁牙齿，美国法规未对牙膏进行明确定义", "B. 美国法规将牙膏视为化妆品，中国法规则将其单独管理", "C. 中国法规要求牙膏必须备案，美国法规则无此要求", "D. 美国法规对牙膏包装有防篡改要求，中国法规则无此规定"], "answer": "A", "type": "Parallel", "explanation": "中国《牙膏监督管理办法》第三条明确将牙膏定义为“以摩擦的方式，施用于人体牙齿表面，以清洁为主要目的的膏状产品”，这是功能性定义。而美国FDA将牙膏归为化妆品（cosmetic），但相关法规（如21 CFR 700.25）主要针对“化妆品液体口腔卫生产品”的防篡改包装要求，并未像中国那样对牙膏本身给出明确定义。选项B部分正确但不够精准（中国牙膏管理虽参照化妆品条例，但有专门办法）；C和D描述的是管理要求差异，非定义本身。", "category": "Cosmetics", "related_concept": "toothpaste definition", "id": "PA_P_00690_001", "match_type": "weak", "match_score": 0.6846744019255087, "lang": "CN", "source_cn": "牙膏监督管理办法（2023年第71号）.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0001_0004_1"}
{"question": "Consider the following statements about regulatory approaches to safety in cosmetics:\nStatement 1: A regulatory system may apply a standardized safety factor (e.g., 100:1) when extrapolating animal toxicity data to humans for a substance, unless justified evidence supports an alternative factor.\nStatement 2: A regulatory system may require that all suspected adverse events related to a cosmetic product be reported, following a 'suspect and report' principle, to ensure comprehensive post-market monitoring.\nWhich option correctly identifies the regulatory systems these statements describe?", "choices": ["A. Statement 1 describes a common US approach; Statement 2 describes a common Chinese approach.", "B. Statement 1 describes a common Chinese approach; Statement 2 describes a common US approach.", "C. Both statements describe common principles in US regulations.", "D. Both statements describe common principles in Chinese regulations."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 directly reflects the US regulatory principle for color additives outlined in the text, which specifies using a 100:1 safety factor from animal to human data unless different evidence is provided. Statement 2 captures the core Chinese regulatory principle for adverse event reporting, which mandates reporting any suspected human damage related to cosmetic use ('suspected then reported'). Therefore, Statement 1 is characteristic of the US approach (for the specific context of color additive safety evaluation), and Statement 2 is characteristic of the Chinese approach to adverse event monitoring.", "category": "Cosmetics", "related_concept": "safety factor application, adverse event monitoring system", "id": "PA_P_00599_006", "match_type": "weak", "match_score": 0.7184465017127603, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0006_0004_2"}
{"question": "请判断以下两个陈述的真假：\n陈述1：中国法规要求，当发生产品抽检不合格或可能引发较大社会影响的化妆品不良反应时，质量安全负责人必须立即启动有因自查，以查找原因并消除隐患。\n陈述2：美国法规要求，对于所有化妆品，一旦发现任何潜在安全风险，企业都必须立即启动有因自查并形成报告。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "C", "type": "Parallel", "explanation": "陈述1正确。它准确概括了中国法规（NMPA框架下）关于“有因启动自查制度”的核心要求：在发生特定涉及产品质量安全的情形（如抽检不合格、可能引发较大社会影响或严重不良反应）时，质量安全负责人有责任立即组织风险控制并启动自查。\n陈述2错误。提供的美国法规文本并未建立普适性的“有因自查”制度。其监管方式不同：例如，对于含有氯乙烯的化妆品气雾剂产品，法规直接将其“视为掺假”；对于某些液体口服或阴道用化妆品，则通过要求“防篡改包装”来预防恶意掺假风险。这些是基于产品类型或成分的特定规定，而非一个由企业内在触发的、针对各类风险的通用自查报告机制。", "category": "Cosmetics", "related_concept": "cause-initiated self-inspection, risk control measures", "id": "PA_P_00594_002", "match_type": "weak", "match_score": 0.746634320560758, "lang": "CN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0007_0003_2"}
{"question": "A company is developing a new color additive for cosmetics. They have conducted animal toxicity studies and need to determine a safe human exposure level. Which regulatory approach is most likely to be applied?", "choices": ["A. The US FDA would apply a default 100-fold safety factor to animal data, while China's NMPA would require specific in vitro mammalian cell genotoxicity tests before considering safety factors.", "B. Both US and Chinese regulations would first require the same battery of in vitro mammalian cell tests before applying any safety factor.", "C. The US FDA would require registration with a designated testing institution, while China's NMPA would apply a variable safety factor based on the color additive's intended use.", "D. China's NMPA would apply a fixed 100-fold safety factor, while the US FDA would evaluate safety based on the 'safe-for-use' principle without a default numerical factor."], "answer": "A", "type": "Parallel", "explanation": "The US regulation explicitly mentions applying a safety factor of 100 to 1 when using animal data for human safety, unless justified otherwise. The Chinese text focuses on the requirement for specific in vitro mammalian cell tests (like gene mutation and chromosome aberration tests) conducted by registered/filing testing institutions, which are part of the data package for safety evaluation. The US approach starts with a default quantitative factor, while the Chinese approach emphasizes specific test protocols from authorized labs.", "category": "Cosmetics", "related_concept": "safety factor application, 体外哺乳动物细胞染色体畸变试验, 注册和备案检验检测机构", "id": "PA_P_00642_023", "match_type": "weak", "match_score": 0.612465759624019, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0044_0004_1"}
{"question": "Statement 1: In China, hospital-prepared medications can only be used within the preparing institution under a physician's prescription. Statement 2: In the US, compounded medications are typically restricted to use within the preparing pharmacy or under specific patient-specific prescriptions. Which option correctly evaluates these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 accurately reflects Chinese regulations, which limit hospital-prepared medications to in-house use under physician supervision. Statement 2 correctly describes US FDA regulations on compounding, which generally restrict compounded drugs to patient-specific prescriptions or in-pharmacy use, unless they meet outsourcing facility criteria.", "category": "Drugs", "related_concept": "制剂使用限制", "id": "PA_P_00074_002", "match_type": "weak", "match_score": 0.6545913760500282, "lang": "EN", "source_cn": "医疗机构制剂注册管理办法（试行）（2005年国家食品药品监督管理局令第20号）.txt", "source_us": "PART_510NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0001_0009_2"}
{"question": "When a cosmetic product requires toxicological safety assessment, which regulatory approach is more likely to involve specific standardized test items versus a more flexible consideration of additive toxic effects?", "choices": ["A. Chinese regulations typically specify standardized toxicological test items, while US regulations consider additive toxic effects from related substances", "B. US regulations mandate specific toxicological test items, while Chinese regulations focus on additive toxic effects", "C. Both regulatory systems require identical standardized test items for all products", "D. Neither system addresses toxicological testing in their regulatory frameworks"], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations for cosmetics typically specify standardized toxicological test items (such as acute eye irritation, skin sensitization, and mutagenicity tests) that must be conducted and reported. US regulations, particularly for color additives, emphasize considering additive toxic effects from related substances, including other color additives, food additives, and pesticide chemicals that may cause similar pharmacological or biological effects.", "category": "Cosmetics", "related_concept": "toxicological test items", "id": "PA_P_00642_012", "match_type": "weak", "match_score": 0.7481880773982156, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0028_0001_1"}
{"question": "关于药物管制中的自愿与强制措施（voluntary and compulsory measures），请判断以下陈述：\n陈述1：中国法规明确建立了以自愿戒毒为基础，辅以社区戒毒、强制隔离戒毒和社区康复的多元化措施体系。\n陈述2：美国法规在评估大麻种植申请时，主要依据申请人的合规历史和供应能力等公共安全因素，不涉及对药物使用者的直接强制或自愿措施规定。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确：中国法规文本明确指出戒毒工作采取‘自愿戒毒、社区戒毒、强制隔离戒毒、社区康复等多种措施’，体现了自愿与强制相结合的原则。陈述2正确：美国法规文本聚焦于大麻种植的注册和监管，其‘公共安全因素’（public interest factors）评估主要针对申请人（如制造商、研究者）的资质、合规性、供应能力等，旨在确保受控物质的合法生产与供应，并未涉及对终端药物使用者的戒毒或治疗措施（无论是自愿还是强制）进行直接规定。因此，两个陈述都准确反映了各自法规在相应概念上的侧重点。", "category": "Controlled_Substances", "related_concept": "voluntary and compulsory measures, public interest factors", "id": "PA_P_00693_002", "match_type": "weak", "match_score": 0.7109067817344387, "lang": "CN", "source_cn": "戒毒条例.txt", "source_us": "PART_1318CONTROLS_TO_SATISFY_THE_REQUIREMENTS_OF_T.txt", "old_id": "comp_0001_0003_2"}
{"question": "When regulatory agencies implement electronic recording of proceedings, which approach best balances transparency with procedural order?", "choices": ["A. Requiring all media to submit formal applications 60 days in advance with detailed equipment specifications", "B. Establishing clear notification procedures in public announcements while allowing media to negotiate representation arrangements", "C. Prohibiting all electronic recording to maintain complete control over the proceeding environment", "D. Allowing unlimited media access with first-come-first-served equipment setup without coordination"], "answer": "B", "type": "Parallel", "explanation": "Option B represents the balanced approach where agencies provide clear notification (ensuring all parties are aware recording may occur) while allowing media flexibility to negotiate practical arrangements. This maintains transparency through media access while preserving procedural order through coordination mechanisms. The other options either create unnecessary barriers (A), eliminate transparency (C), or risk chaos (D).", "category": "General_FDA", "related_concept": "electronic recording notification, media representation negotiation", "id": "PA_P_00757_001", "match_type": "weak", "match_score": 0.749882382102797, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第666号）.txt", "source_us": "PART_10ADMINISTRATIVE_PRACTICES_AND_PROCEDURES.txt", "old_id": "comp_0013_0016_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据美国FDA对色素添加剂的管理原则，一种色素可以被批准用于所有食品、药品和化妆品，也可以被限制仅用于其中某一类或某几类特定产品，这取决于其安全数据是否支持该范围的使用。\n陈述2：根据中国NMPA对化妆品功效宣称的要求，一款宣称具有祛斑美白功效的产品，必须按照相关指导原则进行并出具相应的人体功效评价检验报告。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。美国法规§70.42(a)明确指出，局长（Commissioner）可以根据提交的数据，将一种色素添加剂列入可用于食品、药品或化妆品的“通用用途”（general use），也可以仅批准其用于已证明安全且合适的“更有限用途”（more limited use or uses）。这体现了基于安全数据的用途范围管理。\n陈述2正确。中国法规文本中明确规定：“宣称祛斑美白...的产品，应当按照化妆品功效宣称评价指导原则确定的检验项目要求，进行相应的功效性检验并出具检验报告。”这直接对应了NMPA对特定功效宣称的强制性检验要求。\n因此，两个陈述均正确。", "category": "Cosmetics", "related_concept": "color additive listing conditions, efficacy testing for specific claims", "id": "PA_P_00642_009", "match_type": "weak", "match_score": 0.7270885996707761, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0018_0004_2"}
{"question": "比较中美法规对特定程序的核心要求：\n陈述1：美国法规对电子处方签署有严格的多因素认证流程要求，以确保签署行为的法律效力。\n陈述2：中国社区戒毒法规要求与戒毒人员签订协议，并明确规定了协议内容、人员义务及违规责任，以此作为管理程序的核心。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都不正确", "C. 陈述1正确，陈述2不正确", "D. 陈述1不正确，陈述2正确"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。美国法规（21 CFR §1311.140）明确规定，签署受控物质电子处方时，医师必须在显示特定处方信息和法律声明后，完成双因素认证协议，此操作即构成法律意义上的签署。\n陈述2正确。中国《戒毒条例》规定，乡（镇）人民政府、城市街道办事处需与社区戒毒人员及时签订社区戒毒协议，协议需明确具体措施、戒毒人员应遵守的规定以及违反协议应承担的责任，这构成了社区戒毒管理的核心程序框架。两者分别体现了在药品管控和戒毒管理领域，通过形式化、可追溯的程序（认证/协议）来确立法律关系和责任的核心监管思路。", "category": "Compliance_Procedures", "related_concept": "electronic prescription signing requirements, community drug rehabilitation agreement", "id": "PA_P_00694_004", "match_type": "weak", "match_score": 0.6881712396735017, "lang": "CN", "source_cn": "戒毒条例.txt", "source_us": "PART_1311REQUIREMENTS_FOR_ELECTRONIC_ORDERS_AND_PR.txt", "old_id": "comp_0004_0009_2"}
{"question": "In the context of in vitro diagnostic (IVD) device regulations, which regulatory approach emphasizes the inclusion of clear examples of expected phenotypic patterns and gating strategies in product labeling as part of risk management, while the other focuses on establishing a comprehensive technical system with expert consultation to support registration?", "choices": ["A. US FDA emphasizes clear phenotypic examples in labeling; China NMPA focuses on expert consultation within a technical system", "B. China NMPA requires phenotypic examples in labeling; US FDA emphasizes expert consultation systems", "C. Both require identical labeling content for risk management", "D. Neither has specific requirements for labeling examples or expert systems"], "answer": "A", "type": "Parallel", "explanation": "US FDA regulations under 21 CFR 820.30 design controls require product labeling to include clear examples of expected phenotypic patterns and gating strategies using clinical samples as part of risk management activities. China NMPA regulations establish a technical system where expert consultation is institutionalized to provide technical support during review, verification, and inspection processes.", "category": "Medical_Devices", "related_concept": "product labeling and instructions, risk management principle, expert consultation system", "id": "PA_P_00375_001", "match_type": "weak", "match_score": 0.7494913834238897, "lang": "EN", "source_cn": "体外诊断试剂注册与备案管理办法（2021年第48号令）.txt", "source_us": "PART_864HEMATOLOGY_AND_PATHOLOGY_DEVICES.txt", "old_id": "comp_0006_0016_1"}
{"question": "关于化妆品检验机构出具虚假检验报告的处罚，中美法规在责任人员处罚方面存在显著差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规对责任人员处以罚款并可能禁止从业，美国法规主要关注机构认证撤销。", "B. 中国法规仅对机构进行罚款，美国法规对个人和机构均实施严厉处罚。", "C. 中美法规均对责任人员处以同等严厉的刑事处罚。", "D. 美国法规对虚假报告的责任人员处罚更重，包括终身禁止从业。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如NMPA相关条例）对出具虚假检验报告的直接责任人员规定了具体的经济处罚（处以其上一年度收入的1-3倍罚款）、行政处分（降低岗位等级、撤职或开除）以及从业禁止（10年内禁止从事化妆品检验工作）。而提供的美国法规文本主要围绕色素添加剂的认证、豁免和监管程序，并未具体描述对检验机构或个人出具虚假报告的同类处罚细则；美国对这类违规的处罚可能在其他章节（如FD&C Act相关条款）中规定，通常涉及民事罚款、禁令等，但当前文本未直接对比。因此，A选项准确概括了文本呈现的差异：中国有明确的人员处罚和从业禁止规定，美国文本未突出此点。", "category": "Cosmetics", "related_concept": "false inspection report penalties, direct responsibility personnel", "id": "PA_P_00677_008", "match_type": "weak", "match_score": 0.7383883746826639, "lang": "CN", "source_cn": "化妆品监督管理条例 (1).txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0024_0002_1"}
{"question": "关于质量安全负责人的职责履行独立性，中美法规的主要差异体现在：", "choices": ["A. 中国法规明确禁止兼任可能影响独立性的岗位，美国法规无此具体规定", "B. 美国法规要求独立履职需经法定代表人书面同意，中国法规无此要求", "C. 两国法规均允许在监督下指定他人协助履职，但中国要求建立监督制度", "D. 中国法规强调独立履职不受干扰，美国法规更关注履职记录的可追溯性"], "answer": "A", "type": "Parallel", "explanation": "中国法规（NMPA）明确规定质量安全负责人不得兼任生产部门负责人等可能影响独立性的岗位，而美国法规（FDA）在提供的文本中未涉及此类具体岗位兼任限制。选项B错误，因为中国法规才要求法定代表人书面同意；选项C部分正确但非主要差异；选项D的表述不准确。", "category": "Cosmetics", "related_concept": "independent performance of duties", "id": "PA_P_00592_001", "match_type": "weak", "match_score": 0.7422778044524491, "lang": "CN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0005_0002_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据美国FDA相关法规，在提交申请后补充支持性数据时，若涉及非临床实验室研究，必须声明该研究是否符合GLP（良好实验室规范）要求。\n陈述2：根据中国NMPA对化妆品人体试用试验报告的要求，试验结果部分必须明确填写出现特定等级皮肤不良反应的具体受试者人数。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。美国法规文本明确指出，提交的支持性数据中若包含非临床实验室研究，必须提供声明说明其是否符合21 CFR Part 58（即GLP法规）或说明不合规的原因。\n陈述2正确。中国法规文本中的试验结果表格模板（“人体试用试验结果显示，30人中 ____ 例出现 ____ 级皮肤不良反应”）明确要求填写具体的不良反应发生例数和等级，这体现了对结果报告明确性的要求。", "category": "Cosmetics", "related_concept": "nonclinical laboratory study compliance, skin adverse reaction grading, test subject count", "id": "PA_P_00638_021", "match_type": "weak", "match_score": 0.7337638265167562, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0060_0001_2"}
{"question": "请判断以下关于中美化妆品监管中核心制度要求的陈述：\n陈述1：在中国化妆品监管框架下，注册人/备案人必须建立并维护独立于生产企业的质量管理体系，该体系需明确包含销售管理制度、内审制度以及不良反应监测与评价体系。\n陈述2：在美国FDA的监管框架下，用于外用药品和化妆品的每一批直接色素（straight color）或色淀（lake）都必须获得FDA的单独批次认证（batch certification），以确认其符合身份和规格要求，方可使用。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。根据中国《化妆品监督管理条例》及《化妆品生产质量管理规范》，注册人/备案人作为产品质量安全的责任主体，必须建立并持续运行覆盖全生命周期的质量管理体系。该体系需独立于受托生产企业，并明确包含销售管理、内部审核（内审）以及不良反应监测与评价等关键子系统。\n陈述2正确。根据美国《联邦食品、药品和化妆品法案》及21 CFR Part 82的相关规定，用于外用药品和化妆品的色素（包括直接色素及其衍生的色淀）属于需认证的色素（certifiable colors）。每一批此类产品在上市前，必须由生产商提交样品给FDA，经FDA实验室检测确认其符合法定的身份和规格标准后，方可获得该批次的认证证书。这是美国对化妆品用色素的一项独特且严格的监管要求。", "category": "Cosmetics", "related_concept": "adverse reaction monitoring and evaluation system, batch certification", "id": "PA_P_00657_004", "match_type": "weak", "match_score": 0.7198851043423885, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_82LISTING_OF_CERTIFIED_PROVISIONALLY_LISTED_C.txt", "old_id": "comp_0033_0005_2"}
{"question": "关于临床试验中的质量风险容忍度，中美法规在设定依据上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规强调基于变量的医学和统计学特点及统计设计来设定容忍度，以鉴别系统性问题；美国法规未明确提及质量风险容忍度的概念。", "B. 中国法规要求容忍度设定必须考虑受试者安全和数据可靠性；美国法规则要求基于生产工艺的稳定性来设定。", "C. 中国法规规定容忍度由申办者单方面设定；美国法规则要求由监管机构统一规定。", "D. 两国法规均未对质量风险容忍度的设定提供具体指导，完全依赖企业自行决定。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（NMPA）明确要求，在预先设定质量风险的容忍度时，应当考虑变量的医学和统计学特点及统计设计，目的是鉴别影响受试者安全和数据可靠的系统性问题。而提供的美国法规（FDA）文本是关于防晒标准品制备和HPLC检测的具体操作步骤，并未涉及“质量风险容忍度”这一质量管理体系的概念。因此，差异在于中国法规有明确的设定原则，而美国文本未体现此概念。", "category": "Drugs", "related_concept": "quality risk tolerance", "id": "PA_P_00315_001", "match_type": "weak", "match_score": 0.7219982427811855, "lang": "CN", "source_cn": "药物临床试验质量管理规范.txt", "source_us": "PART_201LABELING.txt", "old_id": "comp_0017_0079_1"}
{"question": "关于麻醉药品和精神药品的总量控制，中美两国法规在实施机制上存在显著差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国实行自上而下的年度计划制定模式，由中央部门直接确定生产总量和种植计划；美国则通过评估年度需求来确定总量，并设有听证程序供利益相关方参与。", "B. 中国和美国都完全由中央政府部门单方面决定年度生产总量，企业必须无条件执行。", "C. 中国要求行业协会参与总量控制决策，而美国完全排除行业组织的参与。", "D. 美国的总量控制仅适用于进口环节，中国的总量控制则涵盖种植、生产到使用的全链条。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如第七条）明确国家根据医疗、储备和生产需求确定需求总量，国务院药品监督管理部门制定年度生产计划，并与农业主管部门共同制定种植计划，体现了中央集权的计划管理模式。美国法规（如§1315.52）则显示，在确定或调整年度需求评估时，管理员可自行决定或应申请举行听证会接收事实证据，体现了程序参与和行政裁量相结合的特点。选项B错误，因为美国法规允许听证参与；选项C错误，中国法规第六条提及行业协会加强自律管理，但未明确其参与总量控制决策；选项D错误，美国法规提及的配额涉及制造、采购和进口，表明其控制范围并非仅限于进口。", "category": "Controlled_Substances", "related_concept": "total quantity control, hearing procedures", "id": "PA_P_00728_001", "match_type": "weak", "match_score": 0.7402068685156175, "lang": "CN", "source_cn": "麻醉药品和精神药品管理条例.txt", "source_us": "PART_1315IMPORTATION_AND_PRODUCTION_QUOTAS_FOR_EPH.txt", "old_id": "comp_0003_0010_1"}
{"question": "Statement 1: Regulatory systems that classify devices as Class I typically require the least stringent controls because they present minimal potential for harm. Statement 2: The primary purpose of diagnostic and monitoring devices is to ensure appropriate therapy through measurement of substances in human specimens.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the risk-based classification approach where Class I devices have the lowest risk profile. Statement 2 accurately characterizes the intended use of diagnostic and monitoring devices, which is to measure substances for therapeutic management. Both statements reflect fundamental regulatory principles across different systems.", "category": "Medical_Devices", "related_concept": "Class I classification, diagnosis and treatment monitoring", "id": "PA_P_00484_002", "match_type": "weak", "match_score": 0.7323767896515957, "lang": "EN", "source_cn": "医疗器械监督管理条例.txt", "source_us": "PART_862CLINICAL_CHEMISTRY_AND_CLINICAL_TOXICOLOGY.txt", "old_id": "comp_0001_0020_2"}
{"question": "关于医疗器械临床试验基本文件的保存期限，中美法规的核心差异主要体现在哪个方面？", "choices": ["A. 中国法规规定了与产品生命周期挂钩的保存期限，而美国法规未在PMA章节中明确具体保存时长。", "B. 美国法规要求永久保存，而中国法规仅要求保存至临床试验结束。", "C. 两者都要求保存至产品退市后10年。", "D. 美国法规要求保存期限比中国法规更长。"], "answer": "A", "type": "Parallel", "explanation": "中国法规（NMPA）明确规定申办者应当保存临床试验基本文件至无该医疗器械使用时，即与产品的市场生命周期挂钩。而提供的美国法规（FDA PMA章节）文本主要描述了研究摘要的内容要求，并未在该部分明确临床试验基本文件的具体保存期限。其他选项的描述与两国法规的实际要求不符。", "category": "Medical_Devices", "related_concept": "clinical trial basic file retention", "id": "PA_P_00402_007", "match_type": "weak", "match_score": 0.698524173971794, "lang": "CN", "source_cn": "医疗器械临床试验质量管理规范.txt", "source_us": "PART_814PREMARKET_APPROVAL_OF_MEDICAL_DEVICES.txt", "old_id": "comp_0020_0001_1"}
{"question": "Statement 1: Regulatory authorities in China have the right to enter regulated facilities at any time without prior notice, and refusal to cooperate can result in severe penalties. Statement 2: In the US regulatory system, FDA employees must follow specific public disclosure procedures when responding to subpoenas for agency records, even declining production during legal proceedings.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 accurately reflects Chinese regulations allowing unannounced inspections with penalties for non-cooperation. Statement 2 correctly describes US FDA procedures requiring employees to follow established disclosure protocols when responding to subpoenas, declining immediate production to ensure proper handling. Both statements represent key differences in regulatory enforcement approaches.", "category": "General_FDA", "related_concept": "right to enter premises at any time, subpoena duces tecum response, public disclosure rules, refusal or evasion of inspection", "id": "PA_P_00810_002", "match_type": "weak", "match_score": 0.728405207363525, "lang": "EN", "source_cn": "药品医疗器械飞行检查办法（2015年第14号令）.txt", "source_us": "PART_20PUBLIC_INFORMATION.txt", "old_id": "comp_0006_0001_2"}
{"question": "A cosmetics company is developing a new sunscreen containing a novel ingredient. The ingredient consists of insoluble particles where one dimension measures 80 nanometers. Under which regulatory framework would this ingredient most likely trigger specific nanomaterial requirements regarding its definition and documentation?", "choices": ["A. US FDA regulations, due to their detailed specifications for particle size in color additives.", "B. Chinese NMPA regulations, due to their explicit dimensional-based definition for nanomaterials.", "C. Both US FDA and Chinese NMPA regulations equally, as both have identical nanomaterial definitions.", "D. Neither framework, as particle size is irrelevant for cosmetic ingredients."], "answer": "B", "type": "Parallel", "explanation": "Chinese NMPA regulations explicitly define nanomaterials based on dimensional criteria (1-100 nm in at least one dimension), which would apply to this 80 nm particle. The provided US FDA text focuses on color additive specifications (like Citrus Red No. 2) and does not present a general nanomaterial definition for novel ingredients, making option B correct. Option A is incorrect because the US text specifies chemical and purity standards, not a general nanoscale definition. Option C is false as the definitions are not identical. Option D is incorrect because particle size can be a regulatory trigger, especially under NMPA.", "category": "Cosmetics", "related_concept": "nanomaterial definition", "id": "PA_P_00617_016", "match_type": "weak", "match_score": 0.7124285677751793, "lang": "EN", "source_cn": "化妆品新原料注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0024_0001_1"}
{"question": "Which regulatory system provides specific timelines for the publication of new regulations after petition submission?", "choices": ["A. US FDA regulations specify publication timelines, while Chinese NMPA regulations do not", "B. Chinese NMPA regulations specify publication timelines, while US FDA regulations do not", "C. Both systems specify publication timelines", "D. Neither system specifies publication timelines"], "answer": "A", "type": "Parallel", "explanation": "US FDA regulations establish specific timelines (90-180 days) for publishing regulations after petition filing, while Chinese NMPA regulations focus on testing and reporting procedures without specifying regulatory publication timelines.", "category": "Cosmetics", "related_concept": "regulation publication timeline", "id": "PA_P_00607_004", "match_type": "weak", "match_score": 0.7439403479179316, "lang": "EN", "source_cn": "化妆品安全风险监测与评价管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0004_0002_2"}
{"question": "关于化妆品中着色剂混合物的认证要求，中美法规存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求所有着色剂混合物都必须进行批次认证，而美国法规则根据混合物成分是否经过认证或是否使用特定稀释剂，规定了豁免认证的情形。", "B. 美国法规要求所有着色剂混合物都必须进行批次认证，而中国法规则根据混合物成分是否经过认证或是否使用特定稀释剂，规定了豁免认证的情形。", "C. 中美法规均要求所有着色剂混合物必须进行批次认证，没有豁免情形。", "D. 中美法规均不要求着色剂混合物进行批次认证，仅对单一着色剂有认证要求。"], "answer": "A", "type": "Parallel", "explanation": "美国法规（如§80.35）明确区分了需要认证的着色剂混合物（含未认证的单一颜色）和可豁免认证的混合物（由已认证的单一颜色与批准的稀释剂简单混合而成）。中国提供的法规文本未涉及着色剂混合物的具体认证规定，因此基于通用原则，美国法规在此方面有更详细的豁免机制描述，而中国法规通常对特定成分（如去屑剂、防晒剂）有明确的检测要求，但未在给定文本中详述着色剂混合物的认证豁免。", "category": "Cosmetics", "related_concept": "color additive mixture certification", "id": "PA_P_00639_007", "match_type": "weak", "match_score": 0.7029069052238133, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0015_0003_1"}
{"question": "关于化妆品注册申请中提交人体功效试验报告的要求，中美两国法规的主要差异体现在：", "choices": ["A. 中国要求所有特殊化妆品必须提交由指定检验机构出具的报告，而美国对特定着色剂的使用有详细规定，但未普遍要求功效试验报告", "B. 两国都要求所有化妆品提交功效试验报告，但中国的检验机构要求更严格", "C. 美国要求所有化妆品提交功效试验报告，而中国仅对进口产品有此要求", "D. 两国均不要求提交人体功效试验报告，仅需提交毒理学报告"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定，申请特殊化妆品注册时必须提交符合相关规定的人体功效试验报告，且报告应由化妆品注册和备案检验机构出具。美国法规（如对D&C Red No. 6等着色剂的规定）侧重于着色剂的认证、规格、使用限制和标签要求，并未普遍要求化妆品提交人体功效试验报告作为注册条件。这体现了中美在化妆品监管重点上的差异：中国更强调功效宣称的实证支持，而美国更关注着色剂等特定成分的安全性和规范使用。", "category": "Cosmetics", "related_concept": "提交人体功效试验报告", "id": "PA_P_00653_021", "match_type": "weak", "match_score": 0.6438744426739285, "lang": "CN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0019_0020_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：根据中美化妆品法规，如果一种成分（如氯乙烯）被证实具有致癌性，两国监管机构均有权直接认定含有该成分的特定类别化妆品（如气雾剂产品）为掺假产品并禁止其销售。\n陈述2：中美法规都明确要求，所有化妆品（如液体口服卫生用品和阴道用品）的零售包装必须采用防篡改包装，并标注相应的安全标识，否则产品将被视为掺假或错误标签。", "choices": ["A. 两个陈述都正确", "B. 两个陈述都错误", "C. 陈述1正确，陈述2错误", "D. 陈述1错误，陈述2正确"], "answer": "C", "type": "Parallel", "explanation": "陈述1正确。美国FDA在提供的法规文本中明确指出，氯乙烯（vinyl chloride）是一种有害物质，含有该成分的化妆品气雾剂产品可被视为掺假（adulterated）。这体现了FDA对已知致癌物在化妆品中使用的直接禁止权。中国NMPA在《化妆品安全技术规范》等法规中同样对禁用组分（包括致癌物）有严格规定，含有禁用物质的化妆品属于严重安全问题，监管部门有权查处。因此，两国在此原则上是相似的。\n陈述2错误。美国法规文本明确规定了针对“化妆品液体口服卫生用品和阴道用品”必须采用防篡改包装并正确标签，否则可能被视为掺假或错误标签。这是一项具体的、针对特定类别产品的强制性要求。中国现行的《化妆品监督管理条例》及配套法规中，并未对所有化妆品设立普遍的、与FDA文本中完全对应的防篡改包装强制性要求。中国的包装和标签要求更侧重于其他安全信息（如成分、警示语等），而非专门针对“防篡改”特性。因此，该要求并非中美法规的共同强制性规定。", "category": "Cosmetics", "related_concept": "carcinogenic substance regulation, tamper-resistant packaging requirement, product safety labeling", "id": "PA_P_00641_012", "match_type": "weak", "match_score": 0.7415271395983418, "lang": "CN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0046_0003_2"}
{"question": "关于化妆品质量安全关键岗位的设置与职责，中美法规的典型差异体现在：", "choices": ["A. 中国法规明确要求企业设立质量安全负责人，协助法定代表人履行管理职责；美国法规通常不强制要求设立此特定职位，而是通过GMP等体系规范人员资质与责任。", "B. 中国法规仅要求法定代表人负责质量安全；美国法规则要求设立独立的质量安全委员会。", "C. 两国法规均强制要求企业必须设立专职的质量安全总监，且职责完全相同。", "D. 美国法规对质量安全关键岗位的要求比中国法规更为具体和严格，规定了详细的任职资格。"], "answer": "A", "type": "Parallel", "explanation": "中国《化妆品监督管理条例》及相关规定明确要求企业建立质量安全责任制，并设立质量安全负责人这一关键岗位，协助法定代表人。美国FDA对化妆品的管理（如对色素D&C Blue No. 4的规定）更侧重于通过《联邦食品、药品和化妆品法案》（FD&C Act）及现行良好生产规范（cGMP）来整体规范生产实践和质量体系，对具体岗位名称的强制性规定不如中国明确，更强调体系合规和最终产品安全。", "category": "Cosmetics", "related_concept": "quality safety key positions, quality safety director", "id": "PA_P_00590_001", "match_type": "weak", "match_score": 0.7337312097637458, "lang": "CN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0001_0005_1"}
{"question": "请判断以下两个陈述的真假：\n陈述1：在促进传统医药发展方面，中国法规明确提出了鼓励生产企业进行数智化转型和建设绿色工厂，并将其作为提升质量控制水平的手段之一。\n陈述2：美国法规中关于HCT/Ps的检查条款，其根本目的是为了确保这些产品的质量、安全性与有效性，并防止传染性疾病的传播。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "A", "type": "Parallel", "explanation": "陈述1正确。中国法规文本第五条明确指出“鼓励持有人、中药生产企业...加快建设高水平数字化车间和智能工厂、绿色工厂，提升中药生产质量控制水平，促进中药生产数智化转型”，这直接体现了通过现代化、绿色化手段提升质量并促进产业发展的导向。\n陈述2正确。虽然提供的美国法规片段（§1271.400）主要描述检查的权限和程序，但其上位法规依据（《公共卫生服务法》第361节）以及关联条款（如关于使用说明以防止传染病传播的条款）的核心监管目标，正是确保HCT/Ps不会引入、传播或扩散传染性疾病，从而保障其使用的安全性与有效性。检查是确保符合这些法规要求、实现该根本目的的关键执法手段。", "category": "Drugs", "related_concept": "promoting inheritance and innovation of traditional Chinese medicine, ensuring quality and safety of traditional Chinese medicine", "id": "PA_P_00049_002", "match_type": "weak", "match_score": 0.7110534292961727, "lang": "CN", "source_cn": "中药生产监督管理专门规定.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0001_0021_2"}
{"question": "Statement 1: Regulatory actions to suspend sales of cosmetic products are primarily justified by the need to protect public health when safety concerns arise. Statement 2: The presence of contamination with known carcinogens in cosmetic ingredients is considered sufficient grounds for regulatory action, even in the absence of specific safe tolerance evidence.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: Regulatory frameworks in both the US and China prioritize public health protection, and suspension of sales is a key tool when safety concerns are identified. Statement 2 is also correct: The presence of known carcinogens (like β-naphthylamine) in ingredients can lead to regulatory action (such as delisting or termination of use) even without establishing a specific safe tolerance level, as seen in US regulations where such contamination is deemed unacceptable for public health protection.", "category": "Cosmetics", "related_concept": "safe tolerance evidence, contamination with carcinogens, public health protection, suspension of sales", "id": "PA_P_00679_002", "match_type": "weak", "match_score": 0.6870844683549887, "lang": "EN", "source_cn": "化妆品监督管理条例 (1).txt", "source_us": "PART_81GENERAL_SPECIFICATIONS_AND_GENERAL_RESTRICT.txt", "old_id": "comp_0022_0003_2"}
{"question": "In regulatory compliance for imported materials, which statement correctly describes the timing requirements for sampling and resubmission processes?", "choices": ["A. Both Chinese and US regulations require sampling to occur within 2 days of notification, but differ on resubmission date determination.", "B. Chinese regulations specify sampling within 2 days of notification, while US regulations define resubmission date as when amended applications are received.", "C. Both systems require 20-day processing windows for testing and application reviews, with identical resubmission date rules.", "D. US regulations mandate immediate sampling upon arrival, while Chinese regulations allow flexible resubmission dates for withdrawn applications."], "answer": "B", "type": "Parallel", "explanation": "Chinese regulations require on-site sampling within 2 days after notification, while US regulations define the resubmission date for amended applications as the date received by FDA. The other options contain incorrect comparisons about timing requirements or processing windows.", "category": "Drugs", "related_concept": "现场抽样时间, resubmission date", "id": "PA_P_00362_001", "match_type": "weak", "match_score": 0.6778290302816473, "lang": "EN", "source_cn": "进口药材管理办法（2019年第9号令）.txt", "source_us": "PART_514NEW_ANIMAL_DRUG_APPLICATIONS.txt", "old_id": "comp_0007_0006_1"}
{"question": "针对药品样品丢失或盗窃事件，中美法规在通知要求上有何异同？请判断以下陈述：陈述1：中国法规要求立即通知监管机构并启动调查。陈述2：美国法规要求在意识到事件后5个工作日内通知FDA并立即启动调查。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Parallel", "explanation": "陈述1错误：提供的中国法规文本未涉及药品样品丢失或盗窃的具体通知要求，它主要关注临床试验数据记录和计算机化系统的权限管理。陈述2正确：根据美国法规（FDA §203.37(b)），制造商或授权分销商在意识到药品样品发生重大丢失或已知盗窃后，应在5个工作日内通知FDA（通过电话或书面），并立即启动调查。这体现了美国法规对药品样品安全事件的明确时间要求和程序规定。", "category": "Drugs", "related_concept": "loss theft notification", "id": "PA_P_00314_002", "match_type": "weak", "match_score": 0.7402157515352253, "lang": "CN", "source_cn": "药物临床试验质量管理规范.txt", "source_us": "PART_203PRESCRIPTION_DRUG_MARKETING.txt", "old_id": "comp_0014_0007_2"}
{"question": "关于化妆品放行检查，中美法规在风险控制措施的实施主体和报告流程上存在差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求质量安全负责人发现风险后立即组织控制并报告法定代表人；美国法规要求企业直接向FDA报告并等待指令。", "B. 中国法规强调质量安全负责人的组织责任和向法定代表人的内部报告；美国法规更侧重于产品因特定成分被直接认定为掺假。", "C. 两国法规都要求由企业法定代表人全权负责风险控制措施的决策与实施。", "D. 美国法规要求所有风险控制措施必须经过第三方机构认证后方可实施；中国法规则无此要求。"], "answer": "B", "type": "Parallel", "explanation": "中国法规（如NMPA相关要求）明确质量安全负责人在发现质量安全风险时，负有“不予放行、立即组织采取风险控制等措施，并及时报告法定代表人”的具体组织责任和内部报告路径。美国法规（如FDA对氯乙烯的规定）则体现了不同的监管逻辑：当化妆品气雾剂产品含有氯乙烯这类已被认定有害的成分时，产品直接“被视为掺假”，这是一种基于成分安全性的法定认定，而非强调企业内部某个岗位的组织和报告流程。选项A错误，因为美国文本并未描述企业向FDA报告并等待指令的流程；选项C错误，中国法规中法定代表人是接收报告和最终决策者，但组织实施责任在质量安全负责人；选项D的第三方认证要求在中美文本中均未体现。", "category": "Cosmetics", "related_concept": "release inspection, risk control measures", "id": "PA_P_00594_001", "match_type": "weak", "match_score": 0.746634320560758, "lang": "CN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_700GENERAL.txt", "old_id": "comp_0007_0003_1"}
{"question": "在化妆品功效宣称的人体功效评价试验中，中美法规对控制试验偏倚的共同核心要求是什么？", "choices": ["A. 均要求使用双盲法并详细记录随机分组过程", "B. 均强调需设立对照组并采用统计学方法确定样本量", "C. 均强制要求所有试验必须由第三方机构独立实施", "D. 均规定必须使用电子数据采集系统并实时监控"], "answer": "B", "type": "Parallel", "explanation": "中国法规明确要求阐述对照组的设定和选择等试验设计基本原则，描述随机分组方式、盲法等减少或控制偏倚的措施，并根据试验目的和统计学原则设定消费者人数。美国法规虽未在此文本中直接描述试验设计，但其GMP（良好生产规范）框架和整个监管体系隐含了对科学试验设计（包括对照组、样本量计算和偏倚控制）的普遍要求，以确保数据可靠性。两者都体现了对科学严谨性和数据有效性的根本追求。", "category": "Cosmetics", "related_concept": "test protocol and bias control", "id": "PA_P_00602_008", "match_type": "weak", "match_score": 0.7422912570201906, "lang": "CN", "source_cn": "化妆品功效宣称评价规范.txt", "source_us": "PART_74LISTING_OF_COLOR_ADDITIVES_SUBJECT_TO_CERTI.txt", "old_id": "comp_0009_0005_1"}
{"question": "关于监管机构主动将某物质列入许可清单并给予豁免的权限，中美法规有何体现？", "choices": ["A. 中国法规未体现此权限，美国法规明确赋予FDA专员此权限", "B. 美国法规未体现此权限，中国法规明确赋予NMPA此权限", "C. 两国法规均明确赋予监管机构此权限", "D. 两国法规均未体现监管机构有此权限"], "answer": "A", "type": "Parallel", "explanation": "美国法规文本明确规定，即使未收到请愿，如果FDA专员掌握的事实表明某色素添加剂应被列入清单和/或无需认证程序以保护公众健康，他可以通过发布适当法规主动将其列入。中国提供的法规文本主要规定的是基于检验结果的复检、报告和调查程序，未体现监管机构可以主动、依职权将某物质列入许可清单并豁免认证的类似权限。", "category": "Cosmetics", "related_concept": "listing and exemption from certification", "id": "PA_P_00609_014", "match_type": "weak", "match_score": 0.720331441744548, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0012_0003_4"}
{"question": "关于在复检或异议审查期间，监管部门对不合格产品的调查工作，中美法规有何异同？", "choices": ["A. 中国法规明确要求调查工作不停止，美国法规对此无明确规定", "B. 美国法规明确要求调查工作不停止，中国法规对此无明确规定", "C. 两国法规均明确要求调查工作不停止", "D. 两国法规均未对此做出明确规定"], "answer": "A", "type": "Parallel", "explanation": "中国法规明确规定，在异议审查和复检期间，核查处置部门不停止对检验结论为不符合规定产品的调查和风险控制工作。美国提供的法规文本主要涉及色素添加剂，未明确提及在类似异议或复检程序期间对不合格产品的调查是否停止。因此，中国有明确规定，而美国文本中无此直接对应规定。", "category": "Cosmetics", "related_concept": "non-stop investigation during re-inspection", "id": "PA_P_00609_011", "match_type": "weak", "match_score": 0.720331441744548, "lang": "CN", "source_cn": "化妆品抽样检验管理办法.txt", "source_us": "PART_71COLOR_ADDITIVE_PETITIONS.txt", "old_id": "comp_0012_0003_1"}
{"question": "关于电子处方传输，中美法规在传输形式要求上存在关键差异。以下哪项描述最准确地反映了这种差异？", "choices": ["A. 中国法规要求电子处方必须由执业医师直接传输至药房，而美国法规则允许通过中介机构转发", "B. 美国法规明确禁止将电子处方转换为传真等其他形式进行传输，中国法规对此未作具体规定", "C. 中国法规要求电子处方传输必须使用国家指定的加密系统，美国法规则允许使用任何符合安全标准的系统", "D. 美国法规要求电子处方在传输前必须经过药监部门预审，中国法规则实行传输后备案制度"], "answer": "B", "type": "Parallel", "explanation": "美国法规明确规定电子处方必须以电子形式从执业医师传输至药房，禁止中介将其转换为传真等其他形式传输。中国提供的法规文本未涉及电子处方传输的具体形式要求，主要关注申请资料真实性、小包装麻黄素定义及兽药监管分工。因此B项准确描述了美国法规有明确禁止性规定而中国法规未具体规定的差异。", "category": "Electronic_Prescriptions", "related_concept": "electronic prescription transmission", "id": "PA_P_00717_001", "match_type": "weak", "match_score": 0.7243081525191875, "lang": "CN", "source_cn": "药品类易制毒化学品管理办法（卫生部令第72号_2010年）.txt", "source_us": "PART_1311REQUIREMENTS_FOR_ELECTRONIC_ORDERS_AND_PR.txt", "old_id": "comp_0016_0011_1"}
{"question": "A company has an in vitro diagnostic (IVD) device currently marketed in China under a Class I filing (Bei'an). During a post-market review, they discover that the device's intended use has expanded to include a new high-risk clinical application. According to Chinese regulatory principles, what is the most likely required regulatory action?", "choices": ["A. Submit a change filing to update the filing information table with the new intended use.", "B. Immediately withdraw the device from the market and apply for a new Class I filing.", "C. Apply for formal registration as a Class II or Class III IVD device.", "D. No action is required if the device's technical specifications remain unchanged."], "answer": "C", "type": "Parallel", "explanation": "The core principle tested is the adjustment of management category. Chinese regulations require that if a filed (Class I) device's risk profile changes such that it should be reclassified as a higher class (II or III), the manufacturer must cease relying on the filing and initiate a formal registration application for the appropriate higher class. A change filing (Option A) is for updates to information within the same class, not for a fundamental change in risk category. Withdrawal (B) is not the specified procedure, and no action (D) would be non-compliant.", "category": "Medical_Devices", "related_concept": "管理类别调整", "id": "PA_P_00385_001", "match_type": "weak", "match_score": 0.6419402630171843, "lang": "EN", "source_cn": "体外诊断试剂注册与备案管理办法（2021年第48号令）.txt", "source_us": "PART_874EAR_NOSE_AND_THROAT_DEVICES.txt", "old_id": "comp_0022_0002_1"}
{"question": "A cosmetics company receives an FDA reference number for its product ingredient statement. Which of the following best describes the regulatory implications of this number in the US compared to how product sampling inspection results are handled for online sales in China?", "choices": ["A. In the US, the FDA reference number signifies official product approval, while in China, negative sampling results must be publicly disclosed for one year to inform consumers.", "B. In the US, the FDA reference number is for administrative tracking and does not imply approval, while in China, negative sampling results from online platforms trigger mandatory public disclosure for consumer reference.", "C. In both jurisdictions, the assignment of a number (FDA reference or inspection case) automatically authorizes public marketing claims about product safety.", "D. In the US, the reference number protects trade secrets from disclosure, while in China, sampling inspection disclosures are kept confidential between the regulator and the company."], "answer": "B", "type": "Parallel", "explanation": "The FDA reference number (per §720.9) is explicitly stated not to denote FDA approval of the firm or product. Any representation creating an impression of official approval because of such a number is considered misleading. In contrast, the Chinese regulation (CN text) mandates that information regarding product sampling inspections found non-compliant must be publicly disclosed and remain available for one year for consumer reference during purchase. Option A is incorrect because the FDA number does not signify approval. Option C is incorrect as neither system uses number assignment to authorize marketing claims; the US explicitly prohibits implying approval from the number. Option D is incorrect because the US text discusses confidentiality regarding trade secret ingredient determinations, not the reference number itself, and the Chinese rule requires public disclosure, not confidentiality.", "category": "Cosmetics", "related_concept": "FDA reference number, product sampling inspection disclosure", "id": "PA_P_00685_001", "match_type": "weak", "match_score": 0.7437209445473618, "lang": "EN", "source_cn": "化妆品网络经营监督管理办法.txt", "source_us": "PART_720VOLUNTARY_FILING_OF_COSMETIC_PRODUCT_INGRE.txt", "old_id": "comp_0008_0003_1"}
{"question": "关于化妆品批次合规性管理，中美法规在监管逻辑上存在显著差异。以下哪项最能体现这种差异？", "choices": ["A. 中国法规强调企业自查和内部考核，美国法规依赖官方审查和认证程序", "B. 中国法规要求质量安全负责人每年培训40学时，美国法规无此要求", "C. 中国法规要求记录保存2年，美国法规未规定具体保存期限", "D. 中国法规鼓励建立激励机制，美国法规强调听证权利"], "answer": "A", "type": "Parallel", "explanation": "中国法规（NMPA）通过企业自查、内部考核、负责人培训等制度构建了以企业主体责任为核心的持续合规管理体系。美国法规（FDA）则建立了以官方审查为基础的批次认证制度，通过审查请求材料、符合性判断、证书签发或拒绝等程序实现外部监管。选项A准确抓住了这种“内部管理驱动”与“外部认证驱动”的核心逻辑差异。", "category": "Cosmetics", "related_concept": "batch compliance", "id": "PA_P_00593_001", "match_type": "weak", "match_score": 0.7433104819109708, "lang": "CN", "source_cn": "企业落实化妆品质量安全主体责任.txt", "source_us": "PART_80COLOR_ADDITIVE_CERTIFICATION.txt", "old_id": "comp_0008_0001_1"}
{"question": "在药物管控领域，中美法规都强调了记录保存与验证的重要性，但侧重点不同。以下哪项组合正确描述了两国法规在这方面的主要要求？\n① 美国法规要求电子处方应用系统对签署后的处方信息进行数字签名和电子存档。\n② 中国法规要求社区戒毒工作小组对戒毒人员提供职业技能培训等帮助措施，并记录在案。\n③ 美国法规允许处方在不携带数字签名的情况下传输，但传输前必须验证开方医师的数字证书有效性。\n④ 中国法规要求社区戒毒人员定期接受检测，但检测结果无需纳入统一的电子档案系统。", "choices": ["A. ①②③", "B. ①③④", "C. ②③④", "D. ①②④"], "answer": "A", "type": "Parallel", "explanation": "组合①②③正确描述了差异。①和③是美国电子处方法规（21 CFR §1311.140, §1311.145）的核心要求：数字签名、电子存档，以及允许无签名传输但需验证证书有效性（通过检查证书吊销列表）。②是中国社区戒毒法规的要求，属于管理帮助措施的一部分，实践中通常会形成记录。④表述不准确，中国法规虽未明文规定“统一的电子档案系统”，但社区戒毒作为执法管理环节，人员的检测、报告、违规情况等必然会形成记录并上报公安机关（如严重违反协议时），并非“无需纳入”任何形式的档案或记录。", "category": "Records_Management", "related_concept": "digital signature and archiving, management and assistance measures", "id": "PA_P_00694_005", "match_type": "weak", "match_score": 0.6881712396735017, "lang": "CN", "source_cn": "戒毒条例.txt", "source_us": "PART_1311REQUIREMENTS_FOR_ELECTRONIC_ORDERS_AND_PR.txt", "old_id": "comp_0004_0009_3"}
{"question": "Statement 1: In Chinese cosmetic regulations, test reports must include specific signatory details and official seals to validate the document. Statement 2: US regulations for color additives in standardized foods require compliance with temporary permits as a condition for regulatory approval.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct: Chinese cosmetic test reports require authorization signatures, dates, and inspection/testing seals as formal validation elements. Statement 2 is correct: US regulations specify that color additive use in standardized foods must comply with temporary permit terms, and regulations may be conditioned on such compliance with expiration tied to the permit.", "category": "Cosmetics", "related_concept": "signatory and seal details, temporary permit compliance", "id": "PA_P_00642_013", "match_type": "weak", "match_score": 0.7481880773982156, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0028_0001_2"}
{"question": "Statement 1: In US regulations, a records management system must facilitate the review of an HCT/P's history before distribution. Statement 2: Chinese regulations require ethics committees to have written procedures for notifying researchers of review opinions promptly. Which of the following is correct?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "A", "type": "Parallel", "explanation": "Statement 1 is correct as per US regulations (1271.270(b)), which require a records management system to facilitate review of an HCT/P's history before distribution. Statement 2 is correct as per Chinese regulations (Article 14(5)), which require ethics committees to establish written procedures for promptly notifying researchers of review opinions. Both statements accurately reflect regulatory requirements in their respective jurisdictions.", "category": "Drugs", "related_concept": "document and record retention", "id": "PA_P_00311_002", "match_type": "weak", "match_score": 0.7293333628967316, "lang": "EN", "source_cn": "药物临床试验质量管理规范.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0005_0017_2"}
{"question": "A pharmaceutical company discovers a significant theft of Schedule II controlled substances from its warehouse. Which regulatory approach best describes the immediate administrative penalty authority for such diversion incidents?", "choices": ["A. Primary authority rests with drug regulatory agencies to impose fines and revoke licenses", "B. Primary authority rests with law enforcement agencies to impose criminal penalties and fines", "C. Both drug regulatory and law enforcement agencies share concurrent penalty authority", "D. Penalties are determined solely by judicial courts after criminal conviction"], "answer": "C", "type": "Parallel", "explanation": "Both US and Chinese regulations establish shared authority between drug regulatory and law enforcement agencies for diversion incidents. Chinese regulations specify that drug regulatory authorities impose administrative penalties (fines, license revocation) while law enforcement handles criminal aspects. US regulations through DEA involve both administrative enforcement (license actions) and criminal investigation pathways when controlled substances are diverted.", "category": "Controlled_Substances", "related_concept": "administrative penalties by drug regulatory authorities", "id": "PA_P_00738_001", "match_type": "weak", "match_score": 0.7445903548369581, "lang": "EN", "source_cn": "麻醉药品和精神药品管理条例.txt", "source_us": "PART_1301REGISTRATION_OF_MANUFACTURERS_DISTRIBUTOR.txt", "old_id": "comp_0025_0002_1"}
{"question": "In comparing US and Chinese medical device regulatory frameworks, which statement accurately describes their approaches to standard implementation monitoring?", "choices": ["A. Both systems delegate primary monitoring responsibility to national-level technical committees.", "B. The US system relies on performance standards as a key monitoring mechanism, while China employs a multi-level system with local authorities collecting implementation feedback.", "C. China focuses exclusively on pre-market notification procedures for monitoring, while the US uses a combination of technical guidance and post-market surveillance.", "D. Neither system has formal mechanisms for tracking the implementation of standards after they are published."], "answer": "B", "type": "Parallel", "explanation": "The US framework uses performance standards (as seen in Class II device classifications) as a regulatory control that inherently monitors device performance against set criteria. The Chinese framework, as described, establishes a structured system where national technical committees are responsible for tracking standard implementation, and local food and drug administrations have the explicit duty to supervise implementation and report problems upward, creating a multi-tiered monitoring approach.", "category": "Medical_Devices", "related_concept": "standard implementation monitoring", "id": "PA_P_00440_001", "match_type": "weak", "match_score": 0.7137652869989487, "lang": "EN", "source_cn": "医疗器械标准管理办法（2017年第33号令）.txt", "source_us": "PART_880GENERAL_HOSPITAL_AND_PERSONAL_USE_DEVICES.txt", "old_id": "comp_0003_0005_1"}
{"question": "Which statement accurately compares the regulatory oversight of hospital-prepared medications in China and the United States?", "choices": ["A. In China, hospital-prepared medications are regulated by both national and provincial authorities, while in the US, oversight is centralized under a single federal agency.", "B. In China, hospital-prepared medications are regulated solely by provincial authorities, while in the US, oversight involves both federal and state agencies.", "C. In China, hospital-prepared medications are regulated by a single national authority, while in the US, oversight is decentralized to state-level agencies only.", "D. In China, hospital-prepared medications are regulated by international bodies, while in the US, oversight is handled exclusively by the FDA."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations specify that the National Medical Products Administration (NMPA) oversees hospital-prepared medications nationally, while provincial authorities manage local approvals and supervision. In the US, the FDA centrally regulates drugs under federal law, though states may have additional requirements for compounding pharmacies.", "category": "Drugs", "related_concept": "监督管理职责", "id": "PA_P_00074_001", "match_type": "weak", "match_score": 0.6545913760500282, "lang": "EN", "source_cn": "医疗机构制剂注册管理办法（试行）（2005年国家食品药品监督管理局令第20号）.txt", "source_us": "PART_510NEW_ANIMAL_DRUGS.txt", "old_id": "comp_0001_0009_1"}
{"question": "Statement 1: In US food safety regulations, waivers can be granted based on economic hardship if they don't impair FDA's ability to respond to foodborne illness outbreaks. Statement 2: Chinese regulatory amendments primarily focus on simplifying administrative procedures and removing redundant requirements rather than establishing formal waiver processes for economic hardship.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 accurately describes US FDA waiver criteria requiring economic hardship justification while ensuring public health protection. Statement 2 correctly characterizes Chinese amendments as streamlining administrative processes (e.g., removing registration steps, simplifying licensing) rather than establishing formal economic hardship waiver mechanisms like the US system.", "category": "General_FDA", "related_concept": "waiver criteria, exemption granting, public health protection", "id": "PA_P_00753_002", "match_type": "weak", "match_score": 0.7345896164938663, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第666号）.txt", "source_us": "PART_1GENERAL_ENFORCEMENT_REGULATIONS.txt", "old_id": "comp_0004_0115_2"}
{"question": "A company operating in both China and the US faces potential penalties for illegal gains from regulatory violations. Which statement best describes a key difference in how Chinese and US regulatory approaches might handle such situations?", "choices": ["A. Chinese regulations typically specify fixed monetary penalty ranges based on illegal gains, while US regulations focus more on compliance timelines and fee structures for information requests.", "B. US regulations mandate immediate business suspension for all illegal gain violations, while Chinese regulations only impose fines without operational restrictions.", "C. Both systems use identical formulas (2-10 times illegal gains) for calculating penalties regardless of the regulatory context.", "D. Chinese regulations exempt companies from penalties if they voluntarily disclose violations, while US regulations impose mandatory criminal charges for any illegal gains."], "answer": "A", "type": "Parallel", "explanation": "Chinese regulations demonstrate structured penalty frameworks with specific multipliers (2-10 times illegal gains) and fixed fine ranges when gains are minimal or absent. US regulations in the provided context focus on procedural aspects like time limits and fee calculations for information requests rather than penalty structures for illegal gains.", "category": "General_Regulatory_Comparison", "related_concept": "penalty for illegal gains", "id": "PA_P_00776_001", "match_type": "weak", "match_score": 0.7401570462296816, "lang": "EN", "source_cn": "《国务院关于修改部分行政法规的决定》（中华人民共和国国务院令第752号）.txt", "source_us": "PART_20PUBLIC_INFORMATION.txt", "old_id": "comp_0011_0007_1"}
{"question": "In regulatory frameworks for medical devices, which statement accurately describes the relationship between expiration dates and device lifecycle management?", "choices": ["A. Expiration dates primarily indicate when a device should be used by to ensure safety and effectiveness, while post-expiration handling focuses on preventing unauthorized use.", "B. Expiration dates are only relevant for implantable devices and have no bearing on post-market surveillance activities.", "C. The Global Unique Device Identification Database (GUDID) directly determines expiration dates based on real-time safety data.", "D. Expiration dates are interchangeable with manufacturing dates and do not require specific regulatory oversight."], "answer": "A", "type": "Parallel", "explanation": "Expiration dates are critical for ensuring device safety and efficacy within specified periods. Regulatory frameworks emphasize proper handling of expired devices to prevent unauthorized use, aligning with lifecycle management principles. Options B, C, and D misrepresent regulatory roles: expiration dates apply broadly, GUDID tracks identification not expiration dates, and expiration dates are distinct from manufacturing dates with specific oversight.", "category": "Medical_Devices", "related_concept": "expiration date", "id": "PA_P_00504_001", "match_type": "weak", "match_score": 0.7468823608918449, "lang": "EN", "source_cn": "医疗器械紧急使用管理规定（试行）.txt", "source_us": "PART_801LABELING.txt", "old_id": "comp_0007_0001_1"}
{"question": "Statement 1: Regulatory systems for cosmetics typically require follow-up investigations and tracking reports when higher-level agencies disagree with initial assessments. Statement 2: Food and drug additive regulations emphasize the consideration of additive toxic effects from related substances during safety evaluations.", "choices": ["A. Both statements are correct", "B. Statement 1 is correct, Statement 2 is incorrect", "C. Statement 1 is incorrect, Statement 2 is correct", "D. Both statements are incorrect"], "answer": "A", "type": "Parallel", "explanation": "Statement 1 correctly describes the cosmetics regulatory approach where follow-up investigations and tracking reports are required when provincial agencies disagree with lower-level assessments. Statement 2 accurately reflects the additive regulatory principle that considers potential additive toxic effects from color additives, food additives, and pesticide chemicals with similar biological activities during safety evaluations.", "category": "Regulatory Frameworks", "related_concept": "Tracking investigation and follow-up reports, Safety information submission", "id": "PA_P_00599_008", "match_type": "weak", "match_score": 0.7338400912917933, "lang": "EN", "source_cn": "化妆品不良反应监测管理办法.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0011_0001_2"}
{"question": "Statement 1: In the US, the net quantity declaration on a cosmetic label must be positioned within the bottom 30% of the principal display panel and separated from other label information by specified minimum spaces. Statement 2: In China, when reporting numerical test results for cosmetics, the data must be rounded and its significant digits retained specifically based on the product's regulatory limit values to ensure compliance. Which of the following is correct regarding these statements?", "choices": ["A. Both statements are correct.", "B. Statement 1 is correct, but Statement 2 is incorrect.", "C. Statement 1 is incorrect, but Statement 2 is correct.", "D. Both statements are incorrect."], "answer": "B", "type": "Parallel", "explanation": "This question compares specific regulatory requirements for label placement and data reporting. Statement 1 is correct: US regulations (21 CFR 701.13) explicitly require the net quantity declaration to be within the bottom 30% of the principal display panel and to have defined spacing from other label information (e.g., a space equal to the lettering height above/below and twice the width of 'N' to the left/right). Statement 2 is incorrect: according to the provided Chinese text, data rounding and significant digit retention for test results should be based on the instrument used and reference standards (like GB 8170—2008), considering the test method's technical provisions, and explicitly NOT based on the product's limit values. This distinction highlights a key difference in regulatory philosophy—the US focuses on precise consumer-facing label formatting for clarity, while China emphasizes technical accuracy in lab reporting independent of compliance thresholds.", "category": "Cosmetics", "related_concept": "principal display panel, numerical result reporting", "id": "PA_P_00643_002", "match_type": "weak", "match_score": 0.7319647388080148, "lang": "EN", "source_cn": "化妆品注册和备案检验工作规范.txt", "source_us": "PART_701COSMETIC_LABELING.txt", "old_id": "comp_0020_0008_2"}
{"question": "A cosmetics company is developing a new color additive for use in lipstick. They have conducted animal studies and need to determine a safe human exposure level. Which regulatory approach best describes how the safety factor would be applied to establish this level?", "choices": ["A. A fixed 100-fold safety factor must always be applied to animal data unless specific justification for a different factor is provided and accepted.", "B. The safety factor is determined through a risk-benefit analysis specific to the product type and intended use, with no predetermined numerical requirement.", "C. A safety factor is applied only after human clinical trial data confirms the animal study results, with the magnitude determined case-by-case.", "D. No specific safety factor is mandated; safety is established solely through comprehensive toxicological testing without extrapolation rules."], "answer": "A", "type": "Parallel", "explanation": "The US regulation explicitly states that a safety factor of 100 to 1 will be used when applying animal data to humans, except where evidence justifies a different factor. This represents a specific, predefined numerical approach. The Chinese text does not specify a numerical safety factor methodology for color additives in this context, focusing instead on general safety assessment requirements. The question tests the understanding of a concrete, rule-based US approach versus more general principles.", "category": "Cosmetics", "related_concept": "safety factor application", "id": "PA_P_00655_009", "match_type": "weak", "match_score": 0.745812118861689, "lang": "EN", "source_cn": "化妆品注册备案资料管理规定.txt", "source_us": "PART_70COLOR_ADDITIVES.txt", "old_id": "comp_0020_0004_1"}
{"question": "In regulatory frameworks, how do definitions of time periods for administrative purposes typically differ between jurisdictions?", "choices": ["A. Some jurisdictions explicitly define 'day' as a working day for administrative timelines, while others may not specify this in general provisions.", "B. All jurisdictions universally define 'day' as a calendar day to ensure consistency in enforcement.", "C. Jurisdictions avoid defining 'day' in regulations to allow for flexible interpretation by authorities.", "D. Definitions are always tied to specific business hours rather than the concept of a working day."], "answer": "A", "type": "Parallel", "explanation": "Regulatory systems often differ in how they calculate administrative timelines. A common distinction is whether 'day' is explicitly defined as a 'working day' (excluding weekends/holidays) for procedural deadlines, or if it defaults to calendar days. This reflects practical considerations for government operations versus strict chronological measurement.", "category": "Drugs", "related_concept": "working day definition", "id": "PA_P_00338_001", "match_type": "weak", "match_score": 0.7141840261664573, "lang": "EN", "source_cn": "药物非临床研究质量管理规范认证.txt", "source_us": "PART_202PRESCRIPTION_DRUG_ADVERTISING.txt", "old_id": "comp_0009_0008_1"}
{"question": "关于易制毒化学品记录保存要求，中美法规在监管逻辑上存在显著差异。以下哪项最能体现这种差异？", "choices": ["A. 中国法规强调交易记录的完整性和及时备案，而美国法规更注重记录保存作为防止滥用的系统性控制措施的一部分", "B. 中国法规仅要求生产单位保存记录，美国法规要求所有相关方保存记录", "C. 中国法规的记录要求主要服务于税务稽查，美国法规服务于医疗研究", "D. 两国法规在记录保存的具体格式和保存年限上完全一致，差异仅在于执行机构不同"], "answer": "A", "type": "Parallel", "explanation": "中国法规（如第四十条第四款）明确要求对交易情况进行记录、保存并向主管部门备案，违规将面临罚款、没收等处罚，体现了以行政监管和事后追责为导向的记录管理逻辑。美国法规（如1318.05(a)(1)及(d)段提及）将记录保存（recordkeeping）作为“防止转移滥用的有效控制措施”这一更广泛的公共安全框架中的关键组成部分，强调其在整个合规体系（包括安全控制）中的系统性作用。选项B错误，中国法规也涉及经营、购买等多方记录；C错误，两国记录核心目的均为管制物质监管而非税务或单一研究目的；D明显不符合事实。", "category": "Controlled_Substances", "related_concept": "recordkeeping requirements", "id": "PA_P_00705_001", "match_type": "weak", "match_score": 0.7376920153827488, "lang": "CN", "source_cn": "易制毒化学品管理条例.txt", "source_us": "PART_1318CONTROLS_TO_SATISFY_THE_REQUIREMENTS_OF_T.txt", "old_id": "comp_0014_0003_1"}
